Low-intensity	O
pulsed	O
ultrasound	O
reduces	O
periodontal	O
atrophy	O
in	O
occlusal	O
hypofunctional	O
teeth	O
.	O

To	O
clarify	O
whether	O
low-intensity	O
pulsed	O
ultrasound	O
(	O
LIPUS	O
)	O
exposure	O
has	O
recovery	O
effects	O
on	O
the	O
hypofunctional	O
periodontal	O
ligament	O
(	O
PDL	O
)	O
and	O
interradicular	O
alveolar	O
bone	O
(	O
IRAB	O
)	O
.	O

Twelve-	O
week	O
-old	O
male	O
Sprague-Dawley	O
rats	O
were	O
divided	O
into	O
three	O
groups	O
(	O
n	O
=	O
5	O
each	O
)	O
:	O
a	O
normal	O
occlusion	O
(	O
C	O
)	O
group	O
,	O
an	O
occlusal	O
hypofunction	O
(	O
H	O
)	O
group	O
,	O
and	O
an	O
occlusal	O
hypofunction	O
group	O
subjected	O
to	O
LIPUS	O
(	O
HL	O
)	O
treatment	O
.	O

Hypofunctional	O
occlusion	O
of	O
the	O
maxillary	O
first	O
molar	O
(	O
M1	O
)	O
of	O
the	O
H	O
and	O
HL	O
groups	O
was	O
induced	O
by	O
the	O
bite-raising	O
technique	O
.	O

Only	O
the	O
HL	O
group	O
was	O
irradiated	O
with	O
LIPUS	O
for	O
5	O
days	O
.	O

The	O
IRAB	O
and	O
PDL	O
of	O
M1	O
were	O
examined	O
by	O
microcomputed	B-P
tomography	I-P
(	O
micro-CT	B-P
)	O
analysis	O
.	O

To	O
quantify	O
mRNA	O
expression	O
of	O
cytokines	O
involved	O
in	O
PDL	O
proliferation	O
and	O
development	O
,	O
real-time	O
reverse	O
transcription	O
quantitative	O
PCR	O
(	O
qRT-PCR	O
)	O
was	O
performed	O
for	O
twist	O
family	O
bHLH	O
transcription	O
factor	O
1	O
(	O
Twist1	O
)	O
,	O
periostin	O
,	O
and	O
connective	O
tissue	O
growth	O
factor	O
(	O
CTGF	O
)	O
in	O
the	O
PDL	O
samples	O
.	O

Micro-CT	B-P
analysis	O
showed	O
that	O
the	O
PDL	O
volume	O
was	O
decreased	O
in	O
the	O
H	O
group	O
compared	O
with	O
that	O
of	O
the	O
C	O
and	O
HL	O
groups	O
.	O

Both	O
bone	O
volume	O
per	O
tissue	O
volume	O
(	O
BV	O
/	O
TV	O
)	O
of	O
IRAB	O
was	O
decreased	O
in	O
the	O
H	O
group	O
compared	O
with	O
that	O
in	O
the	O
C	O
group	O
.	O

LIPUS	O
exposure	O
restored	O
BV	O
/	O
TV	O
in	O
the	O
IRAB	O
of	O
the	O
HL	O
group	O
.	O

qRT-PCR	O
analysis	O
showed	O
that	O
Twist1	O
,	O
periostin	O
,	O
and	O
CTGF	O
mRNA	O
levels	O
were	O
decreased	O
in	O
the	O
H	O
group	O
and	O
increased	O
in	O
the	O
HL	O
group	O
.	O

LIPUS	O
exposure	O
reduced	O
the	O
atrophic	O
changes	O
of	O
alveolar	O
bone	O
by	O
inducing	O
the	O
upregulation	O
of	O
periostin	O
and	O
CTGF	O
expression	O
to	O
promote	O
PDL	O
healing	O
after	O
induction	O
of	O
occlusal	O
hypofunction	O
.	O

A	O
biodistribution	O
study	O
of	O
solid	O
lipid-polyethyleneimine	O
hybrid	O
nanocarrier	O
for	O
cancer	O
RNAi	O
therapy	O
.	O

Solid	O
lipid-polymer	O
hybrid	O
nanocarrier	O
(	O
LPN	O
)	O
was	O
previously	O
reported	O
to	O
achieve	O
high	O
siRNA	O
transfection	O
efficiency	O
and	O
induce	O
sustained	O
RNAi	O
-based	O
chemosensitizing	O
effect	O
at	O
cellular	O
level	O
.	O

In	O
this	O
study	O
,	O
our	O
objectives	O
were	O
to	O
evaluate	O
the	O
in	O
vivo	O
biodistribution	O
of	O
LPNs	O
in	O
a	O
prostate	O
cancer	O
model	O
and	O
determine	O
the	O
factors	O
that	O
potentially	O
affect	O
tumor	O
penetration	O
by	O
LPNs	O
.	O

The	O
LPN	O
formulation	O
with	O
the	O
highest	O
transfection	O
efficiency	O
(	O
64	O
%	O
)	O
and	O
stability	O
was	O
selected	O
for	O
the	O
study	O
.	O

Mice	O
bearing	O
tumors	O
of	O
PC-3Mcells	O
were	O
treated	O
with	O
LPNs	O
labeled	O
with	O
IR780	O
or	O
AF647	O
-	O
siRNA	O
.	O

Near	B-P
infrared	I-P
imaging	I-P
showed	O
that	O
LPNs	O
achieved	O
favorable	O
in	O
vivo	O
biodistribution	O
with	O
high	O
tumor	O
/low	O
organ	O
ratios	O
.	O

LPN	O
accumulation	O
was	O
also	O
observed	O
in	O
liver	O
metastatic	O
tissue	O
.	O

Result	O
of	O
extravasation	O
study	O
confirmed	O
that	O
encapsulated	O
siRNA	O
molecules	O
were	O
able	O
to	O
escape	O
into	O
the	O
tumor	O
tissue	O
at	O
the	O
extravascular	O
area	O
.	O

When	O
LPN	O
levels	O
in	O
large	O
(	O
volume	O
>	O
750mm	O
(	O
3	O
)	O
)	O
and	O
small	O
(	O
<	O
500mm	O
(	O
3	O
)	O
)	O
tumors	O
were	O
compared	O
,	O
no	O
significant	O
difference	O
was	O
observed	O
.	O

However	O
,	O
both	O
docetaxel	O
pretreatment	O
(	O
72hbefore	O
LPN	O
)	O
and	O
concurrent	O
docetaxel	O
treatment	O
significantly	O
enhanced	O
the	O
tumor	O
LPN	O
levels	O
by	O
3.9-	O
and	O
3.1-fold	O
,	O
respectively	O
(	O
both	O
p	O
<	O
0.01	O
)	O
.	O

In	O
conclusion	O
,	O
LPN	O
is	O
a	O
promising	O
carrier	O
system	O
to	O
deliver	O
RNAi	O
therapy	O
to	O
solid	O
malignancies	O
that	O
also	O
receive	O
chemotherapy	O
.	O

Single-Nucleotide	O
Polymorphism	O
rs17611	O
of	O
Complement	O
Component	O
5	O
Shows	O
Association	O
with	O
Ischemic	O
Stroke	O
in	O
Northeast	O
Chinese	O
Population	O
.	O

Complement	O
component	O
5	O
(	O
C5	O
)	O
has	O
been	O
described	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
and	O
progression	O
of	O
atherosclerosis	O
and	O
cardiovascular	O
disease	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
whether	O
genetic	O
variation	O
of	O
C5	O
was	O
associated	O
with	O
ischemic	O
stroke	O
(	O
IS	O
)	O
in	O
northeast	O
Chinese	O
population	O
.	O

We	O
used	O
a	O
case-control	O
study	O
involving	O
386	O
IS	O
patients	O
and	O
386	O
non-IS	O
controls	O
from	O
a	O
rural	O
population	O
and	O
determined	O
the	O
genotypes	O
of	O
five	O
polymorphisms	O
(	O
rs12237774	O
,	O
rs17611	O
,	O
rs4837805	O
,	O
rs7026551	O
,	O
and	O
rs1017119	O
)	O
of	O
C5	O
gene	O
by	O
Snapshot	O
single-nucleotide	B-P
polymorphism	I-P
genotyping	I-P
assays	I-P
to	O
assess	O
any	O
links	O
with	O
IS	O
.	O

In	O
univariate	O
analysis	O
,	O
rs17611	O
was	O
significantly	O
associated	O
with	O
IS	O
in	O
the	O
additive	O
model	O
,	O
the	O
dominant	O
model	O
,	O
and	O
recessive	O
model	O
(	O
additive	O
p	O
0.031	O
,	O
dominant	O
p	O
0.034	O
,	O
and	O
recessive	O
p	O
0.027	O
)	O
.	O

After	O
adjustment	O
for	O
Binary	O
Logistic	O
Regression	O
,	O
rs17611	O
polymorphism	O
was	O
still	O
significant	O
in	O
three	O
models	O
(	O
adjusted	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1.306	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.069-1.595	O
,	O
p-value	O
=	O
0.009	O
in	O
an	O
additive	O
model	O
;	O
OR	O
=	O
1.378	O
,	O
95	O
%	O
CI	O
=	O
1.024-1.856	O
,	O
p-value	O
=	O
0.035	O
in	O
a	O
dominant	O
model	O
;	O
and	O
OR	O
=	O
1.511	O
,	O
95	O
%	O
CI	O
=	O
1.048-2.18	O
,	O
p-value	O
=	O
0.027	O
in	O
a	O
recessive	O
model	O
)	O
.	O

In	O
this	O
sample	O
of	O
patients	O
,	O
genetic	O
variation	O
of	O
rs17611	O
in	O
C5	O
is	O
associated	O
with	O
higher	O
prevalence	O
of	O
IS	O
.	O

Molecular	O
detection	O
of	O
infection	O
homogeneity	O
and	O
impact	O
of	O
miltefosine	O
treatment	O
in	O
a	O
Syrian	O
golden	O
hamster	O
model	O
of	O
Leishmania	O
donovani	O
and	O
L.	O
infantum	O
visceral	O
leishmaniasis	O
.	O

Control	O
of	O
visceral	O
leishmaniasis	O
caused	O
by	O
Leishmania	O
infantum	O
and	O
Leishmania	O
donovani	O
primarily	O
relies	O
on	O
chemotherapy	O
using	O
an	O
increasingly	O
compromised	O
repertoire	O
of	O
antileishmanial	O
compounds	O
.	O

For	O
evaluation	O
of	O
novel	O
drugs	O
,	O
the	O
Syrian	O
golden	O
hamster	O
is	O
considered	O
as	O
a	O
clinically	O
relevant	O
laboratory	O
model	O
.	O

In	O
this	O
study	O
,	O
two	O
molecular	B-P
parasite	I-P
detection	I-P
assays	I-P
were	O
developed	O
targeting	O
cathepsin-like	O
cysteine	O
protease	O
B	O
(	O
CPB	O
)	O
DNA	O
and	O
18S	O
rRNA	O
to	O
achieve	O
absolute	O
amastigote	O
quantification	O
in	O
the	O
major	O
target	O
organs	O
liver	O
and	O
spleen	O
.	O

Both	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
techniques	O
showed	O
excellent	O
agreement	O
with	O
a	O
strong	O
correlation	O
with	O
the	O
conventional	O
microscopic	B-P
reading	I-P
of	O
Giemsa-stained	B-P
tissue	O
smears	B-P
.	O

Using	O
multiple	O
single	O
tissue	O
pieces	O
and	O
all	O
three	O
detection	O
methods	O
,	O
we	O
confirmed	O
homogeneity	O
of	O
infection	O
in	O
liver	O
and	O
spleen	O
and	O
the	O
robustness	O
of	O
extrapolating	O
whole	O
organ	O
burdens	O
from	O
a	O
small	O
single	O
tissue	O
piece	O
.	O

Comparison	O
of	O
pre	O
-	O
and	O
post-treatment	O
burdens	O
in	O
infected	O
hamsters	O
using	O
the	O
three	O
detection	O
methods	O
consistently	O
revealed	O
a	O
stronger	O
parasite	O
reduction	O
in	O
the	O
spleen	O
compared	O
to	O
the	O
liver	O
,	O
indicating	O
an	O
organ	O
-	O
dependent	O
clearance	O
efficacy	O
for	O
miltefosine	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
in	O
the	O
hamster	O
demonstrated	O
high	O
homogeneity	O
of	O
infection	O
in	O
liver	O
and	O
spleen	O
and	O
advocates	O
the	O
use	O
of	O
molecular	O
detection	O
methods	O
for	O
assessment	O
of	O
low	O
(	O
post-treatment	O
)	O
tissue	O
burdens	O
.	O

Relation	O
of	O
Left	O
Ventricular	O
Mass	O
and	O
Infarct	O
Size	O
in	O
Anterior	O
Wall	O
ST-Segment	O
Elevation	O
Acute	O
Myocardial	O
Infarction	O
(	O
from	O
the	O
EMBRACE	O
STEMI	O
Clinical	O
Trial	O
)	O
.	O

Biomarker	O
measures	O
of	O
infarct	O
size	O
and	O
myocardial	O
salvage	O
index	O
(	O
MSI	O
)	O
are	O
important	O
surrogate	O
measures	O
of	O
clinical	O
outcomes	O
after	O
a	O
myocardial	O
infarction	O
.	O

However	O
,	O
there	O
is	O
variability	O
in	O
infarct	O
size	O
unaccounted	O
for	O
by	O
conventional	O
adjustment	O
factors	O
.	O

This	O
post	O
hoc	O
analysis	O
of	O
Evaluation	O
of	O
Myocardial	O
Effects	O
of	O
Bendavia	O
for	O
Reducing	O
Reperfusion	O
Injury	O
in	O
Patients	O
With	O
Acute	O
Coronary	O
Events	O
(	O
EMBRACE	O
)	O
ST-Segment	O
Elevation	O
Myocardial	O
Infarction	O
(	O
STEMI	O
)	O
trial	O
evaluates	O
the	O
association	O
between	O
left	O
ventricular	O
(	O
LV	O
)	O
mass	O
and	O
infarct	O
size	O
as	O
assessed	O
by	O
areas	O
under	O
the	O
curve	O
for	O
creatine	B-P
kinase-MB	I-P
(	O
CK-MB	B-P
)	O
and	O
troponin	B-P
I	I-P
release	I-P
over	O
the	O
first	O
72	O
hours	O
(	O
CK-MB	B-P
area	O
under	O
the	O
curve	O
[	O
AUC	O
]	O
and	O
troponin	O
I	O
[	O
TnI	O
]	O
AUC	O
)	O
and	O
the	O
MSI	O
.	O

Patients	O
with	O
first	O
anterior	O
STEMI	O
,	O
occluded	O
left	O
anterior	O
descending	O
artery	O
,	O
and	O
available	O
LV	O
mass	O
measurement	O
in	O
EMBRACE	O
STEMI	O
trial	O
were	O
included	O
(	O
n	O
=	O
100	O
)	O
(	O
ClinicalTrials.govNCT01572909	O
)	O
.	O

MSI	O
,	O
end-diastolic	O
LV	O
mass	O
on	O
day	O
4	O
cardiac	B-P
magnetic	I-P
resonance	I-P
,	O
and	O
CK-MB	B-P
and	O
troponin	O
I	O
concentrations	O
were	O
evaluated	O
by	O
a	O
core	O
laboratory	O
.	O

After	O
saturated	O
multivariate	O
analysis	O
,	O
dominance	O
analysis	O
was	O
performed	O
to	O
estimate	O
the	O
contribution	O
of	O
each	O
independent	O
variable	O
to	O
the	O
predicted	O
variance	O
of	O
each	O
outcome	O
.	O

In	O
multivariate	O
models	O
that	O
included	O
age	O
,	O
gender	O
,	O
body	O
surface	O
area	O
,	O
lesion	O
location	O
,	O
smoking	O
,	O
and	O
ischemia	O
time	O
,	O
LV	O
mass	O
remained	O
independently	O
associated	O
with	O
biomarker	O
measures	O
of	O
infarct	O
size	O
(	O
CK-MB	B-P
AUC	O
p	O
=	O
0.02	O
,	O
TnI	O
AUC	O
p	O
=	O
0.03	O
)	O
and	O
MSI	O
(	O
p	O
=	O
0.003	O
)	O
.	O

Dominance	O
analysis	O
demonstrated	O
that	O
LV	O
mass	O
accounted	O
for	O
58	O
%	O
,	O
47	O
%	O
,	O
and	O
60	O
%	O
of	O
the	O
predicted	O
variances	O
for	O
CK-MB	B-P
AUC	O
,	O
TnI	O
AUC	O
,	O
and	O
MSI	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
LV	O
mass	O
accounts	O
for	O
approximately	O
half	O
of	O
the	O
predicted	O
variance	O
in	O
biomarker	O
measures	O
of	O
infarct	O
size	O
.	O

It	O
should	O
be	O
considered	O
as	O
an	O
adjustment	O
variable	O
in	O
studies	O
evaluating	O
infarct	O
size	O
.	O

Novel	O
High-grade	O
Endometrial	O
Stromal	O
Sarcoma	O
:	O
A	O
Morphologic	O
Mimicker	O
of	O
Myxoid	O
Leiomyosarcoma	O
.	O

Endometrial	O
stromal	O
sarcomas	O
(	O
ESS	O
)	O
are	O
often	O
underpinned	O
by	O
recurrent	O
chromosomal	O
translocations	O
resulting	O
in	O
the	O
fusion	O
of	O
genes	O
involved	O
in	O
epigenetic	O
regulation	O
.	O

To	O
date	O
,	O
only	O
YWHAE-NUTM2	O
rearrangements	O
are	O
associated	O
with	O
distinctive	O
high-grade	O
morphology	O
and	O
aggressive	O
clinical	O
behavior	O
.	O

We	O
identified	O
3	O
ESS	O
morphologically	O
mimicking	O
myxoid	O
leiomyosarcoma	O
of	O
the	O
uterus	O
and	O
sought	O
to	O
describe	O
their	O
unique	O
histopathologic	O
features	O
and	O
identify	O
genetic	O
alterations	O
using	O
next-generation	O
sequencing	O
.	O

All	O
cases	O
displayed	O
predominantly	O
spindled	O
cells	O
associated	O
with	O
abundant	O
myxoid	O
stroma	O
and	O
brisk	O
mitotic	O
activity	O
.	O

Tumors	O
involved	O
the	O
endometrium	O
and	O
demonstrated	O
tongue-like	O
myometrial	O
infiltration	O
.	O

All	O
3	O
were	O
associated	O
with	O
an	O
aggressive	O
clinical	O
course	O
,	O
including	O
multisite	O
bony	O
metastases	O
in	O
1	O
patient	O
,	O
progressive	O
peritoneal	O
disease	O
after	O
chemotherapy	O
in	O
another	O
,	O
and	O
metastases	O
to	O
the	O
lung	O
and	O
skin	O
in	O
the	O
last	O
patient	O
.	O

All	O
3	O
ESS	O
were	O
found	O
to	O
harbor	O
ZC3H7B	O
-	O
BCOR	O
gene	O
fusions	O
by	O
targeted	B-P
sequencing	I-P
and	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

On	O
the	O
basis	O
of	O
the	O
review	O
of	O
these	O
cases	O
,	O
we	O
find	O
that	O
ESS	O
with	O
ZC3H7B	O
-	O
BCOR	O
fusion	O
constitutes	O
a	O
novel	O
type	O
of	O
high-grade	O
ESS	O
and	O
shares	O
significant	O
morphologic	O
overlap	O
with	O
myxoid	O
leiomyosarcoma	O
.	O

Functional	O
Neuroimaging	O
Pilot	O
Study	O
of	O
Borderline	O
Personality	O
Disorder	O
in	O
Adolescents	O
.	O

Borderline	O
personality	O
disorder	O
(	O
BPD	O
)	O
is	O
being	O
increasingly	O
recognized	O
by	O
clinicians	O
working	O
with	O
adolescents	O
,	O
and	O
the	O
reliability	O
and	O
validity	O
of	O
the	O
diagnosis	O
have	O
been	O
established	O
in	O
the	O
adolescent	O
population	O
.	O

Adolescence	O
is	O
known	O
to	O
be	O
a	O
period	O
of	O
high	O
risk	O
for	O
BPD	O
development	O
as	O
most	O
patients	O
identify	O
the	O
onset	O
of	O
their	O
symptoms	O
to	O
be	O
in	O
the	O
adolescent	O
period	O
.	O

As	O
with	O
other	O
mental	O
health	O
disorders	O
,	O
personality	O
disorder	O
,	O
are	O
thought	O
to	O
result	O
from	O
the	O
interaction	O
between	O
biological	O
and	O
environmental	O
factors	O
.	O

Functional	O
neuroimaging	O
studies	O
are	O
reporting	O
an	O
increasing	O
amount	O
of	O
data	O
on	O
abnormal	O
neuronal	O
functions	O
in	O
BPD	O
adult	O
patients	O
.	O

However	O
,	O
no	O
functional	O
neuroimaging	O
studies	O
have	O
been	O
conducted	O
in	O
adolescents	O
with	O
BPD	O
.Objectives	O
This	O
pilot	O
project	O
aims	O
to	O
evaluate	O
the	O
feasibility	O
of	O
a	O
functional	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
fMRI	B-P
)	O
study	O
coupled	O
with	O
clinical	O
and	O
psychological	O
measures	O
in	O
adolescent	O
girls	O
with	O
a	O
diagnosis	O
of	O
BPD	O
.	O

It	O
also	O
aims	O
to	O
identify	O
neuronal	O
regions	O
of	O
interest	O
(	O
ROI	O
)	O
for	O
the	O
study	O
of	O
BPD	O
in	O
adolescent	O
girls	O
.Method	O
Six	O
female	O
adolescents	O
meeting	O
DSM-IV	O
criteria	O
for	O
BPD	O
and	O
6	O
female	O
adolescents	O
without	O
psychiatric	O
disorder	O
were	O
recruited	O
.	O

Both	O
groups	O
were	O
evaluated	O
for	O
BPD	O
symptoms	O
,	O
depressive	O
symptoms	O
,	O
impulsivity	O
,	O
affective	O
lability	O
,	O
and	O
other	O
potential	O
psychiatric	O
comorbidities	O
.	O

We	O
used	O
fMRI	B-P
to	O
compare	O
patterns	O
of	O
regional	O
brain	O
activation	O
between	O
these	O
two	O
groups	O
as	O
they	O
viewed	O
20	O
positive	O
,	O
20	O
negative	O
and	O
20	O
neutral	O
emotion-inducing	O
pictures	O
,	O
which	O
were	O
presented	O
in	O
random	O
order	O
.Results	O
Participants	O
were	O
recruited	O
over	O
a	O
period	O
of	O
22	O
months	O
.	O

The	O
protocol	O
was	O
well	O
tolerated	O
by	O
participants	O
.	O

Mean	O
age	O
of	O
the	O
BPD	O
group	O
and	O
control	O
group	O
was	O
15.8	O
±	O
0.9	O
years-old	O
and	O
15.5	O
±	O
1.2	O
years-old	O
respectively	O
.	O

Psychiatric	O
comorbidity	O
and	O
use	O
of	O
medication	O
was	O
common	O
among	O
participants	O
in	O
the	O
BPD	O
group	O
.	O

This	O
group	O
showed	O
higher	O
impulsivity	O
and	O
affective	O
lability	O
scores	O
.	O

For	O
the	O
fMRI	B-P
task	O
,	O
BPD	O
patients	O
demonstrated	O
greater	O
differences	O
in	O
activation	O
than	O
controls	O
,	O
when	O
viewing	O
negative	O
pictures	O
compared	O
with	O
neutral	O
pictures	O
,	O
in	O
limbic	O
regions	O
(	O
amygdala	O
and	O
right	O
hippocampus	O
and	O
parahippocampal	O
areas	O
)	O
as	O
well	O
as	O
in	O
the	O
superior	O
frontal	O
gyrus	O
,	O
right	O
precentral	O
gyrus	O
and	O
cerebellum	O
,	O
while	O
control	O
group	O
showed	O
greater	O
activation	O
in	O
left	O
precentral	O
gyrus	O
and	O
right	O
orbitofrontal	O
area	O
.	O

Viewing	O
positive	O
pictures	O
compared	O
with	O
neutral	O
pictures	O
led	O
to	O
increased	O
activation	O
of	O
the	O
left	O
hippocampus	O
and	O
both	O
parahippocampal	O
regions	O
,	O
as	O
well	O
as	O
middle	O
cingulate	O
cortex	O
,	O
superior	O
temporal	O
gyrus	O
and	O
cerebellum	O
in	O
the	O
BPD	O
group	O
.	O

In	O
the	O
control	O
group	O
,	O
positive-scene	O
viewing	O
led	O
to	O
increased	O
activity	O
in	O
the	O
left	O
superior	O
parietal	O
gyrus	O
and	O
right	O
middle	O
/	O
superior	O
temporal	O
gyrus	O
.Conclusion	O
Limbic	O
regions	O
and	O
areas	O
from	O
the	O
prefrontal	O
and	O
orbitofrontal	O
cortex	O
are	O
potential	O
ROI	O
for	O
the	O
study	O
of	O
the	O
neurophysiology	O
of	O
BPD	O
in	O
female	O
adolescents	O
.	O

The	O
larger	O
studies	O
are	O
needed	O
to	O
better	O
understand	O
the	O
neural	O
features	O
found	O
in	O
these	O
young	O
patients	O
.	O

Anger	O
and	O
aggression	O
in	O
borderline	O
personality	O
disorder	O
and	O
attention	O
deficit	O
hyperactivity	O
disorder	O
-	O
does	O
stress	O
matter	O
?	O
.	O

The	O
impact	O
of	O
stress	O
on	O
anger	O
and	O
aggression	O
in	O
Borderline	O
Personality	O
Disorder	O
(	O
BPD	O
)	O
and	O
Attention	O
Deficit	O
Hyperactivity	O
Disorder	O
(	O
ADHD	O
)	O
has	O
not	O
been	O
thoroughly	O
investigated	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
investigate	O
different	O
aspects	O
of	O
anger	O
and	O
aggression	O
in	O
patients	O
with	O
these	O
disorders	O
.	O

Twenty-nine	O
unmedicated	O
female	O
BPD	O
patients	O
,	O
28	O
ADHD	O
patients	O
and	O
30	O
healthy	O
controls	O
(	O
HC	O
)	O
completed	O
self-reports	O
measuring	O
trait	O
anger	O
,	O
aggression	O
and	O
emotion	O
regulation	O
capacities	O
.	O

A	O
modified	O
version	O
of	O
the	O
Point	O
Subtraction	O
Aggression	O
Paradigm	O
and	O
a	O
state	O
anger	O
measurement	O
were	O
applied	O
under	O
resting	O
and	O
stress	O
conditions	O
.	O

Stress	O
was	O
induced	O
by	O
the	O
Mannheim	B-P
Multicomponent	I-P
Stress	I-P
Test	I-P
(	O
MMST	B-P
)	O
.	O

Both	O
patient	O
groups	O
scored	O
significantly	O
higher	O
on	O
all	O
self-report	O
measures	O
compared	O
to	O
HCs	O
.	O

Compared	O
to	O
ADHD	O
patients	O
,	O
BPD	O
patients	O
reported	O
higher	O
trait	O
aggression	O
and	O
hostility	O
,	O
a	O
stronger	O
tendency	O
to	O
express	O
anger	O
when	O
provoked	O
and	O
to	O
direct	O
anger	O
inwardly	O
.	O

Furthermore	O
,	O
BPD	O
patients	O
exhibited	O
higher	O
state	O
anger	O
than	O
HCs	O
and	O
ADHD	O
patients	O
under	O
both	O
conditions	O
and	O
showed	O
a	O
stress-dependent	O
anger	O
increase	O
.	O

At	O
the	O
behavioral	O
level	O
,	O
no	O
significant	O
effects	O
were	O
found	O
.	O

In	O
BPD	O
patients	O
,	O
aggression	O
and	O
anger	O
were	O
positively	O
correlated	O
with	O
emotion	O
regulation	O
deficits	O
.	O

Our	O
findings	O
suggest	O
a	O
significant	O
impact	O
of	O
stress	O
on	O
self-perceived	O
state	O
anger	O
in	O
BPD	O
patients	O
but	O
not	O
on	O
aggressive	O
behavior	O
towards	O
others	O
in	O
females	O
with	O
BPD	O
or	O
ADHD	O
.	O

However	O
,	O
it	O
appears	O
to	O
be	O
pronounced	O
inwardly	O
directed	O
anger	O
which	O
is	O
of	O
clinical	O
importance	O
in	O
BPD	O
patients	O
.	O

Metacarpophalangeal	O
Joint	O
Arthrodesis	O
of	O
the	O
Thumb	O
-	O
Minimum	O
of	O
Eight	O
Months	O
Follow-up	O
.	O

Disorders	O
of	O
the	O
thumb	O
metacarpophalangeal	O
(	O
MCP	O
)	O
joint	O
can	O
lead	O
to	O
significant	O
loss	O
of	O
function	O
and	O
pain	O
.	O

Thumb	O
MCP	O
arthrodesis	O
following	O
traumatic	O
injuries	O
is	O
inadequately	O
described	O
and	O
recent	O
studies	O
have	O
questioned	O
the	O
outcome	O
of	O
this	O
treatment	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
report	O
outcome	O
and	O
disability	O
following	O
thumb	O
MCP	O
joint	O
arthrodesis	O
in	O
the	O
treatment	O
of	O
chronic	O
instability	O
after	O
traumatic	O
injuries	O
.	O

A	O
retrospective	O
review	O
of	O
26	O
patients	O
operated	O
on	O
with	O
MCP	O
joint	O
arthrodesis	O
,	O
median	O
follow-up	O
42	O
months	O
(	O
8-104	O
months	O
)	O
.	O

Subjective	O
outcome	O
was	O
assessed	O
using	O
the	O
disabilities	O
of	O
the	O
Arm	O
,	O
Shoulder	O
,	O
and	O
Hand-questionnaire	O
(	O
DASH	O
)	O
.	O

In	O
addition	O
,	O
patient	O
satisfaction	O
,	O
pain	O
,	O
stiffness	O
,	O
and	O
impairment	O
of	O
activities	O
of	O
daily	O
living	O
were	O
assessed	O
on	O
a	O
Visual	B-P
Analogue	I-P
Scale	I-P
(	O
VAS	B-P
)	O
followed	O
by	O
a	O
question	O
stating	O
whether	O
they	O
would	O
undergo	O
the	O
same	O
procedure	O
again	O
.	O

Two	O
patients	O
(	O
7.7	O
%	O
)	O
needed	O
re-operation	O
due	O
to	O
nonunion	O
.	O

Four	O
patients	O
(	O
15.4	O
%	O
)	O
needed	O
hardware	O
removal	O
.	O

Median	O
DASH	O
-	O
score	O
was	O
18	O
(	O
25-75	O
%	O
range	O
6-47	O
)	O
,	O
with	O
lower	O
DASH	O
score	O
s	O
being	O
better	O
.	O

Score	O
s	O
were	O
significantly	O
worse	O
in	O
gender	O
and	O
age	O
matched	O
individuals	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Median	O
VAS	B-P
for	O
pain	O
was	O
3.7	O
(	O
range	O
0-8	O
)	O
.	O

More	O
than	O
50	O
%	O
of	O
patients	O
reported	O
mild	O
,	O
moderate	O
or	O
severe	O
pain	O
,	O
but	O
all	O
patients	O
reported	O
that	O
they	O
were	O
willing	O
to	O
undergo	O
the	O
same	O
procedure	O
again	O
.	O

Our	O
data	O
suggest	O
,	O
that	O
patients	O
with	O
post-traumatic	O
thumb	O
injuries	O
managed	O
with	O
thumb	O
MCP	O
joint	O
arthrodesis	O
perform	O
worse	O
than	O
gender	O
and	O
age	O
matched	O
individuals	O
.	O

Many	O
lived	O
with	O
pain	O
,	O
but	O
all	O
reported	O
that	O
they	O
were	O
willing	O
to	O
undergo	O
the	O
same	O
procedure	O
again	O
.	O

We	O
suggest	O
that	O
the	O
disability	O
scale	O
by	O
the	O
National	O
Board	O
of	O
Industrial	O
Injuries	O
should	O
be	O
reconsidered	O
for	O
patients	O
operated	O
on	O
with	O
thumb	O
MCP	O
arthrodesis	O
.	O

Variation	O
in	O
the	O
Intensity	O
of	O
Selection	O
on	O
Codon	O
Bias	O
over	O
Time	O
Causes	O
Contrasting	O
Patterns	O
of	O
Base	O
Composition	O
Evolution	O
in	O
Drosophila	O
.	O

Four-fold	O
degenerate	O
coding	O
sites	O
form	O
a	O
major	O
component	O
of	O
the	O
genome	O
,	O
and	O
are	O
often	O
used	O
to	O
make	O
inferences	O
about	O
selection	O
and	O
demography	O
,	O
so	O
that	O
understanding	O
their	O
evolution	O
is	O
important	O
.	O

Despite	O
previous	O
efforts	O
,	O
many	O
questions	O
regarding	O
the	O
causes	O
of	O
base	O
composition	O
changes	O
at	O
these	O
sites	O
in	O
Drosophila	O
remain	O
unanswered	O
.	O

To	O
shed	O
further	O
light	O
on	O
this	O
issue	O
,	O
we	O
obtained	O
a	O
new	O
whole-genome	O
polymorphism	O
data	O
set	O
from	O
D.	O
simulans	O
.	O

We	O
analyzed	O
samples	O
from	O
the	O
putatively	O
ancestral	O
range	O
of	O
D.	O
simulans	O
,	O
as	O
well	O
as	O
an	O
existing	O
polymorphism	O
data	O
set	O
from	O
an	O
African	O
population	O
of	O
D.	O
melanogaster	O
.	O

By	O
using	O
D.	O
yakuba	O
as	O
an	O
outgroup	O
,	O
we	O
found	O
clear	O
evidence	O
for	O
selection	O
on	O
4-fold	O
sites	O
along	O
both	O
lineages	O
over	O
a	O
substantial	O
period	O
,	O
with	O
the	O
intensity	O
of	O
selection	O
increasing	O
with	O
GC	O
content	O
.	O

Based	O
on	O
an	O
explicit	O
model	O
of	O
base	O
composition	O
evolution	O
,	O
we	O
suggest	O
that	O
the	O
observed	O
AT-	O
biased	O
substitution	O
pattern	O
in	O
both	O
lineages	O
is	O
probably	O
due	O
to	O
an	O
ancestral	O
reduction	O
in	O
selection	O
intensity	O
,	O
and	O
is	O
unlikely	O
to	O
be	O
the	O
result	O
of	O
an	O
increase	O
in	O
mutational	O
bias	O
towards	O
AT	O
alone	O
.	O

By	O
using	O
two	O
polymorphism-based	B-P
methods	I-P
for	O
estimating	O
selection	O
coefficients	O
over	O
different	O
timescales	O
,	O
we	O
show	O
that	O
the	O
selection	O
intensity	O
on	O
codon	O
usage	O
has	O
been	O
rather	O
stable	O
in	O
D.	O
simulans	O
in	O
the	O
recent	O
past	O
,	O
but	O
the	O
long-term	O
estimates	O
in	O
D.	O
melanogaster	O
are	O
much	O
higher	O
than	O
the	O
short-term	O
ones	O
,	O
indicating	O
a	O
continuing	O
decline	O
in	O
selection	O
intensity	O
,	O
to	O
such	O
an	O
extent	O
that	O
the	O
short-term	O
estimates	O
suggest	O
that	O
selection	O
is	O
only	O
active	O
in	O
the	O
most	O
GC	O
-rich	O
parts	O
of	O
the	O
genome	O
.	O

Finally	O
,	O
we	O
provide	O
evidence	O
for	O
complex	O
evolutionary	O
patterns	O
in	O
the	O
putatively	O
neutral	O
short	O
introns	O
,	O
which	O
can	O
not	O
be	O
explained	O
by	O
the	O
standard	O
GC	O
-	O
biased	O
gene	O
conversion	O
model	O
.	O

These	O
results	O
reveal	O
a	O
dynamic	O
picture	O
of	O
base	O
composition	O
evolution	O
.	O

Association	O
of	O
leukemia	O
inhibitory	O
factor	O
gene	O
polymorphism	O
and	O
in	O
vitro	O
fertilization	O
outcome	O
in	O
a	O
population	O
in	O
northern	O
Iran	O
.	O

Several	O
studies	O
have	O
been	O
demonstrated	O
that	O
endometrial	O
leukemia	O
inhibitory	O
factor	O
(	O
LIF	O
)	O
is	O
important	O
in	O
embryo	O
implantation	O
.	O

LIF	O
is	O
a	O
secreted	O
glycoprotein	O
with	O
a	O
variety	O
of	O
biological	O
functions	O
including	O
stimulation	O
of	O
cell	O
proliferation	O
,	O
differentiation	O
and	O
survival	O
that	O
are	O
all	O
essential	O
for	O
blastocyete	O
development	O
and	O
implantation	O
.	O

The	O
LIF	O
receptor	O
activates	O
several	O
signaling	O
pathways	O
in	O
diverse	O
cell	O
types	O
,	O
including	O
Jak/STAT	O
,	O
MAPK	O
and	O
PI3-kinase	O
pathways	O
in	O
the	O
endometrium	O
of	O
fertile	O
woman	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
initial	O
lower	O
expression	O
of	O
LIF	O
in	O
proliferative	O
phase	O
may	O
be	O
one	O
of	O
the	O
causes	O
for	O
multiple	O
failure	O
of	O
implantation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
association	O
between	O
maternal	O
genotype	O
of	O
SNP	O
3951C/T	O
LIF	O
and	O
in	O
vitro	O
fertilization	O
and	O
embryo	O
transfer	O
(	O
IVF	O
-	O
ET	O
)	O
outcome	O
in	O
infertile	O
women	O
.	O

This	O
case-control	O
study	O
was	O
comprised	O
of	O
infertile	O
patients	O
(	O
n=70	O
)	O
and	O
women	O
having	O
one	O
healthy	O
child	O
as	O
controls	O
(	O
n=73	O
)	O
.	O

Genotyping	B-P
for	O
SNP-3951C/T	O
was	O
performed	O
by	O
PCR/RFLP	B-P
.	O

Allele	O
and	O
genotype	O
distribution	O
did	O
not	O
differ	O
significantly	O
between	O
patients	O
and	O
controls	O
(	O
P	O
>	O
0.05	O
)	O
.	O

The	O
LIF	O
genotype	O
frequencies	O
amongst	O
the	O
70	O
cases	O
were	O
C/C	O
=40	O
%	O
,	O
C/T	O
=52.8	O
%	O
and	O
T/T	O
=7.2	O
%	O
;	O
the	O
C	O
and	O
T	O
allele	O
frequencies	O
were	O
66	O
%	O
and	O
34	O
%	O
,	O
respectively	O
.	O

The	O
LIF	O
genotype	O
frequencies	O
amongst	O
the	O
73	O
controls	O
were	O
C/C	O
=45.20	O
%	O
,	O
C/T	O
=50.70	O
%	O
and	O
T/T	O
=4.1	O
%	O
;	O
the	O
C	O
and	O
T	O
allele	O
frequencies	O
were	O
70	O
%	O
and	O
30	O
%	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
this	O
study	O
indicate	O
that	O
SNP	O
3951C/T	O
of	O
LIF	O
may	O
not	O
be	O
associated	O
with	O
IVF	O
-	O
ET	O
outcome	O
in	O
this	O
population	O
.	O

Although	O
more	O
studies	O
should	O
be	O
considered	O
with	O
larger	O
number	O
of	O
patients	O
and	O
control	O
subjects	O
to	O
confirm	O
our	O
results	O
.	O

Regulation	O
of	O
bone	O
homeostasis	O
by	O
glucose	O
.	O

Synthesis	O
of	O
type	O
Ⅰ	O
collagen	O
,	O
a	O
m	O
ajor	O
c	O
omponent	O
of	O
the	O
b	O
one	O
matrix	O
,	O
p	O
recedes	O
t	O
he	O
expression	O
of	O
R	O
unt-related	O
transcription	O
factor	O
2	O
(	O
R	O
unx2	O
)	O
,	O
a	O
master	O
regulator	O
in	O
osteoblast	O
differentiation	O
.	O

Thus	O
,	O
a	O
direct	O
link	O
between	O
osteoblast	O
differentiation	O
and	O
bone	O
formation	O
is	O
seemingly	O
absent	O
,	O
and	O
how	O
these	O
are	O
maintained	O
in	O
a	O
coordinated	O
matter	O
remains	O
unclear	O
.	O

It	O
was	O
recently	O
demonstrated	O
that	O
osteoblasts	O
depend	O
on	O
glucose	O
,	O
which	O
glucose	O
transporter	O
type	O
1	O
(	O
GLUT1	O
)	O
takes	O
up	O
as	O
an	O
energy	O
source	O
,	O
and	O
it	O
was	O
found	O
that	O
glucose	O
uptake	O
promotes	O
osteoblast	O
differentiation	O
and	O
bone	O
formation	O
via	O
AMP-activated	O
protein	O
kinase	O
.	O

It	O
was	O
also	O
shown	O
that	O
Runx2	O
upregulates	O
GLUT1	O
expression	O
,	O
and	O
this	O
Runx2	O
-	O
GLUT1	O
feedforward	O
regulation	O
integrates	O
and	O
coordinates	O
osteoblast	O
differentiation	O
and	O
bone	O
formation	O
throughout	O
life	O
.	O

These	O
previous	O
findings	O
revealed	O
that	O
the	O
energy	O
metabolism	O
balance	O
in	O
osteoblasts	O
integrates	O
the	O
differentiation	O
and	O
function	O
of	O
osteoblasts	O
,	O
and	O
re-emphasized	O
the	O
importance	O
of	O
crosstalk	O
between	O
bone	O
and	O
sugar	B-P
metabolism	I-P
.	O

Selection	O
of	O
a	O
marker	O
gene	O
to	O
construct	O
a	O
reference	O
library	O
for	O
wetland	O
plants	O
,	O
and	O
the	O
application	O
of	O
metabarcoding	O
to	O
analyze	O
the	O
diet	O
of	O
wintering	O
herbivorous	O
waterbirds	O
.	O

Food	O
availability	O
and	O
diet	O
selection	O
are	O
important	O
factors	O
influencing	O
the	O
abundance	O
and	O
distribution	O
of	O
wild	O
waterbirds	O
.	O

In	O
order	O
to	O
better	O
understand	O
changes	O
in	O
waterbird	O
population	O
,	O
it	O
is	O
essential	O
to	O
figure	O
out	O
what	O
they	O
feed	O
on	O
.	O

However	O
,	O
analyzing	O
their	O
diet	O
could	O
be	O
difficult	O
and	O
inefficient	O
using	O
traditional	O
methods	O
such	O
as	O
microhistologic	B-P
observation	I-P
.	O

Here	O
,	O
we	O
addressed	O
this	O
gap	O
of	O
knowledge	O
by	O
investigating	O
the	O
diet	O
of	O
greater	O
white-fronted	O
goose	O
Anser	O
albifrons	O
and	O
bean	O
goose	O
Anser	O
fabalis	O
,	O
which	O
are	O
obligate	O
herbivores	O
wintering	O
in	O
China	O
,	O
mostly	O
in	O
the	O
Middle	O
and	O
Lower	O
Yangtze	O
River	O
floodplain	O
.	O

First	O
,	O
we	O
selected	O
a	O
suitable	O
and	O
high-resolution	O
marker	O
gene	O
for	O
wetland	O
plants	O
that	O
these	O
geese	O
would	O
consume	O
during	O
the	O
wintering	O
period	O
.	O

Eight	O
candidate	O
genes	O
were	O
included	O
:	O
rbcL	O
,	O
rpoC1	O
,	O
rpoB	O
,	O
matK	O
,	O
trnH-psbA	O
,	O
trnL	O
(	O
UAA	O
)	O
,	O
atpF-atpH	O
,	O
and	O
psbK-psbI	O
.	O

The	O
selection	O
was	O
performed	O
via	O
analysis	O
of	O
representative	O
sequences	O
from	O
NCBI	O
and	O
comparison	O
of	O
amplification	O
efficiency	O
and	O
resolution	O
power	O
of	O
plant	O
samples	O
collected	O
from	O
the	O
wintering	O
area	O
.	O

The	O
trnL	O
gene	O
was	O
chosen	O
at	O
last	O
with	O
c/h	O
primers	O
,	O
and	O
a	O
local	O
plant	O
reference	O
library	O
was	O
constructed	O
with	O
this	O
gene	O
.	O

Then	O
,	O
utilizing	O
DNA	O
metabarcoding	O
,	O
we	O
discovered	O
15	O
food	O
items	O
in	O
total	O
from	O
the	O
feces	O
of	O
these	O
birds	O
.	O

Of	O
the	O
15	O
unique	O
dietary	O
sequences	O
,	O
10	O
could	O
be	O
identified	O
at	O
specie	O
level	O
.	O

As	O
for	O
greater	O
white-fronted	O
goose	O
,	O
73	O
%	O
of	O
sequences	O
belonged	O
to	O
Poaceae	O
spp.	O
,	O
and	O
26	O
%	O
belonged	O
to	O
Carex	O
spp	O
.	O

In	O
contrast	O
,	O
almost	O
all	O
sequences	O
of	O
bean	O
goose	O
belonged	O
to	O
Carex	O
spp	O
.	O

(	O
99	O
%	O
)	O
.	O

Using	O
the	O
same	O
samples	O
,	O
microhistology	B-P
provided	O
consistent	O
food	O
composition	O
with	O
metabarcoding	O
results	O
for	O
greater	O
white-fronted	O
goose	O
,	O
while	O
13	O
%	O
of	O
Poaceae	O
was	O
recovered	O
for	O
bean	O
goose	O
.	O

In	O
addition	O
,	O
two	O
other	O
taxa	O
were	O
discovered	O
only	O
through	O
microhistologic	B-P
analysis	I-P
.	O

Although	O
most	O
of	O
the	O
identified	O
taxa	O
matched	O
relatively	O
well	O
between	O
the	O
two	O
methods	O
,	O
DNA	O
metabarcoding	O
gave	O
taxonomically	O
more	O
detailed	O
information	O
.	O

Discrepancies	O
were	O
likely	O
due	O
to	O
biased	O
PCR	O
amplification	O
in	O
metabarcoding	O
,	O
low	O
discriminating	O
power	O
of	O
current	O
marker	O
genes	O
for	O
monocots	O
,	O
and	O
biases	O
in	O
microhistologic	B-P
analysis	I-P
.	O

The	O
diet	O
differences	O
between	O
two	O
geese	O
species	O
might	O
indicate	O
deeper	O
ecological	O
significance	O
beyond	O
the	O
scope	O
of	O
this	O
study	O
.	O

We	O
concluded	O
that	O
DNA	O
metabarcoding	O
provides	O
new	O
perspectives	O
for	O
studies	O
of	O
herbivorous	O
waterbird	O
diets	O
and	O
inter-specific	O
interactions	O
,	O
as	O
well	O
as	O
new	O
possibilities	O
to	O
investigate	O
interactions	O
between	O
herbivores	O
and	O
plants	O
.	O

In	O
addition	O
,	O
microhistologic	B-P
analysis	I-P
should	O
be	O
used	O
together	O
with	O
metabarcoding	O
methods	O
to	O
integrate	O
this	O
information	O
.	O

Design	O
considerations	O
for	O
patient-specific	O
surgical	O
templates	O
for	O
total	O
hip	O
arthroplasty	O
with	O
respect	O
to	O
acetabular	O
cartilage	O
.	O

Patient-specific	O
instruments	O
(	O
PSIs	O
)	O
are	O
clinically	O
used	O
to	O
support	O
the	O
surgeon	O
during	O
a	O
planned	O
intervention	O
.	O

The	O
planning	O
is	O
typically	O
done	O
based	O
on	O
volumetric	O
image	O
data	O
from	O
medical	B-P
imaging	I-P
systems	O
,	O
e.g	O
.	O

computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
.	O

The	O
PSI	O
uses	O
the	O
known	O
surface	O
structure	O
of	O
a	O
bone	O
for	O
orientation	O
during	O
the	O
intervention	O
.	O

Some	O
surfaces	O
of	O
human	O
bone	O
are	O
covered	O
with	O
a	O
layer	O
of	O
cartilage	O
which	O
is	O
hardly	O
visible	O
in	O
clinically	O
applied	O
CT-imaging	B-P
.	O

This	O
experimental	O
study	O
investigates	O
ten	O
different	O
PSI	O
designs	O
and	O
their	O
effect	O
to	O
the	O
overall	O
accuracy	O
when	O
neglecting	O
the	O
cartilage	O
in	O
the	O
design	O
process	O
.	O

Therefore	O
,	O
a	O
model	O
of	O
an	O
acetabulum	O
is	O
used	O
to	O
simulate	O
the	O
use	O
case	O
of	O
PSI	O
in	O
total	O
hip	O
arthroplasty	O
.	O

The	O
concept	O
of	O
the	O
different	O
designs	O
is	O
to	O
create	O
structural	O
elasticities	O
in	O
the	O
PSI	O
to	O
avoid	O
shifting	O
of	O
the	O
whole	O
instrument	O
and	O
rather	O
have	O
a	O
small	O
part	O
of	O
it	O
deformed	O
by	O
cartilage	O
.	O

A	O
needle	O
array	O
structure	O
,	O
for	O
instance	O
,	O
should	O
also	O
be	O
able	O
to	O
oust	O
or	O
penetrate	O
remaining	O
soft	O
tissue	O
in	O
the	O
acetabulum	O
.	O

Physiological	O
and	O
molecular	O
responses	O
of	O
juvenile	O
shortnose	O
sturgeon	O
(	O
Acipenser	O
brevirostrum	O
)	O
to	O
thermal	O
stress	O
.	O

The	O
shortnose	O
sturgeon	O
(	O
Acipenser	O
brevirostrum	O
LeSueur	O
,	O
1818	O
)	O
is	O
a	O
vulnerable	O
species	O
that	O
is	O
found	O
along	O
the	O
eastern	O
coast	O
of	O
North	O
America	O
.	O

Little	O
is	O
known	O
about	O
temperature	O
tolerance	O
in	O
this	O
species	O
and	O
with	O
a	O
rapidly	O
changing	O
global	O
climate	O
,	O
it	O
becomes	O
increasingly	O
important	O
to	O
define	O
the	O
thermal	O
tolerance	O
of	O
this	O
species	O
to	O
better	O
predict	O
population	O
distribution	O
.	O

Using	O
a	O
modified	B-P
critical	I-P
thermal	I-P
maximum	I-P
test	I-P
(	O
CTMax	B-P
)	O
,	O
the	O
objectives	O
of	O
this	O
study	O
were	O
to	O
determine	O
the	O
impact	O
of	O
heating	O
rate	O
(	O
0.1	O
,	O
0.2	O
and	O
0.25°Cmin	O
(	O
-1	O
)	O
)	O
on	O
the	O
thermal	O
tolerance	O
,	O
associated	O
hematological	O
responses	O
,	O
and	O
oxygen	O
consumption	O
in	O
juvenile	O
sturgeon	O
.	O

In	O
addition	O
,	O
transcripts	O
associated	O
with	O
physiological	O
stress	O
and	O
heat	O
shock	O
(	O
i.e.	O
,	O
heat	O
shock	O
proteins	O
)	O
were	O
also	O
measured	O
.	O

Heating	O
rate	O
did	O
not	O
alter	O
the	O
CTMax	O
values	O
of	O
shortnose	O
sturgeon	O
.	O

Neither	O
heating	O
rate	O
nor	O
thermal	O
stress	O
affected	O
plasma	B-P
sodium	I-P
and	O
chloride	B-P
levels	I-P
,	O
nor	O
the	O
expression	O
of	O
transcripts	O
that	O
included	O
catalase	O
,	O
glucocorticoid	O
receptor	O
,	O
heat	O
shock	O
protein70	O
(	O
hsp70	O
)	O
,	O
heat	O
shock	O
protein	O
90α	O
(	O
hsp90α	O
)	O
and	O
cytochrome	O
P450	O
1a	O
(	O
cyp1a	O
)	O
.	O

However	O
,	O
regardless	O
of	O
heating	O
rate	O
,	O
thermal	O
stress	O
increased	O
both	O
plasma	O
potassium	O
and	O
lactate	O
concentrations	O
.	O

Glucose	O
levels	O
were	O
increased	O
at	O
heating	O
rates	O
of	O
0.2	O
and	O
0.25°Cmin	O
(	O
-1	O
)	O
,	O
but	O
not	O
at	O
0.1°Cmin	O
(	O
-1	O
)	O
.	O

Overall	O
,	O
oxygen	O
consumption	O
rates	O
increased	O
with	O
thermal	O
stress	O
,	O
but	O
the	O
response	O
patterns	O
were	O
not	O
affected	O
by	O
heating	O
rate	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
shortnose	O
sturgeon	O
can	O
tolerate	O
acute	O
heat	O
stress	O
,	O
as	O
many	O
physiological	O
and	O
molecular	O
parameters	O
measured	O
here	O
were	O
non-responsive	O
to	O
the	O
thermal	O
stress	O
.	O

Galectin-3	O
is	O
a	O
target	O
for	O
proteases	O
involved	O
in	O
the	O
virulence	O
of	O
Staphylococcus	O
aureus	O
.	O

Staphylococcus	O
aureus	O
is	O
a	O
major	O
cause	O
of	O
skin	O
and	O
soft-tissue	O
infection	O
.	O

The	O
bacterium	O
expresses	O
four	O
major	O
proteases	O
emerging	O
as	O
virulence	O
factors	O
;	O
aureolysin	O
(	O
Aur	O
)	O
,	O
V8	O
protease	O
(	O
SspA	O
)	O
,	O
staphopain	O
A	O
(	O
ScpA	O
)	O
,	O
and	O
staphopain	O
B	O
(	O
SspB	O
)	O
.	O

We	O
hypothesized	O
that	O
human	O
galectin-3	O
,	O
a	O
β-galactoside-binding	O
lectin	O
involved	O
in	O
immune	O
regulation	O
and	O
antimicrobial	O
defense	O
,	O
is	O
a	O
target	O
for	O
these	O
proteases	O
,	O
and	O
that	O
proteolysis	O
of	O
galectin-3	O
is	O
a	O
novel	O
immune	O
evasion	O
mechanism	O
.	O

Indeed	O
,	O
supernatants	O
from	O
laboratory	B-P
strains	I-P
and	O
clinical	O
isolates	O
of	O
S.	O
aureus	O
caused	O
galectin-3	O
degradation	O
.	O

Similar	O
proteolytic	O
capacity	O
was	O
found	O
in	O
Staphylococcus	O
epidermidis	O
isolates	O
,	O
but	O
not	O
Staphylococcus	O
saprophyticus	O
Galectin-3	O
-induced	O
activation	O
of	O
the	O
neutrophil	O
NADPH-oxidase	O
was	O
abrogated	O
by	O
bacteria	O
-derived	O
proteolysis	O
of	O
galectin-3	O
,	O
and	O
SspB	O
was	O
identified	O
as	O
the	O
major	O
protease	O
responsible	O
.	O

The	O
impact	O
of	O
galectin-3	O
and	O
protease	O
expression	O
on	O
S.	O
aureus	O
virulence	O
was	O
studied	O
in	O
a	O
murine	O
skin	O
infection	O
model	O
.	O

In	O
galectin-3	O
(	O
+/+	O
)	O
mice	O
,	O
SspB	O
-	O
expressing	O
S.	O
aureus	O
caused	O
larger	O
lesions	O
and	O
higher	O
bacterial	O
load	O
than	O
protease-lacking	O
bacteria	O
.	O

No	O
such	O
difference	O
was	O
detected	O
in	O
galectin-3	O
(	O
-/-	O
)	O
mice	O
,	O
which	O
also	O
showed	O
smaller	O
lesion	O
size	O
as	O
compared	O
to	O
the	O
galectin-3	O
(	O
+/+	O
)	O
animals	O
.	O

In	O
conclusion	O
,	O
the	O
staphylococcal	O
protease	O
SspB	O
inactivates	O
galectin-3	O
,	O
abrogating	O
its	O
stimulation	O
of	O
oxygen	O
radical	O
production	O
in	O
human	O
neutrophils	O
and	O
increasing	O
tissue	O
damage	O
during	O
skin	O
infection	O
.	O

Liver	O
Retransplantation	O
for	O
Hepatic	O
Abscess	O
Due	O
to	O
Hepatic	O
Artery	O
Thrombosis	O
:	O
A	O
Case	O
Report	O
.	O

Hepatic	O
artery	O
thrombosis	O
(	O
HAT	O
)	O
is	O
a	O
well-recognized	O
complication	O
of	O
liver	O
transplantation	O
(	O
LT	O
)	O
.	O

HAT	O
is	O
an	O
important	O
risk	O
factor	O
for	O
infectious	O
,	O
in	O
particular	O
hepatic	O
abscess	O
,	O
which	O
can	O
cause	O
graft	O
loss	O
and	O
increasing	O
morbidity	O
and	O
mortality	O
.	O

We	O
present	O
a	O
case	O
report	O
of	O
complicated	O
LT	O
in	O
a	O
52-	O
year-old	O
Caucasian	O
man	O
with	O
primary	O
sclerosing	O
cholangitis	O
.	O

In	O
2007	O
the	O
patient	O
was	O
included	O
on	O
the	O
waiting	O
list	O
in	O
Padua	O
for	O
LT	O
.	O

In	O
2012	O
the	O
patient	O
underwent	O
percutaneous	O
transhepatic	O
biliary	O
drainage	O
for	O
bile	O
duct	O
stricture	O
,	O
complicated	O
with	O
acute	O
pancreatitis	O
.	O

A	O
diagnostic	B-P
laparoscopy	I-P
was	O
performed	O
with	O
choledochotomy	O
and	O
Kehr	O
's	O
T	O
tube	O
drainage	O
.	O

On	O
February	O
14	O
,	O
2012	O
,	O
the	O
patient	O
underwent	O
LT	O
with	O
arterial	O
reconstruction	O
and	O
choledochojejunostomy	O
.	O

The	O
postoperative	O
course	O
was	O
complicated	O
with	O
HAT	O
,	O
multiple	O
liver	O
abscesses	O
,	O
and	O
sepsis	O
associated	O
with	O
bacteremia	O
due	O
to	O
Enterococcus	O
faecium	O
despite	O
massive	O
intravenous	O
antibiotic	O
therapy	O
and	O
percutaneous	O
drainages	O
.	O

On	O
November	O
28	O
,	O
2012	O
,	O
the	O
patient	O
underwent	O
retransplantation	O
.	O

Four	O
years	O
after	O
transplantation	O
the	O
patient	O
is	O
still	O
in	O
good	O
general	O
condition	O
.	O

Hepatic	O
abscess	O
formation	O
secondary	O
to	O
HAT	O
following	O
LT	O
is	O
a	O
major	O
complication	O
associated	O
with	O
important	O
morbidity	O
and	O
mortality	O
.	O

In	O
selected	O
cases	O
retransplantation	O
should	O
be	O
considered	O
as	O
our	O
case	O
demonstrates	O
.	O

Prevalence	O
of	O
Coronary	O
Artery	O
to	O
Pulmonary	O
Artery	O
Collaterals	O
in	O
Patients	O
with	O
Chronic	O
Thromboembolic	O
Pulmonary	O
Hypertension	O
:	O
Retrospective	O
Analysis	O
from	O
a	O
Single	O
Center	O
.	O

Background	O
Our	O
aim	O
was	O
to	O
determine	O
the	O
prevalence	O
of	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
in	O
patients	O
with	O
chronic	O
thromboembolic	O
pulmonary	O
hypertension	O
(	O
CTEPH	O
)	O
by	O
retrospectively	O
evaluating	O
coronary	B-P
angiograms	I-P
of	O
eligible	O
consecutive	O
patients	O
who	O
had	O
undergone	O
pulmonary	O
endarterectomy	O
(	O
PEA	O
)	O
.	O

We	O
also	O
aimed	O
to	O
evaluate	O
predictors	O
and	O
potential	O
clinical	O
associates	O
of	O
these	O
collaterals	O
.	O

Methods	O
Coronary	B-P
angiograms	I-P
of	O
83	O
consecutive	O
CTEPH	O
patients	O
who	O
had	O
undergone	O
coronary	B-P
angiography	I-P
before	O
PEA	O
operation	O
between	O
January	O
1	O
,	O
2012	O
and	O
June	O
1	O
,	O
2015	O
were	O
retrospectively	O
evaluated	O
for	O
presence	O
of	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
.	O

Medical	O
records	O
of	O
all	O
patients	O
were	O
also	O
retrospectively	O
reviewed	O
for	O
demographic	O
information	O
,	O
cardiovascular	O
risk	O
factors	O
,	O
preoperative	O
right	O
heart	O
catheterization	O
reports	O
,	O
operation	O
reports	O
,	O
and	O
follow-up	O
data	O
.	O

Data	O
of	O
CTEPH	O
patients	O
with	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
were	O
compared	O
with	O
data	O
of	O
CTEPH	O
patients	O
without	O
such	O
collaterals	O
.	O

Results	O
There	O
were	O
15	O
patients	O
(	O
18.1	O
%	O
)	O
with	O
definite	O
and	O
4	O
patients	O
(	O
4.8	O
%	O
)	O
with	O
probable	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
among	O
the	O
study	O
population	O
.	O

CTEPH	O
patients	O
with	O
collaterals	O
had	O
higher	O
preoperative	O
pulmonary	O
artery	O
pressures	O
,	O
higher	O
pulmonary	O
vascular	O
resistance	O
(	O
PVR	O
)	O
and	O
lower	O
cardiac	O
index	O
values	O
compared	O
with	O
CTEPH	O
patients	O
without	O
collaterals	O
.	O

However	O
,	O
CTEPH	O
patients	O
with	O
collaterals	O
displayed	O
higher	O
amount	O
of	O
reduction	O
in	O
PVR	O
after	O
PEA	O
compared	O
with	O
patients	O
without	O
collaterals	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
regarding	O
incidence	O
of	O
reperfusion	O
injury	O
or	O
mortality	O
.	O

Conclusion	O
Prevalence	O
of	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
seems	O
to	O
be	O
increased	O
in	O
our	O
CTEPH	O
patients	O
compared	O
with	O
the	O
general	O
population	O
.	O

The	O
presence	O
of	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
is	O
often	O
combined	O
with	O
proximal	O
disease	O
with	O
the	O
possibility	O
of	O
increased	O
reduction	O
of	O
PVR	O
after	O
PEA	O
operation	O
.	O

Correlation	O
between	O
Decreased	O
Parasympathetic	O
Activity	O
and	O
Reduced	O
Cerebrovascular	O
Reactivity	O
in	O
Patients	O
with	O
Lacunar	O
Infarct	O
.	O

Reduced	O
cerebrovascular	O
reactivity	O
(	O
CVR	O
)	O
was	O
found	O
in	O
patients	O
with	O
recent	O
lacunar	O
infarct	O
.	O

However	O
,	O
its	O
mechanisms	O
were	O
controversial	O
.	O

The	O
breath	O
holding	O
maneuver	O
as	O
a	O
vasodilatory	O
stimulus	O
is	O
clinically	O
useful	O
for	O
an	O
estimation	O
of	O
cerebrovasomotor	O
reactivity	O
in	O
well	O
co-operative	O
patients	O
.	O

Patients	O
with	O
lacunar	O
infarct	O
have	O
no	O
higher	O
cortical	O
dysfunction	O
and	O
remain	O
well	O
co-operation	O
.	O

The	O
breath	O
holding	O
maneuver	O
is	O
feasible	O
and	O
safe	O
to	O
perform	O
in	O
patients	O
with	O
lacunar	O
infarct	O
.	O

Autonomic	O
nervous	O
system	O
regulates	O
systemic	O
vascular	O
activity	O
.	O

Regulation	O
of	O
autonomic	O
function	O
to	O
cerebrovascular	O
reactivity	O
has	O
been	O
reported	O
in	O
the	O
literature	O
.	O

We	O
examined	O
the	O
correlation	O
between	O
autonomic	O
functions	O
with	O
frequency	O
and	O
nonlinear	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
and	O
cerebrovascular	O
reactivity	O
in	O
patients	O
with	O
lacunar	O
infarct	O
by	O
application	O
of	O
breath	O
holding	O
maneuver	O
.	O

Fifteen	O
patients	O
with	O
lacunar	O
infarct	O
(	O
8	O
women	O
,	O
age	O
65.6	O
±	O
13.61	O
)	O
and	O
16	O
healthy	O
controls	O
(	O
11	O
women	O
,	O
age	O
27.33	O
±	O
3.85	O
)	O
were	O
continuously	O
monitored	B-P
at	O
baseline	O
before	O
maneuver	O
(	O
basal	O
phase	O
)	O
,	O
during	O
CVR	O
induction	O
(	O
experimental	O
phase	O
)	O
with	O
breath	O
holding	O
maneuver	O
and	O
after	O
maneuver	O
(	O
recovery	O
phase	O
)	O
,	O
for	O
arterial	O
blood	O
pressure	O
(	O
ABP	O
)	O
,	O
electrocardiography	B-P
(	O
EKG	B-P
)	O
,	O
mean	O
cerebral	O
blood	O
flow	O
velocity	O
(	O
mCBFV	O
)	O
of	O
middle	O
cerebral	O
arteries	O
(	O
MCA	O
)	O
by	O
transcranial	B-P
doppler	I-P
(	O
TCD	B-P
)	O
.	O

The	O
short	O
term-one	O
minute	O
HRV	O
was	O
analyzed	O
from	O
EKG	B-P
signals	O
for	O
low	O
frequency	O
(	O
LF	O
)	O
/	O
high	O
frequency	O
(	O
HF	O
)	O
ratio	O
,	O
nonlinear	O
of	O
standard	O
deviation	O
1	O
(	O
SD1	O
)	O
,	O
standard	O
deviation	O
2	O
(	O
SD2	O
)	O
,	O
cardiac	O
Sample	O
Entropy	O
(	O
SampEn	O
)	O
and	O
Shannon	O
Entropy	O
.	O

Significant	O
increasing	O
in	O
mCBFV	O
,	O
LF	O
/	O
HF	O
ratio	O
,	O
SD2	O
/	O
SD1	O
,	O
Shannon	O
Entropy	O
and	O
inversely	O
decreasing	O
SampEn	O
during	O
breath	O
holding	O
maneuver	O
compared	O
with	O
baseline	O
were	O
found	O
in	O
both	O
groups	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
trend	O
of	O
cerebrovascular	O
reactivity	O
is	O
similar	O
in	O
both	O
groups	O
.	O

However	O
,	O
there	O
were	O
differences	O
of	O
mCBFV	O
,	O
systolic	O
blood	O
pressure	O
(	O
SysBP	O
)	O
in	O
the	O
whole	O
phases	O
(	O
basal	O
,	O
experiment	O
and	O
recovery	O
)	O
between	O
patients	O
and	O
controls	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Less	O
scattered	O
signals	O
of	O
SD1	O
with	O
low	O
value	O
in	O
patient	O
group	O
were	O
illustrated	O
from	O
Poincaré	O
(	O
p	O
<	O
0.05	O
)	O
.	O

This	O
indicated	O
less	O
degree	O
of	O
parasympathetic	O
drive	O
in	O
the	O
patients	O
compared	O
to	O
the	O
controls	O
.	O

Moreover	O
,	O
significant	O
positive	O
correlation	O
between	O
systolic	O
bloods	O
pressure	O
and	O
mCBFV	O
in	O
patients	O
suggests	O
impact	O
of	O
autonomic	O
control	O
and	O
cerebral	O
blood	O
flow	O
on	O
the	O
patho-physiological	O
mechanism	O
of	O
vasodilatation	O
,	O
triggered	O
by	O
hypercapnia	O
from	O
breath	O
holding	O
maneuver	O
in	O
patients	O
with	O
lacunar	O
infarct	O
.	O

Reduction	O
of	O
cerebrovascular	O
reactivity	O
in	O
patients	O
with	O
lacunar	O
infarct	O
may	O
relate	O
with	O
decreased	O
parasympathetic	O
activity	O
.	O

Further	O
study	O
is	O
required	O
to	O
demonstrate	O
whether	O
these	O
findings	O
mean	O
mechanisms	O
of	O
lacunar	O
infarct	O
or	O
the	O
effect	O
of	O
hypertensive	O
response	O
.	O

Molecular	B-P
diagnosis	I-P
of	O
infectious	O
diseases	O
in	O
São	O
Miguel	O
Island	O
(	O
Azores	O
,	O
Portugal	O
)	O
:	O
A	O
hospital	O
-based	O
descriptive	O
study	O
.	O

We	O
performed	O
a	O
descriptive	O
analysis	O
of	O
molecular	B-P
diagnosis	I-P
of	O
infectious	O
agents	O
in	O
the	O
São	O
Miguel	O
Island	O
population	O
,	O
in	O
order	O
to	O
address	O
questions	O
like	O
what	O
is	O
the	O
frequency	O
of	O
clinical	O
requests	O
,	O
is	O
it	O
observable	O
seasonality	O
of	O
pathogens	O
,	O
and	O
what	O
is	O
the	O
positive	O
rate	O
for	O
the	O
clinical	B-P
diagnosis	I-P
.	O

This	O
was	O
a	O
retrospective	O
and	O
descriptive	O
study	O
based	O
on	O
878	O
individuals	O
suspected	O
of	O
harboring	O
infectious	O
diseases	O
during	O
two	O
consecutive	O
years	O
,	O
2012-2013	O
.	O

More	O
than	O
25	O
different	O
pathogens	O
were	O
investigated	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-based	O
methods	O
.	O

The	O
individuals	O
were	O
stratified	O
into	O
gender	O
,	O
occupation	O
,	O
and	O
age	O
groups	O
.	O

The	O
pathogen	O
with	O
more	O
clinical	O
requests	O
was	O
hepatitis	O
C	O
virus	O
,	O
investigated	O
in	O
225	O
individuals	O
(	O
30.0	O
%	O
)	O
,	O
followed	O
by	O
Leptospira	O
spp	O
.	O
,	O
in	O
187	O
(	O
24.9	O
%	O
)	O
.	O

Overall	O
,	O
data	O
demonstrated	O
a	O
gender	O
distribution	O
bias	O
,	O
where	O
72.9	O
%	O
of	O
cases	O
were	O
males	O
.	O

The	O
age	O
group	O
of	O
25	O
to	O
44	O
years	O
was	O
the	O
class	O
with	O
more	O
clinical	O
requests	O
.	O

Regarding	O
occupation	O
,	O
a	O
predominance	O
of	O
construction	O
workers	O
(	O
12.0	O
%	O
)	O
was	O
observed	O
,	O
followed	O
by	O
retired	O
workers	O
(	O
11.0	O
%	O
)	O
.	O

Patient	O
distribution	O
per	O
year	O
showed	O
a	O
higher	O
number	O
of	O
patients	O
in	O
the	O
fall	O
months	O
.	O

Diagnoses	O
of	O
leptospirosis	O
and	O
respiratory	O
virus	O
infections	O
presented	O
seasonality	O
.	O

The	O
present	O
study	O
provides	O
a	O
valid	O
contribution	O
to	O
the	O
knowledge	O
of	O
the	O
epidemiology	O
of	O
infectious	O
diseases	O
in	O
the	O
São	O
Miguel	O
Island	O
(	O
Azores	O
,	O
Portugal	O
)	O
population	O
.	O

Morphology	O
of	O
root	O
canal	O
surface	O
:	O
A	O
reflection	O
on	O
the	O
process	O
of	O
cementation	O
of	O
the	O
composite	O
relined	O
glass	O
fiber	O
post	O
.	O

The	O
present	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
bond	O
strength	O
in	O
the	O
different	O
root	O
thirds	O
(	O
premolars	O
and	O
maxillary	O
central	O
incisors	O
)	O
of	O
composite	O
relined	O
glass	O
fiber	O
posts	O
compared	O
to	O
untreated	O
glass	O
fiber	O
posts	O
cemented	O
with	O
dual-	O
or	O
chemical-cure	O
cements	O
.	O

Sixty	O
human	O
single-rooted	O
premolars	O
(	O
flat	O
canal	O
)	O
(	O
n	O
=	O
15	O
)	O
and	O
12	O
maxillary	O
central	O
incisors	O
were	O
used	O
(	O
round	O
canal	O
)	O
(	O
n	O
=	O
3	O
)	O
.	O

The	O
teeth	O
were	O
sectioned	O
,	O
and	O
the	O
roots	O
received	O
endodontic	O
treatment	O
.	O

The	O
standardized	O
preparation	O
of	O
the	O
canals	O
was	O
carried	O
out	O
,	O
and	O
the	O
roots	O
were	O
randomly	O
divided	O
into	O
four	O
groups	O
according	O
to	O
the	O
cementation	O
systems	O
:	O
G1	O
:	O
cemented	O
posts	O
(	O
dual	O
:	O
Ambar	O
/	O
Allcem	O
)	O
;	O
G2	O
:	O
relined	O
posts	O
(	O
dual	O
:	O
Ambar	O
/	O
Allcem	O
)	O
;	O
G3	O
:	O
cemented	O
posts	O
(	O
chemical	O
:	O
Fusion	O
Duralink	O
/	O
Cement	O
Post	O
)	O
;	O
and	O
G4	O
:	O
relined	O
posts	O
(	O
chemical	O
:	O
Fusion	O
Duralink	O
/	O
Cement	O
Post	O
)	O
.	O

The	O
roots	O
were	O
cut	O
to	O
give	O
two	O
slices	O
of	O
each	O
third	O
of	O
the	O
root	O
canal	O
per	O
specimen	O
.	O

Push-out	B-P
test	I-P
was	O
conducted	O
at	O
a	O
speed	O
of	O
0.5	O
mm/min	O
.	O

Data	O
were	O
analyzed	O
by	O
analysis	O
of	O
variance	O
and	O
Tukey	B-P
's	I-P
post	I-P
hoc	I-P
test	I-P
(	O
α	O
=	O
0.05	O
)	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
groups	O
for	O
the	O
premolars	O
(	O
flat	O
canal	O
)	O
(	O
P	O
=	O
0.959	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
central	O
incisors	O
between	O
the	O
middle	O
and	O
apical	O
thirds	O
in	O
the	O
cemented	O
group	O
when	O
using	O
the	O
dual	O
system	O
(	O
P	O
=	O
0.04	O
)	O
and	O
between	O
the	O
middle	O
and	O
apical	O
thirds	O
(	O
P	O
=	O
0.003	O
)	O
and	O
cervical	O
and	O
apical	O
thirds	O
(	O
P	O
=	O
0.033	O
)	O
when	O
using	O
the	O
chemical	B-P
system	I-P
.	O

Due	O
to	O
the	O
anatomy	O
of	O
the	O
root	O
canal	O
,	O
flat	O
canal	O
of	O
the	O
premolars	O
does	O
not	O
require	O
relining	O
,	O
but	O
round	O
canal	O
of	O
the	O
maxillary	O
central	O
incisors	O
demands	O
it	O
for	O
more	O
secure	O
in	O
the	O
bond	O
strength	O
.	O

Silk	O
I	O
and	O
Silk	O
II	O
studied	O
by	O
fast	B-P
scanning	I-P
calorimetry	I-P
.	O

Using	O
fast	B-P
scanning	I-P
calorimetry	I-P
(	O
FSC	B-P
)	O
,	O
we	O
investigated	O
the	O
glass	O
transition	O
and	O
crystal	O
melting	O
of	O
samples	O
of	O
B.	O
mori	O
silk	O
fibroin	O
containing	O
Silk	O
I	O
and/or	O
Silk	O
II	O
crystal	O
s.	O
Due	O
to	O
the	O
very	O
short	O
residence	O
times	O
at	O
high	O
temperatures	O
during	O
such	O
measurements	O
,	O
thermal	O
decomposition	O
of	O
silk	O
protein	O
can	O
be	O
significantly	O
suppressed	O
.	O

FSC	B-P
was	O
performed	O
at	O
2000K/s	O
using	O
the	O
Mettler	B-P
Flash	I-P
DSC1	I-P
on	O
fibroin	O
films	O
with	O
masses	O
around	O
130-270ng	O
.	O

Films	O
were	O
prepared	O
with	O
different	O
crystalline	O
fractions	O
(	O
ranging	O
from	O
0.26	O
to	O
0.50	O
)	O
and	O
with	O
different	O
crystal	O
structures	O
(	O
Silk	O
I	O
,	O
Silk	O
II	O
,	O
or	O
mixed	O
)	O
by	O
varying	O
the	O
processing	O
conditions	O
.	O

These	O
included	O
water	O
annealing	O
at	O
different	O
temperatures	O
,	O
exposure	O
to	O
50	O
%	O
MeOH	O
in	O
water	O
,	O
or	O
autoclaving	O
.	O

The	O
resulting	O
crystal	O
structure	O
was	O
examined	O
using	O
wide	O
angle	O
X-ray	B-P
scattering	I-P
.	O

Degree	O
of	O
crystallinity	O
was	O
evaluated	O
from	O
Fourier	O
transform	O
infrared	O
(	O
FTIR	O
)	O
spectroscopy	O
and	O
from	O
analysis	O
of	O
the	O
heat	O
capacity	O
increment	O
at	O
the	O
glass	O
transition	O
temperature	O
.	O

Silk	O
fibroin	O
films	O
prepared	O
by	O
water	O
annealing	O
at	O
25°C	O
were	O
the	O
least	O
crystalline	O
and	O
had	O
Silk	O
I	O
structure	O
.	O

FTIR	O
and	O
FSC	B-P
studies	O
showed	O
that	O
films	O
prepared	O
by	O
autoclaving	O
or	O
50	O
%	O
MeOH	O
exposure	O
were	O
the	O
most	O
crystalline	O
and	O
had	O
Silk	O
II	O
structure	O
.	O

Intermediate	O
crystalline	O
fraction	O
and	O
mixed	O
Silk	O
I	O
/	O
Silk	O
II	O
structure	O
s	O
were	O
found	O
in	O
films	O
prepared	O
by	O
water	O
annealing	O
at	O
37°C	O
.	O

FSC	B-P
results	O
indicate	O
that	O
Silk	O
I	O
I	O
crystals	O
exhibit	O
endotherms	O
of	O
narrower	O
width	O
and	O
have	O
higher	O
mean	O
melting	O
temperature	O
Tm	O
(	O
II	O
)	O
=351±2.6°C	O
,	O
compared	O
to	O
Silk	O
I	O
crystals	O
which	O
melt	O
at	O
Tm	O
(	O
I	O
)	O
=292±3.8°C	O
.	O

Films	O
containing	O
mixed	O
Silk	O
I	O
/	O
Silk	O
II	O
structure	O
showed	O
two	O
clearly	O
separated	O
endothermic	O
peaks	O
.	O

Evidence	O
suggests	O
that	O
the	O
two	O
types	O
of	O
crystal	O
s	O
melt	O
separately	O
and	O
do	O
not	O
thermal	O
ly	O
interconvert	O
on	O
the	O
extremely	O
short	O
time	O
scale	O
(	O
0.065s	O
between	O
onset	O
and	O
end	O
of	O
melting	O
)	O
of	O
the	O
FSC	B-P
experiment	I-P
.	O

Silkworm	O
silk	O
is	O
a	O
naturally	O
occurring	O
biomaterial	O
.	O

The	O
fibroin	O
component	O
of	O
silk	O
forms	O
two	O
types	O
of	O
crystals	O
.	O

Silk	O
properties	O
depend	O
upon	O
the	O
amount	O
and	O
type	O
of	O
crystals	O
,	O
and	O
their	O
stability	O
.	O

One	O
measure	O
of	O
stability	O
is	O
crystal	O
melting	O
temperature	O
.	O

Crystal	O
s	O
which	O
are	O
more	O
stable	O
have	O
a	O
higher	O
melting	O
temperature	O
.	O

Until	O
now	O
,	O
it	O
has	O
been	O
challenging	O
to	O
study	O
thermal	O
behavior	O
of	O
silk	O
crystal	O
s	O
because	O
they	O
degrade	O
at	O
high	O
temperature	O
.	O

To	O
avoid	O
degradation	O
,	O
and	O
study	O
the	O
melting	O
properties	O
of	O
silk	O
biomaterial	O
,	O
we	O
heated	O
silk	O
at	O
a	O
very	O
fast	O
rate	O
of	O
2000K/s	O
using	O
a	O
special	O
calorimeter	O
.	O

We	O
have	O
shown	O
that	O
the	O
two	O
crystal	O
types	O
have	O
very	O
different	O
melting	O
temperature	O
s	O
,	O
indicating	O
that	O
one	O
crystal	O
type	O
is	O
much	O
more	O
stable	O
than	O
the	O
other	O
.	O

Dissociation	O
between	O
complete	O
hippocampal	O
context	O
memory	O
formation	O
and	O
context	O
fear	O
acquisition	O
.	O

Rodents	O
require	O
a	O
minimal	O
time	O
period	O
to	O
explore	O
a	O
context	O
prior	O
to	O
footshock	O
to	O
display	O
plateau	O
-	O
level	O
context	O
fear	O
at	O
test	B-P
.	O

To	O
investigate	O
whether	O
this	O
rapid	O
fear	O
plateau	O
reflects	O
complete	O
memory	O
formation	O
within	O
that	O
short	O
time-frame	O
,	O
we	O
used	O
the	O
immediate-early	O
gene	O
product	O
Arc	O
as	O
an	O
indicator	O
of	O
hippocampal	O
context	O
memory	O
formation	O
-related	O
activity	O
.	O

We	O
found	O
that	O
hippocampal	O
Arc	O
expression	O
continued	O
to	O
increase	O
well	O
past	O
the	O
minimal	O
time	O
required	O
for	O
plateau	O
-	O
level	O
fear	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
context	O
fear	O
conditioning	O
occurs	O
more	O
rapidly	O
than	O
complete	O
memory	O
formation	O
.	O

Thus	O
,	O
animals	O
may	O
be	O
able	O
to	O
condition	O
robustly	O
to	O
both	O
complete	O
and	O
incomplete	O
contextual	O
representations	O
.	O

Analysis	O
of	O
patients	O
with	O
diabetes	O
and	O
complicated	O
intra-abdominal	O
infection	O
or	O
complicated	O
urinary	O
tract	O
infection	O
in	O
phase	O
3	O
trials	O
of	O
ceftolozane/tazobactam	O
.	O

Diabetes	O
mellitus	O
and	O
hyperglycemia	O
are	O
associated	O
with	O
increased	O
susceptibility	O
to	O
bacterial	O
infections	O
and	O
poor	O
treatment	O
outcomes	O
.	O

This	O
post	O
hoc	O
evaluation	O
of	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	O
infections	O
(	O
cIAI	O
)	O
and	O
complicated	O
urinary	O
tract	O
infections	O
(	O
cUTI	O
)	O
aimed	O
to	O
evaluate	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
in	O
patients	O
with	O
and	O
without	O
diabetes	O
treated	O
with	O
ceftolozane/tazobactam	O
and	O
comparators	O
.	O

Ceftolozane/tazobactam	O
is	O
an	O
antibacterial	O
with	O
potent	O
activity	O
against	O
Gram-negative	O
pathogens	O
and	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
cIAI	O
(	O
with	O
metronidazole	O
)	O
and	O
cUTI	O
(	O
including	O
pyelonephritis	O
)	O
.	O

Patients	O
from	O
the	O
phase	O
3	O
ASPECT	O
studies	O
with	O
(	O
n	O
=	O
245	O
)	O
and	O
without	O
(	O
n	O
=	O
1802	O
)	O
diabetes	O
were	O
compared	O
to	O
evaluate	O
the	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
of	O
ceftolozane/tazobactam	O
and	O
active	O
comparators	O
.	O

Significantly	O
more	O
patients	O
with	O
than	O
without	O
diabetes	O
were	O
65	O
years	O
of	O
age	O
or	O
older	O
;	O
patients	O
with	O
diabetes	O
were	O
also	O
more	O
likely	O
to	O
weigh	O
≥75	O
kg	O
at	O
baseline	O
(	O
57.1	O
%	O
vs	O
44.5	O
%	O
)	O
,	O
to	O
have	O
renal	O
impairment	O
(	O
48.5	O
%	O
vs	O
30.2	O
%	O
)	O
,	O
or	O
to	O
have	O
APACHE	B-P
II	I-P
scores	I-P
≥10	O
(	O
33.8	O
%	O
vs	O
17.0	O
%	O
)	O
.	O

More	O
patients	O
with	O
diabetes	O
had	O
comorbidities	O
and	O
an	O
increased	O
incidence	O
of	O
complicating	O
factors	O
in	O
both	O
cIAI	O
and	O
cUTI	O
.	O

Clinical	O
cIAI	O
and	O
composite	O
cure	O
cUTI	O
rates	O
across	O
study	O
treatments	O
were	O
lower	O
in	O
patients	O
with	O
than	O
without	O
diabetes	O
(	O
cIAI	O
,	O
75.4	O
%	O
vs	O
86.1	O
%	O
,	O
P	O
=	O
0.0196	O
;	O
cUTI	O
,	O
62.4	O
%	O
vs	O
74.7	O
%	O
,	O
P	O
=	O
0.1299	O
)	O
but	O
were	O
generally	O
similar	O
between	O
the	O
ceftolozane/tazobactam	O
and	O
active	O
comparator	O
treatment	O
groups	O
.	O

However	O
,	O
significantly	O
higher	O
composite	O
cure	O
rates	O
were	O
reported	O
with	O
ceftolozane/tazobactam	O
than	O
with	O
levofloxacin	O
in	O
patients	O
without	O
diabetes	O
with	O
cUTI	O
(	O
79.5	O
%	O
vs	O
69.9	O
%	O
;	O
P	O
=	O
0.0048	O
)	O
.	O

Significantly	O
higher	O
rates	O
of	O
adverse	O
events	O
observed	O
in	O
patients	O
with	O
diabetes	O
were	O
likely	O
due	O
to	O
comorbidities	O
because	O
treatment	O
-related	O
adverse	O
events	O
were	O
similar	O
between	O
groups	O
.	O

In	O
this	O
post	O
hoc	O
analysis	O
,	O
patients	O
with	O
diabetes	O
in	O
general	O
were	O
older	O
,	O
heavier	O
,	O
and	O
had	O
a	O
greater	O
number	O
of	O
complicating	O
comorbidities	O
.	O

Patients	O
with	O
diabetes	O
had	O
lower	O
cure	O
rates	O
and	O
a	O
significantly	O
higher	O
frequency	O
of	O
adverse	O
events	O
than	O
patients	O
without	O
diabetes	O
,	O
likely	O
because	O
of	O
the	O
higher	O
rates	O
of	O
medical	O
complications	O
in	O
this	O
subgroup	O
.	O

Ceftolozane/tazobactam	O
was	O
shown	O
to	O
be	O
at	O
least	O
as	O
effective	O
as	O
comparators	O
in	O
treating	O
cUTI	O
and	O
cIAI	O
in	O
this	O
population	O
.	O

cIAI	O
,	O
NCT01445665	O
and	O
NCT01445678	O
(	O
both	O
trials	O
registered	O
prospectively	O
on	O
September	O
26	O
,	O
2011	O
)	O
;	O
cUTI	O
,	O
NCT01345929	O
and	O
NCT01345955	O
(	O
both	O
trials	O
registered	O
prospectively	O
on	O
April	O
28	O
,	O
2011	O
)	O
.	O

Effect	O
of	O
Low	O
-	O
Dose	O
MDCT	B-P
and	O
Iterative	B-P
Reconstruction	I-P
on	O
Trabecular	O
Bone	O
Microstructure	O
Assessment	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
low	O
-	O
dose	O
multi	B-P
detector	I-P
computed	I-P
tomography	I-P
(	O
MDCT	B-P
)	O
in	O
combination	O
with	O
statistical	B-P
iterative	I-P
reconstruction	I-P
algorithms	O
on	O
trabecular	O
bone	O
microstructure	O
parameters	O
.	O

Twelve	O
donated	O
vertebrae	O
were	O
scanned	B-P
with	O
the	O
routine	O
radiation	B-P
exposure	I-P
used	O
in	O
our	O
department	O
(	O
standard-dose	O
)	O
and	O
a	O
low	O
-	O
dose	O
protocol	O
.	O

Reconstructions	O
were	O
performed	O
with	O
filtered	B-P
backprojection	I-P
(	O
FBP	B-P
)	O
and	O
maximum-likelihood	O
based	O
statistical	B-P
iterative	I-P
reconstruction	I-P
(	O
SIR	B-P
)	O
.	O

Trabecular	O
bone	O
microstructure	O
parameters	O
were	O
assessed	O
and	O
statistically	O
compared	O
for	O
each	O
reconstruction	O
.	O

Moreover	O
,	O
fracture	O
loads	O
of	O
the	O
vertebrae	O
were	O
biomechanically	B-P
determined	O
and	O
correlated	O
to	O
the	O
assessed	O
microstructure	O
parameters	O
.	O

Trabecular	O
bone	O
microstructure	O
parameters	O
based	O
on	O
low	O
-	O
dose	O
MDCT	B-P
and	O
SIR	B-P
significantly	O
correlated	O
with	O
vertebral	O
bone	O
strength	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
microstructure	O
parameters	O
calculated	O
on	O
low	O
-	O
dose	O
SIR	B-P
and	O
standard	O
-	O
dose	O
FBP	B-P
images	O
.	O

However	O
,	O
the	O
results	O
revealed	O
a	O
strong	O
dependency	O
on	O
the	O
regularization	O
strength	O
applied	O
during	O
SIR	B-P
.	O

It	O
was	O
observed	O
that	O
stronger	O
regularization	O
might	O
corrupt	O
the	O
microstructure	O
analysis	O
,	O
because	O
the	O
trabecular	O
structure	O
is	O
a	O
very	O
small	O
detail	O
that	O
might	O
get	O
lost	O
during	O
the	O
regularization	O
process	O
.	O

As	O
a	O
consequence	O
,	O
the	O
introduction	O
of	O
SIR	B-P
for	O
trabecular	O
bone	O
microstructure	O
analysis	O
requires	O
a	O
specific	O
optimization	O
of	O
the	O
regularization	O
parameters	O
.	O

Moreover	O
,	O
in	O
comparison	O
to	O
other	O
approaches	O
,	O
superior	O
noise	O
-	O
resolution	O
trade-offs	O
can	O
be	O
found	O
with	O
the	O
proposed	O
methods	O
.	O

A	O
Revised	O
Approach	O
for	O
the	O
Detection	O
of	O
Sight-Threatening	O
Diabetic	O
Macular	O
Edema	O
.	O

Diabetic	O
macular	O
edema	O
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
vision	O
loss	O
among	O
working-age	O
adults	O
in	O
the	O
United	O
States	O
.	O

Telemedicine	O
screening	O
programs	O
and	O
epidemiological	O
studies	O
rely	O
on	O
monoscopic	B-P
fundus	I-P
photography	I-P
for	O
the	O
detection	O
of	O
clinically	O
significant	O
macular	O
edema	O
(	O
CSME	O
)	O
.	O

Improving	O
the	O
accuracy	O
of	O
detecting	O
CSME	O
from	O
monoscopic	O
images	O
could	O
be	O
valuable	O
while	O
recognizing	O
the	O
limitations	O
of	O
such	O
detection	O
in	O
an	O
era	O
of	O
optical	B-P
coherence	I-P
tomography	I-P
detection	O
of	O
diabetic	O
macular	O
edema	O
.	O

To	O
evaluate	O
the	O
screening	B-P
test	I-P
accuracy	O
of	O
radially	O
arranged	O
sectors	O
affected	O
by	O
hard	O
exudates	O
in	O
the	O
detection	O
of	O
CSME	O
.	O

This	O
investigation	O
was	O
a	O
cross-sectional	O
study	O
of	O
CSME	O
grading	O
in	O
monoscopic	O
images	O
using	O
a	O
sectors	O
approach	O
.	O

The	O
Early	O
Treatment	O
Diabetic	O
Retinopathy	O
Study	O
criteria	O
were	O
used	O
to	O
confirm	O
the	O
presence	O
of	O
CSME	O
by	O
the	O
following	O
2	O
methods	B-P
:	O
stereoscopic	B-P
fundus	I-P
photography	I-P
(	O
method	B-P
1	I-P
)	O
and	O
dilated	O
biomicroscopy	B-P
in	O
combination	O
with	O
optical	B-P
coherence	I-P
tomography	I-P
(	O
method	B-P
2	I-P
)	O
.	O

Participants	O
were	O
recruited	O
at	O
a	O
university	O
-	O
based	O
practice	O
between	O
June	O
14	O
,	O
2014	O
,	O
and	O
December	O
28	O
,	O
2015	O
.	O

Area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
,	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
predictive	O
value	O
,	O
and	O
negative	O
predictive	O
value	O
.	O

A	O
total	O
of	O
207	O
eyes	O
from	O
an	O
ethnically/racially	O
diverse	O
group	O
of	O
207	O
patients	O
(	O
mean	O
[	O
SD	O
]	O
age	O
,	O
53.6	O
[	O
10.8	O
]	O
years	O
;	O
58.9	O
%	O
[	O
122	O
of	O
207	O
]	O
female	O
)	O
were	O
included	O
in	O
the	O
analysis	O
.	O

Twelve	O
eyes	O
(	O
5.8	O
%	O
)	O
were	O
diagnosed	B-P
as	O
having	O
CSME	O
based	O
on	O
method	B-P
1	I-P
.	O

The	O
intermethod	O
and	O
intergrader	O
agreement	O
for	O
CSME	O
diagnosis	B-P
and	O
sector	O
count	O
was	O
substantial	O
(	O
κ	O
range	O
,	O
0.66	O
[	O
95	O
%	O
CI	O
,	O
0.47-0.85	O
]	O
to	O
0.75	O
[	O
95	O
%	O
CI	O
,	O
0.53-0.97	O
]	O
;	O
P	O
<	O
.001	O
for	O
all	O
)	O
.	O

Area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
was	O
93.2	O
%	O
(	O
95	O
%	O
CI	O
,	O
84.2	O
%	O
-100	O
%	O
)	O
when	O
evaluating	O
a	O
sectors	O
approach	O
against	O
method	B-P
1	I-P
as	O
a	O
reference	O
test	O
and	O
offered	O
up	O
to	O
an	O
8.6	O
%	O
(	O
95	O
%	O
CI	O
,	O
3.0	O
%	O
-14.3	O
%	O
)	O
increase	O
in	O
specificity	O
compared	O
with	O
the	O
existing	O
methods	B-P
of	O
detection	O
.	O

The	O
positive	O
predictive	O
value	O
was	O
33.3	O
%	O
(	O
95	O
%	O
CI	O
,	O
25.6	O
%	O
-45.5	O
%	O
)	O
,	O
and	O
the	O
negative	O
predictive	O
value	O
was	O
98.1	O
%	O
(	O
95	O
%	O
CI	O
,	O
96.9	O
%	O
-100	O
%	O
)	O
.	O

The	O
results	O
were	O
similar	O
when	O
comparing	O
a	O
sectors	O
approach	O
with	O
method	B-P
2	I-P
as	O
a	O
reference	O
test	O
.	O

A	O
sectors	O
approach	O
shows	O
good	O
screening	B-P
test	I-P
characteristics	O
for	O
the	O
detection	O
of	O
CSME	O
.	O

Its	O
implementation	O
in	O
the	O
existing	O
telemedicine	O
programs	O
would	O
require	O
minimal	O
resources	O
.	O

This	O
approach	O
will	O
have	O
the	O
greatest	O
effect	O
in	O
a	O
setting	O
where	O
implementation	O
of	O
optical	B-P
coherence	I-P
tomography	I-P
,	O
a	O
more	O
objective	O
and	O
sensitive	O
way	O
to	O
detect	O
retinal	O
thickening	O
,	O
is	O
not	O
feasible	O
.	O

The	O
proposed	O
method	B-P
also	O
may	O
be	O
easily	O
incorporated	O
in	O
the	O
automated	O
diabetic	O
retinopathy	O
detection	O
algorithms	O
.	O

Fine	O
structure	O
of	O
the	O
anterior	O
median	O
eyes	O
of	O
the	O
funnel	O
-	O
web	O
spider	O
Agelena	O
labyrinthica	O
(	O
Araneae	O
:	O
Agelenidae	O
)	O
.	O

Only	O
few	O
electron	B-P
microscopic	I-P
studies	I-P
exist	O
on	O
the	O
structure	O
of	O
the	O
main	O
eyes	O
(	O
anterior	O
median	O
eyes	O
,	O
AME	O
)	O
of	O
web	O
spiders	O
.	O

The	O
present	O
paper	O
provides	O
details	O
on	O
the	O
anatomy	O
of	O
the	O
AME	O
in	O
the	O
funnel-web	O
spider	O
Agelena	O
labyrinthica	O
.	O

The	O
retina	O
consists	O
of	O
two	O
separate	O
regions	O
with	O
differently	O
arranged	O
photoreceptor	O
cells	O
.	O

Its	O
central	O
part	O
has	O
sensory	O
cells	O
with	O
rhabdomeres	O
on	O
2	O
,	O
3	O
,	O
or	O
4	O
sides	O
,	O
whereas	O
those	O
of	O
the	O
ventral	O
retina	O
have	O
only	O
two	O
rhabdomeres	O
on	O
opposite	O
sides	O
.	O

In	O
addition	O
,	O
the	O
rhabdomeres	O
of	O
the	O
ventral	O
retina	O
are	O
arranged	O
in	O
a	O
specific	O
way	O
:	O
Whereas	O
in	O
the	O
most	O
ventral	O
part	O
they	O
form	O
long	O
tangential	O
rows	O
,	O
those	O
towards	O
the	O
center	O
are	O
detached	O
and	O
are	O
arranged	O
radially	O
.	O

All	O
sensory	O
cells	O
are	O
wrapped	O
by	O
unpigmented	O
pigment	O
cell	O
processes	O
.	O

In	O
agelenid	O
spiders	O
the	O
axons	O
of	O
the	O
sensory	O
cells	O
exit	O
from	O
the	O
middle	O
of	O
the	O
cell	O
body	O
;	O
their	O
fine	O
structure	O
and	O
course	O
through	O
the	O
eye	O
cup	O
is	O
described	O
in	O
detail	O
.	O

In	O
the	O
central	O
part	O
of	O
the	O
retina	O
efferent	O
nerve	O
fibres	O
were	O
found	O
forming	O
synapses	O
along	O
the	O
distal	O
region	O
of	O
the	O
receptor	O
cells	O
.	O

A	O
muscle	O
is	O
attached	O
laterally	O
to	O
each	O
eye	O
cup	O
that	O
allows	O
mainly	O
rotational	O
movements	O
of	O
the	O
eyes	O
.	O

The	O
optical	O
performance	O
(	O
image	O
resolution	O
)	O
of	O
these	O
main	O
eyes	O
with	O
relatively	O
few	O
visual	O
cells	O
is	O
discussed	O
.	O

Ultrathin	O
Au	O
nanowires	O
assisted	O
magnetic	O
graphene	O
-	O
silica	O
ZIC-HILIC	O
composites	O
for	O
highly	O
specific	O
enrichment	O
of	O
N-linked	O
glycopeptides	O
.	O

Protein	O
glycosylation	O
has	O
been	O
proven	O
to	O
participate	O
in	O
a	O
variety	O
of	O
complex	O
biological	O
processes	O
;	O
however	O
,	O
the	O
low	O
abundance	O
of	O
glycopeptides	O
in	O
natural	O
samples	O
makes	O
it	O
essential	O
to	O
develop	O
methods	O
to	O
isolate	O
and	O
enrich	O
glycopeptides	O
.	O

In	O
this	O
study	O
,	O
a	O
novel	O
ultrathin	O
Au	O
nanowire	O
assisted	O
zwitterionic	O
hydrophilic	O
magnetic	O
graphene	O
oxide	O
(	O
GO	O
-	O
Fe3O4	O
/	O
SiO2	O
/	O
AuNWs	O
/	O
L-Cys	O
)	O
was	O
synthesized	O
with	O
the	O
good	O
biocompatibility	O
of	O
GO	O
,	O
strong	O
magnetic	O
responses	O
of	O
Fe3O4	O
,	O
large	O
surface	O
area	O
of	O
ultrathin	O
Au	O
nanowires	O
and	O
excellent	O
hydrophilicity	O
of	O
L-Cys	O
via	O
four	O
simple	O
and	O
rapid	O
steps	O
.	O

The	O
ultrathin	O
Au	O
nanowires	O
have	O
a	O
one-dimensional	O
structure	O
and	O
were	O
easily	O
grafted	O
with	O
an	O
abundant	O
amount	O
of	O
L-Cys	O
for	O
the	O
enrichment	O
of	O
glycopeptides	O
.	O

After	O
the	O
GO	O
-	O
Fe3O4	O
/	O
SiO2	O
/	O
AuNWs	O
/	O
L-Cys	O
composites	O
were	O
applied	O
to	O
glycopeptide	O
enrichment	O
,	O
26	O
glycopeptides	O
from	O
a	O
human	O
IgG	O
digest	O
could	O
be	O
identified	O
,	O
with	O
a	O
detection	O
limit	O
as	O
low	O
as	O
10	O
fmol	O
.	O

Due	O
to	O
the	O
abundant	O
amount	O
of	O
grafted	O
L-Cys	O
,	O
the	O
composites	O
also	O
showed	O
a	O
large	O
binding	O
capacity	O
(	O
150	O
μg	O
mg	O
(	O
-1	O
)	O
)	O
.	O

Furthermore	O
,	O
the	O
composites	O
were	O
applied	O
for	O
the	O
analysis	O
of	O
real	O
biological	O
samples	O
.	O

A	O
total	O
of	O
793	O
glycopeptides	O
from	O
467	O
glycoproteins	O
were	O
identified	O
in	O
three	O
replicate	B-P
analyses	I-P
of	O
40	O
μg	O
of	O
mouse	O
liver	O
proteins	O
.	O

The	O
results	O
demonstrated	O
the	O
great	O
potential	O
of	O
GO	O
-	O
Fe3O4	O
/	O
SiO2	O
/	O
AuNWs	O
/	O
L-Cys	O
composites	O
for	O
the	O
analysis	O
of	O
glycoproteins	O
.	O

Enhanced	O
Sensitivity	O
to	O
Hyperpolarizing	O
Inhibition	O
in	O
Mesoaccumbal	O
Relative	O
to	O
Nigrostriatal	O
Dopamine	O
Neuron	O
Subpopulations	O
.	O

Midbrain	O
dopamine	O
neurons	O
recorded	O
in	O
vivo	O
pause	O
their	O
firing	O
in	O
response	O
to	O
reward	O
omission	O
and	O
aversive	O
stimuli	O
.	O

While	O
the	O
initiation	O
of	O
pauses	O
typically	O
involves	O
synaptic	O
or	O
modulatory	O
input	O
,	O
intrinsic	O
membrane	O
properties	O
may	O
also	O
enhance	O
or	O
limit	O
hyperpolarization	O
,	O
raising	O
the	O
question	O
of	O
how	O
intrinsic	O
conductances	O
shape	O
pause	O
s	O
in	O
dopamine	O
neurons	O
.	O

Using	O
retrograde	O
labeling	B-P
and	O
electrophysiological	B-P
techniques	I-P
combined	O
with	O
computational	O
modeling	O
,	O
we	O
examined	O
the	O
intrinsic	O
conductances	O
that	O
shape	O
pauses	O
evoked	O
by	O
current	O
injections	O
and	O
synaptic	O
stimulation	O
in	O
subpopulations	O
of	O
dopamine	O
neurons	O
grouped	O
according	O
to	O
their	O
axonal	O
projections	O
to	O
the	O
nucleus	O
accumbens	O
or	O
dorsal	O
striatum	O
in	O
mice	O
.	O

Testing	O
across	O
a	O
range	O
of	O
conditions	O
and	O
pulse	O
durations	O
,	O
we	O
found	O
that	O
mesoaccumbal	O
and	O
nigrostriatal	O
neurons	O
differ	O
substantially	O
in	O
rebound	O
properties	O
with	O
mesoaccumbal	O
neurons	O
displaying	O
significantly	O
longer	O
delays	O
to	O
spiking	O
following	O
hyperpolarization	O
.	O

The	O
underlying	O
mechanism	O
involves	O
an	O
inactivating	O
potassium	O
(	O
IA	O
)	O
current	O
with	O
decay	O
time	O
constants	O
of	O
up	O
to	O
225	O
ms	O
,	O
and	O
small-amplitude	O
hyperpolarization	O
-	O
activated	O
currents	O
(	O
IH	O
)	O
,	O
characteristics	O
that	O
were	O
most	O
often	O
observed	O
in	O
mesoaccumbal	O
neurons	O
.	O

Pharmacological	O
block	O
of	O
IA	O
completely	O
abolished	O
rebound	O
delays	O
and	O
,	O
importantly	O
,	O
shortened	O
synaptically	O
evoked	O
inhibitory	O
pauses	O
,	O
thereby	O
demonstrating	O
the	O
involvement	O
of	O
A-type	O
potassium	O
channels	O
in	O
prolonging	O
pauses	O
evoked	O
by	O
GABAergic	O
inhibition	O
.	O

Therefore	O
,	O
these	O
results	O
show	O
that	O
mesoaccumbal	O
and	O
nigrostriatal	O
neurons	O
display	O
differential	O
responses	O
to	O
hyperpolarizing	O
inhibitory	O
stimuli	O
that	O
favors	O
a	O
higher	O
sensitivity	O
to	O
inhibition	O
in	O
mesoaccumbal	O
neurons	O
.	O

These	O
findings	O
may	O
explain	O
,	O
in	O
part	O
,	O
observations	O
from	O
in	O
vivo	O
experiments	O
that	O
ventral	O
tegmental	O
area	O
neurons	O
tend	O
to	O
exhibit	O
longer	O
aversive	O
pauses	O
relative	O
to	O
SNc	O
neurons	O
.	O

SIGNIFICANCE	O
STATEMENT	O
Our	O
study	O
examines	O
rebound	O
,	O
postburst	O
,	O
and	O
synaptically	O
evoked	O
inhibitory	O
pauses	O
in	O
subpopulations	O
of	O
midbrain	O
dopamine	O
neurons	O
.	O

We	O
show	O
that	O
pauses	O
in	O
dopamine	O
neuron	O
firing	O
,	O
evoked	O
by	O
either	O
stimulation	O
of	O
GABAergic	O
input	O
s	O
or	O
hyperpolarizing	O
current	O
injections	O
,	O
are	O
enhanced	O
by	O
a	O
subclass	O
of	O
potassium	O
conductances	O
that	O
are	O
recruited	O
at	O
voltages	O
below	O
spike	O
threshold	O
.	O

Importantly	O
,	O
A-type	O
potassium	O
currents	O
recorded	O
in	O
mesoaccumbal	O
neurons	O
displayed	O
substantially	O
slower	O
inactivation	O
kinetics	O
,	O
which	O
,	O
combined	O
with	O
weaker	O
expression	O
of	O
hyperpolarization	O
-	O
activated	O
currents	O
,	O
lengthened	O
hyperpolarization	O
-induced	O
delays	O
in	O
spiking	O
relative	O
to	O
nigrostriatal	O
neurons	O
.	O

These	O
results	O
suggest	O
that	O
input	O
integration	O
differs	O
among	O
dopamine	O
neurons	O
favoring	O
higher	O
sensitivity	O
to	O
inhibition	O
in	O
mesoaccumbal	O
neurons	O
and	O
may	O
partially	O
explain	O
in	O
vivo	O
observations	O
that	O
ventral	O
tegmental	O
area	O
neurons	O
exhibit	O
longer	O
aversive	O
pauses	O
relative	O
to	O
SNc	O
neurons	O
.	O

HoLEP	O
learning	O
curve	O
:	O
Toward	O
a	O
standardised	O
formation	O
and	O
a	O
team	O
strategy	O
.	O

Holmium	O
laser	O
enucleation	O
of	O
prostate	O
(	O
HoLEP	O
)	O
is	O
renowned	O
for	O
the	O
difficulty	O
of	O
its	O
learning	O
curve	O
.	O

Our	O
aim	O
was	O
to	O
evaluate	O
the	O
interest	O
of	O
a	O
three-step	O
tutorial	O
in	O
the	O
HoLEP	O
learning	O
curve	O
,	O
in	O
a	O
university	O
center	O
.	O

It	O
is	O
a	O
retrospective	O
,	O
monocentric	O
study	O
of	O
the	O
82	O
first	O
procedures	O
done	O
consecutively	O
by	O
the	O
same	O
operator	O
with	O
a	O
proctoring	O
in	O
early	O
experience	O
and	O
after	O
40	O
procedures	O
.	O

For	O
all	O
patients	O
were	O
noted	O
:	O
enucleation	O
efficiency	O
(	O
g/min	O
)	O
,	O
morcellation	O
efficiency	O
(	O
g/min	O
)	O
,	O
percentage	O
of	O
enucleated	O
tissue	O
(	O
enucleated	O
tissue	O
/	O
adenome	O
weigth	O
evaluated	O
by	O
ultrasonography	B-P
.	O

g/g	O
)	O
,	O
perioperative	O
morbidity	O
(	O
Clavien	O
)	O
,	O
length	O
of	O
hospital	O
stay	O
,	O
length	O
of	O
urinary	O
drainage	O
,	O
functional	O
outcomes	O
at	O
short	O
and	O
middle	O
term	O
(	O
Qmax	O
,	O
post-void	O
residual	O
volume	O
[	O
PVR	O
]	O
,	O
QOL	O
scores	O
and	O
IPSS	O
at	O
3	O
and	O
6	O
months	O
)	O
.	O

Enucleation	O
and	O
morcellation	O
efficiency	O
were	O
significantly	O
higher	O
after	O
the	O
second	O
proctoring	O
(	O
0.87	O
vs	O
0.44g/min	O
;	O
P	O
<	O
0.0001	O
and	O
4.2	O
vs	O
3.37g/min	O
,	O
P=0.038	O
,	O
respectively	O
)	O
so	O
as	O
the	O
prostatic	O
volume	O
(	O
43.5	O
vs	O
68.1mL	O
,	O
P=0.0001	O
)	O
.	O

Percentage	O
of	O
enucleated	O
tissue	O
was	O
higher	O
in	O
the	O
second	O
group	O
,	O
however	O
,	O
the	O
difference	O
was	O
not	O
significant	O
(	O
69.5	O
%	O
vs	O
80.4	O
%	O
,	O
P=0.03	O
)	O
.	O

Per-	O
and	O
postoperative	O
complications	O
,	O
hospital	O
length	O
of	O
stay	O
,	O
urinary	O
drainage	O
length	O
and	O
functional	O
results	O
at	O
3	O
and	O
6	O
months	O
were	O
not	O
significantly	O
different	O
.	O

The	O
learning	O
curve	O
did	O
not	O
interfere	O
with	O
functional	O
results	O
.	O

The	O
second	O
proctoring	O
was	O
essential	O
to	O
us	O
in	O
order	O
to	O
grasp	O
the	O
technique	O
.	O

These	O
data	O
underlined	O
the	O
necessity	O
of	O
a	O
pedagogic	O
reflexion	O
in	O
order	O
to	O
built	O
a	O
standardized	O
formation	O
technique	O
to	O
the	O
HoLEP	O
.	O

4	O
.	O

Lipid	O
digestibility	O
and	O
energy	O
content	O
of	O
distillers	O
'	O
corn	O
oil	O
in	O
swine	O
and	O
poultry	O
.	O

Two	O
experiments	O
were	O
conducted	O
to	O
determine	O
the	O
DE	O
and	O
ME	O
and	O
apparent	O
total	O
tract	O
digestibility	O
of	O
ether	O
extract	O
of	O
3	O
distillers	O
'	O
corn	O
oil	O
(	O
DCO	O
;	O
4.9	O
,	O
12.8	O
,	O
or	O
13.9	O
%	O
free	O
fatty	O
acids	O
[	O
FFA	O
]	O
)	O
samplescompared	O
with	O
a	O
sample	O
of	O
refined	O
corn	O
oil	O
(	O
CO	O
;	O
0.04	O
%	O
FFA	O
)	O
and	O
an	O
industrially	O
hydrolyzed	O
high-FFA	O
DCO	O
(	O
93.8	O
%	O
FFA	O
)	O
in	O
young	O
pigs	O
and	O
growing	O
broilers	O
.	O

In	O
Exp	O
.	O

1	O
,	O
54	O
barrows	O
(	O
initial	O
age	O
=	O
28	O
d	O
)	O
were	O
fed	O
a	O
common	O
diet	O
for	O
7	O
d	O
and	O
then	O
fed	O
their	O
allotted	O
dietary	O
treatment	O
(	O
either	O
100	O
%	O
basal	O
diet	O
or	O
1	O
of	O
5	O
test	O
diets	O
consisting	O
of	O
90	O
%	O
basal	O
diet	O
plus	O
10	O
%	O
test	O
lipid	O
)	O
for	O
the	O
next	O
7	O
d	O
in	O
group	O
pens	O
(	O
9	O
pigs	O
/	O
pen	O
)	O
.	O

For	O
the	O
next	O
10	O
d	O
,	O
pigs	O
were	O
moved	O
to	O
individual	O
metabolism	O
crates	O
for	O
continued	O
diet	O
and	O
crate	O
adaptation	O
and	O
to	O
a	O
twice-daily	O
feeding	O
regimen	O
.	O

Pigs	O
remained	O
on	O
their	O
respective	O
diets	O
for	O
a	O
4-d	O
total	O
fecal	O
and	O
urine	B-P
collection	I-P
period	O
.	O

For	O
Exp	O
.	O

2	O
,	O
567	O
male	O
broilers	O
were	O
obtained	O
from	O
a	O
commercial	O
hatchery	O
(	O
1	O
d	O
of	O
age	O
)	O
and	O
reared	O
in	O
grower	O
battery	O
cages	O
that	O
contained	O
9	O
chicks	O
per	O
cage	O
.	O

Broilers	O
were	O
fed	O
a	O
common	O
corn	O
-	O
soybean	O
meal	O
starter	O
diet	O
from	O
placement	O
until	O
the	O
beginning	O
of	O
the	O
trial	O
(	O
19	O
d	O
of	O
age	O
)	O
.	O

Birds	O
were	O
then	O
randomly	O
assigned	O
to	O
1	O
of	O
6	O
dietary	O
treatments	O
(	O
94	O
%	O
basal	O
diet	O
plus	O
6	O
%	O
dextrose	O
or	O
94	O
%	O
basal	O
diet	O
plus	O
6	O
%	O
test	O
lipid	O
substituted	O
for	O
dextrose	O
)	O
on	O
d	O
19	O
and	O
were	O
allowed	O
an	O
8-d	O
dietary	O
acclimation	O
period	O
followed	O
by	O
a	O
48-h	O
energy	B-P
balance	I-P
assay	I-P
.	O

In	O
Exp	O
.	O

1	O
,	O
the	O
DCO	O
sample	O
with	O
12.8	O
%	O
FFA	O
contained	O
the	O
lowest	O
(	O
<	O
0.05	O
)	O
DE	O
(	O
8,036	O
kcal/kg	O
)	O
content	O
compared	O
with	O
the	O
0.04	O
%	O
refined	O
CO	O
sample	O
and	O
the	O
4.9	O
or	O
93.8	O
%	O
FFA	O
DCO	O
samples	O
(	O
8,814	O
,	O
8,828	O
,	O
and	O
8,921	O
kcal/kg	O
,	O
respectively	O
)	O
,	O
with	O
the	O
DCO	O
source	O
containing	O
13.9	O
%	O
FFA	O
having	O
intermediate	O
DE	O
(	O
8,465	O
kcal/kg	O
)	O
content	O
.	O

The	O
ME	O
content	O
of	O
these	O
lipid	O
sources	O
also	O
differed	O
among	O
treatments	O
(	O
<	O
0.01	O
)	O
,	O
following	O
trends	O
similar	O
to	O
their	O
DE	O
values	O
,	O
with	O
no	O
differences	O
noted	O
for	O
ME	O
as	O
a	O
percentage	O
of	O
DE	O
(	O
>	O
0.35	O
)	O
content	O
among	O
the	O
lipids	O
evaluated	O
.	O

In	O
Exp	O
.	O

2	O
,	O
lipids	O
containing	O
0.04	O
,	O
4.9	O
,	O
12.8	O
,	O
and	O
13.9	O
%	O
FFA	O
had	O
similar	O
nitrogen	O
corrected	O
apparent	O
ME	O
(	O
AME	O
)	O
values	O
(	O
8,072	O
,	O
7,936	O
,	O
8,036	O
,	O
and	O
7,694	O
respectively	O
)	O
,	O
except	O
for	O
the	O
industrially	O
hydrolyzed	O
DCO	O
sample	O
containing	O
93.8	O
%	O
FFA	O
,	O
which	O
contained	O
6,276	O
kcal/kg	O
(	O
<	O
0.01	O
)	O
.	O

Using	O
published	O
prediction	O
equations	O
,	O
the	O
predicted	O
DE	O
of	O
these	O
lipids	O
for	O
swine	O
was	O
3.5	O
%	O
greater	O
than	O
the	O
values	O
determined	O
in	O
Exp	O
.	O

1	O
for	O
all	O
lipid	O
sources	O
,	O
except	O
for	O
the	O
DCO	O
sample	O
containing	O
93.8	O
%	O
FFA	O
,	O
which	O
the	O
predicted	O
DE	O
was	O
underestimated	O
.	O

Likewise	O
,	O
the	O
predicted	O
AME	O
of	O
these	O
lipids	O
for	O
broilers	O
was	O
7.4	O
%	O
greater	O
than	O
the	O
determined	O
AMEn	O
(	O
Exp	O
.	O

2	O
)	O
for	O
all	O
lipid	O
sources	O
.	O

Duodenal	O
Villous	O
Atrophy	O
in	O
a	O
TTG	B-P
-	O
Negative	O
Patient	O
Taking	O
Olmesartan	O
:	O
A	O
Case	O
Report	O
and	O
Review	O
of	O
the	O
Literature	O
.	O

Olmesartan	O
,	O
an	O
angiotensin	O
II	O
receptor	O
antagonist	O
used	O
to	O
treat	O
hypertension	O
,	O
is	O
associated	O
with	O
few	O
adverse	O
effects	O
.	O

Here	O
,	O
a	O
case	O
of	O
severe	O
sprue-like	O
enteropathy	O
and	O
acute	O
kidney	O
injury	O
is	O
described	O
in	O
a	O
68-year-old	O
male	O
taking	O
olmesartan	O
for	O
3-4	O
years	O
.	O

He	O
presented	O
to	O
hospital	O
with	O
a	O
five-week	O
history	O
of	O
diarrhea	O
,	O
vomiting	O
,	O
and	O
a	O
20	O
lb	O
weight	O
loss	O
.	O

Anti-TTG	O
was	O
negative	O
with	O
a	O
normal	O
IgA	O
.	O

Biopsies	B-P
of	O
the	O
distal	O
duodenum	O
and	O
duodenal	O
cap	O
revealed	O
marked	O
blunting	O
of	O
the	O
villi	O
with	O
near	O
complete	O
villous	O
atrophy	O
of	O
the	O
biopsies	B-P
from	O
the	O
bulb	O
.	O

There	O
was	O
an	O
increase	O
in	O
intraepithelial	O
lymphocytes	O
as	O
well	O
as	O
neutrophils	O
in	O
the	O
surface	O
epithelium	O
.	O

The	O
patient	O
's	O
diarrhea	O
improved	O
upon	O
discontinuation	O
of	O
olmesartan	O
and	O
he	O
returned	O
to	O
his	O
previous	O
weight	O
.	O

Repeat	O
endoscopy	B-P
four	O
months	O
later	O
demonstrated	O
complete	O
resolution	O
of	O
inflammatory	O
change	O
with	O
normal	O
villous	O
architecture	O
.	O

Long-term	O
olmesartan	O
use	O
is	O
associated	O
with	O
severe	O
sprue-like	O
enteropathy	O
.	O

The	O
mechanism	O
of	O
intestinal	O
injury	O
is	O
unknown	O
.	O

Duodenal	B-P
biopsy	I-P
results	O
may	O
mimic	O
other	O
enteropathies	O
such	O
as	O
celiac	O
disease	O
.	O

Physicians	O
should	O
consider	O
medications	O
as	O
potential	O
etiologies	O
of	O
enteropathy	O
.	O

Long-term	O
lamivudine	O
therapy	O
in	O
chronic	O
hepatitis	O
B	O
.	O

One	O
to	O
5	O
years	O
of	O
therapy	O
of	O
chronic	O
hepatitis	O
B	O
with	O
oral	O
nucleoside	O
analogues	O
result	O
in	O
significant	O
clinical	O
improvements	O
,	O
but	O
effects	O
of	O
more	O
prolonged	O
therapy	O
are	O
not	O
well	O
defined	O
.	O

To	O
describe	O
outcomes	O
of	O
chronic	O
hepatitis	O
B	O
with	O
long-term	O
lamivudine	O
therapy	O
.	O

Forty-two	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
treated	O
with	O
lamivudine	O
were	O
followed	O
for	O
3.2-19.5	O
(	O
median	O
=	O
16.1	O
)	O
years	O
.	O

Therapy	O
was	O
switched	O
to	O
other	O
agents	O
(	O
n	O
=	O
16	O
)	O
if	O
patients	O
developed	O
lamivudine	O
resistance	O
and	O
relapse	O
of	O
disease	O
.	O

Among	O
22	O
HBeAg-positive	O
patients	O
,	O
17	O
(	O
77	O
%	O
)	O
became	O
HBeAg	O
negative	O
,	O
of	O
whom	O
5	O
(	O
23	O
%	O
)	O
subsequently	O
cleared	O
HBsAg	O
.	O

Among	O
20	O
HBeAg-negative	O
patients	O
,	O
10	O
(	O
50	O
%	O
)	O
cleared	O
HBsAg	O
.	O

The	O
time	O
to	O
HBsAg	O
clearance	O
ranged	O
from	O
0.9	O
to	O
16.8	O
(	O
median	O
=	O
9.3	O
)	O
years	O
.	O

Lamivudine	O
resistance	O
arose	O
in	O
24	O
patients	O
(	O
57	O
%	O
)	O
of	O
whom	O
6	O
(	O
25	O
%	O
)	O
lost	O
HBsAg	O
.	O

HBsAg	O
clearance	O
was	O
not	O
always	O
accompanied	O
by	O
seroconversion	O
;	O
anti-HBs	B-P
appearing	O
concurrently	O
in	O
only	O
five	O
patients	O
(	O
33	O
%	O
)	O
.	O

Nevertheless	O
,	O
HBsAg	O
loss	O
allowed	O
for	O
stopping	O
therapy	O
in	O
all	O
patients	O
,	O
none	O
re-developing	O
HBsAg	O
or	O
suffering	O
relapse	O
;	O
all	O
having	O
normal	O
alanine	B-P
aminotransferase	I-P
levels	I-P
and	O
no	O
(	O
n	O
=	O
13	O
)	O
or	O
unquantifiable	O
HBV	B-P
DNA	I-P
levels	I-P
(	O
n	O
=	O
2	O
)	O
when	O
last	O
seen	O
.	O

In	O
contrast	O
,	O
seven	O
of	O
27	O
patients	O
(	O
26	O
%	O
)	O
who	O
remained	O
HBsAg-positive	O
died	O
of	O
liver	O
disease	O
or	O
liver	O
cancer	O
or	O
underwent	O
liver	O
transplantation	O
,	O
all	O
of	O
whom	O
had	O
cirrhosis	O
.	O

Long-term	O
viral	O
suppression	O
with	O
nucleoside	O
analogues	O
leads	O
to	O
HBsAg	O
loss	O
in	O
a	O
substantial	O
proportion	O
of	O
patients	O
,	O
particularly	O
if	O
HBeAg-negative	O
.	O

Serious	O
outcomes	O
during	O
the	O
first	O
10-20	O
years	O
of	O
treatment	O
occur	O
largely	O
among	O
patients	O
with	O
pre-existing	O
cirrhosis	O
who	O
do	O
not	O
clear	O
HBsAg	O
with	O
therapy	O
.	O

Relationship	O
between	O
polycythemia	O
and	O
in-hospital	O
mortality	O
in	O
chronic	O
obstructive	O
pulmonary	O
disease	O
patients	O
with	O
low-risk	O
pulmonary	O
embolism	O
.	O

Pulmonary	O
embolism	O
(	O
PE	O
)	O
is	O
frequent	O
in	O
subjects	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
and	O
associated	O
with	O
high	O
mortality	O
.	O

This	O
multi-center	O
retrospective	O
study	O
was	O
performed	O
to	O
investigate	O
if	O
secondary	O
polycythemia	O
is	O
associated	O
with	O
in-hospital	O
mortality	O
in	O
COPD	O
patients	O
with	O
low-risk	O
PE	O
.	O

We	O
identified	O
COPD	O
patients	O
with	O
proven	O
PE	O
between	O
October	O
,	O
2005	O
and	O
October	O
,	O
2015	O
.	O

Patients	O
in	O
risk	O
classes	O
III-V	O
on	O
the	O
basis	O
of	O
the	O
PESI	O
score	O
were	O
excluded	O
.	O

We	O
extracted	O
demographic	O
,	O
clinical	O
and	O
laboratory	O
information	O
at	O
the	O
time	O
of	O
admission	O
from	O
medical	O
records	O
.	O

All	O
subjects	O
were	O
followed	O
until	O
hospital	O
discharge	O
to	O
identify	O
all-cause	O
mortality	O
.	O

We	O
enrolled	O
629	O
consecutive	O
patients	O
with	O
COPD	O
and	O
PE	O
at	O
low	O
risk	O
:	O
132	O
of	O
them	O
(	O
21.0	O
%	O
)	O
with	O
and	O
497	O
(	O
79.0	O
%	O
)	O
without	O
secondary	O
polycythemia	O
.	O

Compared	O
with	O
those	O
without	O
polycythemia	O
,	O
the	O
polycythemia	O
group	O
had	O
significantly	O
lower	O
forced	B-P
expiratory	I-P
volume	I-P
in	I-P
one	I-P
second	I-P
(	I-P
FEV1	I-P
)	I-P
level	I-P
(	O
0.9±0.3	O
vs.	O
1.4±0.5	O
,	O
P=0.000	O
)	O
,	O
lower	O
PaO2	O
and	O
SpO2	O
as	O
well	O
as	O
higher	O
PaCO2	O
(	O
P=0.03	O
,	O
P=0.03	O
and	O
P=0.000	O
,	O
respectively	O
)	O
.	O

COPD	O
patients	O
with	O
polycythemia	O
had	O
a	O
higher	O
proportion	O
of	O
arrhythmia	O
in	O
electrocardiogram	O
(	O
ECG	O
)	O
(	O
49.5	O
%	O
vs.	O
35.7	O
%	O
,	O
P=0.02	O
)	O
,	O
a	O
longer	O
hospital	O
duration	O
time	O
(	O
15.3±10.1	O
vs.	O
9.7±9.1	O
,	O
P=0.001	O
)	O
,	O
a	O
higher	O
mechanical	O
ventilation	O
rate	O
(	O
noninvasive	O
and	O
invasive	O
,	O
51.7	O
%	O
vs.	O
30.3	O
%	O
,	O
P=0.04	O
and	O
31.0	O
%	O
vs.	O
7.9	O
%	O
,	O
P=0.04	O
,	O
respectively	O
)	O
,	O
and	O
a	O
higher	O
in-hospital	O
mortality	O
(	O
12.1	O
%	O
vs.	O
6.6	O
%	O
,	O
P=0.04	O
)	O
.	O

Multivariate	O
logistic	O
regression	O
analysis	O
revealed	O
that	O
polycythemia	O
was	O
associated	O
with	O
mortality	O
in	O
COPD	O
patients	O
with	O
low-risk	O
PE	O
(	O
adjusted	O
OR	O
1.11	O
;	O
95	O
%	O
CI	O
,	O
1.04-1.66	O
)	O
.	O

Polycythemia	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
all-cause	O
in-hospital	O
mortality	O
in	O
COPD	O
patients	O
with	O
PE	O
at	O
low	O
risk	O
.	O

An	O
Improved	O
Culture	B-P
Method	I-P
for	O
Selective	O
Isolation	B-P
of	O
Campylobacter	O
jejuni	O
from	O
Wastewater	O
.	O

Campylobacter	O
jejuni	O
is	O
one	O
of	O
the	O
leading	O
foodborne	O
pathogens	O
worldwide	O
.	O

C.	O
jejuni	O
is	O
isolated	O
from	O
a	O
wide	O
range	O
of	O
foods	O
,	O
domestic	O
animals	O
,	O
wildlife	O
,	O
and	O
environmental	O
sources	O
.	O

The	O
currently	O
available	O
culture-based	B-P
isolation	I-P
methods	I-P
are	O
not	O
highly	O
effective	O
for	O
wastewater	O
samples	O
due	O
to	O
the	O
low	O
number	O
of	O
C.	O
jejuni	O
in	O
the	O
midst	O
of	O
competing	O
bacteria	O
.	O

To	O
detect	O
and	O
isolate	O
C.	O
jejuni	O
from	O
wastewater	O
samples	O
,	O
in	O
this	O
study	O
,	O
we	O
evaluated	O
a	O
few	O
different	O
enrichment	O
conditions	O
using	O
five	O
different	O
antibiotics	O
(	O
i.e.	O
,	O
cefoperazone	O
,	O
vancomycin	O
,	O
trimethoprim	O
,	O
polymyxin	O
B	O
,	O
and	O
rifampicin	O
)	O
,	O
to	O
which	O
C.	O
jejuni	O
is	O
intrinsically	O
resistant	O
.	O

The	O
selectivity	O
of	O
each	O
enrichment	O
condition	O
was	O
measured	O
with	O
C	O
t	O
value	O
using	O
quantitative	O
real-time	O
PCR	O
,	O
and	O
multiplex	O
PCR	O
to	O
determine	O
Campylobacter	O
species	O
.	O

In	O
addition	O
,	O
the	O
efficacy	O
of	O
Campylobacter	O
isolation	B-P
on	O
different	O
culture	O
media	O
after	O
selective	O
enrichment	O
was	O
examined	O
by	O
growing	O
on	O
Bolton	O
and	O
Preston	O
agar	O
plates	O
.	O

The	O
addition	O
of	O
polymyxin	O
B	O
,	O
rifampicin	O
,	O
or	O
both	O
to	O
the	O
Bolton	O
selective	O
supplements	O
enhanced	O
the	O
selective	O
isolation	B-P
of	O
C.	O
jejuni	O
.	O

The	O
results	O
of	O
16S	O
rDNA	O
sequencing	B-P
also	O
revealed	O
that	O
Enterococcus	O
spp	O
.	O

and	O
Pseudomonas	O
aeruginosa	O
are	O
major	O
competing	O
bacteria	O
in	O
the	O
enrichment	O
conditions	O
.	O

Although	O
it	O
is	O
known	O
to	O
be	O
difficult	O
to	O
isolate	O
Campylobacter	O
from	O
samples	O
with	O
heavy	O
contamination	O
,	O
this	O
study	O
well	O
exhibited	O
that	O
the	O
manipulation	O
of	O
antibiotic	O
selective	O
pressure	O
improves	O
the	O
isolation	B-P
efficiency	O
of	O
fastidious	O
Campylobacter	O
from	O
wastewater	O
.	O

Uncoupling	O
of	O
Vascular	O
Nitric	O
Oxide	O
Synthase	O
Caused	O
by	O
Intermittent	O
Hypoxia	O
.	O

Objective	O
.	O

Obstructive	O
sleep	O
apnea	O
(	O
OSA	O
)	O
,	O
characterized	O
by	O
chronic	O
intermittent	O
hypoxia	O
(	O
CIH	O
)	O
,	O
is	O
often	O
present	O
in	O
diabetic	O
(	O
DB	O
)	O
patients	O
.	O

Both	O
conditions	O
are	O
associated	O
with	O
endothelial	O
dysfunction	O
and	O
cardiovascular	O
disease	O
.	O

We	O
hypothesized	O
that	O
diabetic	O
endothelial	O
dysfunction	O
is	O
further	O
compromised	O
by	O
CIH	O
.	O

Methods	O
.	O

Adult	O
male	O
diabetic	O
(	O
BKS.Cg-Dock7	O
(	O
m	O
)	O
+/+	O
Lepr	O
(	O
db	O
)	O
/J	O
)	O
(	O
db/db	O
)	O
mice	O
(	O
10	O
weeks	O
old	O
)	O
and	O
their	O
heterozygote	O
littermates	O
were	O
subjected	O
to	O
CIH	O
or	O
intermittent	O
air	O
(	O
IA	O
)	O
for	O
8	O
weeks	O
.	O

Mice	O
were	O
separated	O
into	O
4	O
groups	O
:	O
IA	O
(	O
intermittent	O
air	O
nondiabetic	O
)	O
,	O
IH	O
(	O
intermittent	O
hypoxia	O
nondiabetic	O
)	O
,	O
IADB	O
(	O
intermittent	O
air	O
diabetic	O
)	O
,	O
and	O
IHDB	O
(	O
intermittent	O
hypoxia	O
diabetic	O
)	O
groups	O
.	O

Endothelium	O
-dependent	O
and	O
endothelium	O
-independent	O
relaxation	O
and	O
modulation	O
by	O
basal	O
nitric	O
oxide	O
(	O
NO	O
)	O
were	O
analyzed	O
using	O
wire	O
myograph	O
.	O

Plasma	O
8-isoprostane	O
,	O
interleukin-6	O
(	O
IL-6	O
)	O
,	O
and	O
asymmetric	O
dimethylarginine	O
(	O
ADMA	O
)	O
were	O
measured	O
using	O
ELISA	B-P
.	O

Uncoupling	O
of	O
eNOS	O
was	O
measured	O
using	O
dihydroethidium	O
(	O
DHE	O
)	O
staining	B-P
.	O

Results	O
.	O

Endothelium	O
-dependent	O
vasodilation	O
and	O
basal	O
NO	O
production	O
were	O
significantly	O
impaired	O
in	O
the	O
IH	O
and	O
IADB	O
group	O
compared	O
to	O
IA	O
group	O
but	O
was	O
more	O
pronounced	O
in	O
IHDB	O
group	O
.	O

Levels	O
of	O
8-isoprostane	O
,	O
IL-6	O
,	O
ADMA	O
,	O
and	O
eNOS	O
uncoupling	O
were	O
≈2-fold	O
higher	O
in	O
IH	O
and	O
IADB	O
groups	O
and	O
were	O
further	O
increased	O
in	O
the	O
IHDB	O
group	O
.	O

Conclusion	O
.	O

Endothelial	O
dysfunction	O
is	O
more	O
pronounced	O
in	O
diabetic	O
mice	O
subjected	O
to	O
CIH	O
compared	O
to	O
diabetic	O
or	O
CIH	O
mice	O
alone	O
.	O

Oxidative	O
stress	O
,	O
ADMA	O
,	O
and	O
eNOS	O
uncoupling	O
were	O
exacerbated	O
by	O
CIH	O
in	O
diabetic	O
mice	O
.	O

Chitosan	O
grafted	O
monomethyl	O
fumaric	O
acid	O
as	O
a	O
potential	O
food	O
preservative	O
.	O

The	O
present	O
study	O
aims	O
at	O
in	O
vitro	O
antibacterial	O
and	O
antioxidant	O
activity	O
evaluation	O
of	O
chitosan	O
modified	O
with	O
monomethyl	O
fumaric	O
acid	O
(	O
MFA	O
)	O
using	O
1-ethyl-3-	O
(	O
3-dimethylaminopropyl	O
)	O
carbodiimide	O
(	O
EDC	O
)	O
as	O
mediator	O
.	O

Three	O
different	O
kinds	O
of	O
chitosan	O
derivatives	O
Ch-Ds-1	O
,	O
Ch-Ds-2	O
and	O
Ch-Ds-3	O
were	O
synthesized	O
by	O
feeding	O
different	O
concentration	O
of	O
MFA	O
.	O

The	O
chemical	O
structures	O
of	O
resulting	O
materials	O
were	O
characterized	O
by	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
,	O
(	B-P
13	I-P
)	I-P
C	I-P
NMR	I-P
,	O
HR-XRD	B-P
,	O
FT-IR	O
and	O
TNBS	B-P
assay	I-P
.	O

The	O
results	O
showed	O
that	O
Ch-Ds-1	O
,	O
Ch-Ds-2	O
and	O
Ch-Ds-3	O
were	O
successfully	O
synthesized	O
.	O

The	O
%	O
amino	O
groups	O
of	O
chitosan	O
modified	O
by	O
MFA	O
were	O
evaluated	O
by	O
TNBS	B-P
assay	I-P
and	O
ranging	O
from	O
1.82±0.05	O
%	O
to	O
7.88±0.04	O
%	O
.	O

All	O
the	O
chitosan	O
derivatives	O
are	O
readily	O
soluble	O
in	O
water	O
and	O
swelled	O
by	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
,	O
toluene	O
and	O
dimethyl	O
formamide	O
(	O
DMF	O
)	O
.	O

The	O
antioxidant	O
activity	O
for	O
all	O
the	O
chitosan	O
derivatives	O
have	O
been	O
significantly	O
improved	O
(	O
P	O
<	O
0.05	O
)	O
compared	O
to	O
the	O
chitosan	O
.	O

Upon	O
antibacterial	O
activity	O
at	O
pH	O
4.0	O
,	O
all	O
the	O
chitosan	O
derivatives	O
showed	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
antibacterial	O
activity	O
against	O
Gram	O
positive	O
Staphylococcus	O
aureus	O
,	O
Listeria	O
monocytogenes	O
strains	O
and	O
Gram	O
negative	O
Escherichia	O
coli	O
and	O
Salmonella	O
enteritidis	O
strains	O
compared	O
to	O
chitosan	O
.	O

In	O
conclusion	O
,	O
MFA	O
modified	O
chitosan	O
has	O
shown	O
enhanced	O
activities	O
along	O
with	O
solubility	O
,	O
and	O
could	O
be	O
used	O
as	O
a	O
novel	O
food	O
preservative	O
and	O
packaging	O
material	O
for	O
long	O
time	O
food	O
safety	O
and	O
security	O
.	O

Gastric	O
metastasis	O
of	O
bilateral	O
breast	O
cancer	O
.	O

Breast	O
cancer	O
is	O
the	O
most	O
common	O
malignancy	O
in	O
women	O
.	O

The	O
most	O
frequent	O
metastatic	O
sites	O
are	O
lung	O
,	O
bone	O
,	O
liver	O
and	O
brain	O
.	O

On	O
the	O
other	O
hand	O
,	O
gastric	O
metastases	O
are	O
rare	O
.	O

Synchronous	O
bilateral	O
breast	O
cancer	O
(	O
SBBC	O
)	O
occurs	O
rarely	O
.	O

Lobular	O
carcinoma	O
is	O
the	O
histological	O
type	O
most	O
often	O
associated	O
with	O
bilateral	O
breast	O
carcinomas	O
and	O
gastric	O
metastases	O
.	O

We	O
made	O
a	O
retrospective	O
study	O
including	O
four	O
patients	O
followed	O
in	O
the	O
Salah	O
Azaiez	O
Institute	O
,	O
for	O
a	O
bilateral	O
breast	O
cancer	O
with	O
gastric	O
metastases	O
.	O

We	O
analyzed	O
the	O
epidemiological	O
,	O
anatomoclinical	O
and	O
therapeutic	O
particularities	O
of	O
this	O
rare	O
entity	O
.	O

Symptoms	O
were	O
unspecific	O
.	O

The	O
diagnosis	B-P
of	O
gastric	O
metastasis	O
of	O
the	O
SBBC	O
was	O
confirmed	O
by	O
a	O
histopathological	O
examination	O
of	O
an	O
endoscopic	B-P
biopsy	I-P
.	O

The	O
median	O
age	O
was	O
46.2	O
years	O
(	O
range	O
,	O
36-51	O
years	O
)	O
and	O
the	O
median	O
time	O
until	O
the	O
gastric	O
involvement	O
was	O
19	O
months	O
(	O
range	O
,	O
0-41	O
months	O
)	O
.	O

None	O
of	O
patients	O
had	O
a	O
surgical	O
treatment	O
for	O
the	O
gastric	O
location	O
.	O

All	O
Patients	O
received	O
at	O
least	O
one	O
line	O
of	O
chemotherapy	O
and	O
radiotherapy	O
.	O

Median	O
survival	O
following	O
the	O
detection	O
of	O
gastric	O
involvement	O
was	O
22	O
months	O
(	O
range	O
,	O
1-56	O
months	O
)	O
.	O

Gastric	O
metastases	O
from	O
breast	O
cancer	O
are	O
rare	O
and	O
frequently	O
associated	O
with	O
other	O
distant	O
metastasis	O
.	O

Symptoms	O
are	O
unspecific	O
and	O
endoscopy	B-P
may	O
not	O
be	O
contributive	O
.	O

Therefore	O
,	O
gastric	O
involvement	O
is	O
underestimated	O
.	O

Lobular	O
infiltrating	O
carcinoma	O
(	O
LIC	O
)	O
is	O
the	O
most	O
histological	O
type	O
incriminated	O
in	O
its	O
occurrence	O
.	O

The	O
supply	O
of	O
immunohistochemistry	B-P
is	O
crucial	O
to	O
distinguish	O
between	O
primary	O
or	O
metastatic	O
gastric	O
cancer	O
.	O

Exercise	O
increases	O
lactoferrin	O
,	O
but	O
decreases	O
lysozyme	O
in	O
salivary	O
granulocytes	O
.	O

Intracellular	O
lactoferrin	O
(	O
Lac	O
)	O
and	O
lysozyme	O
(	O
Lys	O
)	O
content	O
play	O
an	O
important	O
role	O
in	O
regulating	O
inflammation	O
and	O
promoting	O
host	O
protection	O
.	O

While	O
exercise	O
has	O
demonstrated	O
an	O
increase	O
in	O
Lac	O
and	O
Lys	O
concentration	O
in	O
exocrine	O
solutions	O
,	O
little	O
is	O
known	O
regarding	O
intracellular	O
concentration	O
changes	O
in	O
response	O
to	O
exercise	O
.	O

To	O
quantify	O
intracellular	O
Lac	O
and	O
Lys	O
concentration	O
before	O
and	O
after	O
exercise	O
in	O
salivary	O
CD45	O
(	O
+	O
)	O
CD15	O
(	O
+	O
)	O
cells	O
.	O

11	O
males	O
(	O
20.3	O
±	O
0.8	O
years	O
,	O
57.2	O
±	O
7.6	O
mL/kg/min	O
V̇O2pk	O
,	O
11.1	O
±	O
3.9	O
%	O
body	O
fat	O
)	O
ran	O
for	O
45	O
min	O
at	O
75	O
%	O
of	O
VO2pk	O
.	O

12	O
mL	O
of	O
stimulated	O
saliva	O
were	O
collected	O
pre	O
and	O
immediately	O
post	O
exercise	O
.	O

Saliva	O
was	O
filtered	O
through	O
a	O
30-µm	O
filter	O
before	O
analysis	O
of	O
leukocytes	O
(	O
CD45	O
(	O
+	O
)	O
)	O
and	O
granulocytes	O
(	O
CD45	O
(	O
+	O
)	O
CD15	O
(	O
+	O
)	O
)	O
using	O
flow	B-P
cytometry	I-P
.	O

Median	O
fluorescent	O
intensity	O
(	O
MFI	O
)	O
of	O
Lac	O
increased	O
from	O
pre	O
(	O
64,268	O
±	O
46,036	O
MFI	O
)	O
to	O
post	O
(	O
117,134	O
±	O
88,115	O
MFI	O
)	O
exercise	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Lys	O
MFI	O
decreased	O
with	O
exercise	O
(	O
pre	O
:	O
16,933	O
±	O
8249	O
;	O
post	O
:	O
11,616	O
±	O
6875	O
)	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Acute	O
running	O
resulted	O
in	O
an	O
increased	O
Lac	O
concentration	O
which	O
could	O
lead	O
to	O
a	O
decrease	O
in	O
inflammation	O
,	O
adding	O
further	O
evidence	O
of	O
the	O
anti-inflammatory	O
effects	O
of	O
exercise	O
.	O

Conversely	O
,	O
the	O
exercise	O
-associated	O
decrease	O
of	O
intracellular	O
Lys	O
content	O
could	O
be	O
the	O
cause	O
of	O
increased	O
Lys	O
in	O
exocrine	O
solutions	O
.	O

The	O
use	O
of	O
intraosseous	O
needles	O
for	O
injection	O
of	O
contrast	O
media	O
for	O
computed	B-P
tomographic	I-P
angiography	I-P
of	O
the	O
thoracic	O
aorta	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
safety	O
and	O
quality	O
of	O
computed	B-P
tomographic	I-P
angiography	I-P
of	O
the	O
thoracic	O
aorta	O
(	O
CTA-TA	B-P
)	O
exams	O
performed	O
using	O
intraosseous	B-P
needle	I-P
intravenous	I-P
access	I-P
(	O
ION-IVA	B-P
)	O
for	O
contrast	B-P
media	I-P
injection	I-P
(	O
CMI	B-P
)	O
.	O

All	O
CTA-TA	B-P
exams	O
at	O
the	O
study	O
institution	O
performed	O
between	O
1/1/2013	O
and	O
8/14/2015	O
were	O
reviewed	O
retrospectively	O
to	O
identify	O
those	O
exams	O
which	O
had	O
been	O
performed	O
using	O
ION-IVA	B-P
(	O
ION-exams	B-P
)	O
.	O

ION-exams	B-P
were	O
then	O
analyzed	O
to	O
determine	O
aortic	O
attenuation	O
and	O
contrast-to-noise	O
ratio	O
(	O
CNR	O
)	O
.	O

Linear	O
regression	O
was	O
used	O
to	O
determine	O
how	O
injection	O
rate	O
and	O
other	O
variables	O
affected	O
image	O
quality	O
for	O
ION-exams	B-P
.	O

Patient	O
electronic	O
medical	O
records	O
were	O
reviewed	O
to	O
identify	O
any	O
adverse	O
events	O
related	O
to	O
CTA-TA	B-P
or	O
ION-IVA	B-P
.	O

17	O
(	O
∼0.2	O
%	O
)	O
of	O
7401	O
exams	O
were	O
ION-exams	B-P
.	O

ION-exam	B-P
CMI	B-P
rates	O
varied	O
between	O
2.5	O
and	O
4	O
ml/s	O
.	O

Mean	O
attenuation	O
was	O
312	O
HU	O
(	O
SD	O
88	O
HU	O
)	O
and	O
mean	O
CNR	O
was	O
25	O
(	O
SD	O
9.9	O
)	O
.	O

A	O
strong	O
positive	O
linear	O
association	O
between	O
attenuation	O
and	O
injection	O
rate	O
was	O
found	O
.	O

No	O
immediate	O
or	O
delayed	O
complications	O
related	O
to	O
the	O
ION-exams	B-P
,	O
or	O
intraosseous	O
needle	O
use	O
in	O
general	O
,	O
occurred	O
.	O

For	O
CTA-TA	B-P
,	O
ION-IVA	B-P
appears	O
to	O
be	O
a	O
safe	O
and	O
effective	O
route	O
for	O
CMI	B-P
at	O
rates	O
up	O
to	O
4	O
ml/s	O
.	O

A	O
Caucasian	O
JK*A/JK*B	O
woman	O
with	O
Jk	O
(	O
a+b-	O
)	O
red	O
blood	O
cells	O
,	O
anti-Jkb	O
,	O
and	O
a	O
novel	O
JK*B	O
allele	O
c.1038delG	O
.	O

The	O
Kidd	O
blood	O
group	O
on	O
the	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
glycoprotein	O
urea	O
transporter-B	O
has	O
a	O
growing	O
number	O
of	O
weak	O
and	O
null	O
alleles	O
in	O
its	O
gene	O
SLC14A1	O
that	O
are	O
emerging	O
from	O
more	O
widespread	O
genotyping	B-P
of	O
blood	O
donors	O
and	O
patients	O
.	O

We	O
investigated	O
a	O
64-year-old	O
Caucasian	O
woman	O
of	O
Polish-Czech	O
descent	O
who	O
developed	O
anti-Jkb	O
detected	O
in	O
solid-phase	B-P
RBC	O
adherence	O
testing	O
within	O
12	O
days	O
after	O
7	O
units	O
of	O
RBCs	O
were	O
transfused	O
.	O

Her	O
RBCs	O
subsequently	O
typed	B-P
Jk	O
(	O
a+b–	O
)	O
by	O
licensed	O
reagents	O
and	O
human	O
antisera	O
.	O

Nevertheless	O
,	O
in	O
RBC	O
genotyping	B-P
(	O
BioArray	O
HEA	O
BeadChip	O
,	O
Immucor	O
,	O
Warren	O
,	O
NJ	O
)	O
performed	O
in	O
our	O
transfusion	O
service	O
on	O
all	O
patients	O
with	O
alloantibodies	O
,	O
her	O
Kidd	B-P
typing	I-P
was	O
JK*A/JK*B	O
based	O
on	O
the	O
Jka/Jkb	O
single	O
nucleotide	O
polymorphism	O
in	O
exon	O
9	O
(	O
c.838G	O
>	O
A	O
,	O
p.Asp280Asn	O
)	O
.	O

Genomic	O
analysis	O
and	O
cDNA	O
sequencing	B-P
of	O
her	O
JK*B	O
allele	O
revealed	O
a	O
novel	O
single-nucleotide	O
deletion	O
of	O
c.1038G	O
in	O
exon	O
11	O
,	O
predicting	O
a	O
frameshift	O
and	O
premature	O
stop	O
(	O
p.Thr346Thrfs*5	O
)	O
after	O
translation	O
of	O
nearly	O
90	O
percent	O
of	O
the	O
expressed	O
exons	O
4–11	O
.	O

This	O
allele	O
has	O
been	O
provisionally	O
named	O
JK*02N.14	O
,	O
subject	O
to	O
approval	O
by	O
the	O
International	O
Society	O
of	O
Blood	O
Transfusion	O
Working	O
Party	O
.	O

The	O
site	O
of	O
this	O
variant	O
is	O
closer	O
to	O
the	O
C-terminus	O
than	O
that	O
of	O
any	O
allele	O
associated	O
with	O
the	O
Jk	O
(	O
a–b–	O
)	O
phenotype	O
reported	O
to	O
date	O
.	O

Routine	O
genotyping	B-P
of	O
patients	O
with	O
RBC	O
alloantibodies	O
can	O
reveal	O
variants	O
posing	O
potential	O
risk	O
of	O
alloimmunization	O
.	O

Continuing	O
investigation	O
of	O
Kidd	O
variants	O
may	O
shed	O
light	O
on	O
the	O
structure	O
of	O
Kidd	O
antigens	O
and	O
the	O
function	O
of	O
urea	O
transporter-B	O
.	O

Depletion	O
of	O
NFBD1	O
/	O
MDC1	O
Induces	O
Apoptosis	O
in	O
Nasopharyngeal	O
Carcinoma	O
Cells	O
Through	O
the	O
p53	O
-	O
ROS	O
-	O
Mitochondrial	O
Pathway	O
.	O

NFBD1	O
,	O
a	O
signal	O
amplifier	O
of	O
the	O
p53	O
pathway	O
,	O
is	O
vital	O
for	O
protecting	O
cells	O
from	O
p53	O
-mediated	O
apoptosis	O
and	O
the	O
early	O
phase	O
of	O
DNA	O
damage	O
response	O
under	O
normal	B-P
culture	I-P
conditions	I-P
.	O

Here	O
we	O
investigated	O
its	O
expression	O
in	O
patients	O
with	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
,	O
and	O
we	O
describe	O
the	O
biological	O
functions	O
of	O
the	O
NFBD1	O
gene	O
.	O

We	O
found	O
that	O
NFBD1	O
mRNA	O
and	O
protein	O
were	O
more	O
highly	O
expressed	O
in	O
NPC	O
tissues	O
than	O
in	O
nontumorous	O
tissues	O
.	O

To	O
investigate	O
the	O
function	O
of	O
NFBD1	O
,	O
we	O
created	O
NFBD1	O
-	O
depleted	O
NPC	O
cell	O
lines	O
that	O
exhibited	O
decreased	O
cellular	O
proliferation	O
and	O
colony	O
formation	O
,	O
an	O
increase	O
in	O
their	O
rate	O
of	O
apoptosis	O
,	O
and	O
an	O
enhanced	O
sensitivity	O
to	O
chemotherapeutic	O
agents	O
compared	O
with	O
in	O
vitro	O
controls	O
.	O

However	O
,	O
N-acetyl	O
cysteine	O
(	O
NAC	O
)	O
and	O
downregulation	O
of	O
p53	O
expression	O
could	O
partially	O
reverse	O
the	O
apoptosis	O
caused	O
by	O
the	O
loss	O
of	O
NFBD1	O
.	O

Further	O
analysis	O
showed	O
that	O
loss	O
of	O
NFBD1	O
resulted	O
in	O
increased	O
production	O
of	O
intracellular	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
depending	O
on	O
p53	O
,	O
which	O
subsequently	O
triggered	O
the	O
mitochondrial	O
apoptotic	O
pathwa	O
y	O
.	O

Using	O
a	O
xenograft	O
model	O
in	O
nude	O
mice	O
,	O
we	O
showed	O
that	O
silencing	O
NFBD1	O
also	O
significantly	O
inhibited	O
tumor	O
growth	O
and	O
led	O
to	O
apoptosis	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
inhibition	O
of	O
NFBD1	O
in	O
NPC	O
could	O
be	O
therapeutically	O
useful	O
.	O

Intrinsic	O
rifamycin	O
resistance	O
of	O
Mycobacterium	O
abscessus	O
is	O
mediated	O
by	O
ADP-ribosyltransferase	O
MAB_0591	O
.	O

Rifampicin	O
,	O
a	O
potent	O
first-line	O
TB	O
drug	O
of	O
the	O
rifamycin	O
group	O
,	O
shows	O
only	O
little	O
activity	O
against	O
the	O
emerging	O
pathogen	O
Mycobacterium	O
abscessus	O
.	O

Reportedly	O
,	O
bacterial	O
resistance	O
to	O
rifampicin	O
is	O
associated	O
with	O
polymorphisms	O
in	O
the	O
target	O
gene	O
rpoB	O
or	O
the	O
presence	O
of	O
enzymes	O
that	O
modify	O
and	O
thereby	O
inactivate	O
rifampicin	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
the	O
MAB_0591	O
(	O
arrMab	O
)	O
-encoded	O
rifampicin	O
ADP-ribosyltransferase	O
(	O
Arr_Mab	O
)	O
in	O
innate	O
high-level	O
rifampicin	O
resistance	O
in	O
M.	O
abscessus	O
.	O

Recombinant	O
Escherichia	O
coli	O
and	O
Mycobacterium	O
tuberculosis	O
strains	O
expressing	O
MAB_0591	O
were	O
generated	O
,	O
as	O
was	O
an	O
M.	O
abscessus	O
deletion	O
mutant	O
deficient	O
for	O
MAB_0591	O
.	O

MIC	B-P
assays	I-P
were	O
used	O
to	O
study	O
susceptibility	O
to	O
rifampicin	O
and	O
C25	O
carbamate	O
-modified	O
rifamycin	O
derivatives	O
.	O

Heterologous	O
expression	O
of	O
MAB_0591	O
conferred	O
rifampicin	O
resistance	O
to	O
E.	O
coli	O
and	O
M.	O
tuberculosis	O
Rifamycin	O
MIC	O
values	O
were	O
consistently	O
lower	O
for	O
the	O
M.	O
abscessus	O
ΔarrMab	O
mutant	O
as	O
compared	O
with	O
the	O
M.	O
abscessus	O
ATCC	O
19977	O
parental	O
type	O
strain	O
.	O

The	O
rifamycin	O
WT	O
phenotype	O
was	O
restored	O
after	O
complementation	O
of	O
the	O
M.	O
abscessus	O
ΔarrMab	O
mutant	O
with	O
arrMab	O
Further	O
MIC	O
data	O
demonstrated	O
that	O
a	O
C25	O
modification	O
increases	O
rifamycin	O
activity	O
in	O
WT	O
M.	O
abscessus	O
However	O
,	O
MIC	O
studies	O
in	O
the	O
M.	O
abscessus	O
ΔarrMab	O
mutant	O
suggest	O
that	O
C25	O
modified	O
rifamycins	O
are	O
still	O
subject	O
to	O
modification	O
by	O
Arr_Mab	O
CONCLUSIONS	O
:	O
Our	O
findings	O
identify	O
Arr_Mab	O
as	O
the	O
major	O
innate	O
rifamycin	O
resistance	O
determinant	O
of	O
M.	O
abscessus	O
.	O

Our	O
data	O
also	O
indicate	O
that	O
Arr_Mab	O
-mediated	O
rifamycin	O
resistance	O
in	O
M.	O
abscessus	O
can	O
only	O
in	O
part	O
be	O
overcome	O
by	O
C25	O
carbamate	O
modification	O
.	O

ISX-9	O
can	O
potentiate	O
cell	O
proliferation	O
and	O
neuronal	O
commitment	O
in	O
the	O
rat	O
dentate	O
gyrus	O
.	O

Adult	O
hippocampal	O
neurogenesis	O
can	O
be	O
modulated	O
by	O
various	O
physiological	O
and	O
pathological	O
conditions	O
,	O
including	O
stress	O
,	O
affective	O
disorders	O
,	O
and	O
several	O
neurological	O
conditions	O
.	O

Given	O
the	O
proposed	O
role	O
of	O
this	O
form	O
of	O
structural	O
plasticity	O
in	O
the	O
functioning	O
of	O
the	O
hippocampus	O
(	O
namely	O
learning	O
and	O
memory	O
and	O
affective	O
behaviors	O
)	O
,	O
it	O
is	O
believed	O
that	O
alterations	O
in	O
hippocampal	O
neurogenesis	O
might	O
underlie	O
some	O
of	O
the	O
behavioral	O
deficits	O
associated	O
with	O
these	O
psychiatric	O
and	O
neurological	O
conditions	O
.	O

Thus	O
,	O
the	O
search	O
for	O
compounds	O
that	O
can	O
reverse	O
these	O
deficits	O
with	O
minimal	O
side	O
effects	O
has	O
become	O
a	O
recognized	O
priority	O
.	O

In	O
the	O
present	O
study	O
we	O
tested	O
the	O
pro-neurogenic	O
effects	O
of	O
isoxazole	O
9	O
(	O
Isx-9	O
)	O
,	O
a	O
small	O
synthetic	O
molecule	O
that	O
has	O
been	O
recently	O
identified	O
through	O
the	O
screening	B-P
of	I-P
chemical	I-P
libraries	I-P
in	O
stem	B-P
cell-based	I-P
assays	I-P
.	O

We	O
found	O
that	O
administration	O
of	O
Isx-9	O
for	O
14days	O
was	O
able	O
to	O
potentiate	O
cell	O
proliferation	O
and	O
increase	O
the	O
number	O
of	O
immature	O
neurons	O
in	O
the	O
hippocampal	O
DG	O
of	O
adult	O
rats	O
.	O

In	O
addition	O
,	O
Isx-9	O
treatment	O
was	O
able	O
to	O
completely	O
reverse	O
the	O
marked	O
reduction	O
in	O
these	O
initial	O
stages	O
of	O
the	O
neurogenic	O
process	O
observed	O
in	O
vehicle	O
-	O
treated	O
animals	O
(	O
which	O
were	O
submitted	O
to	O
repeated	O
handling	B-P
and	O
exposure	O
to	O
daily	O
intraperitoneal	O
injections	O
)	O
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
recommend	O
that	O
future	O
neurogenesis	O
studies	O
that	O
require	O
repeated	O
handling	B-P
and	O
manipulation	O
of	O
animals	O
should	O
include	O
a	O
naïve	O
(	O
non-manipulated	O
)	O
control	O
to	O
determine	O
the	O
baseline	O
levels	O
of	O
hippocampal	O
cell	O
proliferation	O
and	O
neuronal	O
differentiation	O
.	O

Overall	O
,	O
these	O
findings	O
demonstrate	O
that	O
Isx-9	O
is	O
a	O
promising	O
synthetic	O
compound	O
for	O
the	O
mitigation	O
of	O
stress	O
-	O
induced	O
deficits	O
in	O
adult	O
hippocampal	O
neurogenesis	O
.	O

Future	O
studies	O
are	O
thus	O
warranted	O
to	O
evaluate	O
the	O
pro-neurogenic	O
properties	O
of	O
Isx-9	O
in	O
animal	O
models	O
of	O
affective	O
and	O
neurological	O
disorders	O
associated	O
with	O
impaired	O
hippocampal	O
structural	O
plasticity	O
.	O

Randomized	O
Controlled	O
Trial	O
of	O
Mineralocorticoid	O
Receptor	O
Blockade	O
in	O
Children	O
with	O
Chronic	O
Kidney	O
Allograft	O
Nephropathy	O
.	O

We	O
showed	O
that	O
mineralocorticoid	O
receptor	O
blockade	O
(	O
MRB	O
)	O
prevented	O
acute	O
and	O
chronic	O
cyclosporine	O
nephropathy	O
(	O
CsA-Nx	O
)	O
in	O
the	O
rat	O
.	O

The	O
aim	O
of	O
this	O
translational	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
long-term	O
eplerenone	O
administration	O
on	O
renal	O
allograft	O
function	O
in	O
children	O
with	O
biopsy	B-P
-proven	O
chronic	O
allograft	O
nephropathy	O
(	O
CAN	O
)	O
.	O

Renal	O
transplant	O
children	O
<	O
18	O
years	O
,	O
biopsy	B-P
-proven	O
CAN	O
,	O
and	O
a	O
GFR	B-P
>	O
40	O
ml/min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
were	O
included	O
.	O

Patients	O
with	O
BK	O
virus	O
active	O
nephritis	O
,	O
recurrence	O
of	O
renal	O
disease	O
,	O
GFR	O
decline	O
in	O
previous	O
3	O
months	O
,	O
or	O
treated	O
with	O
calcium	O
antagonists	O
or	O
antifungal	O
drugs	O
were	O
excluded	O
.	O

They	O
were	O
randomized	O
to	O
receive	O
placebo	O
(	O
n=10	O
)	O
or	O
eplerenone	O
25	O
mg/d	O
for	O
24	O
months	O
(	O
n=13	O
)	O
.	O

Visits	O
were	O
scheduled	O
at	O
baseline	O
,	O
6	O
,	O
12	O
,	O
and	O
24	O
months	O
.	O

At	O
each	O
period	O
,	O
a	O
complete	O
clinical	O
examination	O
was	O
performed	O
and	O
blood	O
and	O
urine	O
samples	O
were	O
taken	O
.	O

Urine	B-P
creatinine	I-P
,	O
8-hydroxylated-guanosine	O
,	O
heat	O
shock	O
protein	O
72	O
(	O
HSP72	O
)	O
,	O
and	O
kidney	B-P
injury	I-P
molecule	I-P
(	I-P
KIM-1	I-P
)	I-P
levels	I-P
were	O
also	O
assessed	O
.	O

In	O
kidney	O
biopsy	O
samples	O
,	O
the	O
tubulo-interstitial	B-P
area	I-P
affected	I-P
by	I-P
fibrosis	I-P
(	O
TIF	B-P
)	O
and	O
glomerulosclerosis	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
24	O
months	O
.	O

The	O
baseline	O
eGFR	B-P
was	O
80±6	O
in	O
the	O
placebo	O
and	O
86±6	O
ml/min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
in	O
the	O
eplerenone	O
group	O
;	O
at	O
24	O
months	O
it	O
was	O
66±8	O
and	O
81±7	O
ml/min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
,	O
respectively	O
(	O
P=0.33	O
;	O
95	O
%	O
confidence	O
intervals	O
,	O
-18	O
to	O
33	O
at	O
baseline	O
,	O
and	O
-11	O
to	O
40	O
after	O
24	O
months	O
)	O
.	O

The	O
albumin-to-creatinine	O
ratio	O
was	O
110±74	O
in	O
the	O
placebo	O
,	O
and	O
265±140	O
mg/g	O
in	O
the	O
eplerenone	O
group	O
;	O
and	O
after	O
24	O
months	O
it	O
was	O
276±140	O
and	O
228±88	O
mg/g	O
,	O
respectively	O
(	O
P=0.15	O
;	O
95	O
%	O
confidence	O
intervals	O
,	O
-283	O
to	O
593	O
,	O
and	O
-485	O
to	O
391	O
,	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
the	O
placebo	O
exhibited	O
a	O
greater	O
TIF	B-P
,	O
glomerulosclerosis	O
,	O
and	O
urinary	O
HSP72	O
compared	O
with	O
the	O
eplerenone	O
group	O
.	O

Although	O
this	O
study	O
was	O
underpowered	O
to	O
provide	O
definitive	O
evidence	O
that	O
long-term	O
eplerenone	O
administration	O
attenuates	O
the	O
progression	O
of	O
CAN	O
in	O
pediatric	O
transplant	O
patients	O
,	O
it	O
encourages	O
testing	O
the	O
potential	O
benefit	O
of	O
MRB	O
in	O
this	O
pediatric	O
population	O
.	O

A	O
proteomic	B-P
evaluation	I-P
of	O
urinary	O
changes	O
associated	O
with	O
cardiopulmonary	O
bypass	O
.	O

The	O
urinary	O
proteome	O
of	O
patients	O
undergoing	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
may	O
provide	O
important	O
insights	O
into	O
systemic	O
and	O
renal	O
changes	O
associated	O
with	O
the	O
procedure	O
.	O

Such	O
information	O
may	O
ultimately	O
provide	O
a	O
basis	O
to	O
differentiate	O
changes	O
or	O
properties	O
associated	O
with	O
the	O
development	O
of	O
acute	O
kidney	O
injury	O
.	O

While	O
mass	B-P
spectrometry	I-P
(	O
MS	B-P
)	O
analysis	O
offers	O
the	O
potential	O
for	O
in-depth	O
compositional	O
analysis	O
it	O
is	O
often	O
limited	O
in	O
coverage	O
and	O
relative	O
quantitation	O
capacity	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
process	O
flow	O
for	O
the	O
preparation	O
and	O
comparison	O
of	O
the	O
intraoperative	O
urinary	O
proteome	O
.	O

Urines	O
were	O
collected	O
from	O
patients	O
at	O
the	O
start	O
of	O
CPB	O
and	O
1-h	O
into	O
CPB	O
.	O

Pooled	O
samples	O
(	O
n	O
=	O
5	O
)	O
from	O
each	O
time	O
point	O
were	O
processed	O
using	O
a	O
modified	B-P
Filter	I-P
Assisted	I-P
Sample	I-P
Preparation	I-P
protocol	I-P
.	O

The	O
resulting	O
peptides	O
were	O
analyzed	O
by	O
2D-LC-MS	B-P
/	O
MS	B-P
and	O
by	O
1D-LC-MS	B-P
/	O
MS	B-P
SWATH	B-P
(	O
Sequential	B-P
Window	I-P
acquisition	I-P
of	I-P
All	I-P
Theoretical	I-P
fragment	I-P
ion	I-P
spectra	I-P
)	O
.	O

The	O
2D-LC-MS	B-P
/	O
MS	B-P
analysis	O
identified	O
1324	O
proteins	O
in	O
the	O
two	O
pools	O
,	O
of	O
which	O
744	O
were	O
quantifiable	O
.	O

The	O
SWATH	B-P
approach	I-P
provided	O
quantitation	O
for	O
730	O
proteins	O
,	O
552	O
of	O
which	O
overlapped	O
with	O
the	O
common	O
population	O
from	O
the	O
2D-IDA	O
results	O
.	O

Intensity	O
correlation	O
filtering	O
between	O
the	O
two	O
methods	O
gave	O
475	O
proteins	O
for	O
biological	O
interpretation	O
.	O

Proteins	O
displaying	O
greater	O
than	O
threefold	O
changes	O
(	O
>	O
log2	O
1.59	O
)	O
at	O
1-hour	O
CPB	O
relative	O
to	O
the	O
initiation	O
of	O
CPB	O
(	O
26	O
down-regulated	O
and	O
22	O
up-regulated	O
)	O
were	O
selected	O
for	O
further	O
analysis	O
.	O

Up-regulated	O
proteins	O
were	O
enriched	O
in	O
GO	O
terms	O
related	O
to	O
humoral	O
immune	O
response	O
,	O
predominantly	O
innate	O
immunity	O
(	O
C4b	O
,	O
lactotransferrin	O
,	O
protein	O
S100-A8	O
,	O
cathelicidin	O
,	O
myeloperoxidase	O
)	O
and	O
extracellular	O
matrix	O
reorganization	O
(	O
e.g	O
.	O

MMP-9	O
)	O
.	O

This	O
study	O
describes	O
a	O
scheme	O
for	O
processing	B-P
urine	O
from	O
patients	O
undergoing	O
CPB	O
for	O
mass	B-P
spectrometry	I-P
-based	O
analysis	B-P
.	O

The	O
introduction	O
of	O
SWATH	B-P
into	O
the	O
workflow	O
offers	O
a	O
sample	O
and	O
instrument	O
sparing	O
approach	O
to	O
obtaining	O
consistent	O
in-depth	B-P
sample	I-P
analysis	I-P
.	O

The	O
design	O
of	O
the	O
methodology	O
is	O
such	O
that	O
it	O
can	O
be	O
readily	O
applied	O
to	O
large	O
numbers	O
of	O
clinical	O
samples	O
with	O
the	O
potential	O
for	O
automation	O
.	O

The	O
results	O
also	O
suggest	O
that	O
activation	O
of	O
the	O
innate	O
immune	O
responses	O
occur	O
during	O
cardiac	O
bypass	O
surgery	O
.	O

Discontinued	O
Splenogonadal	O
Fusion	O
and	O
Bilateral	O
Empty	O
Scrotum	O
in	O
an	O
18-	O
Month	O
-Old	O
Boy	O
.	O

Splenogonadal	O
fusion	O
is	O
a	O
rare	O
benign	O
congenital	O
anomaly	O
defined	O
as	O
the	O
presence	O
of	O
splenic	O
tissue	O
adherent	O
to	O
gonads	O
.	O

It	O
was	O
first	O
described	O
in	O
1883	O
by	O
Bostroem	O
,	O
a	O
German	O
pathologist	O
.	O

We	O
present	O
a	O
case	O
of	O
an	O
18-	O
month	O
-old	O
boy	O
who	O
was	O
referred	O
as	O
a	O
case	O
of	O
bilateral	O
empty	O
scrotum	O
since	O
birth	O
.	O

During	O
routine	O
laparoscopic	B-P
exploration	O
,	O
right	O
vas	O
deferens	O
and	O
testicular	O
vessels	O
were	O
entering	O
the	O
right	O
internal	O
inguinal	O
ring	O
so	O
right	O
inguinal	O
exploration	O
was	O
done	O
,	O
which	O
revealed	O
blind	O
ending	O
vas	O
deferens	O
and	O
testicular	O
vessels	O
and	O
the	O
left	O
testis	O
was	O
found	O
intra-abdominally	O
near	O
the	O
left	O
internal	O
ring	O
with	O
a	O
mass	O
on	O
its	O
upper	O
pole	O
.	O

Wedge	B-P
biopsy	I-P
was	O
taken	O
from	O
the	O
upper	O
pole	O
of	O
the	O
testicle	O
(	O
site	O
of	O
the	O
mass	O
)	O
for	O
tissue	O
diagnosis	O
followed	O
by	O
orchidopexy	O
.	O

Histology	B-P
showed	O
splenic	O
tissue	O
.	O

Although	O
splenogonadal	O
fusion	O
is	O
a	O
rare	O
condition	O
,	O
surgeons	O
should	O
be	O
aware	O
of	O
this	O
rare	O
disease	O
entity	O
to	O
avoid	O
unnecessary	O
aggressive	O
interventions	O
such	O
as	O
orchiectomy	O
.	O

Spontaneous	O
regression	O
of	O
a	O
parafalcine	O
meningioma	O
in	O
a	O
multiple	O
sclerosis	O
patient	O
being	O
treated	O
with	O
interferon	O
beta-1a	O
.	O

Regression	O
of	O
meningioma	O
after	O
haemorrhage	O
and	O
the	O
cessation	O
of	O
hormone	O
treatment	O
is	O
well	O
reported	O
.	O

However	O
,	O
spontaneous	O
regression	O
is	O
very	O
rarely	O
observed	O
.	O

Here	O
,	O
we	O
report	O
the	O
spontaneous	O
regression	O
of	O
a	O
parafalcine	O
meningioma	O
in	O
a	O
56-	O
year	O
-old	O
woman	O
with	O
multiple	O
sclerosis	O
,	O
who	O
was	O
referred	O
to	O
our	O
department	O
after	O
an	O
incidental	O
finding	O
on	O
magnetic	B-P
resonance	I-P
imaging	I-P
.	O

She	O
was	O
being	O
treated	O
with	O
interferon	O
beta-1a	O
to	O
manage	O
the	O
symptoms	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
spontaneous	O
regression	O
of	O
meningioma	O
in	O
a	O
patient	O
receiving	O
interferon	O
beta-1a	O
therapy	O
and	O
just	O
the	O
second	O
report	O
of	O
spontaneous	O
regression	O
in	O
general	O
.	O

CD169	O
is	O
a	O
marker	O
for	O
highly	O
pathogenic	O
phagocytes	O
in	O
multiple	O
sclerosis	O
.	O

Phagocytes	O
,	O
such	O
as	O
macrophages	O
and	O
microglia	O
,	O
are	O
key	O
effector	O
cells	O
in	O
the	O
pathophysiology	O
of	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
.	O

It	O
is	O
widely	O
accepted	O
that	O
they	O
instigate	O
and	O
promote	O
neuroinflammatory	O
and	O
neurodegenerative	O
events	O
in	O
MS.	O
An	O
increasing	O
amount	O
of	O
studies	O
indicate	O
that	O
Siglec-1	O
,	O
also	O
known	O
CD169	O
,	O
is	O
a	O
marker	O
for	O
activated	O
phagocytes	O
in	O
inflammatory	O
disorders	O
.	O

In	O
this	O
study	O
,	O
we	O
set	O
out	O
to	O
define	O
how	O
CD169	O
(	O
+	O
)	O
phagocytes	O
contribute	O
to	O
neuroinflammation	O
in	O
MS.	O
CD169	O
-	O
diphtheria	O
toxin	O
receptor	O
(	O
DTR	O
)	O
mice	O
,	O
which	O
express	O
human	O
DTR	O
under	O
control	O
of	O
the	O
CD169	O
promoter	O
,	O
were	O
used	O
to	O
define	O
the	O
impact	O
of	O
CD169	O
(	O
+	O
)	O
cells	O
on	O
neuroinflammation	O
.	O

Flow	B-P
cytometry	I-P
and	O
immunohistochemistry	B-P
were	O
utilized	O
to	O
determine	O
the	O
expression	O
and	O
distribution	O
of	O
CD169	O
.	O

We	O
show	O
that	O
CD169	O
is	O
highly	O
expressed	O
by	O
lesional	O
and	O
circulating	O
phagocytes	O
in	O
MS	O
and	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
.	O

Our	O
data	O
further	O
indicate	O
that	O
CD169	O
represents	O
a	O
selective	O
marker	O
for	O
early	O
activated	O
microglia	O
in	O
MS	O
and	O
EAE	O
lesions	O
.	O

Depletion	O
of	O
CD169	O
(	O
+	O
)	O
cells	O
markedly	O
reduced	O
neuroinflammation	O
and	O
ameliorated	O
disease	O
symptoms	O
in	O
EAE	O
-	O
affected	O
mice	O
.	O

Our	O
findings	O
indicate	O
that	O
CD169	O
(	O
+	O
)	O
cells	O
promote	O
neuroinflammation	O
.	O

Furthermore	O
,	O
they	O
suggest	O
that	O
CD169	O
(	O
+	O
)	O
phagocytes	O
play	O
a	O
key	O
role	O
in	O
the	O
pathophysiology	O
of	O
MS	O
.	O

Hence	O
,	O
targeting	O
CD169	O
(	O
+	O
)	O
phagocytes	O
may	O
hold	O
therapeutic	O
value	O
for	O
MS	O
.	O

Cobalt-60	O
Machines	O
and	O
Medical	O
Linear	O
Accelerators	O
:	O
Competing	O
Technologies	O
for	O
External	O
Beam	O
Radiotherapy	O
.	O

Medical	O
linear	O
accelerators	O
(	O
linacs	O
)	O
and	O
cobalt-60	O
machines	O
are	O
both	O
mature	O
technologies	O
for	O
external	O
beam	O
radiotherapy	O
.	O

A	O
comparison	O
is	O
made	O
between	O
these	O
two	O
technologies	O
in	O
terms	O
of	O
infrastructure	O
and	O
maintenance	O
,	O
dosimetry	B-P
,	O
shielding	O
requirements	O
,	O
staffing	O
,	O
costs	O
,	O
security	O
,	O
patient	O
throughput	O
and	O
clinical	O
use	O
.	O

Infrastructure	O
and	O
maintenance	O
are	O
more	O
demanding	O
for	O
linacs	O
due	O
to	O
the	O
complex	O
electric	O
componentry	O
.	O

In	O
dosimetry	B-P
,	O
a	O
higher	O
beam	O
energy	O
,	O
modulated	O
dose	O
rate	O
and	O
smaller	O
focal	O
spot	O
size	O
mean	O
that	O
it	O
is	O
easier	O
to	O
create	O
an	O
optimised	O
treatment	O
with	O
a	O
linac	O
for	O
conformal	O
dose	O
coverage	O
of	O
the	O
tumour	O
while	O
sparing	O
healthy	O
organs	O
at	O
risk	O
.	O

In	O
shielding	O
,	O
the	O
requirements	O
for	O
a	O
concrete	O
bunker	O
are	O
similar	O
for	O
cobalt-60	O
machines	O
and	O
linacs	O
but	O
extra	O
shielding	O
and	O
protection	O
from	O
neutrons	O
are	O
required	O
for	O
linacs	O
.	O

Staffing	O
levels	O
can	O
be	O
higher	O
for	O
linacs	O
and	O
more	O
staff	O
training	O
is	O
required	O
for	O
linacs	O
.	O

Life	O
cycle	O
costs	O
are	O
higher	O
for	O
linacs	O
,	O
especially	O
multi-energy	O
linacs	O
.	O

Security	O
is	O
more	O
complex	O
for	O
cobalt-60	O
machines	O
because	O
of	O
the	O
high	O
activity	O
radioactive	O
source	O
.	O

Patient	O
throughput	O
can	O
be	O
affected	O
by	O
source	O
decay	O
for	O
cobalt-60	O
machines	O
but	O
poor	O
maintenance	O
and	O
breakdowns	O
can	O
severely	O
affect	O
patient	O
throughput	O
for	O
linacs	O
.	O

In	O
clinical	O
use	O
,	O
more	O
complex	O
treatment	O
techniques	O
are	O
easier	O
to	O
achieve	O
with	O
linacs	O
,	O
and	O
the	O
availability	O
of	O
electron	O
beams	O
on	O
high	O
-	O
energy	O
linacs	O
can	O
be	O
useful	O
for	O
certain	O
treatments	O
.	O

In	O
summary	O
,	O
there	O
is	O
no	O
simple	O
answer	O
to	O
the	O
question	O
of	O
the	O
choice	O
of	O
either	O
cobalt-60	O
machines	O
or	O
linacs	O
for	O
radiotherapy	O
in	O
low-	O
and	O
middle-income	O
countries	O
.	O

In	O
fact	O
a	O
radiotherapy	O
department	O
with	O
a	O
combination	O
of	O
technologies	O
,	O
including	O
orthovoltage	O
X-ray	O
units	O
,	O
may	O
be	O
an	O
option	O
.	O

Local	O
needs	O
,	O
conditions	O
and	O
resources	O
will	O
have	O
to	O
be	O
factored	O
into	O
any	O
decision	O
on	O
technology	O
taking	O
into	O
account	O
the	O
characteristics	O
of	O
both	O
forms	O
of	O
teletherapy	O
,	O
with	O
the	O
primary	O
goal	O
being	O
the	O
sustainability	O
of	O
the	O
radiotherapy	O
service	O
over	O
the	O
useful	O
lifetime	O
of	O
the	O
equipment	O
.	O

Prevalence	O
of	O
Self-Reported	O
Prescription	O
Drug	O
Use	O
in	O
a	O
National	O
Sample	O
of	O
U.S	O
.	O

Drivers	O
.	O

Drug	O
-involved	O
driving	O
has	O
become	O
an	O
increasing	O
concern	O
.	O

Although	O
the	O
focus	O
has	O
been	O
on	O
illegal	O
drugs	O
,	O
there	O
is	O
evidence	O
that	O
prescribed	O
medications	O
can	O
impair	O
driving	O
ability	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	B-P
the	O
self-reported	O
prevalence	O
of	O
prescription	O
drug	O
use	O
,	O
including	O
medical	O
and	O
nonmedical	O
use	O
,	O
among	O
a	O
nationally	O
representative	O
sample	O
of	O
drivers	O
and	O
to	O
report	O
related	O
driver	O
characteristics	O
.	O

As	O
part	O
of	O
the	O
2013-2014	O
National	O
Roadside	O
Survey	O
,	O
drivers	O
from	O
60	O
sites	O
were	O
randomly	O
recruited	O
and	O
asked	O
to	O
complete	O
a	O
survey	O
on	O
prescription	O
drug	O
use	O
.	O

Almost	O
20	O
%	O
of	O
drivers	O
reported	O
using	O
a	O
prescription	O
drug	O
within	O
the	O
past	O
2	O
days	O
,	O
with	O
the	O
most	O
common	O
drug	O
class	O
being	O
sedatives	O
(	O
8.0	O
%	O
)	O
,	O
followed	O
by	O
antidepressants	O
(	O
7.7	O
%	O
)	O
,	O
narcotics	O
(	O
7.5	O
%	O
)	O
,	O
and	O
stimulants	O
(	O
3.9	O
%	O
)	O
.	O

Drivers	O
who	O
reported	O
prescription	O
drug	O
use	O
were	O
significantly	O
more	O
likely	O
to	O
be	O
female	O
,	O
older	O
,	O
non-Hispanic	O
White	O
,	O
and	O
report	O
disability	O
.	O

Three	O
of	O
four	O
drivers	O
who	O
reported	O
medication	O
use	O
(	O
78.2	O
%	O
)	O
said	O
the	O
drug	O
was	O
prescribed	O
for	O
their	O
use	O
;	O
the	O
odds	O
of	O
using	O
without	O
a	O
prescription	O
were	O
significantly	O
higher	O
for	O
males	O
,	O
Black/African	O
American	O
,	O
and	O
Hispanic	O
drivers	O
,	O
and	O
lower	O
for	O
older	O
drivers	O
.	O

Among	O
those	O
with	O
a	O
prescription	O
,	O
taking	O
more	O
than	O
prescribed	O
was	O
most	O
common	O
for	O
narcotics	O
(	O
6.8	O
%	O
)	O
,	O
followed	O
by	O
sedatives	O
(	O
4.8	O
%	O
)	O
,	O
stimulants	O
(	O
3.8	O
%	O
)	O
,	O
and	O
antidepressants	O
(	O
1.5	O
%	O
)	O
.	O

These	O
findings	O
help	O
to	O
identify	O
drivers	O
using	O
potentially	O
impairing	O
prescription	O
drugs	O
,	O
both	O
medically	O
and	O
nonmedically	O
,	O
and	O
may	O
inform	O
the	O
targeting	O
of	O
interventions	O
to	O
reduce	O
impaired	O
driving	O
related	O
to	O
medications	O
.	O

Impact	O
of	O
AAC	O
(	O
6	O
'	O
)	O
-Ib-cr	O
in	O
combination	O
with	O
chromosomal	O
-mediated	O
mechanisms	O
on	O
clinical	O
quinolone	O
resistance	O
in	O
Escherichia	O
coli	O
.	O

aac	O
(	O
6	O
'	O
)	O
-Ib-cr	O
is	O
the	O
most	O
prevalent	O
plasmid	O
-mediated	O
fluoroquinolone	O
(	O
FQ	O
)	O
resistance	O
mechanism	O
in	O
Enterobacteriaceae	O
.	O

We	O
aimed	O
to	O
analyse	O
the	O
interplay	O
between	O
this	O
plasmid	O
-mediated	O
gene	O
and	O
chromosomal	O
-mediated	O
quinolone	O
resistance	O
mechanisms	O
on	O
both	O
FQ	O
resistance	O
and	O
bacterial	O
fitness	O
in	O
Escherichia	O
coli	O
.	O

E.	O
coli	O
ATCC	O
25922	O
and	O
derived	O
isogenic	O
strains	O
carrying	O
chromosomal	O
-mediated	O
quinolone	O
resistance	O
modifications	O
(	O
Ser83Leu-Asp87Asn	O
in	O
GyrA	O
,	O
Ser80Arg	O
in	O
ParC	O
and/or	O
a	O
marR	O
gene	O
deletion	O
)	O
were	O
electroporated	B-P
with	O
a	O
pBK-CMV	O
vector	O
encoding	O
AAC	O
(	O
6	O
'	O
)	O
-Ib-cr	O
.	O

The	O
MICs	O
of	O
FQs	O
were	O
determined	O
by	O
microdilution	B-P
and	O
bactericidal	O
activity	O
was	O
determined	O
using	O
time-kill	O
curves	O
.	O

A	O
peritoneal	O
sepsis	O
murine	O
model	O
was	O
used	O
to	O
evaluate	O
the	O
in	O
vivo	O
impact	O
.	O

Bacterial	O
fitness	O
was	O
analysed	O
using	O
growth	O
curves	O
and	O
competition	B-P
assays	I-P
.	O

The	O
presence	O
of	O
the	O
aac	O
(	O
6	O
'	O
)	O
-Ib-cr	O
gene	O
increased	O
the	O
MICs	O
of	O
ciprofloxacin	O
and	O
norfloxacin	O
4-8-fold	O
for	O
all	O
E.	O
coli	O
genotypes	O
,	O
independently	O
of	O
the	O
initial	O
resistance	O
level	O
.	O

Combination	O
of	O
the	O
aac	O
(	O
6	O
'	O
)	O
-Ib-cr	O
gene	O
with	O
three	O
or	O
four	O
chromosomal	O
mechanisms	O
was	O
necessary	O
to	O
reach	O
MIC	O
values	O
above	O
the	O
susceptible	O
category	O
.	O

Killing	O
curve	O
assays	O
showed	O
a	O
clear	O
selective	O
advantage	O
for	O
survival	O
in	O
strains	O
harbouring	O
the	O
aac	O
(	O
6	O
'	O
)	O
-Ib-cr	O
gene	O
(	O
up	O
to	O
7	O
log10	O
cfu/mL	O
after	O
24	O
h	O
)	O
.	O

AAC	O
(	O
6	O
'	O
)	O
-Ib-cr	O
significantly	O
reduced	O
the	O
ciprofloxacin	O
efficacy	O
in	O
vivo	O
.	O

In	O
terms	O
of	O
bacterial	O
fitness	O
cost	O
,	O
maximal	O
OD	O
was	O
significantly	O
lower	O
for	O
all	O
strains	O
harbouring	O
the	O
aac	O
(	O
6	O
'	O
)	O
-Ib-cr	O
gene	O
,	O
independently	O
of	O
chromosomal	O
mutations	O
associated	O
.	O

The	O
aac	O
(	O
6	O
'	O
)	O
-Ib-cr	O
gene	O
,	O
in	O
spite	O
of	O
producing	O
low-level	O
resistance	O
by	O
itself	O
,	O
plays	O
a	O
relevant	O
role	O
in	O
acquisition	O
of	O
a	O
clinical	O
level	O
of	O
ciprofloxacin	O
and	O
norfloxacin	O
resistance	O
,	O
when	O
combined	O
with	O
three	O
or	O
four	O
chromosomal	O
mutations	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Insensitivity	O
of	O
astrocytes	O
to	O
interleukin	O
10	O
signaling	O
following	O
peripheral	O
immune	O
challenge	O
results	O
in	O
prolonged	O
microglial	O
activation	O
in	O
the	O
aged	O
brain	O
.	O

Immune-activated	O
microglia	O
from	O
aged	O
mice	O
produce	O
exaggerated	O
levels	O
of	O
cytokines	O
.	O

Despite	O
high	O
levels	O
of	O
microglia	O
l	O
interleukin	O
(	O
IL	O
)	O
-10	O
in	O
the	O
aged	O
brain	O
,	O
neuroinflammation	O
was	O
prolonged	O
and	O
associated	O
with	O
depressive-like	O
deficits	O
.	O

Because	O
astrocytes	O
respond	O
to	O
IL-10	O
and	O
,	O
in	O
turn	O
,	O
attenuate	O
microglial	O
activation	O
,	O
we	O
investigated	O
if	O
astrocyte-mediated	O
resolution	O
of	O
microglial	O
activation	O
was	O
impaired	O
with	O
age	O
.	O

Here	O
,	O
aged	O
astrocytes	O
had	O
a	O
dysfunctional	O
profile	O
with	O
higher	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
lower	O
glutamate	O
transporter	O
expression	O
,	O
and	O
significant	O
cytoskeletal	O
re-arrangement	O
.	O

Moreover	O
,	O
aged	O
astrocytes	O
had	O
reduced	O
expression	O
of	O
growth	O
factors	O
and	O
IL-10	O
receptor-1	O
(	O
IL-10R1	O
)	O
.	O

After	O
in	O
vivo	O
lipopolysaccharide	O
immune	O
challenge	O
,	O
aged	O
astrocytes	O
had	O
a	O
molecular	O
signature	O
associated	O
with	O
reduced	O
responsiveness	O
to	O
IL-10	O
.	O

This	O
IL-10	O
insensitivity	O
of	O
aged	O
astrocytes	O
resulted	O
in	O
a	O
failure	O
to	O
induce	O
IL-10R1	O
and	O
transforming	O
growth	O
factor	O
β	O
and	O
resolve	O
microglial	O
activation	O
.	O

In	O
addition	O
,	O
adult	O
astrocytes	O
reduced	O
microglial	O
activation	O
when	O
co-cultured	B-P
ex	O
vivo	O
,	O
whereas	O
aged	O
astrocytes	O
did	O
not	O
.	O

Consistent	O
with	O
the	O
aging	O
studies	O
,	O
IL-10R	O
(	O
KO	O
)	O
astrocytes	O
did	O
not	O
augment	O
transforming	O
growth	O
factor	O
β	O
after	O
immune	O
challenge	O
and	O
failed	O
to	O
resolve	O
microglial	O
activation	O
.	O

Collectively	O
,	O
a	O
major	O
cytokine	O
-	O
regulatory	O
loop	O
between	O
activated	O
microglia	O
and	O
astrocytes	O
is	O
impaired	O
in	O
the	O
aged	O
brain	O
.	O

Potential	O
role	O
of	O
microRNA-10b	O
down-regulation	O
in	O
cardiomyocyte	O
apoptosis	O
in	O
aortic	O
stenosis	O
patients	O
.	O

MicroRNAs	O
have	O
been	O
associated	O
with	O
cardiomyocyte	O
apoptosis	O
,	O
a	O
process	O
involved	O
in	O
myocardial	O
remodelling	O
in	O
aortic	O
valve	O
(	O
Av	O
)	O
stenosis	O
(	O
AS	O
)	O
.	O

Our	O
aim	O
was	O
to	O
analyse	O
whether	O
the	O
dysregulation	O
of	O
myocardial	O
microRNAs	O
was	O
related	O
to	O
cardiomyocyte	O
apoptosis	O
in	O
AS	O
patients	O
.	O

Endomyocardial	B-P
biopsies	I-P
were	O
obtained	O
from	O
28	O
patients	O
with	O
severe	O
AS	O
(	O
based	O
on	O
pressure	O
gradients	O
and	O
Av	O
area	O
)	O
referred	O
for	O
Av	O
replacement	O
and	O
from	O
necropsies	B-P
of	O
10	O
cardiovascular	O
disease-free	O
control	O
subjects	O
.	O

AS	O
patients	O
showed	O
an	O
increased	O
(	O
P	O
<	O
0.001	O
)	O
cardiomyocyte	O
apoptotic	O
index	O
(	O
CMAI	O
)	O
compared	O
with	O
controls	O
.	O

Two	O
clusters	O
of	O
patients	O
were	O
identified	O
according	O
to	O
the	O
CMAI	O
:	O
group	O
1	O
(	O
CMAI	O
≤	O
0.08	O
%	O
;	O
n=16	O
)	O
and	O
group	O
2	O
(	O
CMAI	O
>	O
0.08	O
%	O
;	O
n=12	O
)	O
.	O

Group	O
2	O
patients	O
presented	O
lower	O
cardiomyocyte	O
density	O
(	O
P	O
<	O
0.001	O
)	O
and	O
ejection	O
fraction	O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	O
higher	O
troponin	O
T	O
levels	O
(	O
P	O
<	O
0.05	O
)	O
,	O
prevalence	O
of	O
heart	O
failure	O
(	O
HF	O
;	O
P	O
<	O
0.05	O
)	O
and	O
NT-proBNP	O
levels	O
(	O
P	O
<	O
0.05	O
)	O
than	O
those	O
from	O
group	O
1.	O
miRNA	O
expression	O
profile	B-P
analysed	O
in	O
5	O
patients	O
randomly	O
selected	O
from	O
each	O
group	O
showed	O
64	O
microRNAs	O
down-regulated	O
and	O
6	O
up-regulated	O
(	O
P	O
<	O
0.05	O
)	O
in	O
group	O
2	O
compared	O
with	O
group	O
1	O
.	O

Those	O
microRNAs	O
with	O
the	O
highest	O
fold-change	O
were	O
validated	O
in	O
the	O
full	O
two	O
groups	O
corroborating	O
that	O
miR-10b	O
,	O
miR-125b-2*	O
and	O
miR-338-3p	O
were	O
down-regulated	O
(	O
P	O
<	O
0.05	O
)	O
in	O
group	O
2	O
compared	O
with	O
group	O
1	O
and	O
control	O
subjects	O
.	O

These	O
three	O
microRNAs	O
were	O
inversely	O
correlated	O
(	O
P	O
<	O
0.05	O
)	O
with	O
the	O
CMAI	O
.	O

Inhibition	O
of	O
miR-10b	O
induced	O
an	O
increase	O
(	O
P	O
<	O
0.05	O
)	O
of	O
apoptosis	O
and	O
increased	O
expression	O
(	O
P	O
<	O
0.05	O
)	O
of	O
apoptosis	O
protease-activating	O
factor-1	O
(	O
Apaf-1	O
)	O
in	O
HL-1	O
cardiomyocytes	O
.	O

In	O
conclusion	O
,	O
myocardial	O
down-regulation	O
of	O
miR-10b	O
may	O
be	O
involved	O
in	O
increased	O
cardiomyocyte	O
apoptosis	O
in	O
AS	O
patients	O
,	O
probably	O
through	O
Apaf-1	O
up-regulation	O
,	O
contributing	O
to	O
cardiomyocyte	O
damage	O
and	O
to	O
the	O
development	O
of	O
HF	O
.	O

Multimodal	B-P
brain	I-P
imaging	I-P
with	O
magnetoencephalography	B-P
:	O
A	O
method	B-P
for	O
measuring	O
blood	O
pressure	O
and	O
cardiorespiratory	O
oscillations	O
.	O

Studies	O
with	O
magnetoencephalography	B-P
(	O
MEG	B-P
)	O
are	O
still	O
quite	O
rarely	O
combined	O
simultaneously	O
with	O
methods	B-P
that	O
can	O
provide	O
a	O
metabolic	O
dimension	O
to	O
MEG	B-P
investigation	O
s.	O
In	O
addition	O
,	O
continuous	O
blood	O
pressure	O
measurements	O
which	O
comply	O
with	O
MEG	B-P
compatibility	O
requirements	O
are	O
lacking	O
.	O

For	O
instance	O
,	O
by	O
combining	O
methods	B-P
reflecting	O
neurovascular	O
status	O
one	O
could	O
obtain	O
more	O
information	O
on	O
low	O
frequency	O
fluctuations	O
that	O
have	O
recently	O
gained	O
increasing	O
interest	O
as	O
a	O
mediator	O
of	O
functional	O
connectivity	O
within	O
brain	O
networks	O
.	O

This	O
paper	O
presents	O
a	O
multimodal	B-P
brain	I-P
imaging	I-P
setup	O
,	O
capable	O
to	O
non-invasively	O
and	O
continuously	O
measure	O
cerebral	O
hemodynamic	O
,	O
cardiorespiratory	B-P
and	O
blood	O
pressure	O
oscillations	O
simultaneously	O
with	O
MEG	B-P
.	O

In	O
the	O
setup	O
,	O
all	O
methods	B-P
apart	O
from	O
MEG	B-P
rely	O
on	O
the	O
use	O
of	O
fibre	O
optics	O
.	O

In	O
particular	O
,	O
we	O
present	O
a	O
method	B-P
for	O
measuring	O
of	O
blood	O
pressure	O
and	O
cardiorespiratory	O
oscillations	O
continuously	O
with	O
MEG	B-P
.	O

The	O
potential	O
of	O
this	O
type	O
of	O
multimodal	B-P
setup	O
for	O
brain	O
research	O
is	O
demonstrated	O
by	O
our	O
preliminary	O
studies	O
on	O
human	O
,	O
showing	O
effects	O
of	O
mild	O
hypercapnia	O
,	O
gathered	O
simultaneously	O
with	O
the	O
presented	O
modalities	O
.	O

Habitual	O
physical	O
activity	O
is	O
associated	O
with	O
improved	O
anthropometric	O
and	O
androgenic	O
profile	B-P
in	O
PCOS	O
:	O
a	O
cross-sectional	O
study	O
.	O

To	O
examine	O
the	O
effect	O
of	O
habitual	O
physical	O
activity	O
(	O
PA	O
)	O
on	O
the	O
metabolic	O
and	O
hormonal	B-P
profiles	I-P
of	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
.	O

Anthropometric	O
,	O
metabolic	B-P
and	O
hormonal	B-P
assessment	I-P
and	O
determination	O
of	O
habitual	O
PA	O
levels	O
with	O
a	O
digital	O
pedometer	O
were	O
evaluated	O
in	O
84	O
women	O
with	O
PCOS	O
and	O
67	O
age-	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
-matched	O
controls	O
.	O

PA	O
status	O
was	O
defined	O
according	O
to	O
number	O
of	O
steps	O
(	O
≥7500	O
steps	O
,	O
active	O
,	O
or	O
<	O
7500	O
steps	O
,	O
sedentary	O
)	O
.	O

BMI	O
was	O
lower	O
in	O
active	O
women	O
from	O
both	O
groups	O
.	O

Active	O
PCOS	O
women	O
presented	O
lower	O
waist	O
circumference	O
(	O
WC	O
)	O
and	O
lipid	O
accumulation	O
product	O
(	O
LAP	O
)	O
values	O
versus	O
sedentary	O
PCOS	O
women	O
.	O

In	O
the	O
control	O
group	O
,	O
active	O
women	O
also	O
had	O
lower	O
WC	O
,	O
lower	O
values	O
for	O
fasting	O
and	O
120-min	O
insulin	O
,	O
and	O
lower	O
LAP	O
than	O
sedentary	O
controls	O
.	O

In	O
the	O
PCOS	O
group	O
,	O
androgen	O
levels	O
were	O
lower	O
in	O
active	O
versus	O
sedentary	O
women	O
(	O
p	O
=	O
0.001	O
)	O
.	O

In	O
the	O
control	O
group	O
,	O
free	O
androgen	O
index	O
(	O
FAI	O
)	O
was	O
also	O
lower	O
in	O
active	O
versus	O
sedentary	O
women	O
(	O
p	O
=	O
0.018	O
)	O
.	O

Homeostasis	O
model	O
assessment	O
of	O
insulin	O
resistance	O
and	O
2000	O
daily	O
step	O
increments	O
were	O
independent	O
predictors	O
of	O
FAI	O
.	O

Each	O
2000	O
daily	O
step	O
increment	O
was	O
associated	O
with	O
a	O
decrease	O
of	O
1.07	O
in	O
FAI	O
.	O

Habitual	O
PA	O
was	O
associated	O
with	O
a	O
better	O
anthropometric	O
and	O
androgenic	O
profile	B-P
in	O
PCOS	O
.	O

Transparent	O
nanostructured	O
cellulose	O
acetate	O
films	O
based	O
on	O
the	O
self	O
assembly	O
of	O
PEO-b-PPO-b-PEO	O
block	O
copolymer	O
.	O

In	O
this	O
study	O
fabrication	O
and	O
characterization	O
of	O
transparent	O
nanostructured	O
composite	O
films	O
based	O
on	O
cellulose	O
triacetate	O
(	O
CTA	O
)	O
and	O
poly	O
(	O
ethylene	O
oxide	O
)	O
-b-poly	O
(	O
propylene	O
oxide	O
)	O
-b-poly	O
(	O
ethylene	O
oxide	O
)	O
(	O
EPE	O
)	O
triblock	O
copolymer	O
were	O
presented	O
.	O

The	O
effect	O
of	O
the	O
addition	O
of	O
EPE	O
triblock	O
copolymer	O
on	O
the	O
thermal	B-P
stability	I-P
,	O
morphology	O
,	O
and	O
mechanical	O
properties	O
of	O
cellulose	O
triacetate	O
films	O
was	O
investigated	O
.	O

The	O
triblock	O
EPE	O
was	O
chosen	O
since	O
PEO	O
blocks	O
interact	O
favorably	O
with	O
CTA	O
,	O
whereas	O
,	O
PPO	O
blocks	O
remain	O
immiscible	O
which	O
provokes	O
a	O
microphase	O
separation	O
.	O

This	O
allows	O
to	O
obtain	O
EPE	O
/	O
CTA	O
composite	O
films	O
with	O
ordered	O
microphase-separated	O
structures	O
where	O
PPO	O
spherical	O
microdomains	O
are	O
well-dispersed	O
in	O
PEO	O
/	O
CTA	O
matrix	O
by	O
simple	O
solvent	O
-	O
evaporation	O
process	O
.	O

During	O
this	O
process	O
,	O
PEO	O
block	O
chains	O
selectively	O
interact	O
with	O
CTA	O
by	O
strong	O
interpolymer	O
hydrogen-bonding	O
while	O
PPO	O
block	O
microseparated	O
.	O

The	O
addition	O
even	O
40wt	O
%	O
of	O
EPE	O
leads	O
to	O
nanostructured	O
EPE	O
/	O
CTA	O
composite	O
.	O

The	O
cytotoxicity	B-P
assay	I-P
of	O
CTA	O
and	O
EPE	O
/	O
CTA	O
composite	O
films	O
confirm	O
non-toxic	O
character	O
of	O
designed	O
transparent	O
nanostructured	O
composites	O
based	O
on	O
sustainable	O
matrices	O
.	O

Extensor	O
indicis	O
proprius	O
tendon	O
transfer	O
using	O
shear	B-P
wave	I-P
elastography	I-P
.	O

The	O
means	O
for	O
judging	O
optimal	O
tension	O
during	O
tendon	O
transfers	O
are	O
approximate	O
and	O
not	O
very	O
quantifiable	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
demonstrate	O
the	O
feasibility	O
of	O
quantitatively	O
assessing	O
muscular	O
mechanical	O
properties	O
intraoperatively	O
using	O
ultrasound	B-P
elastography	I-P
(	O
shear	B-P
wave	I-P
elastography	I-P
[	O
SWE	B-P
]	O
)	O
during	O
extensor	O
indicis	O
proprius	O
(	O
EIP	O
)	O
transfer	O
.	O

We	O
report	O
two	O
cases	O
of	O
EIP	O
transfer	O
for	O
post-traumatic	O
rupture	O
of	O
the	O
extensor	O
pollicis	O
longus	O
muscle	O
.	O

Ultrasound	O
acquisitions	O
measured	O
the	O
elasticity	O
modulus	O
of	O
the	O
EIP	O
muscle	O
at	O
different	O
stages	O
:	O
rest	O
,	O
active	O
extension	O
,	O
active	O
extension	O
against	O
resistance	O
,	O
EIP	O
section	O
,	O
distal	O
passive	O
traction	O
of	O
the	O
tendon	O
,	O
after	O
tendon	O
transfer	O
at	O
rest	O
and	O
then	O
during	O
active	O
extension	O
.	O

A	O
preliminary	O
analysis	O
was	O
conducted	O
of	O
the	O
distribution	O
of	O
values	O
for	O
this	O
modulus	O
at	O
the	O
various	O
transfer	O
steps	O
.	O

Different	O
shear	O
wave	O
velocity	O
and	O
elasticity	O
modulus	O
values	O
were	O
observed	O
at	O
the	O
various	O
transfer	O
steps	O
.	O

The	O
tension	O
applied	O
during	O
the	O
transfer	O
seemed	O
close	O
to	O
the	O
resting	O
tension	O
if	O
a	O
traditional	O
protocol	O
were	O
followed	O
.	O

The	O
elasticity	O
modulus	O
varied	O
by	O
a	O
factor	O
of	O
37	O
between	O
the	O
active	O
extension	O
against	O
resistance	O
step	O
(	O
565.1	O
kPa	O
)	O
and	O
after	O
the	O
tendon	O
section	O
(	O
15.3	O
kPa	O
)	O
.	O

The	O
elasticity	O
modulus	O
values	O
were	O
distributed	O
in	O
the	O
same	O
way	O
for	O
each	O
patient	O
.	O

The	O
therapeutic	O
benefit	O
of	O
SWE	B-P
elastography	B-P
was	O
studied	O
for	O
the	O
first	O
time	O
in	O
tendon	O
transfers	O
.	O

Quantitative	O
data	O
on	O
the	O
elasticity	O
modulus	O
during	O
this	O
test	O
may	O
make	O
it	O
an	O
effective	O
means	O
of	O
improving	O
intraoperative	O
adjustments	O
.	O

Encaged	O
Chironomus	O
riparius	O
larvae	O
in	O
assessment	O
of	O
trace	O
metal	O
bioavailability	O
and	O
transfer	O
in	O
a	O
landfill	O
leachate	O
collection	O
pond	O
.	O

Household	O
wastes	O
may	O
constitute	O
a	O
vector	O
of	O
environmental	O
contamination	O
when	O
buried	O
,	O
in	O
particular	O
through	O
degradation	O
and	O
production	O
of	O
leachates	O
containing	O
significant	O
trace	O
metal	O
(	O
TM	O
)	O
concentrations	O
that	O
may	O
constitute	O
a	O
serious	O
risk	O
to	O
biota	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
assess	O
the	O
bioavailability	O
and	O
transfer	O
potential	O
of	O
various	O
TMs	O
present	O
in	O
water	O
and	O
sediments	O
in	O
a	O
reservoir	O
receiving	O
landfill	O
leachates	O
.	O

An	O
active	O
biomonitoring	O
approach	O
was	O
adopted	O
consisting	O
of	O
exposing	O
naive	O
laboratory	O
organisms	O
in	O
cages	O
deployed	O
in	O
the	O
field	O
.	O

Aquatic	O
insects	O
such	O
as	O
Chironomus	O
riparius	O
larvae	O
are	O
good	O
candidates	O
since	O
they	O
represent	O
key	O
organisms	O
in	O
the	O
trophic	O
functioning	O
of	O
aquatic	O
ecosystems	O
.	O

The	O
results	O
show	O
that	O
water	O
,	O
suspended	O
particles	O
,	O
and	O
sediments	O
were	O
significant	O
ly	O
contaminated	O
by	O
various	O
TMs	O
(	O
As	O
,	O
Cd	O
,	O
Cu	O
,	O
Ni	O
,	O
Pb	O
,	O
and	O
Zn	O
)	O
.	O

Their	O
contribution	O
to	O
the	O
transfer	O
of	O
TMs	O
depends	O
,	O
however	O
,	O
on	O
the	O
specific	O
element	O
considered	O
,	O
e.g.	O
,	O
Cd	O
in	O
sediments	O
or	O
Pb	O
in	O
both	O
suspended	O
particles	O
and	O
sediments	O
.	O

The	O
internal	O
fate	O
of	O
TMs	O
was	O
investigated	O
according	O
to	O
their	O
fractionation	B-P
between	O
an	O
insoluble	O
and	O
a	O
cytosolic	O
fraction	O
.	O

This	O
approach	O
revealed	O
different	O
detoxification	O
strategies	O
capable	O
of	O
preventing	O
the	O
induction	O
of	O
deleterious	O
effects	O
at	O
the	O
individual	O
scale	O
.	O

However	O
,	O
the	O
accumulation	O
of	O
several	O
TMs	O
in	O
C.	O
riparius	O
larvae	O
tissues	O
may	O
also	O
represent	O
a	O
significant	O
load	O
potentially	O
transferable	O
to	O
higher	O
trophic	O
levels	O
.	O

Sewage	O
sludge	O
pretreatment	O
by	O
microwave	O
irradiation	O
combined	O
with	O
activated	O
carbon	O
fibre	O
at	O
alkaline	O
pH	O
for	O
anaerobic	O
digestion	O
.	O

This	O
research	O
focuses	O
on	O
the	O
effects	O
of	O
microwave	O
-assisted	O
activated	O
carbon	O
fibre	O
(	O
ACF	O
)	O
(	O
MW	O
-	O
ACF	O
)	O
treatment	O
on	O
sewage	O
sludge	O
at	O
alkaline	O
pH	O
.	O

The	O
disintegration	O
and	O
biodegradability	O
of	O
sewage	O
sludge	O
were	O
studied	O
.	O

It	O
was	O
found	O
that	O
the	O
MW-ACF	O
process	O
at	O
alkaline	O
pH	O
provided	O
a	O
rapid	O
and	O
efficient	O
process	O
to	O
disrupt	O
the	O
microbial	O
cells	O
in	O
the	O
sludge	O
.	O

The	O
results	O
suggested	O
that	O
when	O
irradiated	O
at	O
800	O
W	O
MW	O
for	O
110	O
s	O
with	O
a	O
dose	O
of	O
1.0	O
g	O
ACF	O
/g	O
solid	O
concentration	O
(	O
SS	O
)	O
at	O
pH	O
10.5	O
,	O
the	O
MW	O
-	O
ACF	O
pretreatment	O
achieved	O
55	O
%	O
SS	O
disintegration	O
,	O
23	O
%	O
greater	O
than	O
the	O
value	O
of	O
MW	O
alone	O
(	O
32	O
%	O
)	O
.	O

The	O
concentration	O
of	O
total	B-P
nitrogen	I-P
,	O
total	B-P
phosphorus	I-P
,	O
supernatant	B-P
soluble	I-P
chemical	I-P
oxygen	I-P
demand	I-P
,	O
protein	B-P
,	O
and	O
polysaccharide	O
increased	O
by	O
60	O
%	O
,	O
144	O
%	O
,	O
145	O
%	O
,	O
74	O
%	O
,	O
and	O
77	O
%	O
,	O
respectively	O
.	O

An	O
increase	O
in	O
biogas	O
production	O
by	O
63.7	O
%	O
was	O
achieved	O
after	O
20	O
days	O
of	O
anaerobic	O
digestion	O
(	O
AD	O
)	O
,	O
compared	O
to	O
the	O
control	O
.	O

The	O
results	O
indicated	O
that	O
the	O
MW-ACF	O
pretreatment	O
process	O
at	O
alkaline	O
pH	O
provides	O
novel	O
sludge	O
management	O
options	O
in	O
disintegration	O
of	O
sewage	O
sludge	O
for	O
further	O
AD	O
.	O

Examining	O
the	O
relationship	O
between	O
home	O
literacy	O
environment	O
and	O
neural	O
correlates	O
of	O
phonological	O
processing	O
in	O
beginning	O
readers	O
with	O
and	O
without	O
a	O
familial	O
risk	O
for	O
dyslexia	O
:	O
an	O
fMRI	B-P
study	I-P
.	O

Developmental	O
dyslexia	O
is	O
a	O
language	O
-	O
based	O
learning	O
disability	O
characterized	O
by	O
persistent	O
difficulty	O
in	O
learning	O
to	O
read	O
.	O

While	O
an	O
understanding	O
of	O
genetic	O
contributions	O
is	O
emerging	O
,	O
the	O
ways	O
the	O
environment	O
affects	O
brain	O
functioning	O
in	O
children	O
with	O
developmental	O
dyslexia	O
are	O
poorly	O
understood	O
.	O

A	O
relationship	O
between	O
the	O
home	O
literacy	O
environment	O
(	O
HLE	O
)	O
and	O
neural	O
correlates	O
of	O
reading	O
has	O
been	O
identified	O
in	O
typically	O
developing	O
children	O
,	O
yet	O
it	O
remains	O
unclear	O
whether	O
similar	O
effects	O
are	O
observable	O
in	O
children	O
with	O
a	O
genetic	O
predisposition	O
for	O
dyslexia	O
.	O

Understanding	O
environmental	O
contributions	O
is	O
important	O
given	O
that	O
we	O
do	O
not	O
understand	O
why	O
some	O
genetically	O
at-risk	O
children	O
do	O
not	O
develop	O
dyslexia	O
.	O

Here	O
,	O
we	O
investigate	O
for	O
the	O
first	O
time	O
the	O
relationship	O
between	O
HLE	O
and	O
the	O
neural	O
correlates	O
of	O
phonological	O
processing	O
in	O
beginning	O
readers	O
with	O
(	O
FHD+	O
,	O
n	O
=	O
29	O
)	O
and	O
without	O
(	O
FHD-	O
,	O
n	O
=	O
21	O
)	O
a	O
family	O
history	O
of	O
developmental	O
dyslexia	O
.	O

We	O
further	O
controlled	O
for	O
socioeconomic	O
status	O
to	O
isolate	O
the	O
neurobiological	O
mechanism	O
by	O
which	O
HLE	O
affects	O
reading	O
development	O
.	O

Group	O
differences	O
revealed	O
stronger	O
correlation	O
of	O
HLE	O
with	O
brain	O
activation	O
in	O
the	O
left	O
inferior	O
/	O
middle	O
frontal	O
and	O
right	O
fusiform	O
gyri	O
in	O
FHD-	O
compared	O
to	O
FHD+	O
children	O
,	O
suggesting	O
greater	O
impact	O
of	O
HLE	O
on	O
manipulation	O
of	O
phonological	O
codes	O
and	O
recruitment	O
of	O
orthographic	O
representations	O
in	O
typically	O
developing	O
children	O
.	O

In	O
contrast	O
,	O
activation	O
in	O
the	O
right	O
precentral	O
gyrus	O
showed	O
a	O
significantly	O
stronger	O
correlation	O
with	O
HLE	O
in	O
FHD+	O
compared	O
to	O
FHD-	O
children	O
,	O
suggesting	O
emerging	O
compensatory	O
networks	O
in	O
genetically	O
at-risk	O
children	O
.	O

Overall	O
,	O
our	O
results	O
suggest	O
that	O
genetic	O
predisposition	O
for	O
dyslexia	O
alters	O
contributions	O
of	O
HLE	O
to	O
early	O
reading	O
skills	O
before	O
formal	O
reading	O
instruction	O
,	O
which	O
has	O
important	O
implications	O
for	O
educational	O
practice	O
and	O
intervention	O
models	O
.	O

Quantitative	B-P
Susceptibility	I-P
Mapping	I-P
using	O
Structural	O
Feature	O
based	O
Collaborative	O
Reconstruction	O
(	O
SFCR	O
)	O
in	O
the	O
Human	O
Brain	O
.	O

The	O
reconstruction	O
of	O
MR	O
quantitative	B-P
susceptibility	I-P
mapping	I-P
(	O
QSM	B-P
)	O
from	O
local	O
phase	O
measurements	O
is	O
an	O
ill	O
posed	O
inverse	O
problem	O
and	O
different	O
regularization	O
strategies	O
incorporating	O
a	O
priori	O
information	O
extracted	O
from	O
magnitude	O
and	O
phase	O
images	O
have	O
been	O
proposed	O
.	O

However	O
,	O
the	O
anatomy	O
observed	O
in	O
magnitude	O
and	O
phase	O
images	O
does	O
not	O
always	O
coincide	O
spatially	O
with	O
that	O
in	O
susceptibility	O
maps	O
,	O
which	O
could	O
give	O
erroneous	O
estimation	O
in	O
the	O
reconstructed	O
susceptibility	O
map	O
.	O

In	O
this	O
paper	O
,	O
we	O
develop	O
a	O
structural	O
feature	O
based	O
collaborative	O
reconstruction	O
(	O
SFCR	O
)	O
method	O
for	O
QSM	B-P
including	O
both	O
magnitude	O
and	O
susceptibility	O
based	O
information	O
.	O

The	O
SFCR	O
algorithm	O
is	O
composed	O
of	O
two	O
consecutive	O
steps	O
corresponding	O
to	O
complementary	O
reconstruction	O
models	O
,	O
each	O
with	O
a	O
structural	O
feature	O
based	O
l1	O
norm	O
constraint	O
and	O
a	O
voxel	O
fidelity	O
based	O
l2	O
norm	O
constraint	O
,	O
which	O
allows	O
both	O
the	O
structure	O
edges	O
and	O
tiny	O
features	O
to	O
be	O
recovered	O
,	O
whereas	O
the	O
noise	O
and	O
artifacts	O
could	O
be	O
reduced	O
.	O

In	O
the	O
M-step	O
,	O
the	O
initial	O
susceptibility	O
map	O
is	O
reconstructed	O
by	O
employing	O
a	O
k-space	O
based	O
compressed	O
sensing	O
model	O
incorporating	O
magnitude	O
prior	O
.	O

In	O
the	O
S-step	O
,	O
the	O
susceptibility	O
map	O
is	O
fitted	O
in	O
spatial	O
domain	O
using	O
weighted	O
constraints	O
derived	O
from	O
the	O
initial	O
susceptibility	O
map	O
from	O
the	O
M-step	O
.	O

Simulations	O
and	O
in	O
vivo	O
human	O
experiments	O
at	O
7T	O
MRI	B-P
show	O
that	O
the	O
SFCR	O
method	O
provides	O
high	O
quality	O
susceptibility	O
maps	O
with	O
improved	O
RMSE	O
and	O
MSSIM	O
.	O

Finally	O
,	O
the	O
susceptibility	O
values	O
of	O
deep	O
gray	O
matter	O
are	O
analyzed	O
in	O
multiple	O
head	O
positions	O
,	O
with	O
the	O
supine	O
position	O
most	O
approximate	O
to	O
the	O
gold	O
standard	O
COSMOS	O
result	O
.	O

Graphene	O
oxide	O
/	O
multi-walled	O
carbon	O
nanotubes	O
as	O
nanofeatured	O
scaffolds	O
for	O
the	O
assisted	O
deposition	O
of	O
nanohydroxyapatite	O
:	O
characterization	O
and	O
biological	O
evaluation	O
.	O

Nanohydroxyapatite	O
(	O
nHAp	O
)	O
is	O
an	O
emergent	O
bioceramic	O
that	O
shows	O
similar	O
chemical	O
and	O
crystallographic	O
properties	O
as	O
the	O
mineral	O
phase	O
present	O
in	O
bone	O
.	O

However	O
,	O
nHAp	O
presents	O
low	O
fracture	O
toughness	O
and	O
tensile	O
strength	O
,	O
limiting	O
its	O
application	O
in	O
bone	O
tissue	O
engineering	O
.	O

Conversely	O
,	O
multi-walled	O
carbon	O
nanotubes	O
(	O
MWCNTs	O
)	O
have	O
been	O
widely	O
used	O
for	O
composite	O
applications	O
due	O
to	O
their	O
excellent	O
mechanical	O
and	O
physicochemical	O
properties	O
,	O
although	O
their	O
hydrophobicity	O
usually	O
impairs	O
some	O
applications	O
.	O

To	O
improve	O
MWCNT	O
wettability	O
,	O
oxygen	O
plasma	O
etching	O
has	O
been	O
applied	O
to	O
promote	O
MWCNT	O
exfoliation	O
and	O
oxidation	O
and	O
to	O
produce	O
graphene	O
oxide	O
(	O
GO	O
)	O
at	O
the	O
end	O
of	O
the	O
tips	O
.	O

Here	O
,	O
we	O
prepared	O
a	O
series	O
of	O
nHAp	O
/	O
MWCNT	O
-	O
GO	O
nanocomposites	O
aimed	O
at	O
producing	O
materials	O
that	O
combine	O
similar	O
bone	O
characteristics	O
(	O
nHAp	O
)	O
with	O
high	O
mechanical	O
strength	O
(	O
MWCNT	O
-	O
GO	O
)	O
.	O

After	O
MWCNT	O
production	O
and	O
functionalization	O
to	O
produce	O
MWCNT	O
-	O
GO	O
,	O
ultrasonic	O
irradiation	O
was	O
employed	O
to	O
precipitate	O
nHAp	O
onto	O
the	O
MWCNT	O
-	O
GO	O
scaffolds	O
(	O
at	O
1-3	O
wt	O
%	O
)	O
.	O

We	O
employed	O
various	O
techniques	O
to	O
characterize	O
the	O
nanocomposites	O
,	O
including	O
transmission	B-P
electron	I-P
microscopy	I-P
(	O
TEM	B-P
)	O
,	O
Raman	B-P
spectroscopy	I-P
,	O
thermogravimetry	B-P
,	O
and	O
gas	B-P
adsorption	I-P
(	O
the	O
Brunauer-Emmett-Teller	B-P
method	I-P
)	O
.	O

We	O
used	O
simulated	O
body	O
fluid	O
to	O
evaluate	O
their	O
bioactivity	O
and	O
human	O
osteoblasts	O
(	O
bone-forming	O
cells	O
)	O
to	O
evaluate	O
cytocompatibility	O
.	O

We	O
also	O
investigated	O
their	O
bactericidal	O
effect	O
against	O
Staphylococcus	O
aureus	O
and	O
Escherichia	O
coli	O
.	O

TEM	B-P
analysis	O
revealed	O
homogeneous	O
distributions	O
of	O
nHAp	O
crystal	O
grains	O
along	O
the	O
MWCNT	O
-	O
GO	O
surfaces	O
.	O

All	O
nanocomposites	O
were	O
proved	O
to	O
be	O
bioactive	O
,	O
since	O
carbonated	O
nHAp	O
was	O
found	O
after	O
21	O
days	O
in	O
simulated	O
body	O
fluid	O
.	O

All	O
nanocomposites	O
showed	O
potential	O
for	O
biomedical	O
applications	O
with	O
no	O
cytotoxicity	O
toward	O
osteoblasts	O
and	O
impressively	O
demonstrated	O
a	O
bactericidal	O
effect	O
without	O
the	O
use	O
of	O
antibiotics	O
.	O

All	O
of	O
the	O
aforementioned	O
properties	O
make	O
these	O
materials	O
very	O
attractive	O
for	O
bone	O
tissue	O
engineering	O
applications	O
,	O
either	O
as	O
a	O
matrix	O
or	O
as	O
a	O
reinforcement	O
material	O
for	O
numerous	O
polymeric	O
nanocomposites	O
.	O

Low	O
serum	O
vitamin	O
D	O
is	O
associated	O
with	O
higher	O
cortical	O
porosity	O
in	O
elderly	O
men	O
.	O

Bone	O
loss	O
at	O
peripheral	O
sites	O
in	O
the	O
elderly	O
is	O
mainly	O
cortical	O
and	O
involves	O
increased	O
cortical	O
porosity	O
.	O

However	O
,	O
an	O
association	O
between	O
bone	O
loss	O
at	O
these	O
sites	O
and	O
25-hydroxyvitamin	O
D	O
has	O
not	O
been	O
reported	O
.	O

To	O
investigate	O
the	O
association	O
between	O
serum	O
levels	B-P
of	I-P
25-hydroxyvitamin	I-P
D	I-P
,	O
bone	O
microstructure	O
and	O
areal	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
in	O
elderly	O
men	O
.	O

A	O
population	O
-based	O
cohort	O
of	O
444	O
elderly	O
men	O
(	O
mean	O
±	O
SD	O
age	O
80.2	O
±	O
3.5	O
years	O
)	O
was	O
investigated	O
.	O

Bone	O
microstructure	O
was	O
measured	O
by	O
high-resolution	B-P
peripheral	I-P
quantitative	I-P
computed	I-P
tomography	I-P
,	O
areal	O
BMD	O
by	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
and	O
serum	O
25-hydroxyvitamin	B-P
D	I-P
and	O
parathyroid	B-P
hormone	I-P
levels	I-P
by	O
immunoassay	B-P
.	O

Mean	O
cortical	O
porosity	O
at	O
the	O
distal	O
tibia	O
was	O
14.7	O
%	O
higher	O
(	O
12.5	O
±	O
4.3	O
%	O
vs.	O
10.9	O
±	O
4.1	O
%	O
,	O
P	O
<	O
0.05	O
)	O
whilst	O
cortical	O
volumetric	O
BMD	O
,	O
area	O
,	O
trabecular	O
bone	O
volume	O
fraction	O
and	O
femoral	O
neck	O
areal	O
BMD	O
were	O
lower	O
in	O
men	O
in	O
the	O
lowest	O
quartile	O
of	O
vitamin	B-P
D	I-P
levels	I-P
compared	O
to	O
the	O
highest	O
.	O

In	O
men	O
with	O
vitamin	O
D	O
deficiency	O
(	O
<	O
25	O
nmol	O
L	O
(	O
-1	O
)	O
)	O
or	O
insufficiency	O
[	O
25-49	O
nmol	O
L	O
(	O
-1	O
)	O
,	O
in	O
combination	O
with	O
an	O
elevated	O
serum	O
level	B-P
of	I-P
parathyroid	I-P
hormone	I-P
(	O
>	O
6.8	O
pmol	O
L	O
(	O
-1	O
)	O
)	O
]	O
,	O
cortical	O
porosity	O
was	O
17.2	O
%	O
higher	O
than	O
in	O
vitamin	O
D	O
-	O
sufficient	O
men	O
(	O
P	O
<	O
0.01	O
)	O
.	O

A	O
linear	O
regression	O
model	O
including	O
age	O
,	O
weight	O
,	O
height	O
,	O
daily	O
calcium	O
intake	O
,	O
physical	O
activity	O
,	O
smoking	O
vitamin	O
D	O
supplementation	O
and	O
parathyroid	O
hormone	O
showed	O
that	O
25-hydroxyvitamin	O
D	O
independently	O
predicted	O
cortical	O
porosity	O
(	O
standardized	O
β	O
=	O
-0.110	O
,	O
R	O
(	O
2	O
)	O
=	O
1.1	O
%	O
,	O
P	O
=	O
0.024	O
)	O
,	O
area	O
(	O
β	O
=	O
0.123	O
,	O
R	O
(	O
2	O
)	O
=	O
1.4	O
%	O
,	O
P	O
=	O
0.007	O
)	O
and	O
cortical	O
volumetric	O
BMD	O
(	O
β	O
=	O
0.125	O
,	O
R	O
(	O
2	O
)	O
=	O
1.4	O
%	O
,	O
P	O
=	O
0.007	O
)	O
of	O
the	O
tibia	O
as	O
well	O
as	O
areal	O
BMD	O
of	O
the	O
femoral	O
neck	O
(	O
β	O
=	O
0.102	O
,	O
R	O
(	O
2	O
)	O
=	O
0.9	O
%	O
,	O
P	O
=	O
0.04	O
)	O
.	O

Serum	O
vitamin	O
D	O
is	O
associated	O
with	O
cortical	O
porosity	O
,	O
area	O
and	O
density	O
,	O
indicating	O
that	O
bone	O
fragility	O
as	O
a	O
result	O
of	O
low	O
vitamin	O
D	O
could	O
be	O
due	O
to	O
changes	O
in	O
cortical	O
bone	O
microstructure	O
and	O
geometry	O
.	O

Identification	O
of	O
Predictive	O
DNA	O
Methylation	O
Biomarkers	O
for	O
Chemotherapy	O
Response	O
in	O
Colorectal	O
Cancer	O
.	O

Resistance	O
to	O
5-Fluorouracil	O
(	O
5-FU	O
)	O
is	O
a	O
major	O
obstacle	O
to	O
the	O
successful	O
treatment	O
of	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
and	O
posed	O
an	O
increased	O
risk	O
of	O
recurrence	O
.	O

DNA	O
methylation	O
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
underlying	O
mechanisms	O
for	O
recurrent	O
disease	O
and	O
its	O
contribution	O
to	O
the	O
development	O
of	O
drug	O
resistance	O
remains	O
to	O
be	O
clarified	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
methylation	O
phenotype	O
in	O
CRC	O
for	O
identification	O
of	O
predictive	O
markers	O
for	O
chemotherapy	O
response	O
.	O

We	O
performed	O
DNA	O
methylation	O
profiling	O
on	O
43	O
non-recurrent	O
and	O
five	O
recurrent	O
CRC	O
patients	O
using	O
the	O
Illumina	O
Infinium	O
HumanMethylation450	O
Beadchip	O
assay	O
.	O

In	O
addition	O
,	O
CRC	O
cells	O
with	O
different	O
genetic	O
backgrounds	O
,	O
response	O
to	O
5-FU	O
and	O
global	O
methylation	O
levels	O
(	O
HT29	O
and	O
SW48	O
)	O
were	O
treated	O
with	O
5-FU	O
and	O
DNA	O
methylation	O
inhibitor	O
5-aza-2'-deoxycytidine	O
(	O
5-azadC	O
)	O
.	O

The	O
singular	O
and	O
combined	O
effects	O
of	O
these	O
two	O
drug	O
classes	O
on	O
cell	O
viability	O
and	O
global	O
methylation	O
profiles	B-P
were	O
investigated	O
.	O

Our	O
genome-wide	O
methylation	O
study	O
on	O
the	O
clinical	O
specimens	O
showed	O
that	O
recurrent	O
CRCs	O
exhibited	O
higher	O
methylation	O
levels	O
compared	O
to	O
non-recurrent	O
CRCs	O
.	O

We	O
identified	O
4787	O
significantly	O
differentially	O
methylated	O
genes	O
(	O
P	O
<	O
0.05	O
)	O
;	O
3112	O
genes	O
were	O
hyper	O
-	O
while	O
1675	O
genes	O
were	O
hypomethylated	O
in	O
the	O
recurrent	O
group	O
compared	O
to	O
the	O
non-recurrent	O
.	O

Fifty	O
eight	O
and	O
47	O
of	O
the	O
significantly	O
hypermethylated	O
and	O
hypomethylated	O
genes	O
have	O
an	O
absolute	O
recurrent	O
/	O
non-recurrent	O
methylation	O
difference	O
of	O
≥20	O
%	O
.	O

Most	O
of	O
the	O
hypermethylated	O
genes	O
were	O
involved	O
in	O
the	O
MAPK	O
signaling	O
pathway	O
which	O
is	O
a	O
key	O
regulator	O
for	O
apoptosis	O
while	O
the	O
hypomethylated	O
genes	O
were	O
involved	O
in	O
the	O
PI3K-AKT	O
signaling	O
pathway	O
and	O
proliferation	O
process	O
.	O

We	O
also	O
demonstrate	O
that	O
5-azadC	O
treatment	O
enhanced	O
response	O
to	O
5-FU	O
which	O
resulted	O
in	O
significant	O
growth	O
inhibition	O
compared	O
to	O
5-FU	O
alone	O
in	O
hypermethylated	O
cell	O
lines	O
SW48	O
.	O

In	O
conclusion	O
,	O
we	O
found	O
the	O
evidence	O
of	O
five	O
potentially	O
biologically	O
important	O
genes	O
in	O
recurrent	O
CRCs	O
that	O
could	O
possibly	O
serve	O
as	O
a	O
new	O
potential	O
therapeutic	O
targets	O
for	O
patients	O
with	O
chemoresistance	O
.	O

We	O
postulate	O
that	O
aberrant	O
methylation	O
of	O
CCNEI	O
,	O
CCNDBP1	O
,	O
PON3	O
,	O
DDX43	O
,	O
and	O
CHL1	O
in	O
CRC	O
might	O
be	O
associated	O
with	O
the	O
recurrence	O
of	O
CRC	O
and	O
5-azadC	O
-mediated	O
restoration	O
of	O
5-FU	O
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK	O
signaling	O
pathway	O
.	O

Mandibular	O
position	O
influence	O
on	O
pilots	O
'	O
postural	O
balance	O
analyzed	O
under	O
dynamic	O
conditions	O
.	O

The	O
aim	O
of	O
this	O
study	B-P
is	O
to	O
evaluate	O
the	O
influence	O
of	O
the	O
mandibular	O
position	O
on	O
the	O
postural	O
stability	O
in	O
a	O
sample	O
of	O
civilian	O
and	O
military	O
pilots	O
.	O

Twenty	O
military	O
pilots	O
(	O
males	O
,	O
mean	O
age	O
35.15	O
±	O
3.14	O
years	O
)	O
and	O
17	O
civilian	O
pilots	O
(	O
males	O
,	O
mean	O
34.91	O
±	O
2.15	O
years	O
)	O
were	O
enrolled	O
in	O
this	O
study	B-P
and	O
underwent	O
a	O
Sensory	B-P
Organization	I-P
Test	I-P
(	O
SOT	B-P
)	O
using	O
the	O
EquiTest	B-P
®	O
(	O
NeuroCom	O
International	O
Inc	O
.	O
,	O
Clackamas	O
,	O
OR	O
,	O
USA	O
)	O
computerized	B-P
dynamic	I-P
posturography	I-P
.	O

The	O
composite	O
parameter	O
was	O
recorded	O
and	O
analyzed	O
.	O

The	O
equilibrium	O
score	O
(	O
ES	O
)	O
recorded	O
in	O
centric	O
occlusion	O
is	O
slightly	O
higher	O
than	O
the	O
ES	O
recorded	O
in	O
mandibular	O
rest	O
position	O
;	O
civilian	O
pilots	O
showed	O
ESs	O
slightly	O
higher	O
than	O
military	O
pilots	O
.	O

The	O
two-way	O
ANOVA	O
analysis	O
shows	O
these	O
differences	O
are	O
not	O
statistically	O
significant	O
.	O

The	O
findings	O
of	O
this	O
study	B-P
seem	O
to	O
suggest	O
that	O
the	O
composite	O
parameter	O
of	O
the	O
SOT	B-P
is	O
not	O
sensitive	O
in	O
analyzing	O
the	O
influence	O
of	O
the	O
stomatognathic	O
system	O
on	O
the	O
postural	O
balance	O
of	O
civilian	O
and	O
military	O
pilots	O
.	O

Heart	O
beat	O
characterization	O
from	O
ballistocardiogram	B-P
signals	I-P
using	O
extended	O
functions	O
of	O
multiple	O
instances	O
.	O

A	O
multiple	O
instance	O
learning	O
(	O
MIL	O
)	O
method	O
,	O
extended	O
Function	O
of	O
Multiple	O
Instances	O
(	O
eFUMI	O
)	O
,	O
is	O
applied	O
to	O
ballistocardiogram	B-P
(	O
BCG	B-P
)	O
signals	O
produced	O
by	O
a	O
hydraulic	O
bed	O
sensor	O
.	O

The	O
goal	O
of	O
this	O
approach	O
is	O
to	O
learn	O
a	O
personalized	O
heartbeat	O
``	O
concept	O
``	O
for	O
an	O
individual	O
.	O

This	O
heartbeat	O
concept	O
is	O
a	O
prototype	O
(	O
or	O
``	O
signature	O
``	O
)	O
that	O
characterizes	O
the	O
heartbeat	O
pattern	O
for	O
an	O
individual	O
in	O
ballistocardiogram	B-P
data	O
.	O

The	O
eFUMI	O
method	O
models	O
the	O
problem	O
of	O
learning	O
a	O
heartbeat	O
concept	O
from	O
a	O
BCG	B-P
signal	I-P
as	O
a	O
MIL	O
problem	O
.	O

This	O
approach	O
elegantly	O
addresses	O
the	O
uncertainty	O
inherent	O
in	O
a	O
BCG	B-P
signal	I-P
(	O
e.	O
g.	O
,	O
misalignment	O
between	O
training	O
data	O
and	O
ground	O
truth	O
,	O
mis-collection	O
of	O
heartbeat	O
by	O
some	O
transducers	O
,	O
etc.	O
)	O
.	O

Given	O
a	O
BCG	B-P
training	O
signal	O
coupled	O
with	O
a	O
ground	O
truth	O
signal	O
(	O
e.g.	O
,	O
a	O
pulse	O
finger	O
sensor	O
)	O
,	O
training	O
``	O
bags	O
''	O
labeled	O
with	O
only	O
binary	O
labels	O
denoting	O
if	O
a	O
training	O
bag	O
contains	O
a	O
heartbeat	O
signal	O
or	O
not	O
can	O
be	O
generated	O
.	O

Then	O
,	O
using	O
these	O
bags	O
,	O
eFUMI	O
learns	O
a	O
personalized	O
concept	O
of	O
heartbeat	O
for	O
a	O
subject	O
as	O
well	O
as	O
several	O
non-	O
heartbeat	O
background	O
concepts	O
.	O

After	O
learning	O
the	O
heartbeat	O
concept	O
,	O
heartbeat	O
detection	O
and	O
heart	O
rate	O
estimation	O
can	O
be	O
applied	O
to	O
test	O
data	O
.	O

Experimental	O
results	O
show	O
that	O
the	O
estimated	O
heartbeat	O
concept	O
found	O
by	O
eFUMI	O
is	O
more	O
representative	O
and	O
a	O
more	O
discriminative	O
prototype	O
of	O
the	O
heartbeat	O
signals	O
than	O
those	O
found	O
by	O
comparison	O
MIL	O
methods	O
in	O
the	O
literature	O
.	O

The	O
CLASP2	O
Protein	O
Interaction	O
Network	O
in	O
Adipocytes	O
Links	O
CLIP2	O
to	O
AGAP3	O
,	O
CLASP2	O
to	O
G2L1	O
,	O
MARK2	O
,	O
and	O
SOGA1	O
,	O
and	O
Identifies	O
SOGA1	O
as	O
a	O
Microtubule-Associated	O
Protein	O
.	O

CLASP2	O
is	O
a	O
microtubule-associated	O
protein	O
that	O
undergoes	O
insulin	O
-	O
stimulated	O
phosphorylation	O
and	O
co-localization	O
with	O
reorganized	O
actin	O
and	O
GLUT4	O
at	O
the	O
plasma	O
membrane	O
.	O

To	O
gain	O
insight	O
to	O
the	O
role	O
of	O
CLASP2	O
in	O
this	O
system	O
,	O
we	O
developed	O
and	O
successfully	O
executed	O
a	O
streamlined	O
interactome	O
approach	O
and	O
built	O
a	O
CLASP2	O
protein	O
network	O
in	O
3T3-L1	O
adipocytes	O
.	O

Using	O
two	O
different	O
commercially	O
available	O
antibodies	O
for	O
CLASP2	O
and	O
an	O
antibody	O
for	O
epitope	O
-tagged	O
,	O
overexpressed	O
CLASP2	O
,	O
we	O
performed	O
multiple	O
affinity	B-P
purification	I-P
coupled	O
with	O
mass	B-P
spectrometry	I-P
(	O
AP	B-P
-	O
MS	B-P
)	O
experiments	O
in	O
combination	O
with	O
label-free	O
quantitative	O
proteomics	O
and	O
analyzed	O
the	O
data	O
with	O
the	O
bioinformatics	O
tool	O
Significance	O
Analysis	O
of	O
Interactome	O
(	O
SAINT	O
)	O
.	O

We	O
discovered	O
that	O
CLASP2	O
co-immunoprecipitates	O
(	O
co-IPs	O
)	O
the	O
novel	O
protein	O
SOGA1	O
,	O
the	O
microtubule-associated	O
protein	O
kinase	O
MARK2	O
,	O
and	O
the	O
microtubule	O
/	O
actin	O
-	O
regulating	O
protein	O
G2L1	O
.	O

The	O
GTPase-activating	O
proteins	O
AGAP1	O
and	O
AGAP3	O
were	O
also	O
enriched	O
in	O
the	O
CLASP2	O
interactome	O
,	O
although	O
subsequent	O
AGAP3	O
and	O
CLIP2	O
interactome	O
analysis	O
suggests	O
a	O
preference	O
of	O
AGAP3	O
for	O
CLIP2	O
.	O

Follow-up	O
MARK2	O
interactome	O
analysis	O
confirmed	O
reciprocal	O
co-IP	O
of	O
CLASP2	O
and	O
also	O
revealed	O
MARK2	O
can	O
co-IP	O
SOGA1	O
,	O
glycogen	O
synthase	O
,	O
and	O
glycogenin	O
.	O

Investigating	O
the	O
SOGA1	O
interactome	O
confirmed	O
SOGA1	O
can	O
reciprocal	O
co-IP	O
both	O
CLASP2	O
and	O
MARK2	O
as	O
well	O
as	O
glycogen	O
synthase	O
and	O
glycogenin	O
.	O

SOGA1	O
was	O
confirmed	O
to	O
colocalize	O
with	O
CLASP2	O
and	O
also	O
with	O
tubulin	O
,	O
which	O
identifies	O
SOGA1	O
as	O
a	O
new	O
microtubule-associated	O
protein	O
.	O

These	O
results	O
introduce	O
the	O
metabolic	O
function	O
of	O
these	O
proposed	O
novel	O
protein	O
networks	O
and	O
their	O
relationship	O
with	O
microtubules	O
as	O
new	O
fields	O
of	O
cytoskeleton	O
-	O
associated	O
protein	O
biology	O
.	O

Absorption	O
Characteristics	O
of	O
Vertebrate	O
Non	O
-	O
Visual	O
Opsin	O
,	O
Opn3	O
.	O

Most	O
animals	O
possess	O
multiple	O
opsins	O
which	O
sense	O
light	O
for	O
visual	O
and	O
non	O
-	O
visual	O
functions	O
.	O

Here	O
,	O
we	O
show	O
spectral	O
characteristics	O
of	O
non	O
-	O
visual	O
opsins	O
,	O
vertebrate	O
Opn3s	O
,	O
which	O
are	O
widely	O
distributed	O
among	O
vertebrates	O
.	O

We	O
successfully	O
expressed	O
zebrafish	O
Opn3	O
in	O
mammalian	O
cultured	O
cells	O
and	O
measured	O
its	O
absorption	B-P
spectrum	I-P
spectroscopically	I-P
.	O

When	O
incubated	B-P
with	O
11-cis	O
retinal	O
,	O
zebrafish	O
Opn3	O
formed	O
a	O
blue-sensitive	O
photopigment	O
with	O
an	O
absorption	O
maximum	O
around	O
465	O
nm	O
.	O

The	O
Opn3	O
converts	O
to	O
an	O
all-trans	O
retinal-bearing	O
photoproduct	O
with	O
an	O
absorption	B-P
spectrum	I-P
similar	O
to	O
the	O
dark	O
state	O
following	O
brief	O
blue-light	O
irradiation	O
.	O

The	O
photoproduct	O
experienced	O
a	O
remarkable	O
blue-shift	O
,	O
with	O
changes	O
in	O
position	O
of	O
the	O
isosbestic	O
point	O
,	O
during	O
further	O
irradiation	O
.	O

We	O
then	O
used	O
a	O
cAMP	O
-	O
dependent	O
luciferase	O
reporter	O
assay	B-P
to	O
investigate	O
light	O
-	O
dependent	O
cAMP	O
responses	O
in	O
cultured	O
cells	O
expressing	O
zebrafish	O
,	O
pufferfish	O
,	O
anole	O
and	O
chicken	O
Opn3	O
.	O

The	O
wild	O
type	O
opsins	O
did	O
not	O
produce	O
responses	O
,	O
but	O
cells	O
expressing	O
chimera	O
mutants	O
(	O
WT	O
Opn3s	O
in	O
which	O
the	O
third	O
intracellular	O
loops	O
were	O
replaced	O
with	O
the	O
third	O
intracellular	O
loop	O
of	O
a	O
Gs-coupled	O
jellyfish	O
opsin	O
)	O
displayed	O
light	O
-	O
dependent	O
changes	O
in	O
cAMP	O
.	O

The	O
results	O
suggest	O
that	O
Opn3	O
is	O
capable	O
of	O
activating	O
G	O
protein	O
(	O
s	O
)	O
in	O
a	O
light	O
-	O
dependent	O
manner	O
.	O

Finally	O
,	O
we	O
used	O
this	O
assay	B-P
to	O
measure	O
the	O
relative	O
wavelength	O
-	O
dependent	O
response	O
of	O
cells	O
expressing	O
Opn3	O
chimeras	O
to	O
multiple	O
quantally	O
-	O
matched	O
stimuli	O
.	O

The	O
inferred	O
spectral	O
sensitivity	O
curve	O
of	O
zebrafish	O
Opn3	O
accurately	O
matched	O
the	O
measured	O
absorption	B-P
spectrum	I-P
.	O

We	O
were	O
unable	O
to	O
estimate	O
the	O
spectral	O
sensitivity	O
curve	O
of	O
mouse	O
or	O
anole	O
Opn3	O
,	O
but	O
,	O
like	O
zebrafish	O
Opn3	O
,	O
the	O
chicken	O
and	O
pufferfish	O
Opn3-JiL3	O
chimeras	O
also	O
formed	O
blue-sensitive	O
pigments	O
.	O

These	O
findings	O
suggest	O
that	O
vertebrate	O
Opn3s	O
may	O
form	O
blue-sensitive	O
G	O
protein-coupled	O
pigments	O
.	O

Further	O
,	O
we	O
suggest	O
that	O
the	O
method	O
described	O
here	O
,	O
combining	O
a	O
cAMP	O
-	O
dependent	O
luciferase	O
reporter	O
assay	B-P
with	O
chimeric	O
opsins	O
possessing	O
the	O
third	O
intracellular	O
loop	O
of	O
jellyfish	O
opsin	O
,	O
is	O
a	O
versatile	O
approach	O
for	O
estimating	O
absorption	B-P
spectra	I-P
of	O
opsins	O
with	O
unknown	O
signaling	O
cascades	O
or	O
for	O
which	O
absorption	B-P
spectra	I-P
are	O
difficult	O
to	O
obtain	O
.	O

Torsed	O
and	O
Nontorsed	O
Inguinal	O
Undescended	O
Testis	O
:	O
Comparison	O
of	O
Computed	B-P
Tomography	I-P
Findings	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
computed	B-P
tomography	I-P
imaging	I-P
features	O
of	O
a	O
torsed	O
inguinal	O
testis	O
with	O
nontorsed	O
inguinal	O
testes	O
.	O

Computed	B-P
tomography	I-P
scans	I-P
of	O
patients	O
with	O
undescended	O
testes	O
were	O
retrospectively	O
collected	O
(	O
2011-2016	O
)	O
.	O

Imaging	B-P
features	O
of	O
nontorsed	O
undescended	O
testis	O
were	O
compared	O
with	O
a	O
case	O
of	O
an	O
inguinal	O
torsed	O
testis	O
.	O

Observations	O
included	O
location	O
of	O
the	O
undescended	O
testis	O
,	O
size	O
(	O
length	O
×	O
width	O
)	O
and	O
texture	O
of	O
each	O
testis	O
,	O
peritesticular	O
findings	O
,	O
position	O
of	O
testicular	O
vessels	O
,	O
and	O
enhancement	O
patterns	O
.	O

Twelve	O
nontorsed	O
inguinal	O
undescended	O
testes	O
were	O
compared	O
with	O
1	O
torsed	O
undescended	O
testicle	O
.	O

Torsed	O
testis	O
was	O
larger	O
than	O
nontorsed	O
(	O
44	O
×	O
27	O
mm	O
vs	O
32.9	O
±	O
6.1	O
×	O
22.9	O
±	O
4.9	O
mm	O
)	O
,	O
surrounded	O
by	O
fat	O
stranding	O
and	O
fluid	O
,	O
with	O
heterogeneous	O
texture	O
,	O
enhancement	O
of	O
its	O
outer	O
layers	O
,	O
and	O
an	O
upward	O
kink	O
of	O
its	O
vessels	O
.	O

Because	O
torsed	O
undescended	O
testis	O
can	O
mimic	O
a	O
groin	O
abscess	O
and	O
because	O
torsion	O
is	O
a	O
medical	O
emergency	O
,	O
radiologists	O
should	O
be	O
aware	O
of	O
this	O
entity	O
and	O
its	O
distinguishing	O
imaging	B-P
features	O
.	O

Color	B-P
Doppler	I-P
examination	I-P
can	O
ascertain	O
absence	O
/	O
reduction	O
of	O
blood	O
flow	O
.	O

A	O
Novel	O
BRCA1-Associated	O
Protein-1	O
Isoform	O
Affects	O
Response	O
of	O
Mesothelioma	O
Cells	O
to	O
Drugs	O
Impairing	O
BRCA1	O
-Mediated	O
DNA	O
Repair	O
.	O

BRCA1	O
associated	O
protein1	O
(	O
BAP1	O
)	O
is	O
a	O
tumor	O
suppressor	O
involved	O
in	O
multiple	O
cellular	O
processes	O
such	O
as	O
transcriptional	O
regulation	O
,	O
chromatin	O
modification	O
by	O
deubiquitinating	O
histone	O
2A	O
,	O
and	O
DNA	O
repair	O
.	O

BAP1	O
mutations	O
are	O
frequent	O
in	O
malignant	O
pleural	O
mesothelioma	O
(	O
MPM	O
)	O
.	O

Our	O
aim	O
was	O
to	O
functionally	O
characterize	O
a	O
newly	O
identified	O
isoform	O
of	O
BAP1	O
and	O
investigate	O
the	O
effects	O
of	O
its	O
expression	O
on	O
drug	O
sensitivity	O
in	O
MPM	O
.	O

Expression	O
of	O
BAP1	O
isoforms	O
was	O
detected	O
by	O
quantitative	B-P
polymerase	I-P
chain	I-P
reaction	I-P
in	O
MPM	O
and	O
normal	O
mesothelium	O
cell	O
lines	O
and	O
tumor	O
and	O
nontumor	O
samples	O
.	O

Histone	O
H2A	O
ubiquitination	O
levels	O
were	O
analyzed	O
by	O
Western	B-P
blot	I-P
after	O
acidic	B-P
extraction	I-P
of	O
core	O
histones	O
.	O

Subcellular	O
localization	O
of	O
BAP1	O
isoforms	O
was	O
examined	O
by	O
immunofluorescence	B-P
.	O

MPM	O
cell	O
survival	O
in	O
response	O
to	O
poly	O
(	O
adenosine	O
diphosphate-ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
and	O
dual	O
phosphoinositide	O
3-kinase	O
(	O
PI3K	O
)	O
-	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
inhibitors	O
was	O
analyzed	O
by	O
in	O
vitro	O
assays	O
.	O

We	O
have	O
identified	O
a	O
novel	O
alternative	O
splice	O
isoform	O
of	O
BAP1	O
(	O
BAP1Δ	O
)	O
that	O
misses	O
part	O
of	O
the	O
catalytic	O
domain	O
.	O

Cells	O
transfected	O
with	O
BAP1Δ	O
showed	O
reduced	O
deubiquitinating	O
activity	O
compared	O
with	O
full-length	O
BAP1	O
.	O

The	O
expression	O
of	O
BAP1Δ	O
transcript	O
is	O
more	O
abundant	O
in	O
nontumor	O
than	O
in	O
tumor	O
samples	O
.	O

MPM	O
cell	O
lines	O
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1Δ	O
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	O
inhibitor	O
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	O
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
PI3K	O
-	O
mTOR	O
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O

These	O
observations	O
suggest	O
that	O
BAP1Δ	O
does	O
regulate	O
DNA	O
damage	O
response	O
and	O
influences	O
drug	O
sensitivity	O
.	O

It	O
might	O
therefore	O
be	O
relevant	O
to	O
investigate	O
whether	O
patients	O
with	O
high	O
expression	O
of	O
BAP1Δ	O
may	O
be	O
responsive	O
to	O
PARP	O
/	O
PI3K	O
-	O
mTOR	O
inhibitors	O
.	O

A	O
Systematic	O
Review	O
on	O
Infliximab	O
and	O
Adalimumab	O
Drug	O
Monitoring	O
:	O
Levels	O
,	O
Clinical	O
Outcomes	O
and	O
Assays	B-P
.	O

Immunogenicity	O
to	O
therapeutic	O
proteins	O
has	O
been	O
linked	O
to	O
loss	O
of	O
response	O
by	O
a	O
large	O
percentage	O
of	O
patients	O
taking	O
anti-tumor	O
necrosis	O
factor-alpha	O
agents	O
.	O

Drug	O
monitoring	O
can	O
be	O
extremely	O
useful	O
,	O
allowing	O
physicians	O
to	O
adjust	O
the	O
therapeutic	O
scheme	O
individually	O
.	O

This	O
article	O
aims	O
to	O
systematically	O
review	O
the	O
published	O
data	O
with	O
respect	O
to	O
cutoff	O
levels	O
of	O
infliximab	O
(	O
IFX	O
)	O
and	O
adalimumab	O
(	O
ADA	O
)	O
and	O
relate	O
them	O
to	O
the	O
methodology	O
adopted	O
for	O
quantification	O
of	O
IFX	O
and	O
ADA	O
levels	O
and	O
clinical	O
outcomes	O
.	O

The	O
PubMed	O
database	O
was	O
searched	O
to	O
identify	O
studies	O
focusing	O
on	O
the	O
association	O
between	O
IFX	O
or	O
ADA	O
cutoff	O
levels	O
and	O
clinical	O
outcomes	O
in	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
.	O

Of	O
the	O
1654	O
articles	O
initially	O
selected	O
by	O
queries	O
,	O
20	O
were	O
included	O
.	O

A	O
receiver	O
operating	O
characteristic	O
curve	O
analysis	O
was	O
performed	O
to	O
identify	O
cutoff	O
levels	O
of	O
IFX	O
or	O
ADA	O
that	O
correlated	O
with	O
a	O
clinical	O
outcome	O
,	O
but	O
only	O
6	O
studies	O
performed	O
the	O
same	O
analysis	O
for	O
antidrug	O
antibody	O
levels	O
.	O

Cutoff	O
levels	O
were	O
different	O
between	O
studies	O
.	O

The	O
methodology	O
chosen	O
for	O
level	O
quantifications	O
,	O
clinical	O
outcomes	O
,	O
and	O
sample	O
size	O
and	O
characteristics	O
were	O
also	O
different	O
.	O

Nevertheless	O
,	O
measurement	B-P
of	I-P
drug	I-P
levels	I-P
should	O
be	O
performed	O
during	O
maintenance	O
,	O
and	O
with	O
loss	O
of	O
response	O
,	O
with	O
persistent	O
high	O
levels	O
of	O
C-reactive	O
protein	O
,	O
and	O
when	O
mucosal	O
lesions	O
are	O
still	O
present	O
.	O

In	O
these	O
scenarios	O
,	O
drug	O
and	O
antidrug	O
levels	O
were	O
correlated	O
with	O
clinical	O
outcomes	O
.	O

Concerning	O
drug	O
levels	O
monitoring	O
any	O
methodology	O
is	O
adequate	O
.	O

With	O
respect	O
to	O
antidrug	O
antibody	O
levels	O
,	O
it	O
will	O
be	O
necessary	O
to	O
define	O
a	O
gold	O
standard	O
method	O
or	O
to	O
establish	O
different	O
cutoff	O
levels	O
for	O
different	O
methodologies	O
.	O

Diagnostic	O
utility	O
of	O
additional	O
conventional	O
techniques	B-P
after	O
endobronchial	B-P
ultrasonography	I-P
guidance	O
during	O
transbronchial	B-P
biopsy	I-P
.	O

Endobronchial	B-P
ultrasonography	I-P
with	O
a	O
guide	O
sheath	O
transbronchial	B-P
biopsy	I-P
(	O
EBUS	B-P
-	O
GS	O
TBB	B-P
)	O
has	O
been	O
used	O
to	O
diagnose	O
peripheral	O
pulmonary	O
lesions	O
(	O
PPLs	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
diagnostic	O
utility	O
of	O
conventional	O
TBB	B-P
after	O
EBUS	B-P
-	O
GS	O
TBB	B-P
.	O

A	O
retrospective	O
analysis	O
of	O
patients	O
who	O
underwent	O
conventional	O
TBB	B-P
after	O
EBUS	B-P
-	O
GS	O
TBB	B-P
for	O
PPL	O
between	O
August	O
1	O
,	O
2012	O
and	O
December	O
31	O
,	O
2014	O
.	O

We	O
performed	O
multivariate	O
analysis	O
to	O
examine	O
the	O
association	O
of	O
various	O
clinical	O
factors	O
,	O
including	O
EBUS	B-P
probe	O
distance	O
and	O
sample	O
size	O
area	O
,	O
with	O
diagnostic	O
yield	O
.	O

Of	O
88	O
eligible	O
patients	O
,	O
57	O
(	O
65	O
%	O
)	O
were	O
successfully	O
diagnosed	O
by	O
EBUS	B-P
-	O
GS	O
TBB	B-P
.	O

In	O
31	O
patients	O
not	O
diagnosed	O
by	O
EBUS	B-P
-	O
GS	O
TBB	B-P
,	O
15	O
(	O
48	O
%	O
)	O
were	O
successfully	O
diagnosed	O
by	O
additional	O
conventional	O
TBB	B-P
.	O

Ground	O
glass	O
opacity	O
(	O
GGO	O
)	O
was	O
a	O
significant	O
factor	O
associated	O
with	O
the	O
diagnostic	O
yield	O
of	O
additional	O
conventional	O
TBB	B-P
following	O
EBUS	B-P
-	O
GS	O
TBB	B-P
.	O

Multivariate	O
analysis	O
and	O
receiver	O
operator	O
curves	O
revealed	O
that	O
distance	O
between	O
the	O
PPL	O
and	O
the	O
EBUS	B-P
probe	O
of	O
less	O
than	O
2.55	O
mm	O
favored	O
the	O
utility	O
of	O
conventional	O
TBB	B-P
.	O

Additional	O
conventional	O
TBB	B-P
after	O
EBUS	B-P
-	O
GS	O
TBB	B-P
could	O
be	O
a	O
useful	O
procedure	B-P
for	O
the	O
diagnosis	O
of	O
ground	O
glass	O
opacity	O
PPLs	O
and	O
in	O
cases	O
of	O
a	O
distance	O
of	O
less	O
than	O
2.55	O
mm	O
between	O
the	O
EBUS	B-P
probe	O
and	O
the	O
lesion	O
.	O

Left	O
ventricular	O
rotational	O
mechanics	O
in	O
infants	O
with	O
hypoxic	O
ischemic	O
encephalopathy	O
and	O
preterm	O
infants	O
at	O
36	O
weeks	O
postmenstrual	O
age	O
:	O
A	O
comparison	O
with	O
healthy	O
term	O
controls	O
.	O

There	O
is	O
a	O
paucity	O
of	O
data	O
on	O
left	O
ventricle	O
(	O
LV	O
)	O
rotational	O
physiology	O
in	O
neonates	O
.	O

We	O
aimed	O
to	O
assess	O
rotational	O
mechanics	O
in	O
infants	O
with	O
hypoxic	O
ischemic	O
encephalopathy	O
(	O
HIE	O
)	O
and	O
premature	O
infants	O
(	O
<	O
32	O
weeks	O
)	O
at	O
36	O
weeks	O
postmenstrual	O
age	O
(	O
PMA	O
)	O
(	O
preterm	O
group	O
)	O
and	O
compare	O
them	O
with	O
healthy	O
term	O
controls	O
(	O
term	O
controls	O
)	O
.	O

We	O
also	O
compared	O
the	O
parameters	O
in	O
preterm	O
infants	O
with	O
and	O
without	O
chronic	O
lung	O
disease	O
(	O
CLD	O
)	O
.	O

Echocardiography	B-P
was	O
performed	O
within	O
48	O
hours	O
of	O
birth	O
or	O
at	O
36	O
weeks	O
PMA	O
.	O

LV	O
basal	O
and	O
apical	O
rotation	O
,	O
twist	O
(	O
and	O
torsion	O
=	O
twist	O
/	O
LV	O
length	O
)	O
,	O
twist	O
rate	O
(	O
LVTR	O
)	O
,	O
and	O
untwist	O
rate	O
(	O
LVUTR	O
)	O
were	O
measured	O
.	O

One-way	O
ANOVA	O
was	O
used	O
to	O
compare	O
values	O
.	O

There	O
was	O
no	O
difference	O
in	O
gestation	O
(	O
40.0	O
[	O
39.1-40.3	O
]	O
vs	O
39.9	O
[	O
39.0-40.9	O
]	O
,	O
P	O
>	O
.05	O
)	O
or	O
birthweight	O
(	O
3.7	O
[	O
3.4-4.1	O
]	O
vs	O
3.5	O
[	O
3.2-3.9	O
]	O
,	O
P	O
>	O
.05	O
)	O
between	O
the	O
HIE	O
group	O
(	O
n=16	O
)	O
and	O
term	O
controls	O
(	O
n=30	O
)	O
.	O

The	O
preterm	O
group	O
(	O
n=35	O
)	O
had	O
a	O
gestation	O
and	O
weight	O
of	O
36.0	O
[	O
34.6-36.3	O
]	O
weeks	O
and	O
2.3	O
[	O
2.0-2.4	O
]	O
kg	O
.	O

The	O
HIE	O
group	O
had	O
lower	O
twist	O
,	O
torsion	O
,	O
LVTR	O
,	O
and	O
LVUTR	O
than	O
the	O
other	O
two	O
groups	O
.	O

The	O
preterm	O
group	O
had	O
a	O
more	O
negative	O
(	O
clockwise	O
)	O
basal	O
rotation	O
while	O
the	O
term	O
group	O
had	O
a	O
more	O
positive	O
(	O
counterclockwise	O
)	O
apical	O
rotation	O
.	O

Preterm	O
infants	O
with	O
CLD	O
had	O
higher	O
apical	O
rotation	O
,	O
twist	O
,	O
and	O
torsion	O
when	O
compared	O
to	O
infants	O
without	O
CLD	O
.	O

Infants	O
with	O
HIE	O
have	O
reduced	O
rotational	O
mechanics	O
.	O

Preterm	O
infants	O
at	O
36	O
weeks	O
PMA	O
have	O
comparable	O
measurements	O
of	O
twist	O
to	O
term	O
infants	O
.	O

This	O
is	O
achieved	O
by	O
predominant	O
basal	O
rather	O
than	O
apical	O
rotation	O
.	O

Infants	O
with	O
CLD	O
have	O
increased	O
apical	O
rotation	O
.	O

A	O
comparison	O
of	O
the	O
extent	O
and	O
pattern	O
of	O
cognitive	O
impairment	O
among	O
predialysis	O
,	O
dialysis	O
and	O
transplant	O
patients	O
:	O
a	O
cross	O
sectional	O
study	O
from	O
Australia	O
.	O

A	O
comparison	O
of	O
the	O
extent	O
and	O
pattern	O
of	O
cognitive	O
impairment	O
among	O
predialysis	O
,	O
dialysis	O
and	O
transplant	O
patients	O
:	O
a	O
cross	O
sectional	O
study	O
from	O
Australia	O
AIM	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
extent	O
of	O
cogntive	O
impairment	O
and	O
the	O
types	O
of	O
cognitive	O
deficits	O
in	O
an	O
Australian	O
cohort	O
of	O
four	O
patient	O
groups	O
with	O
end	O
stage	O
kidney	O
disease	O
.	O

Characteristics	O
predicting	O
the	O
presence	O
of	O
cognitive	O
impairment	O
were	O
also	O
evaluated	O
.	O

Observational	O
cross	O
sectional	O
study	O
of	O
one	O
hundred	O
and	O
fifty	O
five	O
patients	O
with	O
end	O
stage	O
kidney	O
disease	O
recruited	O
from	O
a	O
regional	O
Australian	O
renal	O
unit	O
.	O

Eligible	O
participants	O
included	O
those	O
whose	O
estimated	B-P
Glomerular	I-P
Filtration	I-P
Rate	I-P
was	O
<	O
30	O
ml/min/1.73	O
m	O
(	O
2	O
)	O
;	O
were	O
undertaking	O
peritoneal	O
or	O
hemodialysis	O
,	O
or	O
had	O
received	O
a	O
kidney	O
transplant	O
.	O

The	O
Montreal	O
Cognitive	O
Assessment	O
tool	O
was	O
used	O
to	O
screen	O
the	O
study	O
participants	O
for	O
cognitive	O
impairment	O
and	O
evaluate	O
cognitive	O
deficits	O
.	O

Cognitive	O
impairment	O
was	O
defined	O
as	O
a	O
total	O
Montreal	O
Cognitive	O
Assessment	O
tool	O
score	O
≤24/30	O
.	O

The	O
extent	O
of	O
cognitive	O
impairment	O
varied	O
between	O
the	O
four	O
groups	O
with	O
end	O
stage	O
kidney	O
disease	O
.	O

Factors	O
predicting	O
the	O
presence	O
of	O
cognitive	O
impairment	O
included	O
undertaking	O
dialysis	O
,	O
age	O
≥65	O
,	O
male	O
gender	O
,	O
and	O
the	O
presence	O
of	O
diabetes	O
or	O
cerebrovascular	O
disease	O
.	O

Deficits	O
in	O
executive	O
function	O
,	O
attention	O
,	O
language	O
,	O
visuospatial	O
skills	O
,	O
memory	O
and	O
orientation	O
were	O
common	O
amongst	O
the	O
study	O
participants	O
,	O
and	O
these	O
deficits	O
varied	O
according	O
to	O
which	O
end	O
stage	O
kidney	O
disease	O
group	O
the	O
participants	O
were	O
in	O
.	O

Limitations	O
to	O
the	O
study	O
included	O
the	O
cross	O
sectional	O
design	O
and	O
that	O
the	O
presence	O
of	O
confounders	O
like	O
depression	O
were	O
not	O
recorded	O
.	O

The	O
impact	O
of	O
disparities	O
in	O
the	O
cognitive	O
capabilities	O
identified	O
in	O
this	O
study	O
are	O
likely	O
to	O
be	O
far	O
reaching	O
.	O

Tailoring	O
of	O
education	O
and	O
self	O
management	O
programs	O
to	O
the	O
cognitive	O
deficits	O
of	O
individuals	O
is	O
required	O
.	O

Effects	O
of	O
a	O
novel	O
phosphodiesterase	O
10A	O
inhibitor	O
in	O
non-human	O
primates	O
:	O
A	O
therapeutic	O
approach	O
for	O
schizophrenia	O
with	O
improved	O
side	O
effect	O
profile	O
.	O

Schizophrenia	O
symptoms	O
are	O
associated	O
with	O
alterations	O
in	O
basal	O
ganglia-cortical	O
networks	O
that	O
include	O
the	O
cyclic	O
nucleotides	O
(	O
cAMP	O
/	O
cGMP	O
)	O
signaling	O
pathways	O
.	O

Phosphodiesterase	O
10A	O
(	O
PDE10A	O
)	O
inhibitors	O
have	O
been	O
considered	O
as	O
therapeutic	O
agents	O
for	O
schizophrenia	O
because	O
the	O
regulation	O
of	O
cAMP	O
and	O
cGMP	O
in	O
the	O
striatum	O
by	O
PDE10A	O
plays	O
an	O
important	O
role	O
in	O
the	O
signaling	O
mechanisms	O
of	O
the	O
striatal-cortical	O
network	O
,	O
and	O
thereby	O
in	O
cognitive	O
function	O
.	O

In	O
the	O
present	O
study	O
we	O
assessed	O
in	O
non-human	O
primates	O
(	O
NHPs	O
)	O
the	O
effects	O
of	O
a	O
novel	O
PDE10A	O
inhibitor	O
(	O
FRM-6308	O
)	O
that	O
has	O
demonstrated	O
high	O
potency	O
and	O
selectivity	O
for	O
human	O
recombinant	O
PDE10A	O
in	O
vitro	O
.	O

The	O
behavioral	O
effects	O
of	O
FRM-6308	O
in	O
a	O
dose	O
range	O
were	O
determined	O
in	O
rhesus	O
monkeys	O
using	O
a	O
standardized	O
motor	O
disability	O
scale	O
for	O
primates	O
,	O
motor	O
tasks	O
,	O
and	O
the	O
``	O
drug	O
effects	O
on	O
the	O
nervous	O
system	O
''	O
(	O
DENS	O
)	O
scale	O
.	O

The	O
neuronal	O
metabolic	O
effects	O
of	O
FRM-6308	O
were	O
determined	O
with	O
[	B-P
(	I-P
18	I-P
)	I-P
F	I-P
]	I-P
-fluorodeoxyglucose	I-P
PET	I-P
imaging	I-P
.	O

Results	O
showed	O
that	O
FRM-6308	O
did	O
not	O
have	O
any	O
specific	O
effects	O
on	O
the	O
motor	O
system	O
at	O
s.c.	O
doses	O
up	O
to	O
0.32	O
mg/kg	O
in	O
NHPs	O
,	O
which	O
induced	O
a	O
significant	O
increase	O
in	O
the	O
FDG	O
-	O
SUV	O
in	O
striatum	O
(	O
F	O
16.069	O
,	O
p	O
<	O
0.05	O
)	O
and	O
cortical	O
(	O
F	O
15.181	O
,	O
p	O
<	O
0.05	O
)	O
regions	O
.	O

Higher	O
doses	O
induced	O
sedation	O
and	O
occasional	O
involuntary	O
movements	O
with	O
clear	O
development	O
of	O
tolerance	O
after	O
repeated	O
exposures	O
.	O

These	O
findings	O
suggest	O
that	O
FRM-6308	O
has	O
the	O
adequate	O
pharmacological	O
profile	O
to	O
advance	O
testing	O
in	O
clinical	O
trials	O
and	O
demonstrate	O
antipsychotic	O
efficacy	O
of	O
PDE10A	O
inhibition	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
patients	O
.	O

In	O
vivo	O
assessment	O
of	O
periodontal	O
structures	O
and	O
measurement	O
of	O
gingival	O
sulcus	O
with	O
Optical	B-P
Coherence	I-P
Tomography	I-P
:	O
a	O
pilot	O
study	O
.	O

There	O
has	O
been	O
increasing	O
interest	O
on	O
the	O
development	O
of	O
clinically	O
acceptable	O
,	O
more	O
sensitive	O
and	O
specific	O
methods	O
for	O
non-invasive	O
diagnosis	O
in	O
Periodontics	O
.	O

In	O
this	O
pilot	O
study	O
,	O
the	O
performance	O
of	O
an	O
Optical	B-P
Coherence	I-P
Tomography	I-P
(	O
OCT	B-P
)	O
system	O
in	O
imaging	B-P
periodontal	O
structures	O
in	O
humans	O
was	O
evaluated	O
.	O

Gingival	O
sulcus	O
depth	O
measurements	O
were	O
obtained	O
and	O
compared	O
with	O
traditional	O
probes	O
.	O

In	O
total	O
,	O
445	O
sites	O
of	O
23	O
periodontally	O
healthy	O
individuals	O
were	O
measured	O
by	O
3	O
instruments	O
:	O
North	O
Carolina	O
manual	O
probe	O
,	O
Florida	O
automated	O
probe	O
and	O
OCT	B-P
at	O
1325	O
nm	O
.	O

To	O
obtain	O
quantitative	O
measurements	O
from	O
OCT	B-P
images	O
,	O
the	O
gingival	O
refractive	O
index	O
was	O
also	O
determined	O
.	O

Discomfort	O
/	O
pain	O
perception	O
and	O
the	O
duration	O
of	O
examinations	O
were	O
compared	O
among	O
the	O
instruments	O
.	O

The	O
analysis	O
of	O
OCT	B-P
images	O
allowed	O
the	O
identification	O
of	O
relevant	O
anatomic	O
dental	O
and	O
periodontal	O
regions	O
.	O

The	O
average	O
sulcus	O
depth	O
measured	O
by	O
OCT	B-P
,	O
0.85	O
±	O
0.27	O
mm	O
and	O
0.87	O
±	O
0.28	O
mm	O
,	O
was	O
lower	O
than	O
the	O
values	O
obtained	O
by	O
manual	O
and	O
automated	O
probing	O
.	O

Discomfort	O
/	O
pain	O
were	O
prevalent	O
for	O
traditional	O
probes	O
,	O
which	O
are	O
invasive	O
methods	O
,	O
than	O
for	O
the	O
non-invasive	O
OCT	B-P
technique	O
.	O

OCT	B-P
has	O
the	O
potential	O
to	O
be	O
a	O
reliable	O
tool	O
for	O
in	O
vivo	O
periodontal	O
tissues	O
evaluation	O
and	O
for	O
reproducible	O
sulcus	O
depth	O
measurements	O
in	O
healthy	O
sites	O
.	O

Further	O
technological	O
advances	O
are	O
required	O
to	O
reduce	O
the	O
procedure	O
time	O
and	O
promote	O
evaluation	O
of	O
posterior	O
oral	O
regions	O
.	O

Photonic	O
assessment	O
of	O
periodontal	O
tissue	O
with	O
OCT	B-P
(	O
top	O
)	O
in	O
a	O
clinical	O
environment	O
,	O
showing	O
tooth	O
/	O
gingiva	O
features	O
(	O
bottom	O
)	O
.	O

Cost-Effectiveness	O
of	O
the	O
'	O
One4All	B-P
'	O
HIV	O
Linkage	O
Intervention	O
in	O
Guangxi	O
Zhuang	O
Autonomous	O
Region	O
,	O
China	O
.	O

In	O
Guangxi	O
Zhuang	O
Autonomous	O
Region	O
,	O
China	O
,	O
an	O
estimated	O
80	O
%	O
of	O
newly-identified	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
-eligible	O
patients	O
are	O
not	O
engaged	O
in	O
ART	O
.	O

Delayed	O
ART	O
uptake	O
ultimately	O
translates	O
into	O
high	O
rates	O
of	O
HIV	O
morbidity	O
,	O
mortality	O
,	O
and	O
transmission	O
.	O

To	O
enhance	O
HIV	O
testing	O
receipt	O
and	O
subsequent	O
treatment	O
uptake	O
in	O
Guangxi	O
,	O
the	O
Chinese	O
Center	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
executed	O
a	O
cluster-randomized	O
trial	O
to	O
assess	O
the	O
effectiveness	O
and	O
cost-effectiveness	O
of	O
a	O
streamlined	O
HIV	O
testing	O
algorithm	O
(	O
the	O
One4All	B-P
intervention	O
)	O
in	O
12	O
county-level	O
hospitals	O
.	O

To	O
determine	O
the	O
incremental	O
cost-effectiveness	O
of	O
the	O
One4All	B-P
intervention	O
delivered	O
at	O
county	O
hospitals	O
in	O
Guangxi	O
,	O
China	O
,	O
compared	O
to	O
the	O
current	O
standard	O
of	O
care	O
(	O
SOC	O
)	O
.	O

Health	O
System	O
.	O

1-	O
,	O
5-and	O
25-years	O
.	O

We	O
adapted	O
a	O
dynamic	O
,	O
compartmental	O
HIV	O
transmission	O
model	O
to	O
simulate	O
HIV	O
transmission	O
and	O
progression	O
in	O
Guangxi	O
,	O
China	O
and	O
identify	O
the	O
economic	O
impact	O
and	O
health	O
benefits	O
of	O
implementing	O
the	O
One4All	B-P
intervention	O
in	O
all	O
Guangxi	O
hospitals	O
.	O

The	O
One4All	B-P
intervention	O
algorithm	O
entails	O
rapid	O
point-of-care	O
HIV	O
screening	B-P
,	O
CD4	O
and	O
viral	B-P
load	I-P
testing	O
of	O
individuals	O
presenting	O
for	O
HIV	O
screening	B-P
,	O
with	O
same-day	O
results	O
and	O
linkage	O
to	O
counselling	O
.	O

We	O
populated	O
the	O
model	O
with	O
data	O
from	O
the	O
One4All	B-P
trial	I-P
(	O
CTN-0056	B-P
)	O
,	O
China	O
CDC	O
HIV	O
registry	O
and	O
published	O
reports	O
.	O

Model	O
outcomes	O
were	O
HIV	O
incidence	O
,	O
mortality	O
,	O
costs	O
,	O
quality-adjusted	O
life	O
years	O
(	O
QALYs	O
)	O
,	O
and	O
the	O
incremental	O
cost-effectiveness	O
ratio	O
(	O
ICER	O
)	O
of	O
the	O
One4All	O
intervention	O
compared	O
to	O
SOC	O
.	O

The	O
One4All	O
testing	O
intervention	O
was	O
more	O
costly	O
than	O
SOC	O
(	O
CNY	O
2,182	O
vs.	O
CNY	O
846	O
)	O
,	O
but	O
facilitated	O
earlier	O
ART	O
access	O
,	O
resulting	O
in	O
delayed	O
disease	O
progression	O
and	O
mortality	O
.	O

Over	O
a	O
25-year	O
time	O
horizon	O
,	O
we	O
estimated	O
that	O
introducing	O
One4All	B-P
in	O
Guangxi	O
would	O
result	O
in	O
802	O
averted	O
HIV	O
cases	O
and	O
1629	O
averted	O
deaths	O
at	O
an	O
ICER	O
of	O
CNY	O
11,678	O
per	O
QALY	O
gained	O
.	O

Sensitivity	O
analysis	O
revealed	O
that	O
One4All	B-P
remained	O
cost-effective	O
at	O
even	O
minimal	O
levels	O
of	O
effectiveness	O
.	O

Results	O
were	O
robust	O
to	O
changes	O
to	O
a	O
range	O
of	O
parameters	O
characterizing	O
the	O
HIV	O
epidemic	O
over	O
time	O
.	O

The	O
One4All	B-P
HIV	O
testing	O
strategy	O
was	O
highly	O
cost-effective	O
by	O
WHO	O
standards	O
,	O
and	O
should	O
be	O
prioritized	O
for	O
widespread	O
implementation	O
in	O
Guangxi	O
,	O
China	O
.	O

Integrating	O
the	O
intervention	O
within	O
a	O
broader	O
combination	O
prevention	O
strategy	O
would	O
enhance	O
the	O
public	O
health	O
response	O
to	O
HIV	O
/	O
AIDS	O
in	O
Guangxi	O
.	O

Sarcoid-like	O
reaction	O
in	O
a	O
patient	O
with	O
uveitis	O
and	O
underlying	O
cancer	O
.	O

Sarcoidosis	O
is	O
a	O
granulomatous	O
disease	O
of	O
unknown	O
etiology	O
.	O

Occasionally	O
,	O
triggering	O
causes	O
are	O
identified	O
,	O
such	O
as	O
neoplasms	O
,	O
and	O
they	O
are	O
termed	O
sarcoid-like	O
reactions	O
,	O
which	O
may	O
appear	O
in	O
any	O
sarcoidotic	O
target	O
tissue	O
.	O

Choroidal	O
metastases	O
appear	O
as	O
part	O
of	O
widespread	O
metastatic	O
disease	O
or	O
as	O
the	O
first	O
suggestion	O
of	O
neoplastic	O
disease	O
.	O

They	O
can	O
also	O
be	O
a	O
part	O
of	O
the	O
differential	B-P
diagnosis	I-P
of	O
a	O
spectrum	O
of	O
inflammatory	O
eye	O
diseases	O
.	O

We	O
present	O
a	O
case	O
in	O
which	O
a	O
lung	O
carcinoma	O
,	O
pulmonary	O
and	O
eye	O
sarcoid-like	O
reactions	O
,	O
and	O
choroidal	O
metastasis	O
take	O
place	O
in	O
the	O
same	O
patient	O
.	O

A	O
60-	O
year-old	O
male	O
with	O
a	O
past	O
history	O
of	O
pulmonary	O
sarcoidosis	O
and	O
associated	O
anterior	O
uveitis	O
was	O
diagnosed	O
with	O
a	O
lung	O
carcinoma	O
with	O
no	O
regional	O
lymph	O
nodes	O
extension	O
,	O
so	O
that	O
the	O
resection	O
surgery	O
was	O
performed	O
without	O
additional	O
systemic	O
treatment	O
.	O

At	O
the	O
same	O
time	O
,	O
he	O
complained	O
of	O
visual	O
acuity	O
loss	O
and	O
pain	O
in	O
his	O
right	O
eye	O
.	O

An	O
intense	O
ocular	O
inflammatory	O
reaction	O
and	O
a	O
choroidal	O
mass	O
compatible	O
with	O
metastasis	O
were	O
identified	O
.	O

A	O
vitrectomy	O
with	O
an	O
accompanied	O
histological	O
exam	O
of	O
the	O
lesion	O
was	O
deemed	O
inconclusive	O
.	O

Ocular	O
symptoms	O
progressively	O
worsened	O
showing	O
mass	O
growth	O
,	O
and	O
as	O
a	O
result	O
,	O
an	O
enucleation	O
was	O
performed	O
and	O
the	O
histological	O
study	O
subsequently	O
revealed	O
metastasis	O
from	O
his	O
lung	O
carcinoma	O
.	O

Sarcoid-like	O
reactions	O
may	O
be	O
due	O
to	O
incipient	O
malignancies	O
.	O

Any	O
diagnosis	O
of	O
sarcoidosis	O
requires	O
ruling	O
out	O
other	O
diseases	O
that	O
can	O
produce	O
secondary	O
sarcoid-like	O
reactions	O
.	O

In	O
addition	O
,	O
any	O
choroidal	O
mass	O
suggestive	O
of	O
metastasis	O
requires	O
exclusion	O
of	O
metastatic	O
disease	O
even	O
in	O
the	O
absence	O
of	O
clinical	O
signs	O
indicating	O
tumor	O
extension	O
.	O

Differential	O
Immunohistochemical	B-P
Profiles	B-P
for	O
Distinguishing	O
Prostate	O
Carcinoma	O
and	O
Urothelial	O
Carcinoma	O
.	O

The	O
pathologic	O
distinction	O
between	O
high-grade	O
prostate	O
adenocarcinoma	O
(	O
PAC	O
)	O
involving	O
the	O
urinary	O
bladder	O
and	O
high-grade	O
urothelial	O
carcinoma	O
(	O
UC	O
)	O
infiltrating	O
the	O
prostate	O
can	O
be	O
difficult	O
.	O

However	O
,	O
making	O
this	O
distinction	O
is	O
clinically	O
important	O
because	O
of	O
the	O
different	O
treatment	O
modalities	O
for	O
these	O
two	O
entities	O
.	O

A	O
total	O
of	O
249	O
patient	O
cases	O
(	O
PAC	O
,	O
111	O
cases	O
;	O
UC	O
,	O
138	O
cases	O
)	O
collected	O
between	O
June	O
1995	O
and	O
July	O
2009	O
at	O
Seoul	O
St.	O
Mary	O
's	O
Hospital	O
were	O
studied	O
.	O

An	O
immunohistochemical	B-P
evaluation	B-P
of	O
prostatic	O
markers	O
(	O
prostate-specific	O
antigen	O
[	O
PSA	O
]	O
,	O
prostate-specific	O
membrane	O
antigen	O
[	O
PSMA	O
]	O
,	O
prostate	O
acid	O
phosphatase	O
[	O
PAP	O
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-methylacyl	O
coenzyme	O
A	O
racemase	O
[	O
AMACR	O
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34βE12	O
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	O
protein	O
3	O
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

The	O
sensitivities	O
of	O
prostatic	O
markers	O
in	O
PAC	O
were	O
100	O
%	O
for	O
PSA	O
,	O
83.8	O
%	O
for	O
PSMA	O
,	O
91.9	O
%	O
for	O
PAP	O
,	O
93.7	O
%	O
for	O
P501s	O
,	O
88.3	O
%	O
for	O
NKX	O
3.1	O
,	O
and	O
66.7	O
%	O
for	O
AMACR	O
.	O

However	O
,	O
the	O
urothelial	O
markers	O
CK34βE12	O
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA3	O
were	O
also	O
positive	O
in	O
1.8	O
%	O
,	O
0	O
%	O
,	O
0	O
%	O
,	O
3.6	O
%	O
,	O
and	O
0	O
%	O
of	O
PAC	O
,	O
respectively	O
.	O

The	O
sensitivities	O
of	O
urothelial	O
markers	O
in	O
UC	O
were	O
75.4	O
%	O
for	O
CK34βE12	O
,	O
73.9	O
%	O
for	O
p63	O
,	O
45.7	O
%	O
for	O
thrombomodulin	O
,	O
22.5	O
%	O
for	O
S100P	O
,	O
and	O
84.8	O
%	O
for	O
GATA3	O
.	O

Conversely	O
,	O
the	O
prostatic	O
markers	O
PSA	O
,	O
PSMA	O
,	O
PAP	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
AMACR	O
were	O
also	O
positive	O
in	O
9.4	O
%	O
,	O
0.7	O
%	O
,	O
18.8	O
%	O
,	O
0.7	O
%	O
,	O
0	O
%	O
,	O
and	O
8.7	O
%	O
of	O
UC	O
s	O
,	O
respectively	O
.	O

Prostatic	O
and	O
urothelial	O
markers	O
,	O
including	O
PSA	O
,	O
NKX3.1	O
,	O
p63	O
,	O
thrombomodulin	O
,	O
and	O
GATA3	O
are	O
very	O
useful	O
for	O
differentiating	O
PAC	O
from	O
UC	O
.	O

The	O
optimal	O
combination	O
of	O
prostatic	O
and	O
urothelial	O
markers	O
could	O
improve	O
the	O
ability	O
to	O
differentiate	O
PAC	O
from	O
UC	O
pathologically	O
.	O

Yersinia	O
ruckeri	O
Isolates	O
Recovered	O
from	O
Diseased	O
Atlantic	O
Salmon	O
(	O
Salmo	O
salar	O
)	O
in	O
Scotland	O
Are	O
More	O
Diverse	O
than	O
Those	O
from	O
Rainbow	O
Trout	O
(	O
Oncorhynchus	O
mykiss	O
)	O
and	O
Represent	O
Distinct	O
Subpopulations	O
.	O

Yersinia	O
ruckeri	O
is	O
the	O
etiological	O
agent	O
of	O
enteric	O
redmouth	O
(	O
ERM	O
)	O
disease	O
of	O
farmed	O
salmonids	O
.	O

Enteric	O
redmouth	O
disease	O
is	O
traditionally	O
associated	O
with	O
rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
,	O
Walbaum	O
)	O
,	O
but	O
its	O
incidence	O
in	O
Atlantic	O
salmon	O
(	O
Salmo	O
salar	O
)	O
is	O
increasing	O
.	O

Yersinia	O
ruckeri	O
isolates	O
recovered	O
from	O
diseased	O
Atlantic	O
salmon	O
have	O
been	O
poorly	O
characterized	O
,	O
and	O
very	O
little	O
is	O
known	O
about	O
the	O
relationship	O
of	O
the	O
isolates	O
associated	O
with	O
these	O
two	O
species	O
.	O

Phenotypic	O
approaches	O
were	O
used	O
to	O
characterize	O
109	O
Y.	O
ruckeri	O
isolates	O
recovered	O
over	O
a	O
14-year	O
period	O
from	O
infected	O
Atlantic	O
salmon	O
in	O
Scotland	O
;	O
26	O
isolates	O
from	O
infected	O
rainbow	O
trout	O
were	O
also	O
characterized	O
.	O

Biotyping	B-P
,	O
serotyping	B-P
,	O
and	O
comparison	O
of	O
outer	O
membrane	O
protein	O
profiles	O
identified	O
19	O
Y.	O
ruckeri	O
clones	O
associated	O
with	O
Atlantic	O
salmon	O
but	O
only	O
five	O
associated	O
with	O
rainbow	O
trout	O
;	O
none	O
of	O
the	O
Atlantic	O
salmon	O
clones	O
occurred	O
in	O
rainbow	O
trout	O
and	O
vice	O
versa	O
These	O
findings	O
suggest	O
that	O
distinct	O
subpopulations	O
of	O
Y.	O
ruckeri	O
are	O
associated	O
with	O
each	O
species	O
.	O

A	O
new	O
O	O
serotype	O
(	O
designated	O
O8	O
)	O
was	O
identified	O
in	O
56	O
biotype	O
1	O
Atlantic	O
salmon	O
isolates	O
and	O
was	O
the	O
most	O
common	O
serotype	O
identified	O
from	O
2006	O
to	O
2011	O
and	O
in	O
2014	O
,	O
suggesting	O
an	O
increased	O
prevalence	O
during	O
the	O
time	O
period	O
sampled	O
.	O

Rainbow	O
trout	O
isolates	O
were	O
represented	O
almost	O
exclusively	O
by	O
the	O
same	O
biotype	O
2	O
,	O
serotype	O
O1	O
clone	O
that	O
has	O
been	O
responsible	O
for	O
the	O
majority	O
of	O
ERM	O
outbreaks	O
in	O
this	O
species	O
within	O
the	O
United	O
Kingdom	O
since	O
the	O
1980s	O
.	O

However	O
,	O
the	O
identification	O
of	O
two	O
biotype	O
2	O
,	O
serotype	O
O8	O
isolates	O
in	O
rainbow	O
trout	O
suggests	O
that	O
vaccines	O
containing	O
serotypes	O
O1	O
and	O
O8	O
should	O
be	O
evaluated	O
in	O
both	O
rainbow	O
trout	O
and	O
Atlantic	O
salmon	O
for	O
application	O
in	O
Scotland	O
.	O

Vaccination	O
plays	O
an	O
important	O
role	O
in	O
protecting	O
Atlantic	O
salmon	O
against	O
the	O
bacterial	O
pathogen	O
Yersinia	O
ruckeri	O
,	O
but	O
,	O
in	O
recent	O
years	O
,	O
there	O
has	O
been	O
an	O
increasing	O
incidence	O
of	O
vaccine	O
breakdown	O
in	O
salmon	O
.	O

This	O
is	O
largely	O
because	O
current	O
vaccines	O
are	O
aimed	O
at	O
rainbow	O
trout	O
and	O
are	O
based	O
on	O
serotypes	O
specific	O
for	O
this	O
species	O
.	O

A	O
wider	O
range	O
of	O
serotypes	O
is	O
responsible	O
for	O
infection	O
in	O
Atlantic	O
salmon	O
,	O
but	O
very	O
little	O
is	O
known	O
about	O
the	O
diversity	O
of	O
these	O
strains	O
and	O
their	O
relationships	O
to	O
those	O
recovered	O
from	O
rainbow	O
trout	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
Y.	O
ruckeri	O
isolates	O
recovered	O
from	O
diseased	O
Atlantic	O
salmon	O
in	O
Scotland	O
are	O
more	O
diverse	O
than	O
those	O
from	O
rainbow	O
trout	O
;	O
furthermore	O
,	O
isolates	O
from	O
the	O
two	O
species	O
represent	O
distinct	O
subpopulations	O
.	O

In	O
addition	O
,	O
a	O
new	O
O	O
serotype	O
was	O
identified	O
that	O
is	O
responsible	O
for	O
a	O
significant	O
proportion	O
of	O
the	O
disease	O
in	O
Atlantic	O
salmon	O
.	O

Our	O
findings	O
are	O
likely	O
to	O
have	O
important	O
implications	O
for	O
the	O
development	O
of	O
improved	O
vaccines	O
against	O
Y.	O
ruckeri	O
.	O

Tumor-suppressive	O
function	O
of	O
long	O
noncoding	O
RNA	O
MALAT1	O
in	O
glioma	O
cells	O
by	O
suppressing	O
miR-155	O
expression	O
and	O
activating	O
FBXW7	O
function	O
.	O

The	O
human	O
metastasis	O
associated	O
lung	O
adenocarcinoma	O
transcript	O
1	O
(	O
MALAT1	O
)	O
is	O
a	O
long	O
non-coding	O
RNA	O
associated	O
with	O
metastasis	O
,	O
and	O
is	O
a	O
favorable	O
prognostic	O
factor	O
for	O
lung	O
cancer	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
MALAT1	O
plays	O
an	O
important	O
role	O
in	O
many	O
malignancies	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
MALAT1	O
in	O
glioma	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
expression	O
of	O
MALAT1	O
and	O
explored	O
its	O
prognostic	O
value	O
in	O
glioma	O
.	O

Further	O
,	O
we	O
investigated	O
the	O
regulatory	O
mechanism	O
of	O
MALAT1	O
in	O
glioma	O
progression	O
.	O

Our	O
results	O
showed	O
that	O
the	O
expression	O
of	O
MALAT1	O
was	O
significantly	O
decreased	O
in	O
glioma	O
specimens	O
than	O
in	O
noncancerous	O
brain	O
tissues	O
.	O

In	O
addition	O
,	O
MALAT1	O
expression	O
was	O
significantly	O
correlated	O
with	O
tumor	O
size	O
,	O
WHO	O
grade	O
and	O
Karnofsky	B-P
Performance	I-P
Status	I-P
(	O
KPS	B-P
)	O
,	O
and	O
was	O
an	O
independent	O
prognostic	O
factor	O
for	O
survival	O
of	O
glioma	O
patients	O
.	O

The	O
gain-	O
and	O
loss-of-function	O
experiments	O
revealed	O
miR-155	O
down-regulation	O
by	O
MALAT1	O
,	O
resulting	O
in	O
reciprocal	O
effects	O
.	O

Further	O
,	O
MALAT1	O
suppresses	O
cell	O
viability	O
by	O
down-regulating	O
miR-155	O
.	O

FBXW7	O
mRNA	O
was	O
identified	O
as	O
a	O
direct	O
target	O
of	O
miR-155	O
in	O
glioma	O
.	O

The	O
miR-155	O
-induced	O
tumorigenesis	O
is	O
mediated	O
through	O
FBXW7	O
function	O
.	O

Finally	O
,	O
we	O
found	O
that	O
MALAT1	O
positively	O
regulated	O
FBXW7	O
expression	O
,	O
which	O
was	O
responsible	O
for	O
glioma	O
progression	O
mediated	O
by	O
MALAT1	O
-	O
miR-155	O
pathway	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
demonstrated	O
that	O
MALAT1	O
may	O
be	O
a	O
novel	O
prognostic	O
biomarker	O
and	O
therapeutic	O
target	O
in	O
glioma	O
.	O

Restoration	O
of	O
MALAT1	O
levels	O
represents	O
a	O
novel	O
therapeutic	O
strategy	O
against	O
glioma	O
.	O

Survival	O
of	O
ovarian	O
cancer	O
patients	O
in	O
Denmark	O
:	O
Results	O
from	O
the	O
Danish	O
gynaecological	O
cancer	O
group	O
(	O
DGCG	O
)	O
database	O
,	O
1995-2012	O
.	O

Ovarian	O
cancer	O
has	O
a	O
high	O
mortality	O
rate	O
,	O
especially	O
in	O
Denmark	O
where	O
mortality	O
rates	O
have	O
been	O
reported	O
higher	O
than	O
in	O
adjacent	O
countries	O
with	O
similar	O
demographics	O
.	O

This	O
study	O
therefore	O
examined	O
recent	O
survival	O
and	O
mortality	O
among	O
Danish	O
ovarian	O
cancer	O
patients	O
over	O
an	O
18-year	O
study	O
period	O
.	O

This	O
nationwide	O
registry-based	O
observational	O
study	O
used	O
data	O
from	O
the	O
Danish	O
Gynecology	O
Cancer	O
Database	O
,	O
Danish	O
Pathology	O
Registry	O
,	O
and	O
Danish	O
National	O
Patient	O
Registry	O
.	O

All	O
patients	O
with	O
ovarian	O
cancer	O
diagnosed	B-P
between	O
1995	O
and	O
2012	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
data	O
sources	O
were	O
linked	O
via	O
the	O
patients	O
'	O
personal	O
identification	O
number	O
and	O
the	O
analyses	O
included	O
data	O
on	O
cancer	B-P
stage	I-P
,	O
age	O
,	O
survival	O
,	O
surgery	O
status	O
and	O
comorbidity	O
.	O

The	O
computed	O
outcome	O
measures	O
were	O
age-adjusted	O
mortality	O
rates	O
and	O
age-adjusted	O
overall	O
and	O
relative	O
survival	O
rates	O
for	O
one	O
and	O
five	O
years	O
.	O

We	O
identified	O
9972	O
patients	O
diagnosed	O
with	O
ovarian	O
cancer	O
in	O
the	O
period	O
1995-2012	O
.	O

The	O
absolute	O
one-year	O
mortality	O
rate	O
decreased	O
from	O
42.8	O
(	O
CI	O
40.3-45.6	O
)	O
in	O
1995-1999	O
to	O
28.3	O
(	O
CI	O
25.9-30.9	O
)	O
in	O
2010-2012	O
,	O
and	O
the	O
five-year	O
mortality	O
rate	O
decreased	O
from	O
28.2	O
(	O
CI	O
27.0-29.5	O
)	O
in	O
1995-1999	O
to	O
23.9	O
(	O
CI	O
22.9-25.0	O
)	O
in	O
2005-2009	O
.	O

After	O
stratification	O
by	O
age	O
,	O
comorbidity	O
and	O
cancer	B-P
stage	I-P
,	O
the	O
decrease	O
in	O
one-year	O
mortality	O
was	O
most	O
substantial	O
in	O
the	O
65-74	O
year	O
old	O
age	O
group	O
41.1	O
(	O
CI	O
38.8-43.5	O
)	O
to	O
26.5	O
(	O
CI	O
24.4-28.7	O
)	O
and	O
for	O
stage	O
III	O
39.1	O
(	O
CI	O
35.1-43.6	O
)	O
to	O
22.9	O
(	O
CI	O
19.9-26.5	O
)	O
and	O
stage	O
IV	O
91.3	O
(	O
CI	O
80.8-103.2	O
)	O
to	O
41.9	O
(	O
CI	O
35.5-49.5	O
)	O
.	O

For	O
overall	O
survival	O
,	O
we	O
showed	O
an	O
increase	O
in	O
one-year	O
survival	O
from	O
68	O
%	O
(	O
CI	O
66-69	O
%	O
)	O
in	O
1995-1999	O
to	O
76	O
%	O
(	O
CI	O
74-78	O
%	O
)	O
in	O
2010-2012	O
and	O
an	O
increase	O
in	O
five-year	O
survival	O
from	O
33	O
%	O
(	O
CI	O
32-35	O
%	O
)	O
in	O
1995-1999	O
to	O
36	O
%	O
(	O
CI	O
34-38	O
%	O
)	O
in	O
2005-2009	O
.	O

Relative	O
survival	O
showed	O
similar	O
increases	O
through	O
the	O
period	O
.	O

Ovarian	O
cancer	O
survival	O
in	O
Denmark	O
has	O
improved	O
substantially	O
from	O
1995	O
to	O
2012	O
,	O
bringing	O
Denmark	O
closer	O
to	O
the	O
standards	O
set	O
by	O
adjacent	O
countries	O
.	O

miR-376c	O
inhibits	O
cervical	O
cancer	O
cell	O
proliferation	O
and	O
invasion	O
by	O
targeting	O
BMI1	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
play	O
crucial	O
roles	O
in	O
cancer	O
development	O
and	O
progression	O
.	O

The	O
purposes	O
of	O
this	O
study	O
were	O
to	O
explore	O
the	O
role	O
of	O
miR-376c	O
in	O
cervical	O
cancer	O
and	O
to	O
clarify	O
the	O
regulation	O
of	O
BMI1	O
by	O
miR-376c	O
.	O

Quantitative	O
RT-PCR	O
was	O
used	O
to	O
measure	O
miR-376c	O
expression	O
in	O
cervical	O
cancer	O
tissues	O
and	O
cell	O
lines	O
.	O

The	O
cell	O
proliferation	O
,	O
cell	B-P
cycle	I-P
and	O
Transwell	B-P
invasion	I-P
assays	I-P
were	O
performed	O
.	O

A	O
luciferase	B-P
reporter	I-P
assay	I-P
was	O
conducted	O
to	O
confirm	O
the	O
target	O
gene	O
of	O
miR-376c	O
,	O
and	O
the	O
results	O
were	O
validated	O
in	O
cervical	O
cancer	O
cell	O
lines	O
and	O
tissues	O
.	O

MiR-376c	O
was	O
significantly	O
downregulated	O
in	O
cervical	O
cancer	O
cell	O
lines	O
and	O
clinical	O
tissues	O
.	O

Upregulation	O
of	O
miR-376c	O
impaired	O
cell	O
proliferation	O
,	O
blocked	O
G1/S	O
checkpoint	O
of	O
cell	O
cycle	O
and	O
suppressed	O
cell	O
invasion	O
in	O
vitro	O
.	O

BMI1	O
was	O
verified	O
as	O
a	O
direct	O
target	O
of	O
miR-376c	O
,	O
which	O
was	O
further	O
confirmed	O
by	O
the	O
inverse	O
expression	O
of	O
miR-376c	O
and	O
BMI1	O
in	O
patient	O
specimens	O
.	O

The	O
newly	O
identified	O
miR-376c	O
/	O
BMI1	O
pathway	O
provides	O
an	O
insight	O
into	O
cervical	O
cancer	O
progression	O
and	O
may	O
represent	O
a	O
novel	O
therapeutic	O
target	O
.	O

Elevated	O
Serum	O
Uric	O
Acid	O
Level	O
Predicts	O
Rapid	O
Decline	O
in	O
Kidney	O
Function	O
.	O

While	O
elevated	O
serum	O
uric	O
acid	O
level	O
(	O
SUA	O
)	O
is	O
a	O
recognized	O
risk	O
factor	O
for	O
chronic	O
kidney	O
disease	O
,	O
it	O
remains	O
unclear	O
whether	O
change	O
in	O
SUA	O
is	O
independently	O
associated	O
with	O
change	O
in	O
estimated	B-P
glomerular	I-P
filtration	I-P
rate	I-P
(	O
eGFR	B-P
)	O
over	O
time	O
.	O

Accordingly	O
,	O
we	O
examined	O
the	O
longitudinal	O
associations	O
between	O
change	O
in	O
SUA	O
and	O
change	O
in	O
eGFR	B-P
over	O
5	O
years	O
in	O
a	O
general	O
Japanese	O
population	O
.	O

This	O
was	O
a	O
large	O
,	O
single-center	O
,	O
retrospective	O
5-	O
year	O
cohort	O
study	O
at	O
St.	O
Luke	O
's	O
International	O
Hospital	O
,	O
Tokyo	O
,	O
Japan	O
,	O
between	O
2004	O
and	O
2009	O
.	O

We	O
included	O
13,070	O
subjects	O
(	O
30-85	O
years	O
)	O
in	O
our	O
analyses	O
whose	O
data	O
were	O
available	O
between	O
2004	O
and	O
2009	O
.	O

Of	O
those	O
,	O
we	O
excluded	O
492	O
subjects	O
with	O
eGFR	B-P
<	O
60	O
mL/min/1.73	O
m2	O
at	O
baseline	O
.	O

In	O
addition	O
to	O
examining	O
the	O
entire	O
cohort	O
(	O
n	O
=	O
12,578	O
)	O
,	O
we	O
stratified	O
our	O
analyses	O
by	O
baseline	O
eGFR	B-P
groups	O
:	O
60-90	O
,	O
90-120	O
,	O
and	O
≥120	O
mL/min/1.73	O
m2	O
.	O

Linear	O
and	O
logistic	O
regressions	O
models	O
were	O
applied	O
to	O
examine	O
the	O
relationships	O
between	O
baseline	O
and	O
change	O
in	O
SUA	O
,	O
change	O
in	O
eGFR	B-P
,	O
and	O
rapid	O
eGFR	B-P
decline	O
(	O
defined	O
as	O
the	O
highest	O
quartile	O
of	O
change	O
in	O
eGFR	B-P
)	O
,	O
adjusted	O
for	O
age	O
,	O
gender	O
,	O
body	O
mass	O
index	O
,	O
abdominal	O
circumference	O
,	O
hypertension	O
,	O
dyslipidemia	O
,	O
and	O
diabetes	O
mellitus	O
.	O

After	O
multivariable	O
adjustments	O
including	O
baseline	O
eGFR	B-P
,	O
1	O
mg/dL	O
increase	O
in	O
baseline	O
SUA	O
was	O
associated	O
with	O
greater	O
odds	O
of	O
developing	O
rapid	O
eGFR	B-P
decline	O
(	O
OR	O
1.27	O
,	O
95	O
%	O
CI	O
1.17-1.38	O
)	O
,	O
and	O
1	O
mg/dL	O
increase	O
in	O
SUA	O
over	O
5	O
years	O
was	O
associated	O
with	O
3.77-fold	O
greater	O
odds	O
of	O
rapid	O
eGFR	B-P
decline	O
(	O
OR	O
3.77	O
,	O
95	O
%	O
CI	O
3.35-4.26	O
)	O
.	O

Elevated	O
baseline	O
SUA	O
and	O
increasing	O
SUA	O
over	O
time	O
were	O
independent	O
risk	O
factors	O
for	O
rapid	O
eGFR	B-P
decline	O
over	O
5	O
years	O
.	O

American	O
cutaneous	O
leishmaniasis	O
:	O
In	O
situ	O
immune	O
response	O
of	O
patients	O
with	O
recent	O
and	O
late	O
lesions	O
.	O

TNF-α	O
,	O
IFN-γ	O
,	O
IL-10	O
,	O
IL-17	O
,	O
CD68	O
and	O
CD57	O
were	O
evaluated	O
in	O
biopsies	B-P
of	O
patients	O
with	O
American	O
cutaneous	O
leishmaniasis	O
living	O
in	O
Sorocaba	O
,	O
Brazil	O
.	O

The	O
analyses	O
were	O
performed	O
considering	O
the	O
time	O
of	O
lesions	O
from	O
23	O
patients	O
with	O
recent	O
lesions	O
(	O
Group	O
I	O
)	O
and	O
19	O
patients	O
with	O
late	O
lesions	O
(	O
Group	O
II	O
)	O
.	O

All	O
patients	O
were	O
infected	O
with	O
Leishmania	O
(	O
Viannia	O
)	O
braziliensis	O
.	O

Immunostaining	B-P
cells	O
for	O
CD68	O
,	O
CD57	O
,	O
TNF-	O
α	O
,	O
IFN-γ	O
,	O
IL-10	O
and	O
IL-17	O
were	O
performed	O
by	O
immunohistochemistry	B-P
.	O

Except	O
for	O
CD68	O
and	O
IL-17	O
,	O
the	O
distribution	O
of	O
in	O
situ	O
for	O
CD57	O
,	O
IL-10	O
,	O
TNF-α	O
and	O
IFN-γ	O
showed	O
that	O
patients	O
with	O
recent	O
lesions	O
expressed	O
higher	O
levels	O
than	O
those	O
with	O
late	O
lesions	O
.	O

The	O
comparison	O
of	O
cytokine	O
expression	O
/	O
group	O
showed	O
that	O
IL-10	O
was	O
significantly	O
higher	O
than	O
IL-17	O
and	O
IFN-γ	O
(	O
similar	O
data	O
were	O
shown	O
in	O
IL-17	O
compared	O
with	O
TNF-α	O
)	O
,	O
suggesting	O
an	O
immunological	O
balance	O
between	O
inflammatory	O
-	O
anti-inflammatory	O
agents	O
.	O

This	O
balance	O
was	O
similar	O
for	O
two	O
groups	O
of	O
patients	O
.	O

In	O
conclusion	O
,	O
these	O
data	O
suggested	O
that	O
(	O
i	O
)	O
patients	O
from	O
Group	O
I	O
had	O
recent	O
lesions	O
(	O
in	O
the	O
beginning	O
of	O
chronic	O
phase	O
)	O
compared	O
to	O
those	O
from	O
Group	O
II	O
and	O
(	O
ii	O
)	O
the	O
modulation	O
of	O
inflammatory	O
response	O
in	O
patients	O
with	O
recent	O
American	O
cutaneous	O
leishmaniasis	O
was	O
correlated	O
with	O
IL-10	O
expression	O
in	O
skin	O
lesions	O
preventing	O
the	O
development	O
of	O
mucosal	O
forms	O
.	O

The	O
parasite	O
treatment	O
also	O
prevented	O
the	O
evolution	O
of	O
severe	O
forms	O
.	O

Morphogenetic	O
Alterations	O
of	O
Alternaria	O
alternata	O
Exposed	O
to	O
Dicarboximide	O
Fungicide	O
,	O
Iprodione	O
.	O

Fungicide-resistant	O
Alternaria	O
alternata	O
impede	O
the	O
practical	O
control	O
of	O
the	O
Alternaria	O
diseases	O
in	O
crop	O
fields	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
cytological	O
fungicide	O
resistance	O
mechanisms	O
of	O
A.	O
alternata	O
against	O
dicarboximide	O
fungicide	O
iprodione	O
.	O

A.	O
alternata	O
isolated	O
from	O
cactus	O
brown	O
spot	O
was	O
cultured	B-P
on	O
potato-dextrose	O
agar	O
(	O
PDA	O
)	O
with	O
or	O
without	O
iprodione	O
,	O
and	O
the	O
fungal	B-P
cultures	I-P
with	O
different	O
growth	O
characteristics	O
from	O
no	O
,	O
initial	O
and	O
full	O
growth	O
were	O
observed	O
by	O
light	B-P
and	O
electron	B-P
microscopy	I-P
.	O

Mycelia	O
began	O
to	O
grow	O
from	O
one	O
day	O
after	O
incubation	O
(	O
DAI	O
)	O
and	O
continued	O
to	O
be	O
in	O
full	O
growth	O
(	O
control-growth	O
,	O
Con-G	O
)	O
on	O
PDA	O
without	O
fungicide	O
,	O
while	O
on	O
PDA	O
with	O
iprodione	O
,	O
no	O
fungal	O
growth	O
(	O
iprodione-no	O
growth	O
,	O
Ipr-N	O
)	O
occurred	O
for	O
the	O
first	O
3	O
DAI	O
,	O
but	O
once	O
the	O
initial	O
growth	O
(	O
iprodione-initial	O
growth	O
,	O
Ipr-I	O
)	O
began	O
at	O
4-5	O
DAI	O
,	O
the	O
colonies	O
grew	O
and	O
expanded	O
continuously	O
to	O
be	O
in	O
full	O
growth	O
(	O
iprodione-growth	O
,	O
Ipr-G	O
)	O
,	O
suggesting	O
Ipr-I	O
may	O
be	O
a	O
turning	O
moment	O
of	O
the	O
morphogenetic	O
changes	O
resisting	O
fungicidal	O
toxicity	O
.	O

Con-G	O
formed	O
multicellular	O
conidia	O
with	O
cell	O
walls	O
and	O
septa	O
and	O
intact	O
dense	O
cytoplasm	O
.	O

In	O
Ipr-N	O
,	O
fungal	O
sporulation	O
was	O
inhibited	O
by	O
forming	O
mostly	O
undeveloped	O
unicellular	O
conidia	O
with	O
degraded	O
and	O
necrotic	O
cytoplasm	O
.	O

However	O
,	O
in	O
Ipr-I	O
,	O
conspicuous	O
cellular	O
changes	O
occurred	O
during	O
sporulation	O
by	O
forming	O
multicellular	O
conidia	O
with	O
double	O
layered	O
(	O
thickened	O
)	O
cell	O
walls	O
and	O
accumulation	O
of	O
proliferated	O
lipid	O
bodies	O
in	O
the	O
conidial	O
cytoplasm	O
,	O
which	O
may	O
inhibit	O
the	O
penetration	O
of	O
the	O
fungicide	O
into	O
conidial	O
cells	O
,	O
reducing	O
fungicide	O
-	O
associated	O
toxicity	O
,	O
and	O
may	O
be	O
utilized	O
as	O
energy	O
and	O
nutritional	O
sources	O
,	O
respectively	O
,	O
for	O
the	O
further	O
fungal	O
growth	O
to	O
form	O
mature	O
colonies	O
as	O
in	O
Ipr-G	O
that	O
formed	O
multicellular	O
conidia	O
with	O
cell	O
walls	O
and	O
intact	O
cytoplasm	O
with	O
lipid	O
bodies	O
as	O
in	O
Con-G	O
.	O

Relationship	O
between	O
interpersonal	O
trauma	O
exposure	O
and	O
addictive	O
behaviors	O
:	O
a	O
systematic	O
review	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
systematically	O
summarize	O
knowledge	O
on	O
the	O
association	O
between	O
exposure	O
to	O
interpersonal	O
trauma	O
and	O
addictive	O
behaviors	O
.	O

Extant	O
reviews	O
on	O
this	O
association	O
focused	O
on	O
a	O
restricted	O
range	O
of	O
substance-related	O
addictions	O
,	O
and/or	O
used	O
a	O
narrative	O
instead	O
of	O
a	O
systematic	O
approach	O
.	O

Systematic	O
searches	O
of	O
8	O
databases	O
yielded	O
29,841	O
studies	O
,	O
of	O
which	O
3054	O
studies	O
were	O
included	O
and	O
subsequently	O
classified	O
in	O
relation	O
to	O
study	O
design	O
(	O
scoping	O
review	O
)	O
.	O

A	O
subset	O
of	O
observational	O
studies	O
(	O
N	O
=	O
181	O
)	O
prospectively	O
investigating	O
the	O
relationship	O
between	O
exposure	O
to	O
interpersonal	O
traumata	O
and	O
subsequent	O
behavioral	O
or	O
substance-related	O
addiction	O
problems	O
were	O
characterized	O
.	O

Heterogeneity	O
in	O
study	O
methodologies	O
and	O
types	O
of	O
addictive	O
behaviors	O
and	O
traumatic	O
experiences	O
assessed	O
precluded	O
meta-analysis	O
.	O

Instead	O
,	O
the	O
proportions	O
of	O
associations	O
tested	O
in	O
this	O
literature	O
that	O
revealed	O
positive	O
,	O
negative	O
,	O
or	O
null	O
relationships	O
between	O
trauma	O
exposure	O
and	O
subsequent	O
addictive	O
behaviors	O
were	O
recorded	O
,	O
along	O
with	O
other	O
methodological	O
features	O
.	O

Of	O
3054	O
included	O
studies	O
,	O
70.7	O
%	O
(	O
n	O
=	O
2160	O
)	O
used	O
a	O
cross-sectional	O
design	O
.	O

In	O
the	O
181	O
prospective	O
observational	O
studies	O
(	O
407,041	O
participants	O
,	O
98.8	O
%	O
recruited	O
from	O
developed	O
countries	O
)	O
,	O
35.1	O
%	O
of	O
the	O
tested	O
associations	O
between	O
trauma	O
exposure	O
and	O
later	O
addictive	O
behaviors	O
was	O
positive	O
,	O
1.3	O
%	O
was	O
negative	O
,	O
and	O
63.6	O
%	O
was	O
non-significant	O
.	O

These	O
results	O
were	O
primarily	O
obtained	O
among	O
non-treatment	O
seeking	O
samples	O
(	O
80.7	O
%	O
of	O
studies	O
;	O
n	O
=	O
146	O
)	O
,	O
using	O
single	O
and	O
multi-item	O
measures	O
of	O
addictive	O
behaviors	O
of	O
unknown	O
psychometric	B-P
quality	O
(	O
46.4	O
%	O
of	O
studies	O
)	O
.	O

Positive	O
associations	O
were	O
more	O
frequently	O
observed	O
in	O
studies	O
examining	O
childhood	O
versus	O
adult	O
traumatization	O
(	O
39.7	O
%	O
vs.	O
29.7	O
%	O
)	O
.	O

Longitudinal	O
research	O
in	O
this	O
area	O
emphasizes	O
alcohol	O
abuse	O
,	O
and	O
almost	O
no	O
research	O
has	O
examined	O
behavioral	O
addictions	O
.	O

Results	O
provide	O
some	O
support	O
for	O
a	O
positive	O
association	O
between	O
exposure	O
to	O
interpersonal	O
trauma	O
and	O
subsequent	O
addictive	O
behaviors	O
but	O
this	O
relationship	O
was	O
not	O
consistently	O
reported	O
.	O

Longitudinal	O
studies	O
typically	O
assessed	O
trauma	O
exposure	O
retrospectively	O
,	O
often	O
after	O
addictive	O
behavior	O
onset	O
,	O
thus	O
precluding	O
robust	O
inferences	O
about	O
whether	O
traumatization	O
affects	O
initial	O
onset	O
of	O
addictive	O
behaviors	O
.	O

Are	O
TMCs	O
the	O
Mechanotransduction	O
Channels	O
of	O
Vertebrate	O
Hair	O
Cells	O
?	O
.	O

Sensory	O
transduction	O
in	O
vertebrate	O
hair	O
cells	O
and	O
the	O
molecules	O
that	O
mediate	O
it	O
have	O
long	O
been	O
of	O
great	O
interest	O
.	O

Some	O
components	O
of	O
the	O
mechanotransduction	O
apparatus	O
have	O
been	O
identified	O
,	O
most	O
as	O
deafness	O
gene	O
products	O
.	O

Although	O
prior	O
candidates	O
for	O
the	O
mechanotransduction	O
channel	O
have	O
been	O
proposed	O
,	O
each	O
has	O
faded	O
with	O
new	O
evidence	O
.	O

Now	O
,	O
two	O
strong	O
candidates	O
,	O
TMC1	O
and	O
TMC2	O
(	O
transmembrane	O
channel-like	O
)	O
,	O
have	O
emerged	O
from	O
discovery	O
of	O
deafness	O
genes	O
in	O
humans	O
and	O
mice	O
.	O

They	O
are	O
expressed	O
at	O
the	O
right	O
time	O
during	O
development	O
:	O
exactly	O
at	O
the	O
onset	O
of	O
mechanosensitivity	O
.	O

They	O
are	O
expressed	O
in	O
the	O
right	O
place	O
:	O
in	O
hair	O
cells	O
but	O
not	O
surrounding	O
cells	O
.	O

Fluorescently	B-P
tagged	I-P
TMCs	O
localize	O
to	O
the	O
tips	O
of	O
stereocilia	O
,	O
the	O
site	O
of	O
the	O
transduction	O
channels	O
.	O

TMCs	O
bind	O
other	O
proteins	O
essential	O
for	O
mechanosensation	O
,	O
suggesting	O
a	O
larger	O
transduction	O
complex	O
.	O

Although	O
TMC1	O
and	O
TMC2	O
can	O
substitute	O
for	O
each	O
other	O
,	O
genetic	O
deletion	O
of	O
both	O
renders	O
mouse	O
hair	O
cells	O
mechanically	O
insensitive	O
.	O

Finally	O
,	O
the	O
conductance	O
and	O
Ca	O
(	O
2+	O
)	O
selectivity	O
of	O
the	O
transduction	O
channels	O
depend	O
on	O
the	O
TMC	O
proteins	O
,	O
differing	O
when	O
hair	O
cells	O
express	O
one	O
or	O
the	O
other	O
TMC	O
,	O
and	O
differing	O
if	O
TMC1	O
harbors	O
a	O
point	O
mutation	O
.	O

Some	O
contrary	O
evidence	O
has	O
emerged	O
:	O
a	O
current	O
activated	O
in	O
hair	O
cells	O
by	O
negative	O
pressure	O
,	O
with	O
some	O
similarity	O
to	O
the	O
transduction	O
current	O
,	O
persists	O
in	O
TMC	O
knock-outs	O
.	O

But	O
it	O
is	O
not	O
clear	O
that	O
this	O
anomalous	O
current	O
is	O
carried	O
by	O
the	O
same	O
proteins	O
.	O

Further	O
evidence	O
is	O
desired	O
,	O
such	O
as	O
production	O
of	O
a	O
mechanically	O
gated	O
conductance	O
by	O
pure	O
TMCs	O
.	O

But	O
the	O
great	O
majority	O
of	O
evidence	O
is	O
consistent	O
with	O
these	O
TMCs	O
as	O
pore-forming	O
subunits	O
of	O
the	O
long-sought	O
hair-cell	O
transduction	O
channel	O
.	O

Anticholinergic	O
premedication	O
to	O
prevent	O
bradycardia	O
in	O
combined	O
spinal	O
anesthesia	O
and	O
dexmedetomidine	O
sedation	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

When	O
dexmedetomidine	O
is	O
used	O
in	O
patients	O
undergoing	O
spinal	O
anesthesia	O
,	O
high	O
incidence	O
of	O
bradycardia	O
in	O
response	O
to	O
parasympathetic	O
activation	O
is	O
reported	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
atropine	O
premedication	O
for	O
preventing	O
the	O
incidence	O
of	O
bradycardia	O
and	O
the	O
hemodynamic	O
effect	O
on	O
patients	O
undergoing	O
spinal	O
anesthesia	O
with	O
sedation	O
by	O
dexmedetomidine	O
.	O

Randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

Operating	O
room	O
.	O

One	O
hundred	O
fourteen	O
patients	O
(	O
age	O
range	O
,	O
2-65	O
years	O
;	O
American	O
Society	O
of	O
Anesthesiology	O
class	O
I-II	O
)	O
participated	O
in	O
this	O
study	O
,	O
willing	O
to	O
be	O
sedated	O
and	O
to	O
undergo	O
spinal	O
anesthesia	O
.	O

The	O
patients	O
were	O
divided	O
into	O
2	O
groups	O
:	O
group	O
A	O
and	O
group	O
C.	O
After	O
performing	O
spinal	O
anesthesia	O
,	O
dexmedetomidine	O
was	O
infused	O
at	O
a	O
loading	O
dose	O
of	O
0.6	O
μg/kg	O
for	O
10	O
minutes	O
,	O
followed	O
by	O
an	O
infusion	O
at	O
0.25	O
μg/	O
(	O
kg	O
h	O
)	O
.	O

Simultaneously	O
with	O
the	O
loading	O
dose	O
of	O
dexmedetomidine	O
,	O
patients	O
in	O
group	O
A	O
received	O
an	O
intravenous	O
bolus	O
of	O
0.5	O
mg	O
atropine	O
,	O
whereas	O
patients	O
in	O
group	O
C	O
received	O
an	O
intravenous	O
normal	O
saline	O
bolus	O
.	O

Data	O
on	O
administration	O
of	O
atropine	O
and	O
ephedrine	O
were	O
collected	O
.	O

Hemodynamic	B-P
data	O
including	O
heart	O
rate	O
,	O
systolic	O
blood	O
pressure	O
,	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
,	O
and	O
mean	O
blood	O
pressure	O
(	O
MBP	O
)	O
were	O
also	O
recorded	O
.	O

The	O
incidence	O
of	O
bradycardia	O
requiring	O
atropine	O
treatment	O
was	O
significantly	O
higher	O
in	O
group	O
C	O
than	O
group	O
A	O
(	O
P=.035	O
)	O
.	O

However	O
,	O
the	O
incidence	O
of	O
hypotension	O
needing	O
ephedrine	O
treatment	O
showed	O
no	O
significant	O
difference	O
between	O
the	O
2	O
groups	O
(	O
P=.7	O
)	O
.	O

Systolic	O
blood	O
pressure	O
and	O
heart	O
rate	O
showed	O
no	O
significant	O
differences	O
between	O
the	O
2	O
groups	O
(	O
P=.138	O
and	O
.464	O
,	O
respectively	O
)	O
.	O

However	O
,	O
group	O
A	O
showed	O
significant	O
increases	O
in	O
DBP	O
and	O
MBP	O
,	O
and	O
group	O
C	O
did	O
not	O
(	O
P=.014	O
and	O
.008	O
,	O
respectively	O
)	O
.	O

Prophylactic	O
atropine	O
reduces	O
the	O
incidence	O
of	O
bradycardia	O
in	O
patients	O
undergoing	O
spinal	O
anesthesia	O
with	O
dexmedetomidine	O
sedation	O
.	O

However	O
,	O
DBP	O
and	O
MBP	O
showed	O
significant	O
increases	O
in	O
patients	O
when	O
prophylactic	O
atropine	O
was	O
administrated	O
.	O

Therefore	O
,	O
atropine	O
premedication	O
should	O
be	O
administered	O
cautiously	O
.	O

Evaluation	O
of	O
Drug	O
Sorption	O
to	O
PVC	O
-	O
and	O
Non-PVC	O
-based	O
Tubes	O
in	O
Administration	O
Sets	O
Using	O
a	O
Pump	O
.	O

Administration	O
sets	O
are	O
delivery	O
tools	O
for	O
the	O
direct	O
application	O
of	O
drugs	O
into	O
the	O
body	O
and	O
are	O
composed	O
of	O
a	O
spike	O
,	O
a	O
drip	O
chamber	O
,	O
tubes	O
,	O
Luer	O
adapters	O
(	O
connectors	O
)	O
,	O
a	O
needle	O
cover	O
for	O
protection	O
,	O
and	O
other	O
accessories	O
.	O

Drug	O
sorption	O
to	O
tubes	O
of	O
administration	O
sets	O
is	O
a	O
critical	O
issue	O
in	O
terms	O
of	O
safety	O
and	O
efficacy	O
.	O

Although	O
drug	O
sorption	O
is	O
an	O
important	O
factor	O
in	O
the	O
quality	O
of	O
an	O
administration	O
set	O
,	O
there	O
are	O
no	O
standard	O
evaluation	O
methods	O
for	O
the	O
regulation	O
of	O
drug	O
sorption	O
to	O
the	O
tubes	O
.	O

Here	O
,	O
we	O
describe	O
an	O
evaluation	O
protocol	O
for	O
drug	O
sorption	O
to	O
tubes	O
of	O
administration	O
sets	O
.	O

Tubes	O
made	O
of	O
polyvinyl	O
chloride	O
(	O
PVC	O
)	O
-	O
and	O
non-PVC	O
-based	O
polymeric	O
materials	O
were	O
cut	O
to	O
1	O
m	O
in	O
length	O
.	O

Diazepam	O
and	O
tacrolimus	O
were	O
used	O
as	O
model	O
drugs	O
.	O

In	O
the	O
kinetic	O
sorption	O
study	O
,	O
we	O
selected	O
the	O
drug	O
concentration	O
and	O
flow	O
rate	O
based	O
on	O
the	O
clinical	O
usage	O
of	O
these	O
drugs	O
.	O

After	O
the	O
dilution	B-P
of	O
each	O
drug	O
in	O
a	O
glass	O
bottle	O
,	O
the	O
diluted	O
drug	O
solution	O
was	O
delivered	O
through	O
tubes	O
of	O
administration	O
sets	O
using	O
a	O
pump	O
.	O

Samples	O
were	O
collected	O
in	O
amber	O
vials	O
at	O
appropriate	O
time	O
points	O
and	O
the	O
drugs	O
were	O
analyzed	O
using	O
high-performance	B-P
liquid	I-P
chromatography	I-P
.	O

Drug	O
concentrations	O
and	O
sorption	O
levels	O
to	O
tubes	O
of	O
the	O
administration	O
sets	O
were	O
calculated	O
.	O

Acceptable	O
criteria	O
to	O
ensure	O
the	O
quality	O
of	O
administration	O
sets	O
are	O
recommended	O
.	O

Detection	O
of	O
busulfan	O
adducts	O
on	O
proteins	O
.	O

Busulfan	O
is	O
a	O
bifunctional	O
alkyl	O
sulfonate	O
antineoplastic	O
drug	O
.	O

This	O
alkylating	O
agent	O
was	O
described	O
as	O
forming	O
covalent	O
adducts	O
on	O
proteins	O
.	O

However	O
,	O
only	O
limited	O
data	O
are	O
available	O
regarding	O
the	O
interaction	O
of	O
busulfan	O
with	O
proteins	O
.	O

Mass	B-P
spectrometry	I-P
and	O
bioinformatics	O
were	O
used	O
to	O
identify	O
busulfan	O
adducts	O
on	O
human	O
serum	O
albumin	O
and	O
hemoglobin	O
.	O

Albumin	O
and	O
hemoglobin	O
were	O
incubated	B-P
with	O
busulfan	O
or	O
control	O
compounds	O
,	O
digested	O
with	O
trypsin	O
and	O
analyzed	O
by	O
LC-MS	B-P
/	O
MS	B-P
on	O
a	O
Thermo	O
Fisher	O
LTQ	O
Orbitrap	O
Velos	O
Pro	O
.	O

MS	B-P
data	O
were	O
used	O
to	O
generate	O
spectral	O
libraries	O
of	O
non-modified	O
peptides	O
and	O
an	O
open	O
modification	O
search	O
was	O
performed	O
to	O
identify	O
potential	O
adduct	O
mass	O
shifts	O
and	O
possible	O
modification	O
sites	O
.	O

Results	O
were	O
confirmed	O
by	O
a	O
second	O
database	O
search	O
including	O
identified	O
mass	O
shifts	O
and	O
by	O
visual	O
inspection	O
of	O
annotated	O
tandem	O
mass	O
spectra	O
of	O
adduct	O
-carrying	O
peptides	O
.	O

Five	O
structures	O
of	O
busulfan	O
adducts	O
were	O
detected	O
and	O
a	O
chemical	O
structure	O
could	O
be	O
attributed	O
to	O
four	O
of	O
them	O
.	O

Two	O
were	O
primary	O
adducts	O
corresponding	O
to	O
busulfan	O
monoalkylation	O
and	O
alkylation	O
of	O
two	O
amino	O
acid	O
residues	O
by	O
a	O
single	O
busulfan	O
molecule	O
.	O

Two	O
others	O
corresponded	O
to	O
secondary	O
adducts	O
generated	O
during	O
sample	O
processing	O
.	O

Adducts	O
were	O
mainly	O
detected	O
on	O
Asp	O
,	O
Glu	O
,	O
and	O
His	O
residues	O
.	O

These	O
findings	O
were	O
confirmed	O
by	O
subsequent	O
database	O
searches	O
and	O
experiments	O
with	O
synthetic	O
peptides	O
.	O

The	O
combination	O
of	O
in	O
vitro	O
incubation	B-P
of	O
proteins	O
with	O
the	O
drug	O
of	O
interest	O
or	O
control	O
compounds	O
,	O
high-resolution	B-P
mass	I-P
spectrometry	I-P
,	O
and	O
open	O
modification	O
search	O
allowed	O
confirming	O
direct	O
interaction	O
of	O
busulfan	O
with	O
proteins	O
and	O
characterizing	O
resulting	O
adducts	O
.	O

Our	O
results	O
also	O
showed	O
that	O
careful	O
analysis	O
of	O
the	O
data	O
is	O
required	O
to	O
detect	O
experimental	O
artifacts	O
.	O

Short-Term	O
Influence	O
of	O
Radiofrequency	O
Ablation	O
on	O
NT-proBNP	O
,	O
MR-proANP	O
,	O
Copeptin	O
,	O
and	O
MR-proADM	O
in	O
Patients	O
With	O
Atrial	O
Fibrillation	O
:	O
Data	O
From	O
the	O
Observational	O
SMURF	O
Study	O
.	O

There	O
is	O
limited	O
knowledge	O
on	O
the	O
short-term	O
influence	O
of	O
radiofrequency	O
ablation	O
(	O
RFA	O
)	O
of	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
on	O
2	O
cardiac	O
biomarkers	O
;	O
the	O
N-terminal	O
pro-B-type	O
natriuretic	O
peptide	O
(	O
NT-proBNP	O
)	O
and	O
the	O
midregional	O
fragment	O
of	O
the	O
N-terminal	O
of	O
pro-ANP	O
(	O
MR-proANP	O
)	O
and	O
2	O
extracardiac	O
biomarkers	O
;	O
the	O
c-terminal	O
provasopressin	O
(	O
copeptin	O
)	O
and	O
the	O
midregional	O
portion	O
of	O
proadrenomedullin	O
(	O
MR-proADM	O
)	O
.	O

There	O
are	O
also	O
limited	O
data	O
concerning	O
cardiac	O
production	O
of	O
the	O
latter	O
two	O
.	O

We	O
studied	O
192	O
consecutive	O
patients	O
eligible	O
for	O
RFA	O
of	O
AF	O
referred	O
to	O
the	O
University	O
Hospital	O
,	O
Linköping	O
,	O
Sweden	O
.	O

NT-proBNP	O
,	O
MR-proANP	O
,	O
copeptin	O
,	O
and	O
MR-proADM	O
levels	O
were	O
measured	O
in	O
peripheral	O
blood	O
,	O
the	O
coronary	O
sinus	O
(	O
CS	O
)	O
,	O
and	O
the	O
left	O
atrium	O
before	O
ablation	O
,	O
and	O
in	O
peripheral	O
blood	O
immediately	O
and	O
the	O
day	O
after	O
RFA	O
.	O

The	O
level	O
of	O
NT-proBNP	O
decreased	O
the	O
day	O
after	O
RFA	O
in	O
participants	O
in	O
AF	O
at	O
the	O
time	O
of	O
RFA	O
,	O
compared	O
to	O
the	O
participants	O
in	O
sinus	O
rhythm	O
who	O
showed	O
a	O
slight	O
increase	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Furthermore	O
,	O
regardless	O
of	O
the	O
actual	O
rhythm	O
,	O
the	O
level	O
of	O
MR-proANP	O
showed	O
an	O
increase	O
immediately	O
after	O
RFA	O
(	O
P	O
<	O
0.001	O
)	O
,	O
followed	O
by	O
a	O
decrease	O
the	O
day	O
after	O
ablation	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Copeptin	B-P
level	I-P
showed	O
a	O
6-fold	O
increase	O
immediately	O
after	O
RFA	O
compared	O
to	O
baseline	O
(	O
P	O
<	O
0.001	O
)	O
,	O
whereas	O
MR-proADM	O
level	O
increased	O
the	O
day	O
after	O
RFA	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Levels	O
of	O
copeptin	O
and	O
MR-proADM	O
were	O
not	O
higher	O
in	O
the	O
CS	O
compared	O
to	O
peripheral	O
blood	O
.	O

RFA	O
of	O
AF	O
is	O
a	O
strong	O
stimulus	O
with	O
a	O
significant	O
and	O
direct	O
impact	O
on	O
different	O
neurohormonal	O
systems	O
.	O

We	O
found	O
no	O
sign	O
of	O
a	O
cardiac	O
release	O
of	O
MR-proADM	O
or	O
copeptin	O
.	O

URL	O
:	O
http	O
:	O
//www.clinicaltrials.gov	O
.	O

Unique	O
Identifier	O
:	O
NCT01553045	O
.	O

An	O
ancient	O
role	O
for	O
nitric	O
oxide	O
in	O
regulating	O
the	O
animal	O
pelagobenthic	O
life	O
cycle	O
:	O
evidence	O
from	O
a	O
marine	O
sponge	O
.	O

In	O
many	O
marine	O
invertebrates	O
,	O
larval	O
metamorphosis	O
is	O
induced	O
by	O
environmental	O
cues	O
that	O
activate	O
sensory	O
receptors	O
and	O
signalling	O
pathways	O
.	O

Nitric	O
oxide	O
(	O
NO	O
)	O
is	O
a	O
gaseous	O
signalling	O
molecule	O
that	O
regulates	O
metamorphosis	O
in	O
diverse	O
bilaterians	O
.	O

In	O
most	O
cases	O
NO	O
inhibits	O
or	O
represses	O
this	O
process	O
,	O
although	O
it	O
functions	O
as	O
an	O
activator	O
in	O
some	O
species	O
.	O

Here	O
we	O
demonstrate	O
that	O
NO	O
positively	O
regulates	O
metamorphosis	O
in	O
the	O
poriferan	O
Amphimedon	O
queenslandica	O
.	O

High	O
rates	O
of	O
A.	O
queenslandica	O
metamorphosis	O
normally	O
induced	O
by	O
a	O
coralline	O
alga	O
are	O
inhibited	O
by	O
an	O
inhibitor	O
of	O
nitric	O
oxide	O
synthase	O
(	O
NOS	O
)	O
and	O
by	O
a	O
NO	O
scavenger	O
.	O

Consistent	O
with	O
this	O
,	O
an	O
artificial	O
donor	O
of	O
NO	O
induces	O
metamorphosis	O
even	O
in	O
the	O
absence	O
of	O
the	O
alga	O
.	O

Inhibition	O
of	O
the	O
ERK	O
signalling	O
pathway	O
prevents	O
metamorphosis	O
in	O
concert	O
with	O
,	O
or	O
downstream	O
of	O
,	O
NO	O
signalling	O
;	O
a	O
NO	O
donor	O
can	O
not	O
override	O
the	O
ERK	O
inhibitor	O
.	O

NOS	O
gene	O
expression	O
is	O
activated	O
late	O
in	O
embryogenesis	O
and	O
in	O
larvae	O
,	O
and	O
is	O
enriched	O
in	O
specific	O
epithelial	O
and	O
subepithelial	O
cell	O
types	O
,	O
including	O
a	O
putative	O
sensory	O
cell	O
,	O
the	O
globular	O
cell	O
;	O
DAF-FM	O
staining	B-P
supports	O
these	O
cells	O
being	O
primary	O
sources	O
of	O
NO	O
.	O

Together	O
,	O
these	O
results	O
are	O
consistent	O
with	O
NO	O
playing	O
an	O
activating	O
role	O
in	O
induction	O
of	O
A.	O
queenslandica	O
metamorphosis	O
,	O
evidence	O
of	O
its	O
highly	O
conserved	O
regulatory	O
role	O
in	O
metamorphosis	O
throughout	O
the	O
Metazoa	O
.	O

An	O
assessment	O
of	O
the	O
importance	O
of	O
exposure	O
routes	O
to	O
the	O
uptake	O
and	O
internal	O
localisation	O
of	O
fluorescent	O
nanoparticles	O
in	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
,	O
using	O
light	B-P
sheet	I-P
microscopy	I-P
.	O

A	O
major	O
challenge	O
in	O
nanoecotoxicology	O
is	O
finding	O
suitable	O
methods	O
to	O
determine	O
the	O
uptake	O
and	O
localisation	O
of	O
nanoparticles	O
on	O
a	O
whole-organism	O
level	O
.	O

Some	O
uptake	O
methods	O
have	O
been	O
associated	O
with	O
artefacts	O
induced	O
by	O
sample	O
preparation	O
,	O
including	O
staining	O
for	O
electron	B-P
microscopy	I-P
.	O

This	O
study	O
used	O
light	B-P
sheet	I-P
microscopy	I-P
(	O
LSM	B-P
)	O
to	O
define	O
the	O
uptake	O
and	O
localisation	O
of	O
fluorescently	O
labelled	O
nanoparticles	O
in	O
living	O
organisms	O
with	O
minimal	O
sample	O
preparation	O
.	O

Zebrafish	O
(	O
Danio	O
rerio	O
)	O
were	O
exposed	O
to	O
fluorescent	O
gold	O
nanoparticles	O
(	O
Au	O
NPs	O
)	O
and	O
fluorescent	O
polystyrene	O
NPs	O
via	O
aqueous	O
or	O
dietary	O
exposure	O
.	O

The	O
in	O
vivo	O
uptake	O
and	O
localisation	O
of	O
NPs	O
were	O
investigated	O
using	O
LSM	B-P
at	O
different	O
time	O
points	O
(	O
1	O
,	O
3	O
and	O
7	O
days	O
)	O
.	O

A	O
time	O
-	O
dependent	O
increase	O
in	O
fluorescence	O
was	O
observed	O
in	O
the	O
gut	O
after	O
dietary	O
exposure	O
to	O
both	O
Au	O
NPs	O
and	O
polystyrene	O
NPs	O
.	O

No	O
fluorescence	O
was	O
observed	O
within	O
gut	O
epithelia	O
regardless	O
of	O
the	O
NP	O
exposure	O
route	O
indicating	O
no	O
or	O
limited	O
uptake	O
via	O
intestinal	O
villi	O
.	O

Fish	O
exposed	O
to	O
polystyrene	O
NPs	O
through	O
the	O
aqueous	O
phase	O
emitted	O
fluorescence	O
signals	O
from	O
the	O
gills	O
and	O
intestine	O
.	O

Fluorescence	O
was	O
also	O
detected	O
in	O
the	O
head	O
region	O
of	O
the	O
fish	O
after	O
aqueous	O
exposure	O
to	O
polystyrene	O
NPs	O
.	O

This	O
was	O
not	O
observed	O
for	O
Au	O
NPs	O
.	O

Aqueous	O
exposure	O
to	O
Au	O
NPs	O
resulted	O
in	O
increased	O
relative	O
swimming	O
distance	O
,	O
while	O
no	O
effect	O
was	O
observed	O
for	O
other	O
exposures	O
.	O

This	O
study	O
supports	O
that	O
the	O
route	O
of	O
exposure	O
is	O
essential	O
for	O
the	O
uptake	O
and	O
subsequent	O
localisation	O
of	O
nanoparticles	O
in	O
zebrafish	O
.	O

Furthermore	O
,	O
it	O
demonstrates	O
that	O
the	O
localisation	O
of	O
NPs	O
in	O
whole	O
living	O
organisms	O
can	O
be	O
visualised	O
in	O
real-time	O
,	O
using	O
LSM	B-P
.	O

Applicability	O
of	O
drinking	O
water	O
treatment	O
residue	O
for	O
lake	O
restoration	O
in	O
relation	O
to	O
metal	O
/	O
metalloid	O
risk	O
assessment	O
.	O

Drinking	O
water	O
treatment	O
residue	O
(	O
DWTR	O
)	O
,	O
a	O
byproduct	O
generated	O
during	O
potable	O
water	O
production	O
,	O
exhibits	O
a	O
high	O
potential	O
for	O
recycling	O
to	O
control	O
eutrophication	O
.	O

However	O
,	O
this	O
beneficial	O
recycling	O
is	O
hampered	O
by	O
unclear	O
metal	O
/	O
metalloid	O
pollution	O
risks	O
related	O
to	O
DWTR	O
.	O

In	O
this	O
study	O
,	O
the	O
pollution	O
risks	O
of	O
Al	O
,	O
As	O
,	O
Ba	O
,	O
Be	O
,	O
Cd	O
,	O
Co	O
,	O
Cr	O
,	O
Cu	O
,	O
Fe	O
,	O
Mn	O
,	O
Mo	O
,	O
Ni	O
,	O
Pb	O
,	O
and	O
Zn	O
due	O
to	O
DWTR	O
application	O
were	O
first	O
evaluated	O
for	O
lake	O
water	O
based	O
on	O
human	O
health	O
risk	O
assessment	O
models	O
and	O
comparison	O
of	O
regulatory	O
standards	O
.	O

The	O
risks	O
of	O
DWTR	O
were	O
also	O
evaluated	O
for	O
sediments	O
on	O
the	O
basis	O
of	O
toxicity	O
characteristics	O
leaching	O
procedure	O
and	O
fractionation	O
in	O
relation	O
to	O
risk	O
assessment	O
code	O
.	O

Variations	O
in	O
the	O
biological	O
behaviors	O
of	O
metal	O
/	O
metalloid	O
in	O
sediments	O
caused	O
by	O
DWTR	O
were	O
assessed	O
using	O
Chironomus	O
plumosus	O
larvae	O
and	O
Hydrilla	O
verticillata	O
.	O

Kinetic	B-P
luminescent	I-P
bacteria	I-P
test	I-P
(	O
using	O
Aliivibrio	O
fischeri	O
)	O
was	O
conducted	O
to	O
analyze	O
the	O
possibility	O
of	O
acute	O
and	O
chronic	O
detrimental	O
effects	O
of	O
sediment	O
with	O
DWTR	O
application	O
.	O

According	O
to	O
the	O
obtained	O
results	O
,	O
we	O
identify	O
a	O
potential	O
undesirable	O
effect	O
of	O
DWTR	O
related	O
to	O
Fe	O
and	O
Mn	O
(	O
typically	O
under	O
anaerobic	O
conditions	O
)	O
;	O
roughly	O
present	O
a	O
dosage	O
threshold	O
calculation	O
model	O
;	O
and	O
recommend	O
a	O
procedure	O
for	O
DWTR	O
prescreening	O
to	O
ensure	O
safe	O
application	O
.	O

Overall	O
,	O
managed	O
DWTR	O
application	O
is	O
necessary	O
for	O
successful	O
eutrophication	O
control	O
.	O

Parallel-processing	O
continuous-flow	O
device	O
for	O
optimization	O
-	O
free	O
polymerase	O
chain	O
reaction	O
.	O

A	O
parallel-processing	O
four-station	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
device	O
has	O
been	O
developed	O
,	O
which	O
performs	O
continuous-flow	O
PCR	O
without	O
optimization	O
of	O
the	O
annealing	O
temperature	O
.	O

Since	O
the	O
annealing	O
temperature	O
of	O
each	O
station	O
can	O
be	O
controlled	O
independently	O
,	O
the	O
device	O
covers	O
an	O
annealing	O
temperature	O
range	O
of	O
50-68	O
°C	O
,	O
which	O
is	O
wide	O
enough	O
to	O
perform	O
PCR	O
for	O
any	O
DNA	O
fragment	O
regardless	O
of	O
its	O
optimum	O
annealing	O
condition	O
.	O

This	O
arrangement	O
lets	O
us	O
continuously	O
obtain	O
an	O
amplified	O
amount	O
of	O
a	O
DNA	O
fragment	O
at	O
least	O
from	O
one	O
of	O
the	O
stations	O
.	O

The	O
device	O
consists	O
of	O
four	O
identical	O
cylindrical	O
stations	O
(	O
diameter	O
20	O
mm	O
,	O
height	O
55	O
mm	O
)	O
.	O

A	O
polytetrafluoroethylene	O
capillary	O
reactor	O
(	O
length	O
2	O
m	O
,	O
I.D	O
.	O

100	O
μm	O
,	O
O.D	O
.	O

400	O
μm	O
)	O
is	O
wound	O
helically	O
up	O
around	O
each	O
station	O
.	O

The	O
whole	O
assembly	O
is	O
designed	O
to	O
minimize	O
the	O
number	O
of	O
heating	O
blocks	O
(	O
for	O
providing	O
temperatures	O
of	O
denaturation	O
,	O
annealing	O
,	O
and	O
extension	O
)	O
to	O
be	O
seven	O
and	O
to	O
shape	O
a	O
compact	O
cube	O
(	O
height	O
55	O
mm	O
,	O
base	O
60	O
mm	O
×	O
60	O
mm	O
)	O
.	O

The	O
reproducibility	O
for	O
continuous-flow	O
PCR	O
is	O
reasonably	O
high	O
(	O
run	O
-to-	O
run	O
and	O
station	O
-to-	O
station	O
relative	O
standard	O
deviation	O
of	O
their	O
amplification	O
is	O
lower	O
than	O
6	O
%	O
and	O
about	O
4	O
%	O
,	O
respectively	O
)	O
.	O

Performance	O
on	O
the	O
optimization	O
-	O
free	O
DNA	O
amplification	O
has	O
been	O
evaluated	O
with	O
four	O
DNA	O
samples	O
with	O
different	O
annealing	O
conditions	O
and	O
product	O
sizes	O
(	O
323	O
,	O
608	O
,	O
828	O
,	O
and	O
1101	O
bp	O
)	O
,	O
which	O
has	O
demonstrated	O
that	O
in	O
all	O
cases	O
,	O
PCR	O
is	O
successful	O
at	O
least	O
on	O
one	O
station	O
.	O

In	O
addition	O
,	O
three	O
DNA	O
fragment	O
s	O
with	O
different	O
lengths	O
(	O
323	O
,	O
1101	O
,	O
and	O
2836	O
bp	O
)	O
have	O
been	O
successfully	O
amplified	O
in	O
a	O
segmented	O
-	O
flow	O
mode	O
without	O
the	O
carry-over	O
contamination	O
between	O
segments	O
.	O

This	O
result	O
suggests	O
that	O
this	O
device	O
could	O
serve	O
as	O
the	O
PCR	O
module	O
of	O
a	O
continuous-flow	O
high-throughput	B-P
on-line	I-P
total	I-P
DNA	I-P
analysis	I-P
system	O
integrating	O
all	O
necessary	O
modules	O
from	O
cell	O
lysis	O
/	O
DNA	O
extraction	O
to	O
PCR	O
product	O
analysis	O
.	O

Juicer	O
Provides	O
a	O
One-Click	O
System	O
for	O
Analyzing	O
Loop-Resolution	B-P
Hi-C	I-P
Experiments	I-P
.	O

Hi-C	B-P
experiments	I-P
explore	O
the	O
3D	O
structure	O
of	O
the	O
genome	O
,	O
generating	O
terabases	O
of	O
data	O
to	O
create	O
high-resolution	B-P
contact	O
maps	O
.	O

Here	O
,	O
we	O
introduce	O
Juicer	O
,	O
an	O
open-source	O
tool	O
for	O
analyzing	O
terabase-scale	O
Hi-C	O
datasets	O
.	O

Juicer	O
allows	O
users	O
without	O
a	O
computational	O
background	O
to	O
transform	O
raw	O
sequence	O
data	O
into	O
normalized	O
contact	O
maps	O
with	O
one	O
click	O
.	O

Juicer	O
produces	O
a	O
hic	O
file	O
containing	O
compressed	O
contact	O
matrices	O
at	O
many	O
resolutions	O
,	O
facilitating	O
visualization	O
and	O
analysis	O
at	O
multiple	O
scales	O
.	O

Structural	O
features	O
,	O
such	O
as	O
loops	O
and	O
domains	O
,	O
are	O
automatically	O
annotated	O
.	O

Juicer	O
is	O
available	O
as	O
open	O
source	O
software	O
at	O
http	O
:	O
//aidenlab.org/juicer/	O
.	O

Multiplexing	O
Fluorescence	O
Anisotropy	O
Using	O
Frequency	B-P
Encoding	I-P
.	O

In	O
this	O
report	O
,	O
a	O
method	O
to	O
multiplex	O
fluorescence	O
anisotropy	O
measurements	O
is	O
described	O
using	O
frequency	B-P
encoding	I-P
.	O

As	O
a	O
demonstration	O
of	O
the	O
method	O
,	O
simultaneous	O
competitive	O
immunoassays	B-P
for	O
insulin	O
and	O
glucagon	O
were	O
performed	O
by	O
measuring	O
the	O
ratio	O
of	O
bound	O
and	O
free	O
Cy5-insulin	O
and	O
FITC-glucagon	O
in	O
the	O
presence	O
of	O
their	O
respective	O
antibodies	O
.	O

A	O
vertically	O
polarized	O
635	O
nm	O
laser	O
was	O
pulsed	O
at	O
73	O
Hz	O
and	O
used	O
to	O
excite	O
Cy5-insulin	O
,	O
while	O
a	O
vertically	O
polarized	O
488	O
nm	O
laser	O
pulsed	O
at	O
137	O
Hz	O
excited	O
FITC-glucagon	O
.	O

The	O
total	O
emission	O
was	O
split	O
into	O
parallel	O
and	O
perpendicular	O
polarizations	B-P
and	O
collected	O
onto	O
separate	O
photomultiplier	O
tubes	O
.	O

The	O
signals	O
from	O
each	O
channel	O
were	O
demodulated	O
using	O
a	O
fast	O
Fourier	O
transform	O
,	O
resolving	O
the	O
contributions	O
from	O
each	O
fluorophore	O
.	O

Anisotropy	O
calculations	B-P
were	O
carried	O
out	O
using	O
the	O
magnitude	O
of	O
the	O
peaks	O
in	O
the	O
frequency	O
domain	O
.	O

The	O
method	O
produced	O
the	O
expected	O
shape	O
of	O
the	O
calibration	O
curves	O
with	O
limits	O
of	O
detection	O
of	O
0.6	O
and	O
5	O
nM	O
for	O
insulin	O
and	O
glucagon	O
,	O
respectively	O
.	O

This	O
methodology	O
could	O
readily	O
be	O
expanded	O
to	O
other	O
biological	O
systems	O
and	O
further	O
multiplexed	O
to	O
monitor	O
increased	O
numbers	O
of	O
analytes	O
.	O

High	B-P
throughput	I-P
selection	O
of	O
antibiotic-resistant	O
transgenic	O
Arabidopsis	O
plants	O
.	O

Kanamycin	O
resistance	O
is	O
the	O
most	O
frequently	O
used	O
antibiotic-resistance	O
marker	O
for	O
Arabidopsis	O
transformations	O
,	O
however	O
,	O
this	O
method	O
frequently	O
causes	O
escape	O
of	O
untransformed	O
plants	O
,	O
particularly	O
at	O
the	O
high	O
seedling	O
density	O
during	O
the	O
selection	O
.	O

Here	O
we	O
developed	O
a	O
robust	O
high	O
-	O
density	O
selection	O
method	O
using	O
top	O
agar	O
for	O
Arabidopsis	O
thaliana	O
.	O

Top	O
agar	O
effectively	O
suppressed	O
growth	O
of	O
untransformed	O
wild-type	O
plants	O
on	O
selection	O
media	O
at	O
high	O
density	O
.	O

Survival	O
of	O
the	O
transformed	O
plants	O
during	O
the	O
selection	O
were	O
confirmed	O
by	O
production	O
of	O
green	O
true	O
leaves	O
and	O
expression	O
of	O
a	O
firefly	O
luciferase	O
reporter	O
gene	O
.	O

Top	O
agar	O
method	O
allowed	O
selection	O
using	O
a	O
large	O
amount	O
of	O
seeds	O
in	O
Arabidopsis	O
transformation	O
.	O

Microcapillary	O
sign	O
of	O
flap	O
alignment	O
in	O
femtosecond	O
laser	O
-assisted	O
in	O
situ	O
keratomileusis	O
.	O

We	O
present	O
an	O
observational	B-P
sign	O
that	O
ensures	O
perfect	O
alignment	O
during	O
femtosecond	O
laser	O
-assisted	O
in	O
situ	O
keratomileusis	O
(	O
FS	O
LASIK	O
)	O
.	O

Alignment	O
is	O
assured	O
when	O
a	O
microsponge	O
is	O
used	O
to	O
dry	O
the	O
flap	O
and	O
the	O
area	O
of	O
dryness	O
exceeds	O
the	O
area	O
of	O
direct	O
touch	O
of	O
the	O
microsponge	O
.	O

The	O
area	O
might	O
even	O
reach	O
the	O
whole	O
circumference	O
of	O
the	O
flap	O
at	O
the	O
first	O
touch	O
.	O

This	O
sign	O
of	O
alignment	O
can	O
be	O
explained	O
by	O
microcapillary	O
action	O
.	O

This	O
sign	O
was	O
not	O
elicited	O
in	O
flaps	O
created	O
by	O
a	O
microkeratome	O
.	O

Anatomic	O
variations	O
of	O
levator	O
scapulae	O
in	O
a	O
normal	O
cohort	O
:	O
an	O
MRI	B-P
study	I-P
.	O

Accessory	O
attachments	O
of	O
the	O
levator	O
scapulae	O
(	O
LS	O
)	O
muscle	O
have	O
been	O
described	O
in	O
the	O
literature	O
in	O
previous	O
cadaveric	O
studies	O
,	O
but	O
there	O
is	O
little	O
knowledge	O
about	O
the	O
incidence	O
and	O
distribution	O
.	O

Knowledge	O
of	O
LS	O
accessory	O
attachments	O
is	O
relevant	O
to	O
clinicians	O
working	O
in	O
the	O
fields	O
of	O
radiology	O
,	O
surgery	O
,	O
neurology	O
,	O
and	O
musculoskeletal	O
medicine	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
incidence	O
and	O
spectrum	O
of	O
LS	O
caudal	O
accessory	O
attachments	O
in	O
vivo	O
using	O
magnetic	B-P
resonance	I-P
(	I-P
MR	I-P
)	I-P
imaging	I-P
in	O
a	O
young	O
cohort	O
.	O

MR	B-P
images	O
of	O
the	O
cervical	O
spine	O
were	O
obtained	O
from	O
37	O
subjects	O
(	O
13	O
males	O
and	O
24	O
females	O
)	O
aged	O
18-36	O
years	O
using	O
an	O
axial	O
T1-weighted	O
spin	O
echo	O
sequence	O
acquired	O
from	O
a	O
3-Tesla	B-P
MR	I-P
scanner	I-P
.	O

The	O
LS	O
muscle	O
was	O
identified	O
,	O
and	O
the	O
presence	O
of	O
caudal	O
accessory	O
attachments	O
was	O
recorded	O
and	O
described	O
.	O

LS	O
caudal	O
accessory	O
attachments	O
were	O
identified	O
in	O
16	O
subjects	O
(	O
4	O
right	O
,	O
6	O
left	O
,	O
and	O
6	O
bilateral	O
;	O
12	O
female	O
)	O
.	O

Ten	O
had	O
unilateral	O
accessory	O
attachments	O
to	O
the	O
serratus	O
anterior	O
,	O
serratus	O
posterior	O
superior	O
or	O
the	O
first/second	O
rib	O
.	O

Four	O
had	O
bilateral	O
accessory	O
attachments	O
to	O
serratus	O
anterior	O
.	O

One	O
had	O
bilateral	O
accessory	O
attachments	O
to	O
serratus	O
posterior	O
superior	O
and	O
unilateral	O
accessory	O
attachment	O
to	O
serratus	O
anterior	O
.	O

One	O
had	O
bilateral	O
attachments	O
to	O
both	O
muscles	O
.	O

Both	O
unilateral	O
and	O
bilateral	O
LS	O
caudal	O
accessory	O
attachments	O
were	O
present	O
in	O
nearly	O
half	O
of	O
the	O
subjects	O
examined	O
.	O

They	O
were	O
relatively	O
more	O
frequent	O
in	O
females	O
than	O
males	O
.	O

The	O
findings	O
indicate	O
that	O
these	O
accessory	O
attachments	O
are	O
common	O
,	O
and	O
in	O
some	O
cases	O
,	O
those	O
accessory	O
attachments	O
can	O
occur	O
bilaterally	O
and	O
to	O
more	O
than	O
one	O
site	O
.	O

Phishing	O
suspiciousness	O
in	O
older	O
and	O
younger	O
adults	O
:	O
The	O
role	O
of	O
executive	O
functioning	O
.	O

Phishing	O
is	O
the	O
spoofing	O
of	O
Internet	O
websites	O
or	O
emails	O
aimed	O
at	O
tricking	O
users	O
into	O
entering	O
sensitive	O
information	O
,	O
with	O
such	O
goals	O
as	O
financial	O
or	O
identity	O
theft	O
.	O

The	O
current	O
study	O
sought	O
to	O
determine	O
whether	O
age	O
is	O
associated	O
with	O
increased	O
susceptibility	O
to	O
phishing	O
and	O
whether	O
tests	O
of	O
executive	O
functioning	O
can	O
predict	O
phishing	O
susceptibility	O
.	O

A	O
total	O
of	O
193	O
cognitively	O
intact	O
participants	O
,	O
91	O
younger	O
adults	O
and	O
102	O
older	O
adults	O
,	O
were	O
primarily	O
recruited	O
through	O
a	O
Psychology	O
department	O
undergraduate	O
subject	O
pool	O
and	O
a	O
gerontology	O
research	O
registry	O
,	O
respectively	O
.	O

The	O
Executive	O
Functions	O
Module	O
from	O
the	O
Neuropsychological	O
Assessment	O
Battery	O
and	O
the	O
Iowa	O
Gambling	O
Task	O
were	O
the	O
primary	O
cognitive	O
predictors	O
of	O
reported	O
phishing	O
suspiciousness	O
.	O

Other	O
predictors	O
included	O
age	O
group	O
(	O
older	O
vs.	O
younger	O
)	O
,	O
sex	O
,	O
education	O
,	O
race	O
,	O
ethnicity	O
,	O
prior	O
knowledge	O
of	O
phishing	O
,	O
prior	O
susceptibility	O
to	O
phishing	O
,	O
and	O
whether	O
or	O
not	O
browsing	O
behaviors	O
were	O
reportedly	O
different	O
in	O
the	O
laboratory	O
setting	O
versus	O
at	O
home	O
.	O

A	O
logistic	O
regression	O
,	O
which	O
accounted	O
for	O
a	O
22.7	O
%	O
reduction	O
in	O
error	O
variance	O
compared	O
to	O
the	O
null	O
model	O
and	O
predicted	O
phishing	O
suspiciousness	O
with	O
73.1	O
%	O
(	O
95	O
%	O
CI	O
[	O
66.0	O
,	O
80.3	O
]	O
)	O
accuracy	O
,	O
revealed	O
three	O
statistically	O
significant	O
predictors	O
:	O
the	O
main	O
effect	O
of	O
education	O
(	O
b	O
=	O
0.58	O
,	O
SE	O
=	O
0.27	O
)	O
and	O
the	O
interactions	O
of	O
age	O
group	O
with	O
prior	O
awareness	O
of	O
phishing	O
(	O
b	O
=	O
2.31	O
,	O
SE	O
=	O
1.12	O
)	O
and	O
performance	O
on	O
the	O
Neuropsychological	B-P
Assessment	I-P
Battery	I-P
Mazes	I-P
test	I-P
(	O
b	O
=	O
0.16	O
,	O
SE	O
=	O
0.07	O
)	O
.	O

Whether	O
or	O
not	O
older	O
adults	O
reported	O
being	O
suspicious	O
of	O
the	O
phishing	O
attacks	O
used	O
in	O
this	O
study	O
was	O
partially	O
explained	O
by	O
educational	O
history	O
and	O
prior	O
phishing	O
knowledge	O
.	O

This	O
suggests	O
that	O
simple	O
educational	O
interventions	O
may	O
be	O
effective	O
in	O
reducing	O
phishing	O
vulnerability	O
.	O

Although	O
one	O
test	O
of	O
executive	O
functioning	O
was	O
found	O
useful	O
for	O
identifying	O
those	O
at	O
risk	O
of	O
phishing	O
susceptibility	O
,	O
four	O
tests	O
were	O
not	O
found	O
to	O
be	O
useful	O
;	O
these	O
results	O
speak	O
to	O
the	O
need	O
for	O
more	O
ecologically	O
valid	O
tools	O
in	O
clinical	O
neuropsychology	O
.	O

Association	O
of	O
Toll-Like	O
Receptor	O
4	O
on	O
Human	O
Monocyte	O
Subsets	O
and	O
Vulnerability	O
Characteristics	O
of	O
Coronary	O
Plaque	O
as	O
Assessed	O
by	O
64-Slice	B-P
Multidetector	I-P
Computed	I-P
Tomography	I-P
.	O

Although	O
Toll-like	O
receptor	O
4	O
(	O
TLR-4	O
)	O
is	O
involved	O
in	O
monocyte	O
activation	O
in	O
patients	O
with	O
accelerated	O
forms	O
of	O
atherosclerosis	O
,	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
TLR-4	O
on	O
circulating	O
monocyte	O
s	O
and	O
coronary	O
plaque	O
vulnerability	O
has	O
not	O
previously	O
been	O
evaluated	O
.	O

We	O
investigated	O
this	O
relationship	O
using	O
64-slice	B-P
multidetector	I-P
computed	I-P
tomography	I-P
(	O
MDCT	B-P
)	O
in	O
patients	O
with	O
stable	O
angina	O
pectoris	O
(	O
SAP	O
)	O
.Methods	O
and	O
Results	O
:	O
We	O
enrolled	O
65	O
patients	O
with	O
SAP	O
who	O
underwent	O
MDCT	B-P
.	O

Three	O
monocyte	O
subsets	O
(	O
CD14	O
(	O
++	O
)	O
CD16	O
(	O
-	O
)	O
,	O
CD14	O
(	O
++	O
)	O
CD16	O
(	O
+	O
)	O
,	O
and	O
CD14	O
(	O
+	O
)	O
CD16	O
(	O
+	O
)	O
)	O
and	O
expression	O
of	O
TLR-4	O
were	O
measured	O
by	O
flow	B-P
cytometry	I-P
.	O

Intracoronary	O
plaques	O
were	O
assessed	O
by	O
64-slice	B-P
MDCT	I-P
.	O

We	O
defined	O
vulnerability	O
of	O
intracoronary	O
plaques	O
according	O
to	O
the	O
presence	O
of	O
positive	O
remodeling	O
(	O
remodeling	O
index	O
>	O
1.05	O
)	O
and/or	O
low	O
CT	B-P
attenuation	O
(	O
<	O
35	O
HU	O
)	O
.	O

The	O
circulating	O
CD14	O
(	O
++	O
)	O
CD16	O
(	O
+	O
)	O
monocytes	O
more	O
frequently	O
expressed	O
TLR-4	O
than	O
CD14	O
(	O
++	O
)	O
CD16	O
(	O
-	O
)	O
and	O
CD14	O
(	O
+	O
)	O
CD16	O
(	O
+	O
)	O
monocytes	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
relative	O
proportion	O
of	O
the	O
expression	O
of	O
TLR-4	O
on	O
CD14	O
(	O
++	O
)	O
CD16	O
(	O
+	O
)	O
monocytes	O
was	O
significantly	O
greater	O
in	O
patients	O
with	O
vulnerable	O
plaque	O
compared	O
with	O
those	O
without	O
(	O
10.4	O
[	O
4.1-14.5	O
]	O
%	O
vs.	O
4.5	O
[	O
2.8-7.8	O
]	O
%	O
,	O
P=0.012	O
)	O
.	O

In	O
addition	O
,	O
the	O
relative	O
proportion	O
of	O
TLR-4	O
expression	O
on	O
CD14	O
(	O
++	O
)	O
CD16	O
(	O
+	O
)	O
monocytes	O
positively	O
correlated	O
with	O
the	O
remodeling	O
index	O
(	O
r=0.28	O
,	O
P=0.025	O
)	O
and	O
negatively	O
correlated	O
with	O
CT	B-P
attenuation	O
value	O
(	O
r=-0.31	O
,	O
P=0.013	O
)	O
.	O

Upregulation	O
of	O
TLR-4	O
on	O
CD14	O
(	O
++	O
)	O
CD16	O
(	O
+	O
)	O
monocytes	O
might	O
be	O
associated	O
with	O
coronary	O
plaque	O
vulnerability	O
in	O
patients	O
with	O
SAP	O
.	O

A	O
92-	O
year	O
-	O
old	O
man	O
with	O
primary	O
cutaneous	O
diffuse	O
large	O
B-cell	O
non-Hodgkin	O
's	O
lymphoma	O
manifesting	O
as	O
a	O
giant	O
scalp	O
mass	O
:	O
A	O
case	O
report	O
.	O

Primary	O
cutaneous	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
is	O
an	O
uncommon	O
entity	O
,	O
representing	O
10	O
%	O
of	O
all	O
extranodal	O
NHLs	O
.	O

Among	O
all	O
cutaneous	O
sites	O
,	O
the	O
scalp	O
is	O
a	O
rare	O
site	O
of	O
representation	O
.	O

A	O
92-	O
year	O
-old	O
Chinese	O
man	O
visited	O
our	O
hospital	O
with	O
a	O
multiple-nodular	O
huge	O
scalp	O
mass	O
on	O
the	O
right	O
parieto-occipital	O
regions	O
.	O

The	O
mass	O
was	O
of	O
7-	O
month	O
duration	O
and	O
progressively	O
enlarging	O
in	O
size	O
.	O

On	O
the	O
basis	O
of	O
the	O
result	O
of	O
biopsy	B-P
,	O
diffuse	O
large	O
B-cell	O
NHL	O
was	O
diagnosed	O
.	O

The	O
mass	O
was	O
partially	O
resected	O
by	O
surgery	O
and	O
no	O
further	O
treatment	O
was	O
conducted	O
due	O
to	O
the	O
advanced	O
age	O
and	O
poor	O
physical	O
status	O
.	O

The	O
tumor	O
relapsed	O
in	O
situ	O
after	O
6	O
months	O
and	O
the	O
patient	O
died	O
after	O
2	O
years	O
.	O

This	O
case	O
highlighted	O
the	O
limited	O
access	O
to	O
standard	O
treatment	O
options	O
in	O
patients	O
with	O
advanced	O
age	O
.	O

A	O
thorough	O
examination	O
is	O
necessary	O
to	O
decide	O
upon	O
the	O
treatment	O
for	O
the	O
primary	O
cutaneous	O
lymphoma	O
.	O

Weighing	O
Scale	O
-Based	O
Pulse	O
Transit	O
Time	O
is	O
a	O
Superior	O
Marker	O
of	O
Blood	O
Pressure	O
than	O
Conventional	O
Pulse	O
Arrival	O
Time	O
.	O

Pulse	O
transit	O
time	O
(	O
PTT	O
)	O
is	O
being	O
widely	O
pursued	O
for	O
cuff-less	O
blood	O
pressure	O
(	O
BP	O
)	O
monitoring	O
.	O

Most	O
efforts	O
have	O
employed	O
the	O
time	O
delay	O
between	O
ECG	B-P
and	O
finger	O
photoplethysmography	B-P
(	O
PPG	B-P
)	O
waveforms	O
as	O
a	O
convenient	O
surrogate	O
of	O
PTT	O
.	O

However	O
,	O
these	O
conventional	O
pulse	O
arrival	O
time	O
(	O
PAT	O
)	O
measurements	O
include	O
the	O
pre-ejection	O
period	O
(	O
PEP	O
)	O
and	O
the	O
time	O
delay	O
through	O
small	O
,	O
muscular	O
arteries	O
and	O
may	O
thus	O
be	O
an	O
unreliable	O
marker	O
of	O
BP	O
.	O

We	O
assessed	O
a	O
bathroom	O
weighing	O
scale-like	O
system	O
for	O
convenient	O
measurement	O
of	O
ballistocardiography	B-P
and	O
foot	O
PPG	B-P
waveforms	O
-	O
and	O
thus	O
PTT	O
through	O
larger	O
,	O
more	O
elastic	O
arteries	O
-	O
in	O
terms	O
of	O
its	O
ability	O
to	O
improve	O
tracking	O
of	O
BP	O
in	O
individual	O
subjects	O
.	O

We	O
measured	O
``	O
scale	O
PTT	O
``	O
,	O
conventional	O
PAT	O
,	O
and	O
cuff	O
BP	O
in	O
humans	O
during	O
interventions	O
that	O
increased	O
BP	O
but	O
changed	O
PEP	O
and	O
smooth	O
muscle	O
contraction	O
differently	O
.	O

Scale	O
PTT	O
tracked	O
the	O
diastolic	O
BP	O
changes	O
well	O
,	O
with	O
correlation	O
coefficient	O
of	O
-0.80	O
±	O
0.02	O
(	O
mean	O
±	O
SE	O
)	O
and	O
root-mean-squared-error	O
of	O
7.6	O
±	O
0.5	O
mmHg	O
after	O
a	O
best-case	O
calibration	O
.	O

Conventional	O
PAT	O
was	O
significantly	O
inferior	O
in	O
tracking	O
these	O
changes	O
,	O
with	O
correlation	O
coefficien	O
t	O
of	O
-0.60	O
±	O
0.04	O
and	O
root-mean-squared-error	O
of	O
14.6	O
±	O
1.5	O
mmHg	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Scale	O
PTT	O
also	O
tracked	O
the	O
systolic	O
BP	O
changes	O
better	O
than	O
conventional	O
PAT	O
but	O
not	O
to	O
an	O
acceptable	O
level	O
.	O

With	O
further	O
development	O
,	O
scale	O
PTT	O
may	O
permit	O
reliable	O
,	O
convenient	O
measurement	O
of	O
BP	O
.	O

Experience	O
of	O
Varied	O
Presentation	O
of	O
Chronic	O
Progressive	O
Disseminated	O
Histoplasmosis	O
in	O
Immunocompetent	O
Patients	O
:	O
A	O
Diagnostic	O
Conundrum	O
.	O

We	O
report	O
two	O
cases	O
of	O
chronic	O
progressive	O
disseminated	O
histoplasmosis	O
with	O
unusual	O
and	O
rare	O
clinical	O
picture	O
in	O
a	O
patient	O
with	O
no	O
underlying	O
risk	O
factor	O
.	O

One	O
50-year-old	O
male	O
,	O
presented	O
with	O
hoarseness	O
of	O
voice	O
,	O
chronic	O
cough	O
,	O
with	O
a	O
history	O
of	O
nonresponding	O
anti-tubercular	O
therapy	O
,	O
revealed	O
mucocutaneous	O
lesions	O
on	O
examination	O
.	O

Fungating	O
vocal	O
cord	O
lesions	O
were	O
visualized	O
on	O
bronchoscopy	B-P
,	O
raised	O
suspicion	O
of	O
carcinoma	O
.	O

The	O
second	O
case	O
,	O
a	O
22-year-	O
old	O
female	O
,	O
referred	O
to	O
hospital	O
with	O
suspected	O
vasculitis	O
,	O
with	O
complaints	O
of	O
``	O
off	O
and	O
on	O
''	O
fever	O
with	O
decreased	O
oral	O
intake	O
,	O
arthralgia	O
,	O
who	O
later	O
developed	O
generalized	O
nodular	O
skin	O
eruptions	O
.	O

On	O
investigation	O
,	O
human	B-P
immunodeficiency	I-P
virus	I-P
test	I-P
was	O
found	O
to	O
be	O
negative	O
in	O
both	O
the	O
cases	O
.	O

Histopathological	O
findings	O
of	O
skin	B-P
biopsy	I-P
,	O
adrenal	O
and	O
bone	O
marrow	O
aspirates	O
raised	O
suspicion	O
,	O
whereas	O
fungal	B-P
cultures	I-P
confirmed	O
Histoplasma	O
infection	O
.	O

Although	O
diagnosis	O
was	O
delayed	O
,	O
but	O
both	O
of	O
them	O
were	O
successfully	O
treated	O
with	O
amphotericin	O
B	O
.	O

Systemic	O
and	O
microcirculatory	O
effects	O
of	O
blood	O
transfusion	O
in	O
experimental	O
hemorrhagic	O
shock	O
.	O

The	O
microvascular	O
reperfusion	O
injury	O
after	O
retransfusion	O
has	O
not	O
been	O
completely	O
characterized	O
.	O

Specifically	O
,	O
the	O
question	O
of	O
heterogeneity	O
among	O
different	O
microvascular	O
beds	O
needs	O
to	O
be	O
addressed	O
.	O

In	O
addition	O
,	O
the	O
identification	O
of	O
anaerobic	O
metabolism	O
is	O
elusive	O
.	O

The	O
venoarterial	O
PCO2	B-P
to	O
arteriovenous	B-P
oxygen	I-P
content	I-P
difference	I-P
ratio	O
(	O
Pv-a	O
CO2	O
/Ca-v	O
O2	O
)	O
might	O
be	O
a	O
surrogate	O
for	O
respiratory	O
quotient	O
,	O
but	O
this	O
has	O
not	O
been	O
validated	O
.	O

Therefore	O
,	O
our	O
goal	O
was	O
to	O
characterize	O
sublingual	O
and	O
intestinal	O
(	O
mucosal	O
and	O
serosal	O
)	O
microvascular	O
injury	O
after	O
blood	O
resuscitation	O
in	O
hemorrhagic	O
shock	O
and	O
its	O
relation	O
with	O
O2	O
and	O
CO2	O
metabolism	O
.	O

Anesthetized	O
and	O
mechanically	O
ventilated	O
sheep	O
were	O
assigned	O
to	O
stepwise	O
bleeding	O
and	O
blood	O
retransfusion	O
(	O
n	O
=	O
10	O
)	O
and	O
sham	O
(	O
n	O
=	O
7	O
)	O
groups	O
.	O

We	O
performed	O
analysis	O
of	O
expired	O
gases	O
,	O
arterial	O
and	O
mixed	B-P
venous	I-P
blood	I-P
gases	I-P
,	O
and	O
intestinal	O
and	O
sublingual	O
videomicroscopy	B-P
.	O

In	O
the	O
bleeding	O
group	O
during	O
the	O
last	O
step	O
of	O
hemorrhage	O
,	O
and	O
compared	O
to	O
the	O
sham	O
group	O
,	O
there	O
were	O
decreases	O
in	O
oxygen	O
consumption	O
(	O
3.7	O
[	O
2.8-4.6	O
]	O
vs.	O
6.8	O
[	O
5.8-8.0	O
]	O
mL	O
min	O
(	O
-1	O
)	O
kg	O
(	O
-1	O
)	O
,	O
P	O
<	O
0.001	O
)	O
and	O
increases	O
in	O
respiratory	O
quotient	O
(	O
0.96	O
[	O
0.91-1.06	O
]	O
vs.	O
0.72	O
[	O
0.69-0.77	O
]	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Retransfusion	O
normalized	O
these	O
variables	O
.	O

The	O
Pv-a	O
CO2	O
/Ca-v	O
O2	O
increased	O
in	O
the	O
last	O
step	O
of	O
bleeding	O
(	O
2.4	O
[	O
2.0-2.8	O
]	O
vs.	O
1.1	O
[	O
1.0-1.3	O
]	O
,	O
P	O
<	O
0.001	O
)	O
and	O
remained	O
elevated	O
after	O
retransfusion	O
,	O
compared	O
to	O
the	O
sham	O
group	O
(	O
1.8	O
[	O
1.5-2.0	O
]	O
vs.	O
1.1	O
[	O
0.9-1.3	O
]	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Pv-a	O
CO2	O
/Ca-v	O
O2	O
had	O
a	O
weak	O
correlation	O
with	O
respiratory	O
quotient	O
(	O
Spearman	O
R	O
=	O
0.42	O
,	O
P	O
<	O
0.001	O
)	O
.	O

All	O
the	O
intestinal	O
and	O
sublingual	O
microcirculatory	O
variables	O
were	O
affected	O
during	O
hemorrhage	O
and	O
improved	O
after	O
retransfusion	O
.	O

The	O
recovery	O
was	O
only	O
complete	O
for	O
intestinal	O
red	O
blood	O
cell	O
velocity	O
and	O
sublingual	O
total	O
and	O
perfused	O
vascular	O
densities	O
.	O

Although	O
there	O
were	O
some	O
minor	O
differences	O
,	O
intestinal	O
and	O
sublingual	O
microcirculation	O
behaved	O
similarly	O
.	O

Therefore	O
,	O
sublingual	O
mucosa	O
might	O
be	O
an	O
adequate	O
window	O
to	O
track	O
intestinal	O
microvascular	O
reperfusion	O
injury	O
.	O

Additionally	O
,	O
Pv-a	O
CO2	O
/Ca-v	O
O2	O
was	O
poorly	O
correlated	O
with	O
respiratory	O
quotient	O
,	O
and	O
its	O
physiologic	O
behavior	O
was	O
different	O
.	O

Thus	O
,	O
it	O
might	O
be	O
a	O
misleading	O
surrogate	O
for	O
anaerobic	O
metabolism	O
.	O

Results	O
of	O
a	O
Single	O
Institution	O
Experience	O
with	O
Dose-Escalated	O
Chemoradiation	O
for	O
Locally	O
Advanced	O
Unresectable	O
Non-Small	O
Cell	O
Lung	O
Cancer	O
.	O

We	O
determined	O
factors	O
associated	O
with	O
morbidity	O
and	O
outcomes	O
of	O
a	O
series	O
of	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
patients	O
treated	O
with	O
dose-escalated	O
chemoradiotherapy	O
at	O
the	O
University	O
of	O
Pittsburgh	O
Lung	O
Cancer	O
Program	O
.	O

The	O
records	O
of	O
170	O
stage	O
III	O
NSCLC	O
patients	O
treated	O
with	O
definitive	O
intent	O
were	O
retrospectively	O
reviewed	O
.	O

All	O
patients	O
received	O
four-dimensional	B-P
CT	I-P
simulation	I-P
scan	I-P
and	O
had	O
respiratory	O
gating	O
if	O
tumor	O
movement	O
exceeded	O
5	O
mm	O
.	O

Overall	O
survival	O
(	O
OS	O
)	O
,	O
locoregional	O
control	O
(	O
LRC	O
)	O
,	O
and	O
freedom	O
from	O
distant	O
metastasis	O
(	O
FFDM	O
)	O
were	O
calculated	O
using	O
log-rank	O
and	O
Cox	O
regression	O
analysis	O
.	O

For	O
the	O
present	O
series	O
of	O
patients	O
,	O
median	O
follow-up	O
was	O
36.6	O
months	O
,	O
median	O
survival	O
27.4	O
months	O
,	O
and	O
the	O
2-	O
and	O
4-	O
year	O
OS	O
was	O
56.0	O
and	O
30.7	O
%	O
,	O
respectively	O
.	O

The	O
4-	O
year	O
LRC	O
and	O
FFDM	O
were	O
43.9	O
and	O
40.7	O
%	O
,	O
respectively	O
.	O

No	O
benefit	O
was	O
associated	O
with	O
irradiation	O
doses	O
above	O
66	O
Gy	O
in	O
OS	O
(	O
p	O
=	O
0.586	O
)	O
,	O
LRC	O
(	O
p	O
=	O
0.440	O
)	O
,	O
or	O
FFDM	O
(	O
p	O
=	O
0.230	O
)	O
.	O

On	O
univariate	O
analysis	O
,	O
variables	O
associated	O
with	O
worse	O
survival	O
included	O
:	O
clinical	O
stage	O
IIIB	O
(	O
p	O
=	O
0.037	O
)	O
,	O
planning	O
target	O
volume	O
(	O
PTV	O
)	O
over	O
450	O
cc	O
(	O
p	O
<	O
0.001	O
)	O
,	O
heart	O
V30	O
over	O
40	O
%	O
(	O
p	O
=	O
-0.048	O
)	O
,	O
and	O
esophageal	O
mean	O
dose	O
over	O
20	O
%	O
(	O
p	O
=	O
0.024	O
)	O
,	O
V5	O
(	O
p	O
=	O
-0.015	O
)	O
,	O
and	O
V60	O
(	O
p	O
=	O
-0.011	O
)	O
.	O

On	O
multivariable	O
analysis	O
,	O
PTV	O
above	O
450	O
cc	O
(	O
52.2	O
vs.	O
25.3	O
months	O
,	O
p	O
<	O
0.001	O
)	O
and	O
esophageal	O
V60	O
>	O
20	O
%	O
(	O
43.8	O
vs.	O
21.3	O
months	O
,	O
p	O
=	O
-0.01	O
)	O
were	O
associated	O
with	O
lower	O
survival	O
.	O

Grade	O
2	O
or	O
higher	O
acute	O
lung	O
toxicity	O
and	O
esophagitis	O
were	O
detected	O
in	O
9.5	O
and	O
59.7	O
%	O
,	O
respectively	O
of	O
patients	O
.	O

Grade	O
2	O
or	O
higher	O
acute	O
lung	O
toxicity	O
was	O
reduced	O
if	O
lung	O
V5	O
was	O
≤65	O
(	O
7.4	O
vs.	O
23.8	O
%	O
,	O
p	O
=	O
0.03	O
)	O
.	O

Grade	O
2	O
or	O
higher	O
acute	O
esophagitis	O
was	O
reduced	O
if	O
V60	O
≤	O
20	O
%	O
(	O
62	O
vs.	O
81.3	O
%	O
,	O
p	O
=	O
0.018	O
)	O
.	O

The	O
use	O
of	O
intensity-modulated	O
radiation	O
therapy	O
was	O
more	O
frequent	O
in	O
stage	O
IIIB	O
compared	O
to	O
stage	O
IIIA	O
patients	O
(	O
56.5	O
vs.	O
39.5	O
%	O
,	O
p	O
=	O
0.048	O
)	O
and	O
was	O
associated	O
with	O
a	O
higher	O
lung	O
V5	O
and	O
V10	O
.	O

The	O
outcomes	O
of	O
a	O
program	O
of	O
dose-escalated	O
chemoradiotherapy	O
for	O
unresectable	O
stage	O
IIIA	O
and	O
IIIB	O
NSCLC	O
patients	O
were	O
consistent	O
with	O
other	O
studies	O
and	O
showed	O
no	O
benefit	O
to	O
radiation	O
doses	O
above	O
66	O
Gy	O
.	O

Furthermore	O
,	O
maintaining	O
low	O
esophageal	O
V60	O
and	O
lung	O
V5	O
were	O
associated	O
with	O
lower	O
morbidity	O
and	O
mortality	O
.	O

CT	B-P
-guided	O
fine-needle	O
aspiration	O
of	O
abdominal	O
and	O
retroperitoneal	O
small	O
lesions	O
with	O
the	O
coaxial	B-P
technique	I-P
using	O
MPR	B-P
images	O
.	O

To	O
demonstrate	O
the	O
advantages	O
of	O
CT	B-P
-guided	O
fine-needle	O
aspiration	O
(	O
FNA	O
)	O
of	O
abdominal	O
and	O
retroperitoneal	O
small	O
lesions	O
with	O
the	O
coaxial	B-P
technique	I-P
using	O
MPR	B-P
images	O
.	O

The	O
study	O
included	O
retrospectively	O
50	O
patients	O
who	O
underwent	O
CT	B-P
-guided	O
FNA	O
of	O
abdominal	O
and/or	O
retroperitoneal	O
small	O
lesion	O
(	O
<	O
30	O
mm	O
)	O
.	O

Patients	O
with	O
suspected	O
lymphomas	O
or	O
sarcomas	O
were	O
excluded	O
.	O

Cytology	O
reports	O
were	O
the	O
reference	O
standard	O
.	O

The	O
cytology	O
was	O
diagnostic	O
in	O
48/50	O
biopsies	B-P
(	O
96	O
%	O
)	O
:	O
out	O
of	O
41	O
neoplastic	O
lesions	O
(	O
85	O
%	O
)	O
,	O
37	O
were	O
malignant	O
(	O
90.2	O
%	O
)	O
and	O
4	O
were	O
benign	O
(	O
9.8	O
%	O
)	O
;	O
7	O
out	O
of	O
48	O
were	O
non-neoplastic	O
(	O
14.6	O
%	O
)	O
.	O

No	O
procedural	O
complications	O
were	O
observed	O
(	O
0	O
%	O
)	O
.	O

By	O
using	O
MPR	B-P
images	O
there	O
is	O
an	O
effective	O
improvement	O
in	O
coaxial	O
CT	B-P
-guided	O
FNA	O
of	O
abdominal	O
and	O
retroperitoneal	O
small	O
lesions	O
.	O

Sequential	O
Immunoprecipitation	B-P
of	O
Secretory	O
Vesicle	O
Proteins	O
from	O
Biosynthetically	O
Labelled	O
Cells	O
.	O

Pulse	B-P
radiolabelling	I-P
of	O
cells	O
with	O
radioactive	O
amino	O
acids	O
is	O
a	O
common	O
method	O
for	O
studying	O
the	O
biosynthesis	O
of	O
proteins	O
.	O

The	O
labelled	O
proteins	O
can	O
then	O
be	O
immunoprecipitated	B-P
and	O
analysed	O
by	O
electrophoresis	B-P
and	O
imaging	B-P
techniques	I-P
.	O

This	O
chapter	O
presents	O
a	O
protocol	O
for	O
the	O
biosynthetic	O
labelling	O
and	O
immunoprecipitation	B-P
of	O
pancreatic	O
islet	O
proteins	O
which	O
are	O
known	O
to	O
be	O
affected	O
in	O
psychiatric	O
disorders	O
such	O
as	O
schizophrenia	O
.	O

Kinematics	O
and	O
kinetics	O
during	O
stair	O
ascent	O
in	O
individuals	O
with	O
Gluteal	O
Tendinopathy	O
.	O

Individuals	O
with	O
gluteal	O
tendinopathy	O
commonly	O
report	O
lateral	O
hip	O
pain	O
and	O
disability	O
during	O
stair	O
ascent	O
.	O

This	O
study	O
aimed	O
to	O
compare	O
kinematics	O
and	O
kinetics	O
between	O
individuals	O
with	O
and	O
without	O
gluteal	O
tendinopathy	O
during	O
a	O
step	O
up	O
task	O
.	O

35	O
individuals	O
with	O
unilateral	O
gluteal	O
tendinopathy	O
and	O
35	O
pain-free	O
controls	O
underwent	O
three-dimensional	O
motion	B-P
analysis	I-P
of	O
stance	O
phase	O
during	O
stair	O
ascent	O
.	O

An	O
analysis	O
of	O
covariance	O
was	O
performed	O
to	O
compare	O
hip	O
,	O
pelvis	O
and	O
trunk	O
kinematic	O
and	O
kinetic	O
variables	O
between	O
groups	O
.	O

A	O
K-means	O
cluster	O
analysis	O
was	O
performed	O
to	O
identify	O
subgroups	O
from	O
the	O
entire	O
group	O
(	O
n=70	O
)	O
based	O
on	O
the	O
characteristics	O
of	O
the	O
external	O
hip	O
adduction	O
moment	O
.	O

Finally	O
,	O
a	O
Newcombe-Wilson	O
test	O
was	O
performed	O
to	O
evaluate	O
the	O
relationship	O
between	O
group	O
and	O
cluster	O
codes	O
and	O
a	O
3×2	O
ANOVA	O
to	O
investigate	O
the	O
differences	O
in	O
kinematics	O
between	O
groups	O
and	O
cluster	O
codes	O
.	O

Individuals	O
with	O
gluteal	O
tendinopathy	O
exhibited	O
a	O
greater	O
hip	O
adduction	O
moment	O
impulse	O
during	O
stair	O
ascent	O
(	O
ES=0.83	O
)	O
,	O
greater	O
internal	O
rotation	O
impulse	O
during	O
the	O
first	O
50	O
%	O
stance	O
phase	O
(	O
ES=0.63	O
)	O
and	O
greater	O
contralateral	O
trunk	O
lean	O
throughout	O
stance	O
than	O
controls	O
(	O
ranging	O
from	O
ES=0.67-0.93	O
)	O
.	O

Three	O
subgroups	O
based	O
on	O
hip	O
adduction	O
moment	O
characteristics	O
were	O
identified	O
.	O

Individuals	O
with	O
GT	O
were	O
4.5	O
times	O
more	O
likely	O
to	O
have	O
a	O
hip	O
adduction	O
moment	O
characteristic	O
of	O
a	O
large	O
impulse	O
and	O
greater	O
lateral	O
pelvic	O
translation	O
at	O
heel	O
strike	O
than	O
the	O
subgroup	O
most	O
likely	O
to	O
contain	O
controls	O
.	O

Individuals	O
with	O
GT	O
exhibit	O
greater	O
hip	O
adduction	O
moment	O
impulse	O
and	O
alterations	O
in	O
trunk	O
and	O
pelvic	O
kinematics	O
during	O
stair	O
ascent	O
.	O

Findings	O
provide	O
a	O
basis	O
to	O
consider	O
frontal	O
plane	O
trunk	O
and	O
pelvic	O
control	O
in	O
the	O
management	O
of	O
gluteal	O
tendinopathy	O
.	O

Effect	O
of	O
endodontic	O
access	O
cavity	O
preparation	O
on	O
monolithic	O
and	O
ceramic	O
veneered	O
zirconia	O
restorations	O
.	O

Due	O
to	O
the	O
high	O
chipping	O
rates	O
observed	O
in	O
veneered	O
zirconia	O
ceramic	O
restorations	O
,	O
the	O
use	O
of	O
monolithic	O
zirconia	O
restorations	O
has	O
been	O
recommended	O
.	O

This	O
study	O
tried	O
to	O
compare	O
veneered	O
and	O
monolithic	O
zirconia	O
fixed	O
dental	O
prostheses	O
(	O
FDPs	O
)	O
with	O
respect	O
to	O
the	O
amount	O
of	O
damage	O
induced	O
by	O
endodontic	O
access	O
preparation	O
.	O

Monolithic	O
and	O
ceramic	O
veneered	O
(	O
n	O
=	O
10	O
)	O
three-unit	O
restorations	O
(	O
retainers	O
:	O
first	O
premolar	O
and	O
first	O
molar	O
;	O
pontic	O
:	O
second	O
premolar	O
)	O
were	O
subject	O
to	O
endodontic	O
access	O
cavity	O
preparation	O
in	O
both	O
retainers	O
using	O
a	O
diamond	O
rotary	O
instrument	O
under	O
continuous	O
water	O
cooling	O
.	O

The	O
number	O
of	O
chipping	O
fractures	O
and	O
microfractures	O
detected	O
using	O
the	O
fluorescent	B-P
penetrant	I-P
method	I-P
were	O
recorded	O
.	O

Statistical	O
analysis	O
was	O
based	O
on	O
Wilcoxon	O
rank	O
sum	O
tests	O
with	O
Bonferroni	O
correction	O
(	O
level	O
of	O
significance	O
α	O
=	O
.05	O
)	O
.	O

Only	O
one	O
microfracture	O
could	O
be	O
identified	O
in	O
the	O
group	O
of	O
monolithic	O
FDPs	O
while	O
a	O
maximum	O
of	O
seven	O
microfractures	O
and	O
three	O
chipping	O
fractures	O
per	O
retainer	O
crown	O
were	O
recorded	O
in	O
the	O
group	O
of	O
veneered	O
restorations	O
.	O

At	O
the	O
premolar	O
site	O
,	O
the	O
veneered	O
restorations	O
showed	O
significantly	O
more	O
microfractures	O
(	O
P	O
=	O
.0055	O
)	O
and	O
chipping	O
fractures	O
(	O
P	O
=	O
.0008	O
)	O
.	O

At	O
the	O
molar	O
site	O
,	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
microfractures	O
could	O
be	O
detected	O
(	O
P	O
=	O
.0767	O
)	O
,	O
while	O
significantly	O
more	O
chipping	O
fractures	O
occurred	O
in	O
the	O
veneered	O
samples	O
(	O
P	O
=	O
.0293	O
)	O
.	O

Monolithic	O
zirconia	O
restorations	O
seem	O
to	O
be	O
less	O
susceptible	O
to	O
damage	O
when	O
endodontic	O
access	O
cavities	O
have	O
to	O
be	O
prepared	O
as	O
compared	O
to	O
veneered	O
zirconia	O
reconstructions	O
.	O

However	O
,	O
no	O
conclusions	O
can	O
be	O
drawn	O
on	O
the	O
longterm	O
performance	O
of	O
a	O
specific	O
restoration	O
based	O
on	O
this	O
study	O
.	O

Self-preserving	O
personal	O
care	O
products	O
.	O

As	O
questions	O
on	O
the	O
safety	O
of	O
some	O
popular	O
preservatives	O
are	O
on	O
the	O
rise	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
developing	O
'	O
self-preserving	O
'	O
personal	O
care	O
products	O
.	O

Use	O
of	O
multifunctional	O
ingredients	O
/	O
actives	O
with	O
antimicrobial	O
properties	O
has	O
been	O
explored	O
as	O
replacements	O
for	O
conventional	O
preservatives	O
.	O

This	O
study	O
explores	O
the	O
use	O
of	O
combinations	O
of	O
multifunctional	O
actives	O
(	O
MFA	O
)	O
and	O
other	O
cosmetic	O
ingredients	O
in	O
various	O
personal	O
care	O
formulations	O
,	O
to	O
deliver	O
microbiologically	O
safe	O
self-preserving	O
products	O
.	O

Products	O
studied	O
in	O
this	O
study	O
include	O
face	O
wash	O
,	O
gel-based	O
leave-on	O
skin	O
care	O
product	O
and	O
face	O
mask	O
.	O

Minimum	B-P
inhibitory	I-P
concentration	I-P
(	O
MIC	B-P
)	O
of	O
several	O
cosmetic	O
ingredients	O
was	O
determined	O
to	O
identify	O
multifunctional	O
actives	O
with	O
antimicrobial	O
activity	O
.	O

Personal	O
care	O
formulations	O
made	O
with	O
multifunctional	O
actives	O
and	O
other	O
cosmetic	O
ingredients	O
were	O
studied	O
for	O
preservative	O
efficacy	O
by	O
challenging	O
the	O
product	O
with	O
six	O
multiple	O
cycles	O
of	O
microbial	O
challenge	O
.	O

Formulations	O
with	O
combinations	O
of	O
multifunctional	O
actives	O
with	O
antioxidant	O
(	O
AO	O
)	O
and	O
chelators	O
(	O
CHL	O
)	O
were	O
found	O
to	O
work	O
synergistically	O
and	O
were	O
highly	O
efficacious	O
in	O
controlling	O
multiple	O
microbial	O
challenges	O
as	O
observed	O
in	O
the	O
preservative	O
efficacy	O
test	O
(	O
PET	O
)	O
studies	O
.	O

The	O
effective	O
combinations	O
were	O
able	O
to	O
withstand	O
up	O
to	O
six	O
multiple	O
microbial	O
challenges	O
without	O
product	O
degradation	O
.	O

The	O
preservative	O
efficacy	O
profile	B-P
was	O
similar	O
to	O
control	O
formula	O
containing	O
preservatives	O
.	O

Self-preserving	O
personal	O
care	O
/	O
cosmetic	O
products	O
can	O
be	O
developed	O
which	O
are	O
as	O
efficacious	O
as	O
preserved	O
products	O
by	O
a	O
prudent	O
selection	O
of	O
multifunctional	O
actives	O
,	O
antioxidants	O
and	O
chelators	O
as	O
a	O
part	O
of	O
the	O
formulation	O
.	O

Assessment	O
of	O
the	O
interaction	O
of	O
Portland	O
cement-based	O
materials	O
with	O
blood	O
and	O
tissue	O
fluids	O
using	O
an	O
animal	O
model	O
.	O

Portland	O
cement	O
used	O
in	O
the	O
construction	O
industry	O
improves	O
its	O
properties	O
when	O
wet	O
.	O

Since	O
most	O
dental	O
materials	O
are	O
used	O
in	O
a	O
moist	O
environment	O
,	O
Portland	O
cement	O
has	O
been	O
developed	O
for	O
use	O
in	O
dentistry	O
.	O

The	O
first	O
generation	O
material	O
is	O
mineral	O
trioxide	O
aggregate	O
(	O
MTA	O
)	O
,	O
used	O
in	O
surgical	O
procedures	O
,	O
thus	O
in	O
contact	O
with	O
blood	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
setting	O
of	O
MTA	O
in	O
vitro	O
and	O
in	O
vivo	O
in	O
contact	O
with	O
blood	O
by	O
subcutaneous	O
implantation	O
in	O
rats	O
.	O

The	O
tissue	O
reaction	O
to	O
the	O
material	O
was	O
also	O
investigated	O
.	O

ProRoot	O
MTA	O
(	O
Dentsply	O
)	O
was	O
implanted	O
in	O
the	O
subcutaneous	O
tissues	O
of	O
Sprague-Dawley	O
rats	O
in	O
opposite	O
flanks	O
and	O
left	O
in	O
situ	O
for	O
3	O
months	O
.	O

Furthermore	O
the	O
material	O
was	O
also	O
stored	O
in	O
physiological	O
solution	O
in	O
vitro	O
.	O

At	O
the	O
end	O
of	O
the	O
incubation	O
time	O
,	O
tissue	O
histology	B-P
and	O
material	O
characterization	O
were	O
performed	O
.	O

Surface	O
assessment	O
showed	O
the	O
formation	O
of	O
calcium	O
carbonate	O
for	O
both	O
environments	O
.	O

The	O
bismuth	O
was	O
evident	O
in	O
the	O
tissues	O
thus	O
showing	O
heavy	O
element	O
contamination	O
of	O
the	O
animal	O
specimen	O
.	O

The	O
tissue	O
histology	B-P
showed	O
a	O
chronic	O
inflammatory	O
cell	O
infiltrate	O
associated	O
with	O
the	O
MTA	O
.	O

MTA	O
interacts	O
with	O
the	O
host	O
tissues	O
and	O
causes	O
a	O
chronic	O
inflammatory	O
reaction	O
when	O
implanted	O
subcutaneously	O
.	O

Hydration	O
in	O
vivo	O
proceeds	O
similarly	O
to	O
the	O
in	O
vitro	O
model	O
with	O
some	O
differences	O
particularly	O
in	O
the	O
bismuth	O
oxide	O
leaching	O
patterns	O
.	O

Demonstration	O
of	O
a	O
bronchobiliary	O
fistula	O
using	O
magnetic	B-P
resonance	I-P
image	I-P
with	O
hepatospecific	O
contrast	O
agent	O
.	O

Bronchobiliary	O
fistulas	O
are	O
a	O
rare	O
entity	O
of	O
difficult	O
diagnosis	O
.	O

The	O
utility	O
of	O
magnetic	B-P
resonance	I-P
image	I-P
(	O
MRI	B-P
)	O
with	O
hepatospecific	O
contrast	O
agents	O
to	O
demonstrate	O
such	O
condition	O
is	O
seldom	O
described	O
in	O
the	O
literature	O
.	O

This	O
case	O
reports	O
a	O
patient	O
with	O
pulmonary	O
infection	O
with	O
a	O
past	O
history	O
of	O
hepatic	O
surgery	O
for	O
hydatid	O
disease	O
in	O
whom	O
the	O
presence	O
of	O
bile	O
in	O
the	O
sputum	O
rose	O
the	O
suspicious	O
of	O
a	O
bronchobiliary	O
fistula	O
.	O

MRI	B-P
with	O
hepatospecific	O
contrast	O
agents	O
showed	O
the	O
communication	O
between	O
the	O
biliary	O
and	O
bronchial	O
tree	O
and	O
provided	O
anatomic	O
data	O
to	O
allow	O
a	O
therapeutic	O
approach	O
.	O

N-	O
(	O
1H-Pyrazol-3-yl	O
)	O
quinazolin-4-amines	O
as	O
a	O
novel	O
class	O
of	O
casein	O
kinase	O
1δ	O
/	O
ε	O
inhibitors	O
:	O
Synthesis	O
,	O
biological	O
evaluation	O
and	O
molecular	O
modeling	O
studies	O
.	O

Described	O
herein	O
is	O
the	O
design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
N-	O
(	O
1H-pyrazol-3-yl	O
)	O
quinazolin-4-amines	O
against	O
a	O
panel	O
of	O
eight	O
disease	O
relevant	O
protein	O
kinases	O
.	O

The	O
kinase	O
inhibition	O
results	O
indicated	O
that	O
two	O
compounds	O
inhibited	O
casein	O
kinase	O
1δ	O
/	O
ε	O
(	O
CK1δ	O
/	O
ε	O
)	O
with	O
some	O
selectivity	O
over	O
related	O
kinases	O
,	O
namely	O
CDK5/p25	O
,	O
GSK-3α	O
/	O
β	O
,	O
and	O
DYRK1A	O
.	O

Docking	O
studies	B-P
with	O
3c	O
and	O
3d	O
revealed	O
the	O
key	O
interactions	O
with	O
desired	O
amino	O
acids	O
in	O
the	O
ATP	O
binding	O
site	O
of	O
CK1δ	O
.	O

Furthermore	O
,	O
compound	O
3c	O
also	O
elicited	O
selective	O
cytotoxic	O
activity	O
against	O
the	O
pancreas	O
ductal	O
adenocarcinoma	O
(	O
PANC-1	O
)	O
cell	O
line	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
establish	O
N-	O
(	O
1H-pyrazol-3-yl	O
)	O
quinazolin-4-amines	O
especially	O
3c	O
and	O
3d	O
as	O
valuable	O
lead	O
molecules	O
with	O
great	O
potential	O
for	O
CK1δ	O
/	O
ε	O
inhibitor	O
development	O
targeting	O
neurodegenerative	O
disorders	O
and	O
cancer	O
.	O

Methods	O
to	O
Study	O
Autophagy	O
in	O
Zebrafish	O
.	O

Autophagy	O
(	O
cellular	O
self-eating	O
)	O
is	O
a	O
highly	O
regulated	O
degradation	O
process	O
of	O
the	O
eukaryotic	O
cell	O
during	O
which	O
parts	O
of	O
the	O
cytoplasm	O
are	O
delivered	O
into	O
,	O
and	O
broken	O
down	O
within	O
,	O
the	O
lysosomal	O
compartment	O
.	O

The	O
process	O
serves	O
as	O
a	O
main	O
route	O
for	O
the	O
elimination	O
of	O
superfluous	O
and	O
damaged	O
cellular	O
constituents	O
,	O
thereby	O
mediating	O
macromolecular	O
and	O
organellar	O
turnover	O
.	O

In	O
addition	O
to	O
maintaining	O
cellular	O
homeostasis	O
,	O
autophagy	O
is	O
involved	O
in	O
various	O
other	O
cellular	O
and	O
developmental	O
processes	O
by	O
degrading	O
specific	O
regulatory	O
proteins	O
,	O
and	O
contributing	O
to	O
the	O
clearance	O
of	O
intracellular	O
pathogens	O
.	O

The	O
physiological	O
roles	O
and	O
pathological	O
involvement	O
of	O
autophagy	O
can	O
be	O
effectively	O
studied	O
in	O
divergent	O
eukaryotic	O
model	O
systems	O
ranging	O
from	O
yeast	O
to	O
mice	O
.	O

Such	O
a	O
tractable	O
animal	O
model	O
applied	O
only	O
recently	O
for	O
autophagy	O
researchis	O
the	O
zebrafish	O
Danio	O
rerio	O
,	O
which	O
also	O
facilitates	O
the	O
analysis	O
of	O
more	O
specific	O
biological	O
processes	O
such	O
as	O
tissue	O
regeneration	O
.	O

In	O
this	O
chapter	O
,	O
we	O
overview	O
the	O
main	O
methods	O
and	O
tools	O
that	O
are	O
used	O
to	O
monitor	O
autophagic	O
structures	O
and	O
to	O
assay	B-P
autophagic	O
responses	O
in	O
this	O
vertebrate	O
organism	O
.	O

We	O
place	O
emphasis	O
on	O
genetic	O
(	O
functional	O
)	O
approaches	O
applied	O
for	O
exploring	O
novel	O
cellular	O
and	O
developmental	O
roles	O
of	O
the	O
autophagic	O
process	O
.	O

Comparison	O
of	O
pulse	O
wave	O
velocity	O
derived	O
from	O
accelerometer	O
and	O
reflective	B-P
photo-plethysmography	I-P
signals	I-P
placed	O
at	O
the	O
carotid	O
and	O
femoral	O
artery	O
.	O

Carotid	O
-	O
femoral	O
pulse	O
wave	O
velocity	O
is	O
an	O
established	O
measure	O
to	O
assess	O
cardiovascular	O
risk	O
and	O
an	O
interesting	O
surrogate	O
parameter	O
towards	O
non-invasive	O
continuous	O
blood	O
pressure	O
inference	O
.	O

Due	O
to	O
progress	O
in	O
sensing	O
technologies	O
for	O
wearable	O
wrist	O
worn	O
sensors	O
,	O
there	O
are	O
low	O
cost	O
sensor	O
combinations	O
of	O
photo-plethysmography	B-P
and	O
high	O
fidelity	O
accelerometer	O
s	O
available	O
offering	O
access	O
to	O
pulse	O
information	O
from	O
larger	O
arteries	O
complemented	O
by	O
blood	O
volume	O
changes	O
in	O
the	O
superficial	O
tissue	O
.	O

In	O
this	O
work	O
we	O
compare	O
pulse	O
wave	O
velocities	O
derived	O
from	O
accelerometer	O
and	O
reflective	B-P
photo-plethysmography	I-P
signals	I-P
placed	O
at	O
the	O
carotid	O
and	O
femoral	O
artery	O
.	O

We	O
discuss	O
the	O
different	O
underlying	O
physiological	O
processes	O
for	O
the	O
two	O
sensing	O
principles	O
and	O
present	O
experimental	O
results	O
obtained	O
in	O
a	O
study	O
with	O
healthy	O
subjects	O
.	O

Enhanced	O
Performance	O
of	O
Colorimetric	B-P
Biosensing	B-P
on	O
Paper	O
Microfluidic	B-P
Platforms	I-P
Through	O
Chemical	O
Modification	O
and	O
Incorporation	O
of	O
Nanoparticles	O
.	O

This	O
chapter	O
describes	O
two	O
different	O
methodologies	O
used	O
to	O
improve	O
the	O
analytical	O
performance	O
of	O
colorimetric	B-P
paper	O
-based	O
biosensors	O
.	O

Microfluidic	O
paper-based	O
analytical	O
devices	O
(	O
μPADs	O
)	O
have	O
been	O
produced	O
by	O
a	O
stamping	O
process	O
and	O
CO2	O
laser	O
ablation	O
and	O
modified	O
,	O
respectively	O
,	O
through	O
an	O
oxidation	O
step	O
and	O
incorporation	O
of	O
silica	O
nanoparticles	O
on	O
the	O
paper	O
structure	O
.	O

Both	O
methods	O
are	O
employed	O
in	O
order	O
to	O
overcome	O
the	O
largest	O
problem	O
associated	O
with	O
colorimetric	B-P
detection	I-P
,	O
the	O
heterogeneity	O
of	O
the	O
color	O
distribution	O
in	O
the	O
detection	O
zones	O
.	O

The	O
modification	O
steps	O
are	O
necessary	O
to	O
improve	O
the	O
interaction	O
between	O
the	O
paper	O
surface	O
and	O
the	O
selected	O
enzymes	O
.	O

The	O
enhanced	O
performance	O
has	O
ensured	O
reliability	O
for	O
quantitative	O
analysis	O
of	O
clinically	O
relevant	O
compounds	O
.	O

Aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
rs2066853	O
gene	O
polymorphism	O
association	O
with	O
infertile	O
oligoasthenoteratozoospermic	O
men	O
and	O
seminal	O
oxidative	O
stress	O
.	O

This	O
study	O
aimed	O
to	O
assess	O
the	O
association	O
between	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
rs2066853	O
gene	O
polymorphism	O
with	O
infertile	O
oligoasthenoteratozoospermic	O
(	O
OAT	O
)	O
men	O
and	O
seminal	O
oxidative	O
stress	O
(	O
OS	O
)	O
.	O

A	O
total	O
of	O
170	O
Egyptian	O
men	O
were	O
allocated	O
according	O
to	O
their	O
semen	B-P
analysis	I-P
into	O
fertile	O
normozoospermic	O
controls	O
(	O
n	O
=	O
50	O
)	O
and	O
infertile	O
OAT	O
men	O
(	O
n	O
=	O
120	O
)	O
.	O

They	O
were	O
subjected	O
to	O
history	O
taking	O
,	O
clinical	O
examination	O
,	O
semen	B-P
analysis	I-P
,	O
estimation	O
of	O
seminal	O
glutathione	O
peroxidase	O
(	O
GPx	O
)	O
,	O
and	O
malondialdehyde	O
(	O
MDA	O
)	O
.	O

AhR	O
rs2066853	O
gene	O
polymorphism	O
was	O
identified	O
in	O
the	O
blood	O
by	O
PCR	O
-	O
RFLP	O
.	O

Comparing	O
infertile	O
OAT	O
men	O
with	O
fertile	O
controls	O
,	O
AhR	O
rs2066853	O
genotypes	O
showed	O
decreased	O
prevalence	O
for	O
wild	O
homozygous	O
genotype	O
GG	O
(	O
35.8	O
vs	O
56	O
%	O
)	O
and	O
for	O
heterozygous	O
genotype	O
GA	O
(	O
17.5	O
vs	O
30	O
%	O
)	O
and	O
an	O
increased	O
prevalence	O
for	O
homozygous	O
genotype	O
AA	O
(	O
46.7	O
vs	O
14	O
%	O
)	O
.	O

Distribution	O
of	O
alleles	O
of	O
AhR	O
rs2066853	O
among	O
OAT	O
men	O
compared	O
with	O
fertile	O
men	O
showed	O
decreased	O
prevalence	O
of	O
G	O
allele	O
(	O
44.6	O
vs	O
71	O
%	O
)	O
and	O
an	O
increased	O
prevalence	O
of	O
A	O
allele	O
(	O
55.4	O
vs	O
29	O
%	O
)	O
.	O

Seminal	O
MDA	O
demonstrated	O
significant	O
increase	O
whereas	O
seminal	O
GPx	O
demonstrated	O
significant	O
decrease	O
in	O
cases	O
with	O
AA	O
and	O
GA	O
/	O
AA	O
genotypes	O
compared	O
to	O
cases	O
with	O
GG	O
genotype	O
.	O

It	O
is	O
concluded	O
that	O
there	O
is	O
a	O
significant	O
association	O
between	O
AhR	O
rs2066853	O
genotype	O
polymorphism	O
with	O
decreased	O
sperm	O
parameters	O
as	O
well	O
as	O
increased	O
seminal	O
oxidative	O
stress	O
in	O
infertile	O
OAT	O
men	O
.	O

Direct	O
effects	O
of	O
glucose	O
,	O
insulin	O
,	O
GLP-1	O
,	O
and	O
GIP	O
on	O
bulbospinal	O
neurons	O
in	O
the	O
rostral	O
ventrolateral	O
medulla	O
in	O
neonatal	O
wistar	O
rats	O
.	O

Although	O
patients	O
with	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
often	O
exhibit	O
hypertension	O
,	O
the	O
mechanisms	O
responsible	O
for	O
this	O
correlation	O
are	O
not	O
well	O
known	O
.	O

We	O
hypothesized	O
that	O
the	O
bulbospinal	O
neurons	O
in	O
the	O
rostral	O
ventrolateral	O
medulla	O
(	O
RVLM	O
)	O
are	O
affected	O
by	O
the	O
levels	O
of	O
glucose	O
,	O
insulin	O
,	O
or	O
incretins	O
(	O
glucagon	O
like	O
peptide-1	O
[	O
GLP-1	O
]	O
or	O
glucose-dependent	O
insulinotropic	O
peptide	O
[	O
GIP	O
]	O
)	O
in	O
patients	O
with	O
DM	O
.	O

To	O
investigate	O
whether	O
RVLM	O
neurons	O
are	O
activated	O
by	O
glucose	O
,	O
insulin	O
,	O
GLP-1	O
,	O
or	O
GIP	O
,	O
we	O
examined	O
changes	O
in	O
the	O
membrane	O
potentials	O
of	O
bulbospinal	O
RVLM	O
neurons	O
using	O
whole-cell	O
patch-clamp	O
technique	O
during	O
superfusion	O
with	O
various	O
levels	O
of	O
glucose	O
or	O
these	O
hormones	O
in	O
neonatal	O
Wistar	O
rats	O
.	O

A	O
brainstem	O
-	O
spinal	O
cord	O
preparation	O
was	O
used	O
for	O
the	O
experiments	O
.	O

A	O
low	O
level	O
of	O
glucose	O
stimulated	O
bulbospinal	O
RVLM	O
neurons	O
.	O

During	O
insulin	O
superfusion	O
,	O
almost	O
all	O
the	O
RVLM	O
neurons	O
were	O
depolarized	O
,	O
while	O
during	O
GLP-1	O
or	O
GIP	O
superfusion	O
,	O
almost	O
all	O
the	O
RVLM	O
neurons	O
were	O
hyperpolarized	O
.	O

Next	O
,	O
histological	B-P
examinations	I-P
were	O
performed	O
to	O
examine	O
transporters	O
for	O
glucose	O
and	O
receptors	O
for	O
insulin	O
,	O
GLP-1	O
,	O
and	O
GIP	O
on	O
RVLM	O
neurons	O
.	O

Low	O
-	O
level	O
glucose	O
-	O
depolarized	O
RVLM	O
neurons	O
exhibited	O
the	O
presence	O
of	O
glucose	O
transporter	O
3	O
(	O
GLUT3	O
)	O
.	O

Meanwhile	O
,	O
insulin	O
-	O
depolarized	O
,	O
GLP-1	O
-	O
hyperpolarized	O
,	O
and	O
GIP	O
-	O
hyperpolarized	O
RVLM	O
neurons	O
showed	O
each	O
of	O
the	O
respective	O
specific	O
receptor	O
.	O

These	O
results	O
indicate	O
that	O
a	O
low	O
level	O
of	O
glucose	O
stimulates	O
bulbospinal	O
RVLM	O
neurons	O
via	O
specific	O
transporters	O
on	O
these	O
neurons	O
,	O
inducing	O
hypertension	O
.	O

Furthermore	O
,	O
an	O
increase	O
in	O
insulin	O
or	O
a	O
reduction	O
in	O
incretins	O
may	O
also	O
activate	O
the	O
sympathetic	O
nervous	O
system	O
and	O
induce	O
hypertension	O
by	O
activating	O
RVLM	O
neurons	O
via	O
their	O
own	O
receptors	O
.	O

2016	O
Updated	O
MASCC	O
/	O
ESMO	O
consensus	O
recommendations	O
:	O
Management	O
of	O
nausea	O
and	O
vomiting	O
in	O
advanced	O
cancer	O
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
review	O
the	O
existing	O
literature	O
related	O
to	O
the	O
management	O
of	O
nausea	O
and	O
vomiting	O
(	O
N	O
&	O
V	O
)	O
in	O
advanced	O
cancer	O
and	O
derive	O
clinical	O
evidence	O
-based	O
recommendations	O
for	O
its	O
management	O
.	O

Available	O
systematic	O
reviews	O
on	O
antiemetic	O
drug	O
effectiveness	O
were	O
used	O
.	O

One	O
generic	O
systematic	O
review	O
of	O
antiemetics	O
in	O
advanced	O
cancer	O
(	O
to	O
2009	O
)	O
was	O
updated	O
to	O
February	O
2016	O
.	O

Agreement	O
on	O
recommendations	O
was	O
reached	O
between	O
panel	O
members	O
,	O
and	O
these	O
were	O
voted	O
in	O
favor	O
unanimously	O
by	O
the	O
larger	O
antiemetic	O
committee	O
membership	O
(	O
n	O
=	O
37	O
)	O
.	O

The	O
evidence	O
base	O
in	O
this	O
field	O
is	O
minimal	O
with	O
largely	O
poor	O
quality	O
trials	O
or	O
uncontrolled	O
trials	O
and	O
case	O
studies	O
.	O

The	O
level	O
of	O
evidence	O
in	O
most	O
studies	B-P
is	O
low	O
.	O

The	O
drug	O
of	O
choice	O
for	O
managing	O
N	O
&	O
V	O
in	O
advanced	O
cancer	O
is	O
metoclopramide	O
titrated	O
to	O
effect	O
.	O

Alternative	O
options	O
include	O
haloperidol	O
,	O
levomepromazine	O
,	O
or	O
olanzapine	O
.	O

For	O
bowel	O
obstruction	O
,	O
the	O
recommendation	O
is	O
to	O
use	O
octreotide	O
given	O
alongside	O
an	O
antiemetic	O
(	O
haloperidol	O
)	O
and	O
where	O
octreotide	O
is	O
not	O
an	O
option	O
to	O
use	O
an	O
anticholinergic	O
antisecretory	O
agent	O
.	O

For	O
opioid	O
-	O
induced	O
N	O
&	O
V	O
,	O
no	O
recommendation	O
could	O
be	O
made	O
.	O

These	O
new	O
guidelines	O
,	O
based	O
on	O
the	O
existing	O
(	O
but	O
poor	O
)	O
evidence	O
,	O
could	O
help	O
clinicians	O
manage	O
more	O
effectively	O
the	O
complex	O
and	O
challenging	O
symptoms	O
of	O
N	O
&	O
V	O
in	O
advanced	O
cancer	O
.	O

Basal	O
ryanodine	O
receptor	O
activity	O
suppresses	O
autophagic	O
flux	O
.	O

The	O
inositol	O
1,4,5-trisphosphate	O
receptors	O
(	O
IP3Rs	O
)	O
and	O
intracellular	O
Ca	O
(	O
2+	O
)	O
signaling	O
are	O
critically	O
involved	O
in	O
regulating	O
different	O
steps	O
of	O
autophagy	O
,	O
a	O
lysosomal	O
degradation	O
pathway	O
.	O

The	O
ryanodine	O
receptors	O
(	O
RyR	O
)	O
,	O
intracellular	O
Ca	O
(	O
2+	O
)	O
-release	O
channels	O
mainly	O
expressed	O
in	O
excitable	O
cell	O
types	O
including	O
muscle	O
and	O
neurons	O
,	O
have	O
however	O
not	O
yet	O
been	O
extensively	O
studied	O
in	O
relation	O
to	O
autophagy	O
.	O

Yet	O
,	O
aberrant	O
expression	O
and	O
excessive	O
activity	O
of	O
RyRs	O
in	O
these	O
tissues	O
has	O
been	O
implicated	O
in	O
the	O
onset	O
of	O
several	O
diseases	O
including	O
Alzheimer	O
's	O
disease	O
,	O
where	O
impaired	O
autophagy	O
regulation	O
contributes	O
to	O
the	O
pathology	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	B-P
whether	O
pharmacological	O
RyR	O
inhibition	O
could	O
modulate	O
autophagic	O
flux	O
in	O
ectopic	O
RyR	O
-	O
expressing	O
models	O
,	O
like	O
HEK293	O
cells	O
and	O
in	O
cell	O
types	O
that	O
endogenously	O
express	O
RyR	O
s	O
,	O
like	O
C2C12	O
myoblasts	O
and	O
primary	O
hippocampal	O
neurons	O
.	O

Importantly	O
,	O
RyR3	O
overexpression	O
in	O
HEK293	O
cells	O
impaired	O
the	O
autophagic	O
flux	O
.	O

Conversely	O
,	O
in	O
all	O
cell	O
models	O
tested	O
,	O
pharmacological	O
inhibition	O
of	O
endogenous	O
or	O
ectopically	O
expressed	O
RyRs	O
,	O
using	O
dantrolene	O
or	O
ryanodine	O
,	O
augmented	O
autophagic	O
flux	O
by	O
increasing	O
lysosomal	O
turn-over	O
(	O
number	O
of	O
autophagosomes	O
and	O
autolysosomes	O
measured	O
as	O
mCherry	O
-	O
LC3	O
punctae	O
/	O
cell	O
increased	O
from	O
70.37±7.81	O
in	O
control	O
HEK	O
RyR3	O
cells	O
to	O
111.18±7.72	O
and	O
98.14±7.31	O
after	O
dantrolene	O
and	O
ryanodine	O
treatments	O
,	O
respectively	O
)	O
.	O

Moreover	O
,	O
in	O
differentiated	O
C2C12	O
cells	O
,	O
transmission	B-P
electron	I-P
microscopy	I-P
demonstrated	O
that	O
dantrolene	O
treatment	O
decreased	O
the	O
number	O
of	O
early	O
autophagic	O
vacuoles	O
from	O
5.9±2.97	O
to	O
1.8±1.03	O
per	O
cellular	O
cross	O
section	O
.	O

The	O
modulation	O
of	O
the	O
autophagic	O
flux	O
could	O
be	O
linked	O
to	O
the	O
functional	O
inhibition	O
of	O
RyR	O
channels	O
as	O
both	O
RyR	O
inhibitors	O
efficiently	O
diminished	O
the	O
number	O
of	O
cells	O
showing	O
spontaneous	O
RyR3	O
activity	O
in	O
the	O
HEK293	O
cell	O
model	O
(	O
from	O
41.14	O
%	O
±2.12	O
in	O
control	O
cells	O
to	O
18.70	O
%	O
±2.25	O
and	O
9.74	O
%	O
±2.67	O
after	O
dantrolene	O
and	O
ryanodine	O
treatments	O
,	O
respectively	O
)	O
.	O

In	O
conclusion	O
,	O
basal	O
RyR	O
-mediated	O
Ca	O
(	O
2+	O
)	O
-release	O
events	O
suppress	O
autophagic	O
flux	O
at	O
the	O
level	O
of	O
the	O
lysosomes	O
.	O

Self-assembled	O
polymeric	O
vectors	O
mixtures	O
:	O
characterization	O
of	O
the	O
polymorphism	O
and	O
existence	O
of	O
synergistic	O
effects	O
in	O
photodynamic	O
therapy	O
.	O

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
assess	O
the	O
relation	O
between	O
the	O
purity	O
of	O
polymeric	O
self-assemblies	O
vectors	O
solution	O
and	O
their	O
photodynamic	O
therapeutic	O
efficiency	O
.	O

For	O
this	O
,	O
several	O
amphiphilic	O
block	O
copolymers	O
of	O
poly	O
(	O
ethyleneoxide-b-ε-caprolactone	O
)	O
have	O
been	O
used	O
to	O
form	O
self-assemblies	O
with	O
different	O
morphologies	O
(	O
micelles	O
,	O
worm-like	O
micelles	O
or	O
vesicles	O
)	O
.	O

In	O
a	O
first	O
step	O
,	O
controlled	O
mixtures	O
of	O
preformed	O
micelles	O
and	O
vesicles	O
have	O
been	O
characterized	O
both	O
by	O
dynamic	B-P
light	I-P
scattering	I-P
and	O
asymmetrical	B-P
flow	I-P
field	I-P
flow	I-P
fractionation	I-P
(	O
AsFlFFF	B-P
)	O
.	O

For	O
this	O
,	O
a	O
custom-made	O
program	O
,	O
STORMS	O
,	O
was	O
developed	O
to	O
analyze	O
DLS	B-P
data	O
in	O
a	O
thorough	O
manner	O
by	O
providing	O
a	O
large	O
set	O
of	O
fitting	O
parameters	O
.	O

This	O
showed	O
that	O
DLS	B-P
only	O
sensed	O
the	O
larger	O
vesicles	O
when	O
the	O
micelles	O
/	O
vesicles	O
ratio	O
was	O
80/20	O
w/w	O
.	O

On	O
the	O
other	O
hand	O
,	O
AsFlFFF	B-P
allowed	O
clear	O
detection	O
of	O
the	O
presence	O
of	O
micelles	O
when	O
this	O
same	O
ratio	O
was	O
as	O
low	O
as	O
10/90	O
.	O

Subsequently	O
,	O
the	O
photodynamic	O
therapy	O
efficiency	O
of	O
various	O
controlled	O
mixtures	O
was	O
assessed	O
using	O
multicellular	O
spheroids	O
when	O
a	O
photosensitizer	O
,	O
pheophorbide	O
a	O
,	O
was	O
encapsulated	O
in	O
the	O
polymer	O
self-assemblies	O
.	O

Some	O
mixtures	O
were	O
shown	O
to	O
be	O
as	O
efficient	O
as	O
monomorphous	O
systems	O
.	O

In	O
some	O
cases	O
,	O
mixtures	O
were	O
found	O
to	O
exhibit	O
a	O
higher	O
PDT	O
efficiency	O
compared	O
to	O
the	O
individual	O
nano	O
-	O
objects	O
,	O
revealing	O
a	O
synergistic	O
effect	O
for	O
the	O
efficient	O
delivery	O
of	O
the	O
photosensitizer	O
.	O

Polymorphous	O
vectors	O
can	O
therefore	O
be	O
superior	O
in	O
therapeutic	O
applications	O
.	O

Silk	O
fibroin	O
based	O
carrier	O
system	O
for	O
delivery	O
of	O
fibrinogen	O
and	O
thrombin	O
as	O
coagulant	O
supplements	O
.	O

The	O
control	O
of	O
bleeding	O
is	O
one	O
of	O
the	O
most	O
important	O
interventions	O
after	O
a	O
traumatic	O
injury	O
.	O

Hemostatic	O
devices	O
delivering	O
blood	O
clotting	O
accelerating	O
agents	O
such	O
as	O
fibrinogen	O
are	O
increasingly	O
used	O
due	O
to	O
their	O
efficacy	O
and	O
their	O
ease	O
of	O
application	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
describe	O
a	O
method	O
to	O
incorporate	O
the	O
coagulant	O
supplements	O
fibrinogen	O
and	O
thrombin	O
in	O
silk	O
protein	O
sponges	O
by	O
mixing	O
the	O
coagulants	O
with	O
an	O
aqueous	O
silk	O
solution	O
,	O
followed	O
by	O
molding	B-P
,	O
freeze-drying	B-P
and	O
water	B-P
annealing	I-P
.	O

In	O
this	O
combination	O
system	O
we	O
demonstrate	O
the	O
delivery	O
of	O
fibrinogen	O
while	O
maintaining	O
its	O
hemostatic	O
potential	O
.	O

Concentration	O
ratios	O
of	O
silk	O
to	O
fibrinogen	O
of	O
1.0	O
%	O
/2.8	O
%	O
,	O
2.3	O
%	O
/1.5	O
%	O
and	O
3.0	O
%	O
/0.8	O
%	O
were	O
used	O
.	O

The	O
thrombin	O
-induced	O
fibrin	O
polymeric	O
network	O
filled	O
the	O
space	O
in	O
and	O
next	O
to	O
the	O
silk	O
spongy	O
structure	O
but	O
also	O
remained	O
interconnected	O
to	O
the	O
silk	O
,	O
providing	O
an	O
intact	O
network	O
.	O

The	O
mechanical	O
characterization	O
of	O
the	O
fibrinogen-releasing	O
silk	O
sponges	O
before	O
and	O
after	O
the	O
induction	O
of	O
the	O
fibrinogen	O
polymerization	O
demonstrated	O
that	O
the	O
fibrin	O
network	O
resulted	O
in	O
reduced	O
permanent	O
deformation	O
from	O
21.1	O
%	O
to	O
6.5	O
%	O
,	O
19.6	O
%	O
to	O
5.7	O
%	O
and	O
12.7	O
%	O
to	O
9.4	O
%	O
for	O
the	O
2.8	O
%	O
,	O
1.5	O
%	O
and	O
0.8	O
%	O
fibrinogen	O
-containing	O
silk	O
sponges	O
,	O
respectively	O
.	O

Moreover	O
,	O
the	O
fibrin	O
formation	O
lead	O
to	O
a	O
more	O
linear	O
elastic	O
behavior	O
over	O
longer	O
strain	O
ranges	O
.	O

In	O
combination	O
,	O
the	O
Calcein-AM	O
/	O
PI	O
stainings	O
and	O
MTT	O
assay	O
results	O
indicate	O
uniform	O
cell	O
adhesion	O
on	O
the	O
surface	O
and	O
cytocompatibility	O
of	O
the	O
silk	O
/	O
fibrin	O
sponges	O
,	O
respectively	O
.	O

Moreover	O
,	O
the	O
co-delivery	O
of	O
thrombin	O
with	O
fibrinogen	O
via	O
silk	O
as	O
carrier	O
material	O
is	O
described	O
,	O
offering	O
a	O
more	O
mechanically	O
robust	O
and	O
durable	O
system	O
while	O
preserving	O
hemostatic	O
features	O
of	O
the	O
coagulant	O
substances	O
for	O
the	O
generation	O
of	O
hemostatic	O
devices	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Morphological	O
characteristics	O
regulating	O
phallic	O
glans	O
engorgement	O
in	O
the	O
American	O
alligator	O
.	O

The	O
distal	O
part	O
of	O
the	O
crocodilian	O
phallus	O
consists	O
of	O
a	O
bulbous	O
glans	O
containing	O
well-developed	O
vascular	O
tissues	O
that	O
can	O
inflate	O
before	O
or	O
during	O
sexual	O
activity	O
,	O
enlarging	O
and	O
elaborating	O
the	O
glans	O
into	O
a	O
complex	O
,	O
though	O
still	O
functionally	O
undefined	O
,	O
copulatory	O
structure	O
.	O

An	O
enlarged	O
glans	O
putatively	O
interacts	O
with	O
the	O
female	O
cloaca	O
and	O
may	O
change	O
the	O
shape	O
of	O
her	O
reproductive	O
tract	O
to	O
facilitate	O
insemination	O
and	O
increase	O
the	O
probability	O
of	O
fertilization	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
cellular-level	O
properties	O
of	O
the	O
glans	O
and	O
other	O
inflatable	O
phallic	O
tissues	O
associated	O
with	O
the	O
sperm	O
-conducting	O
sulcus	O
spermaticus	O
in	O
the	O
American	O
alligator	O
(	O
Alligator	O
mississippiensis	O
)	O
.	O

Using	O
histochemical	B-P
staining	I-P
,	O
we	O
visualized	O
and	O
defined	O
collagen	O
and	O
elastin	O
fiber	O
densities	O
and	O
orientations	O
in	O
these	O
tissues	O
.	O

Extracellular	O
matrix	O
architectures	O
provided	O
insights	O
about	O
phallic	O
glans	O
material	O
properties	O
and	O
how	O
they	O
may	O
affect	O
tissue	O
strength	O
and	O
flexibility	O
during	O
inflation	O
and	O
in	O
response	O
to	O
copulatory	O
forces	O
.	O

We	O
also	O
investigated	O
the	O
potential	O
sources	O
of	O
fluids	O
that	O
induce	O
inflation	O
in	O
alligator	O
phalli	O
.	O

Combining	O
serial	B-P
sectioning	I-P
and	O
three-dimensional	B-P
reconstruction	I-P
,	O
we	O
identified	O
a	O
pair	O
of	O
supracrucal	O
plexus	O
vascular	O
bodies	O
at	O
the	O
proximal	O
end	O
of	O
the	O
alligator	O
phallus	O
that	O
extend	O
distally	O
adjacent	O
to	O
ventro-medial	O
sulcus	O
tissues	O
.	O

Together	O
,	O
our	O
gross	O
and	O
histological	O
examination	O
of	O
the	O
American	O
alligator	O
phallic	O
glans	O
suggests	O
that	O
its	O
tissues	O
are	O
arranged	O
in	O
a	O
manner	O
that	O
would	O
allow	O
vascular	O
inflation	O
to	O
expand	O
the	O
glans	O
to	O
a	O
specific	O
and	O
repeatable	O
shape	O
,	O
and	O
potentially	O
release	O
secretory	O
products	O
into	O
the	O
female	O
reproductive	O
tract	O
.	O

Both	O
elements	O
could	O
play	O
roles	O
in	O
postcopulatory	O
sexual	O
selection	O
,	O
by	O
mechanically	O
and/or	O
chemically	O
affecting	O
female	O
reproductive	O
physiology	O
.	O

Unplanned	O
readmissions	O
within	O
30	O
days	O
after	O
discharge	O
:	O
improving	O
quality	O
through	O
easy	O
prediction	O
.	O

To	O
propose	O
an	O
easy	O
predictive	O
model	O
for	O
the	O
risk	O
of	O
rehospitalization	O
,	O
built	O
from	O
hospital	O
administrative	O
data	O
,	O
in	O
order	O
to	O
prevent	O
repeated	O
admissions	O
and	O
to	O
improve	O
transitional	O
care	O
.	O

Retrospective	O
cohort	O
study	O
.	O

Azienda	O
Ospedaliero	O
Universitaria	O
Pisana	O
(	O
Pisa	O
University	O
Hospital	O
)	O
.	O

Patients	O
residing	O
in	O
the	O
territory	O
of	O
the	O
province	O
of	O
Pisa	O
(	O
Tuscany	O
Region	O
)	O
with	O
at	O
least	O
one	O
unplanned	O
hospital	O
admission	O
leading	O
to	O
a	O
medical	O
Diagnosis-Related	O
Group	O
(	O
DRG	O
)	O
in	O
the	O
calendar	O
year	O
2012	O
.	O

We	O
compared	O
two	O
groups	O
of	O
patients	O
:	O
patients	O
coded	O
as	O
'RA30	O
'	O
(	O
readmitted	O
within	O
30	O
days	O
after	O
the	O
previous	O
discharge	O
)	O
and	O
patients	O
coded	O
as	O
'NRA30	O
'	O
(	O
either	O
admitted	O
only	O
once	O
or	O
readmitted	O
after	O
30	O
days	O
since	O
the	O
latest	O
discharge	O
)	O
.	O

The	O
effect	O
of	O
age	O
,	O
sex	O
,	O
length	O
of	O
stay	O
,	O
number	O
of	O
diagnoses	O
,	O
normalized	O
number	O
of	O
admissions	O
and	O
presence	O
of	O
diseases	O
on	O
the	O
probability	O
of	O
rehospitalization	O
within	O
30	O
days	O
after	O
discharge	O
was	O
evaluated	O
.	O

The	O
significant	O
variables	O
included	O
in	O
the	O
predictive	O
model	O
were	O
:	O
age	O
,	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1.018	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.011-1.026	O
;	O
normalized	O
number	O
of	O
admissions	O
,	O
OR	O
=	O
1.257	O
,	O
CI	O
=	O
1.225-1.290	O
;	O
number	O
of	O
diagnoses	O
,	O
OR	O
=	O
1.306	O
,	O
CI	O
=	O
1.174-1.452	O
and	O
presence	O
of	O
cancer	B-P
diagnosis	I-P
,	O
OR	O
=	O
1.479	O
,	O
CI	O
=	O
1.088-2.011	O
.	O

The	O
model	O
can	O
be	O
easily	O
applied	O
when	O
discharging	O
patients	O
who	O
have	O
been	O
hospitalized	O
after	O
an	O
access	O
to	O
the	O
Emergency	O
Department	O
to	O
predict	O
the	O
risk	O
of	O
rehospitalization	O
within	O
30	O
days	O
.	O

The	O
prediction	O
can	O
be	O
used	O
to	O
activate	O
focused	O
hospital-primary	O
care	O
transitional	O
interventions	O
.	O

The	O
model	O
has	O
to	O
be	O
validated	O
first	O
in	O
order	O
to	O
be	O
implemented	O
in	O
clinical	O
practice	O
.	O

Glomerulonephritis	O
With	O
Masked	O
Monotypic	O
Immunoglobulin	O
Deposits	O
and	O
Concurrent	O
Lymphomatous	O
Infiltration	O
.	O

Kidney	O
injury	O
can	O
be	O
a	O
complication	O
of	O
hematopoietic	O
neoplasia	O
by	O
both	O
direct	O
and	O
indirect	O
mechanisms	O
.	O

Virtually	O
all	O
lymphomas	O
and	O
plasma	O
cell	O
dyscrasias	O
can	O
show	O
kidney	O
involvement	O
,	O
including	O
parenchymal	O
infiltration	O
and	O
by	O
secondary	O
injury	O
.	O

Recently	O
,	O
a	O
unique	O
form	O
of	O
glomerulonephritis	O
with	O
masked	O
monotypic	O
immunoglobulin	O
deposits	O
has	O
been	O
reported	O
,	O
which	O
shows	O
frequent	O
association	O
with	O
hematopoietic	O
neoplasia	O
and	O
a	O
propensity	O
for	O
progressive	O
kidney	O
disease	O
.	O

In	O
many	O
instances	O
,	O
these	O
cases	O
are	O
likely	O
diagnosed	O
as	O
glomerulonephritis	O
with	O
dominant	O
C3	O
due	O
to	O
the	O
absence	O
of	O
immunoglobulin	O
staining	O
by	O
routine	O
immunofluorescence	B-P
microscopy	I-P
.	O

The	O
patient	O
reported	O
here	O
showed	O
lymphomatous	O
infiltration	O
on	O
kidney	B-P
biopsy	I-P
and	O
mesangial	O
proliferative	O
glomerulonephritis	O
with	O
dominant	O
staining	O
for	O
C3	O
without	O
immunoglobulins	O
on	O
initial	O
immunofluorescence	B-P
;	O
however	O
,	O
monotypic	O
immunoglobulin	O
G	O
κ	O
light	O
chain	O
was	O
revealed	O
after	O
additional	O
immunofluorescence	B-P
staining	I-P
was	O
performed	O
on	O
the	O
paraffin-embedded	O
tissue	O
.	O

This	O
patient	O
's	O
case	O
highlights	O
the	O
evolving	O
state	O
of	O
kidney	B-P
biopsy	I-P
interpretation	O
and	O
the	O
expanding	O
spectrum	O
of	O
kidney	O
disease	O
in	O
the	O
setting	O
of	O
hematopoietic	O
neoplasia	O
.	O

Proximal	B-P
Soil	I-P
Sensing	I-P
-	O
A	O
Contribution	O
for	O
Species	O
Habitat	O
Distribution	O
Modelling	O
of	O
Earthworms	O
in	O
Agricultural	O
Soils	O
?	O
.	O

Earthworms	O
are	O
important	O
for	O
maintaining	O
soil	O
ecosystem	O
functioning	O
and	O
serve	O
as	O
indicators	O
of	O
soil	O
fertility	O
.	O

However	O
,	O
detection	O
of	O
earthworms	O
is	O
time-consuming	O
,	O
which	O
hinders	O
the	O
assessment	O
of	O
earthworm	O
abundances	O
with	O
high	O
sampling	O
density	O
over	O
entire	O
fields	O
.	O

Recent	O
developments	O
of	O
mobile	O
terrestrial	O
sensor	O
platforms	O
for	O
proximal	B-P
soil	I-P
sensing	I-P
(	O
PSS	B-P
)	O
provided	O
new	O
tools	O
for	O
collecting	O
dense	O
spatial	O
information	O
of	O
soils	O
using	O
various	O
sensing	O
principles	O
.	O

Yet	O
,	O
the	O
potential	O
of	O
PSS	B-P
for	O
assessing	O
earthworm	O
habitats	O
is	O
largely	O
unexplored	O
.	O

This	O
study	O
investigates	O
whether	O
PSS	B-P
data	O
contribute	O
to	O
the	O
spatial	O
prediction	O
of	O
earthworm	O
abundances	O
in	O
species	O
distribution	O
models	O
of	O
agricultural	O
soils	O
.	O

Proximal	B-P
soil	I-P
sensing	I-P
data	O
,	O
e.g.	O
,	O
soil	O
electrical	O
conductivity	O
(	O
EC	O
)	O
,	O
pH	O
,	O
and	O
near	B-P
infrared	I-P
absorbance	I-P
(	O
NIR	B-P
)	O
,	O
were	O
collected	O
in	O
real-time	O
in	O
a	O
field	O
with	O
two	O
management	O
strategies	O
(	O
reduced	O
tillage	O
/	O
conventional	O
tillage	O
)	O
and	O
sandy	O
to	O
loam	O
soils	O
.	O

PSS	B-P
was	O
related	O
to	O
observations	O
from	O
a	O
long-term	O
(	O
11	O
years	O
)	O
earthworm	O
observation	O
study	O
conducted	O
at	O
42	O
plots	O
.	O

Earthworms	O
were	O
sampled	O
from	O
0.5	O
x	O
0.5	O
x	O
0.2	O
m³	O
soil	O
blocks	O
and	O
identified	O
to	O
species	O
level	O
.	O

Sensor	O
data	O
were	O
highly	O
correlated	O
with	O
earthworm	O
abundances	O
observed	O
in	O
reduced	O
tillage	O
but	O
less	O
correlated	O
with	O
earthworm	O
abundances	O
observed	O
in	O
conventional	O
tillage	O
.	O

This	O
may	O
indicate	O
that	O
management	O
influences	O
the	O
sensor	O
-	O
earthworm	O
relationship	O
.	O

Generalized	O
additive	O
models	O
and	O
state-space	O
models	O
showed	O
that	O
modelling	O
based	O
on	O
data	O
fusion	O
from	O
EC	O
,	O
pH	O
,	O
and	O
NIR	B-P
sensors	O
produced	O
better	O
results	O
than	O
modelling	O
without	O
sensor	O
data	O
or	O
data	O
from	O
just	O
a	O
single	O
sensor	O
.	O

Regarding	O
the	O
individual	O
earthworm	O
species	O
,	O
particular	O
sensor	O
combinations	O
were	O
more	O
appropriate	O
than	O
others	O
due	O
to	O
the	O
different	O
habitat	O
requirements	O
of	O
the	O
earthworms	O
.	O

Earthworm	O
species	O
with	O
soil	O
-specific	O
habitat	O
preferences	O
were	O
spatially	O
predicted	O
with	O
higher	O
accuracy	O
by	O
PSS	B-P
than	O
more	O
ubiquitous	O
species	O
.	O

Our	O
findings	O
suggest	O
that	O
PSS	B-P
contributes	O
to	O
the	O
spatial	O
modelling	O
of	O
earthworm	O
abundances	O
at	O
field	O
scale	O
and	O
that	O
it	O
will	O
support	O
species	O
distribution	O
modelling	O
in	O
the	O
attempt	O
to	O
understand	O
the	O
soil	O
-	O
earthworm	O
relationships	O
in	O
agroecosystems	O
.	O

Case	O
Report	O
of	O
Necrotizing	O
Fasciitis	O
Associated	O
with	O
Streptococcus	O
pneumoniae	O
.	O

Necrotizing	O
fasciitis	O
,	O
caused	O
by	O
Streptococcus	O
pneumoniae	O
,	O
is	O
an	O
extremely	O
rare	O
and	O
life-threatening	O
bacterial	O
soft	O
tissue	O
infection	O
.	O

We	O
report	O
a	O
case	O
of	O
early	O
necrotizing	O
fasciitis	O
associated	O
with	O
Streptococcus	O
pneumoniae	O
infection	O
in	O
a	O
26-	O
year	O
-old	O
man	O
who	O
was	O
immunocompromised	O
with	O
mixed	O
connective	O
tissue	O
disease	O
.	O

The	O
patient	O
presented	O
with	O
acute	O
,	O
painful	O
,	O
erythematous	O
,	O
and	O
edematous	O
skin	O
lesions	O
of	O
his	O
right	O
lower	O
back	O
,	O
which	O
rapidly	O
progressed	O
to	O
the	O
right	O
knee	O
.	O

The	O
patient	O
underwent	O
surgical	B-P
exploration	I-P
,	O
and	O
a	O
diagnosis	O
of	O
necrotizing	O
fasciitis	O
was	O
confirmed	O
by	O
pathological	O
evidence	O
of	O
necrosis	O
of	O
the	O
fascia	O
and	O
neutrophil	O
infiltration	O
in	O
tissue	B-P
biopsies	I-P
.	O

Cultures	B-P
of	O
fascial	O
tissue	B-P
biopsies	I-P
and	O
blood	O
samples	O
were	O
positive	O
for	O
Streptococcus	O
pneumoniae	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
necrotizing	O
fasciitis	O
resulting	O
from	O
Streptococcus	O
pneumoniae	O
diagnosed	O
at	O
early	O
phase	O
;	O
the	O
patient	O
recovered	O
well	O
without	O
surgical	O
debridement	O
.	O

STRANGULATION	O
-INDUCED	O
CENTRAL	O
RETINAL	O
ARTERY	O
OCCLUSION	O
:	O
CASE	O
REPORT	O
AND	O
REVIEW	O
OF	O
THE	O
LITERATURE	O
.	O

To	O
describe	O
a	O
patient	O
with	O
central	O
retinal	O
artery	O
occlusion	O
following	O
an	O
episode	O
of	O
mechanical	O
strangulation	O
.	O

A	O
retrospective	O
case	O
report	O
.	O

An	O
83-	O
year-old	O
man	O
presented	O
with	O
acute	O
vision	O
loss	O
in	O
his	O
right	O
eye	O
after	O
a	O
strangling	O
episode	O
.	O

Multimodal	B-P
clinical	I-P
imaging	I-P
was	O
performed	O
.	O

Visual	O
acuity	O
in	O
the	O
affected	O
right	O
eye	O
was	O
no	O
light	O
perception	O
.	O

Examination	O
revealed	O
optic	O
nerve	O
edema	O
and	O
optic	O
nerve	O
pallor	O
and	O
also	O
severe	O
vascular	O
attenuation	O
and	O
a	O
cherry-red	O
spot	O
in	O
the	O
macula	O
.	O

Mechanical	O
disruption	O
of	O
carotid	O
plaque	O
can	O
lead	O
to	O
occlusion	O
of	O
the	O
central	O
retinal	O
artery	O
,	O
which	O
may	O
portend	O
a	O
dismal	O
visual	O
prognosis	O
.	O

Myocardial	O
Blood	O
Flow	O
and	O
Inflammatory	O
Cardiac	O
Sarcoidosis	O
.	O

This	O
study	O
sought	O
to	O
evaluate	O
the	O
effects	O
of	O
inflammatory	O
sarcoid	O
disease	O
on	O
coronary	O
circulatory	O
function	O
and	O
the	O
response	O
to	O
immune-suppressive	O
treatment	O
.	O

Although	O
positron	B-P
emission	I-P
tomography	I-P
assessment	O
of	O
myocardial	O
inflammation	O
is	O
increasingly	O
applied	O
to	O
identify	O
active	O
cardiac	O
sarcoidosis	O
,	O
its	O
effect	O
on	O
coronary	O
flow	O
and	O
immune-suppressive	O
treatment	O
remains	O
to	O
be	O
characterized	O
.	O

Thirty-two	O
individuals	O
,	O
who	O
were	O
referred	O
for	O
positron	B-P
emission	I-P
tomography	I-P
/	O
computed	B-P
tomography	I-P
,	O
were	O
evaluated	O
for	O
known	O
or	O
suspected	O
cardiac	O
sarcoidosis	O
applying	O
(	O
18	O
)	O
F-fluorodeoxyglucose	O
to	O
determine	O
inflammation	O
and	O
(	O
13	O
)	O
N-ammonia	O
to	O
assess	O
for	O
perfusion	O
deficits	O
following	O
a	O
high-fat	O
/	O
low-carbohydrate	O
diet	O
and	O
fasting	O
state	O
>	O
12	O
h	O
to	O
suppress	O
myocardial	O
glucose	O
uptake	O
.	O

Inflammation	O
was	O
quantified	O
with	O
standardized	O
uptake	O
value	O
and	O
regional	O
myocardial	O
blood	O
flow	O
at	O
rest	O
and	O
during	O
regadenoson	O
-	O
stimulated	O
hyperemia	O
was	O
determined	O
in	O
ml/g/min	O
.	O

Positron	B-P
emission	I-P
tomography	I-P
studies	O
were	O
repeated	O
in	O
18	O
cases	O
with	O
a	O
median	O
follow-up	O
of	O
2.5	O
years	O
(	O
interquartile	O
range	O
[	O
IQR	O
]	O
:1.3	O
to	O
3.4	O
years	O
)	O
.	O

Twenty-five	O
exams	O
had	O
normal	O
perfusion	O
but	O
evidence	O
of	O
regional	O
inflammation	O
(	O
group	O
1	O
)	O
,	O
and	O
21	O
exams	O
presented	O
a	O
regional	O
perfusion	O
deficit	O
associated	O
with	O
inflammation	O
(	O
group	O
2	O
)	O
.	O

Median	O
myocardial	O
blood	O
flow	O
did	O
not	O
differ	O
between	O
inflamed	O
and	O
noninflamed	O
myocardium	O
in	O
both	O
groups	O
(	O
0.86	O
ml/g/min	O
[	O
IQR	O
:	O
0.66	O
to	O
1.11	O
ml/g/min	O
]	O
vs.	O
0.83	O
ml/g/min	O
[	O
IQR	O
:	O
0.64	O
to	O
1.12	O
ml/g/min	O
]	O
and	O
0.74	O
ml/g/min	O
[	O
IQR	O
:	O
0.60	O
to	O
0.93	O
ml/g/min	O
]	O
vs.	O
0.77	O
ml/g/min	O
[	O
IQR	O
:	O
0.59	O
to	O
0.95	O
ml/g/min	O
]	O
,	O
respectively	O
)	O
.	O

As	O
regards	O
median	O
hyperemic	O
myocardial	O
blood	O
flows	O
,	O
they	O
were	O
significantly	O
lower	O
in	O
the	O
inflamed	O
than	O
in	O
the	O
remote	O
regions	O
in	O
group	O
1	O
and	O
2	O
(	O
2.31	O
ml/g/min	O
[	O
IQR	O
:	O
1.81	O
to	O
2.95	O
ml/g/min	O
]	O
vs.	O
2.70	O
ml/g/min	O
[	O
IQR	O
:	O
2.07	O
to	O
3.30	O
ml/g/min	O
]	O
and	O
1.61	O
ml/g/min	O
[	O
IQR	O
:	O
1.17	O
to	O
2.18	O
ml/g/min	O
]	O
vs.	O
1.94	O
ml/g/min	O
[	O
IQR	O
:	O
1.49	O
to	O
2.39	O
ml/g/min	O
]	O
;	O
p	O
<	O
0.001	O
,	O
respectively	O
)	O
.	O

Immune-suppression	O
-mediated	O
decrease	O
in	O
inflammation	O
was	O
associated	O
with	O
preserved	O
myocardial	O
flow	O
reserve	O
(	O
MFR	O
)	O
at	O
follow-up	O
,	O
whereas	O
MFR	O
significantly	O
worsened	O
in	O
regions	O
without	O
changes	O
or	O
even	O
increases	O
in	O
inflammation	O
(	O
median	O
Δ	O
MFR	O
:	O
0.07	O
[	O
IQR	O
:	O
-0.29	O
to	O
0.45	O
]	O
vs.	O
-0.24	O
[	O
IQR	O
:	O
-0.84	O
to	O
0.21	O
]	O
;	O
p	O
<	O
0.001	O
)	O
.	O

There	O
was	O
an	O
inverse	O
correlation	O
between	O
pronounced	O
alterations	O
in	O
myocardial	O
inflammation	O
(	O
Δ	O
regional	O
myocardial	O
volume	O
with	O
standardized	O
uptake	O
value	O
>	O
4.1	O
)	O
and	O
Δ	O
MFR	O
(	O
r	O
=	O
-0.47	O
;	O
p	O
=	O
0.048	O
)	O
.	O

Sarcoid	O
-mediated	O
myocardial	O
inflammation	O
is	O
associated	O
with	O
a	O
regional	O
impairment	O
of	O
coronary	O
circulatory	O
function	O
.	O

The	O
association	O
between	O
immune-suppressive	O
treatment	O
-related	O
alterations	O
in	O
myocardial	O
inflammation	O
and	O
changes	O
in	O
coronary	O
vasodilator	O
capacity	O
suggests	O
direct	O
adverse	O
effect	O
of	O
inflammation	O
on	O
coronary	O
circulatory	O
function	O
in	O
cardiac	O
sarcoidosis	O
.	O

Chronic	O
exposure	O
to	O
haloperidol	O
and	O
olanzapine	O
leads	O
to	O
common	O
and	O
divergent	O
shape	O
changes	O
in	O
the	O
rat	O
hippocampus	O
in	O
the	O
absence	O
of	O
grey-matter	O
volume	O
loss	O
.	O

One	O
of	O
the	O
most	O
consistently	O
reported	O
brain	O
abnormalities	O
in	O
schizophrenia	O
(	O
SCZ	O
)	O
is	O
decreased	O
volume	O
and	O
shape	O
deformation	O
of	O
the	O
hippocampus	O
.	O

However	O
,	O
the	O
potential	O
contribution	O
of	O
chronic	O
antipsychotic	O
medication	O
exposure	O
to	O
these	O
phenomena	O
remains	O
unclear	O
.	O

We	O
examined	O
the	O
effect	O
of	O
chronic	O
exposure	O
(	O
8	O
weeks	O
)	O
to	O
clinically	O
relevant	O
doses	O
of	O
either	O
haloperidol	O
(	O
HAL	O
)	O
or	O
olanzapine	O
(	O
OLZ	O
)	O
on	O
adult	O
rat	O
hippocampal	O
volume	O
and	O
shape	O
using	O
ex	O
vivo	O
structural	B-P
MRI	I-P
with	O
the	O
brain	O
retained	O
inside	O
the	O
cranium	O
to	O
prevent	O
distortions	O
due	O
to	O
dissection	O
,	O
followed	O
by	O
tensor-based	B-P
morphometry	I-P
(	O
TBM	B-P
)	O
and	O
elastic	O
surface-based	O
shape	O
deformation	O
analysis	O
.	O

The	O
volume	O
of	O
the	O
hippocampus	O
was	O
also	O
measured	O
post-mortem	B-P
from	O
brain	O
tissue	O
sections	O
in	O
each	O
group	O
.	O

Chronic	O
exposure	O
to	O
either	O
HAL	O
or	O
OLZ	O
had	O
no	O
effect	O
on	O
the	O
volume	O
of	O
the	O
hippocampus	O
,	O
even	O
at	O
exploratory	B-P
thresholds	I-P
,	O
which	O
was	O
confirmed	O
post-mortem	B-P
.	O

In	O
contrast	O
,	O
shape	O
deformation	O
analysis	O
revealed	O
that	O
chronic	O
HAL	O
and	O
OLZ	O
exposure	O
lead	O
to	O
both	O
common	O
and	O
divergent	O
shape	O
deformations	O
(	O
q	O
=	O
0.05	O
,	O
FDR-corrected	O
)	O
in	O
the	O
rat	O
hippocampus	O
.	O

In	O
particular	O
,	O
in	O
the	O
dorsal	O
hippocampus	O
,	O
HAL	O
exposure	O
led	O
to	O
inward	O
shape	O
deformation	O
,	O
whereas	O
OLZ	O
exposure	O
led	O
to	O
outward	O
shape	O
deformation	O
.	O

Interestingly	O
,	O
outward	O
shape	O
deformations	O
that	O
were	O
common	O
to	O
both	O
drugs	O
occurred	O
in	O
the	O
ventral	O
hippocampus	O
.	O

These	O
effects	O
remained	O
significant	O
after	O
controlling	O
for	O
hippocampal	O
volume	O
suggesting	O
true	O
shape	O
changes	O
.	O

Chronic	O
exposure	O
to	O
either	O
HAL	O
or	O
OLZ	O
leads	O
to	O
both	O
common	O
and	O
divergent	O
effects	O
on	O
rat	O
hippocampal	O
shape	O
in	O
the	O
absence	O
of	O
volume	O
change	O
.	O

The	O
implications	O
of	O
these	O
findings	O
for	O
the	O
clinic	O
are	O
discussed	O
.	O

Effect	O
of	O
Soil	O
Fumigation	O
on	O
Degradation	O
of	O
Pendimethalin	O
and	O
Oxyfluorfen	O
in	O
Laboratory	B-P
and	O
Ginger	O
Field	O
Studies	O
.	O

Herbicides	O
are	O
usually	O
applied	O
to	O
agricultural	O
fields	O
following	O
soil	O
fumigation	O
to	O
provide	O
effective	O
weed	O
control	O
in	O
high-value	O
cash	O
crops	O
.	O

However	O
,	O
phytotoxicity	O
has	O
been	O
observed	O
in	O
ginger	O
seedlings	O
following	O
the	O
application	O
of	O
herbicides	O
in	O
fumigated	O
fields	O
.	O

This	O
study	O
tested	O
a	O
mixture	O
of	O
herbicides	O
(	O
pendimethalin	O
and	O
oxyfluorfen	O
)	O
and	O
several	O
fumigant	O
treatments	O
in	O
laboratory	B-P
and	O
field	O
studies	O
to	O
determine	O
their	O
effect	O
on	O
the	O
growth	O
of	O
ginger	O
.	O

The	O
results	O
showed	O
that	O
soil	O
fumigation	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
extended	O
the	O
degradation	O
period	O
of	O
these	O
herbicides	O
in	O
the	O
field	O
and	O
in	O
laboratory	B-P
studies	I-P
.	O

The	O
half-life	O
of	O
pendimethalin	O
was	O
extended	O
by	O
an	O
average	O
of	O
approximately	O
1.29	O
times	O
in	O
the	O
field	O
and	O
1.74	O
times	O
in	O
the	O
laboratory	O
.	O

The	O
half-life	O
of	O
oxyfluorfen	O
was	O
extended	O
by	O
an	O
average	O
of	O
about	O
1.19	O
times	O
in	O
the	O
field	O
and	O
1.32	O
times	O
in	O
the	O
laboratory	O
.	O

Moreover	O
,	O
the	O
extended	O
period	O
of	O
herbicide	O
degradation	O
in	O
the	O
fumigant	O
and	O
nonfumigant	O
treatments	O
significantly	O
reduced	O
ginger	O
plant	O
height	O
,	O
leaf	O
number	O
,	O
stem	O
diameter	O
,	O
and	O
the	O
chlorophyll	O
content	O
.	O

The	O
study	O
concluded	O
that	O
applying	O
a	O
dose	O
below	O
the	O
recommended	O
rate	O
of	O
these	O
herbicides	O
in	O
chloropicrin	O
(	O
CP	O
)	O
or	O
CP	O
+	O
1,3-dichloropropene	O
fumigated	O
ginger	O
fields	O
is	O
appropriate	O
,	O
as	O
application	O
of	O
the	O
recommended	O
herbicide	O
dose	O
in	O
fumigated	O
soil	O
may	O
be	O
phytotoxic	O
to	O
ginger	O
.	O

Low	O
efficacy	O
of	O
albendazole	O
against	O
Trichuris	O
trichiura	O
infection	O
in	O
schoolchildren	O
from	O
Port	O
Elizabeth	O
,	O
South	O
Africa	O
.	O

Albendazole	O
is	O
one	O
of	O
two	O
standard	O
drugs	O
for	O
the	O
control	O
of	O
soil-transmitted	O
helminthiasis	O
.	O

A	O
total	O
of	O
149	O
schoolchildren	O
from	O
Port	O
Elizabeth	O
,	O
South	O
Africa	O
,	O
were	O
examined	O
for	O
soil-transmitted	O
helminth	O
infections	O
using	O
duplicate	B-P
Kato-Katz	I-P
thick	I-P
smears	I-P
before	O
and	O
2	O
weeks	O
after	O
administration	O
of	O
albendazole	O
(	O
400	O
mg	O
)	O
.	O

Trichuris	O
trichiura	O
was	O
the	O
predominant	O
soil-transmitted	O
helminth	O
species	O
(	O
prevalence	O
60.4	O
%	O
)	O
,	O
followed	O
by	O
Ascaris	O
lumbricoides	O
(	O
47.7	O
%	O
)	O
.	O

While	O
albendazole	O
was	O
highly	O
efficacious	O
against	O
A.	O
lumbricoides	O
(	O
cure	O
rate	O
[	O
CR	O
]	O
97.2	O
%	O
;	O
egg	O
reduction	O
rate	O
[	O
ERR	O
]	O
94.3	O
%	O
)	O
,	O
it	O
lacked	O
efficacy	O
against	O
T.	O
trichiura	O
(	O
CR	O
1.1	O
%	O
;	O
ERR	O
46.0	O
%	O
)	O
.	O

Our	O
study	O
confirms	O
low	O
efficacy	O
of	O
single	O
dose	O
albendazole	O
against	O
T.	O
trichiura	O
.	O

There	O
is	O
a	O
need	O
for	O
safe	O
and	O
efficacious	O
drugs	O
against	O
T.	O
trichiura	O
.	O

Recovery	O
from	O
alcohol	O
dependence	O
:	O
Do	O
smoking	O
indicators	O
predict	O
abstinence	O
?	O
.	O

There	O
is	O
inconsistent	O
evidence	O
about	O
the	O
potential	O
influence	O
of	O
smoking	O
on	O
recovery	O
from	O
alcohol	O
dependence	O
.	O

Our	O
study	B-P
aimed	O
at	O
assessing	O
the	O
impact	O
of	O
smoking-behavior	O
on	O
relapse	O
during	O
a	O
12	O
months	O
follow-up	O
period	O
following	O
a	O
detoxification	O
in	O
patients	O
with	O
Alcohol	O
Use	O
Disorder	O
(	O
AUD	O
)	O
.	O

Three	O
hundred	O
Patients	O
with	O
AUD	O
(	O
74.9	O
%	O
smoking	O
)	O
were	O
recruited	O
from	O
two	O
inpatient	O
detoxification	O
units	O
in	O
psychiatric	O
hospitals	O
in	O
Germany	O
and	O
their	O
alcohol	O
consumption	O
was	O
prospectively	O
followed	O
for	O
1	O
year	O
.	O

Data	O
on	O
different	O
indicators	O
of	O
smoking	O
behavior	O
was	O
gathered	O
.	O

Cox	O
regression	O
model	O
was	O
used	O
to	O
evaluate	O
potential	O
risk	O
factors	O
on	O
time	O
to	O
relapse	O
of	O
alcohol	O
consumption	O
.	O

Two	O
hundred	O
seventy-nine	O
participants	O
(	O
n	O
=	O
279	O
)	O
were	O
included	O
in	O
the	O
final	O
analysis	O
.	O

Smoking	O
increased	O
the	O
risk	O
for	O
alcohol	O
relapse	O
(	O
hazard	O
ratio	O
=	O
3.962	O
,	O
95	O
%	O
CI	O
1.582-9.921	O
)	O
.	O

However	O
,	O
this	O
increased	O
risk	O
is	O
slightly	O
reduced	O
with	O
higher	O
numbers	O
of	O
daily	O
consumed	O
cigarettes	O
(	O
hazard	O
ratio	O
per	O
cigarette	O
=	O
.986	O
,	O
95	O
%	O
CI	O
.976-.995	O
)	O
.	O

Smoking	O
reduced	O
the	O
probability	O
of	O
maintaining	O
alcohol	O
abstinence	O
significantly	O
,	O
whereas	O
higher	O
number	O
of	O
cigarettes	O
smoked	O
daily	O
diminished	O
the	O
increased	O
risk	O
of	O
alcohol	O
relapse	O
in	O
alcohol-dependent	O
patients	O
.	O

Coordinated	O
psychiatric	O
and	O
substance	O
abuse	O
interventions	O
for	O
different	O
subgroups	O
of	O
patients	O
with	O
AUD	O
in	O
the	O
post-acute	O
treatment	O
phase	O
are	O
necessary	O
.	O

Individualized	O
treatment	O
planning	O
is	O
especially	O
important	O
in	O
smoking	O
patients	O
with	O
AUD	O
who	O
are	O
vulnerable	O
for	O
a	O
relapse	O
to	O
alcohol	O
drinking	O
and	O
for	O
somatic	O
complications	O
.	O

Our	O
findings	O
might	O
support	O
individualized	O
treatment	O
plans	O
.	O

(	O
Am	O
J	O
Addict	O
2017	O
;	O
XX:1-8	O
)	O
.	O

Carbon	O
Monoxide	O
Improves	O
Efficacy	O
of	O
Mesenchymal	O
Stromal	O
Cells	O
During	O
Sepsis	O
by	O
Production	O
of	O
Specialized	O
Proresolving	O
Lipid	O
Mediators	O
.	O

Mesenchymal	O
stromal	O
cells	O
are	O
being	O
investigated	O
as	O
a	O
cell-based	O
therapy	O
for	O
a	O
number	O
of	O
disease	O
processes	O
,	O
with	O
promising	O
results	O
in	O
animal	O
models	O
of	O
systemic	O
inflammation	O
and	O
sepsis	O
.	O

Studies	O
are	O
ongoing	O
to	O
determine	O
ways	O
to	O
further	O
improve	O
the	O
therapeutic	O
potential	O
of	O
mesenchymal	O
stromal	O
cells	O
.	O

A	O
gas	O
molecule	O
that	O
improves	O
outcome	O
in	O
experimental	O
sepsis	O
is	O
carbon	O
monoxide	O
.	O

We	O
hypothesized	O
that	O
preconditioning	O
of	O
mesenchymal	O
stromal	O
cells	O
with	O
carbon	O
monoxide	O
ex	O
vivo	O
would	O
promote	O
further	O
therapeutic	O
benefit	O
when	O
cells	O
are	O
administered	O
in	O
vivo	O
after	O
the	O
onset	O
of	O
polymicrobial	O
sepsis	O
in	O
mice	O
.	O

Animal	O
study	O
and	O
primary	B-P
cell	I-P
culture	I-P
.	O

Laboratory	O
investigation	O
.	O

BALB/c	O
mice	O
.	O

Polymicrobial	O
sepsis	O
was	O
induced	O
by	O
cecal	O
ligation	O
and	O
puncture	O
.	O

Mesenchymal	O
stromal	O
cells	O
,	O
mesenchymal	O
stromal	O
cells	O
-	O
conditioned	O
with	O
carbon	O
monoxide	O
,	O
fibroblasts	O
,	O
or	O
fibroblasts	O
-	O
conditioned	O
with	O
carbon	O
monoxide	O
were	O
delivered	O
by	O
tail	O
vein	O
injections	O
to	O
septic	O
mice	O
.	O

The	O
mice	O
were	O
assessed	O
for	O
survival	O
,	O
bacterial	O
clearance	O
,	O
and	O
the	O
inflammatory	O
response	O
during	O
sepsis	O
in	O
each	O
of	O
the	O
groups	O
.	O

Mesenchymal	O
stromal	O
cells	O
were	O
also	O
assessed	O
for	O
their	O
ability	O
to	O
promote	O
bacterial	O
phagocytosis	O
by	O
neutrophils	O
,	O
the	O
production	O
of	O
specialized	O
proresolving	O
lipid	O
mediators	O
,	O
and	O
their	O
importance	O
for	O
mesenchymal	O
stromal	O
cells	O
function	O
using	O
gene	O
silencing	O
.	O

Ex	O
vivo	O
preconditioning	O
with	O
carbon	O
monoxide	O
allowed	O
mesenchymal	O
stromal	O
cells	O
to	O
be	O
administered	O
later	O
after	O
the	O
onset	O
of	O
sepsis	O
(	O
6	O
hr	O
)	O
,	O
and	O
yet	O
maintain	O
their	O
therapeutic	O
effect	O
with	O
increased	O
survival	O
.	O

Carbon	O
monoxide	O
preconditioned	O
mesenchymal	O
stromal	O
cells	O
were	O
also	O
able	O
to	O
alleviate	O
organ	O
injury	O
,	O
improve	O
bacterial	O
clearance	O
,	O
and	O
promote	O
the	O
resolution	O
of	O
inflammation	O
.	O

Mesenchymal	O
stromal	O
cells	O
exposed	O
to	O
carbon	O
monoxide	O
,	O
with	O
docosahexaenoic	O
acid	O
substrate	O
,	O
produced	O
specialized	O
proresolving	O
lipid	O
mediators	O
,	O
particularly	O
D-series	O
resolvins	O
,	O
which	O
promoted	O
survival	O
.	O

Silencing	O
of	O
lipoxygenase	O
pathways	O
(	O
5-lipoxygenase	O
and	O
12	O
/	O
15-lipoxygenase	O
)	O
,	O
which	O
are	O
important	O
enzymes	O
for	O
specialized	O
proresolving	O
lipid	O
mediator	O
biosynthesis	O
,	O
resulted	O
in	O
a	O
loss	O
of	O
therapeutic	O
benefit	O
bestowed	O
on	O
mesenchymal	O
stromal	O
cells	O
by	O
carbon	O
monoxide	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
production	O
of	O
specialized	O
proresolving	O
lipid	O
mediators	O
contribute	O
to	O
improved	O
mesenchymal	O
stromal	O
cell	O
efficacy	O
when	O
exposed	O
to	O
carbon	O
monoxide	O
,	O
resulting	O
in	O
an	O
improved	O
therapeutic	O
response	O
during	O
sepsis	O
.	O

Function	O
analysis	O
of	O
Mef2c	O
promoter	O
in	O
muscle	O
differentiation	O
.	O

Regeneration	O
of	O
adult	O
skeletal	O
muscle	O
following	O
injury	O
occurs	O
through	O
the	O
activation	O
of	O
satellite	O
cells	O
,	O
that	O
proliferates	O
,	O
differentiates	O
,	O
and	O
fuses	O
with	O
injured	O
myofibers	O
.	O

Myocyte	O
enhancer	O
factor	O
2	O
(	O
MEF2	O
)	O
proteins	O
are	O
reported	O
that	O
they	O
have	O
the	O
potential	O
contributions	O
to	O
adult	O
muscle	O
regeneration	O
.	O

In	O
order	O
to	O
further	O
understand	O
Mef2c	O
gene	O
,	O
the	O
promoter	O
of	O
pig	O
Mef2c	O
gene	O
was	O
analyzed	O
in	O
this	O
paper	O
.	O

Quantitative	O
real-time	O
PCR	O
(	O
qRT-PCR	O
)	O
revealed	O
the	O
expression	O
pattern	O
of	O
Mef2c	O
gene	O
in	O
muscle	O
of	O
eight	O
tissues	O
.	O

The	O
Mef2c	O
promoter	O
had	O
the	O
higher	O
transcriptional	O
activity	O
in	O
differentiated	O
C2C12	O
cells	O
than	O
that	O
in	O
proliferating	O
C2C12	O
cells	O
,	O
which	O
was	O
accompanied	O
by	O
the	O
up-regulation	O
of	O
mRNA	O
expression	O
of	O
Mef2c	O
gene	O
.	O

Function	O
deletion	O
and	O
mutation	O
analyses	O
showed	O
that	O
MyoD	O
and	O
MEF2	O
binding	O
sites	O
within	O
the	O
Mef2c	O
promoter	O
were	O
responsible	O
for	O
the	O
regulation	O
of	O
Mef2c	O
transcription	O
.	O

MEF2C	O
could	O
up-regulate	O
the	O
transcriptional	O
activities	O
of	O
Mef2c	O
promoter	O
constructs	O
which	O
contained	O
a	O
3'-end	O
nucleotide	O
sequence	O
with	O
p300	O
binding	O
site	O
.	O

The	O
Electrophoretic	B-P
mobility	I-P
shift	I-P
assays	I-P
(	O
EMSA	B-P
)	O
and	O
chromatin	B-P
immunoprecipitation	I-P
(	I-P
ChIP	I-P
)	I-P
assays	I-P
determined	O
the	O
MyoD	O
binding	O
site	O
in	O
Mef2c	O
promoter	O
.	O

These	O
results	O
advanced	O
our	O
knowledge	O
of	O
the	O
promoter	O
of	O
the	O
pig	O
Mef2c	O
gene	O
.	O

And	O
the	O
study	O
of	O
Mef2c	O
promoter	O
regulator	O
elements	O
helped	O
to	O
elucidating	O
the	O
regulation	O
mechanisms	O
of	O
Mef2c	O
in	O
muscle	O
differentiation	O
or	O
muscle	O
repair	O
and	O
regeneration	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Diverse	O
Colletotrichum	O
species	O
cause	O
anthracnose	O
of	O
tea	O
plants	O
(	O
Camellia	O
sinensis	O
(	O
L.	O
)	O
O.	O
Kuntze	O
)	O
in	O
China	O
.	O

Anthracnose	O
caused	O
by	O
Colletotrichum	O
is	O
one	O
of	O
the	O
most	O
severe	O
diseases	O
that	O
can	O
afflict	O
Camellia	O
sinensis	O
.	O

However	O
,	O
research	O
on	O
the	O
diversity	O
and	O
geographical	O
distribution	O
of	O
Colletotrichum	O
in	O
China	O
remain	O
limited	O
.	O

In	O
this	O
study	O
,	O
106	O
Colletotrichum	O
isolates	O
were	O
collected	O
from	O
diseased	O
leaves	O
of	O
Ca	O
.	O

sinensis	O
cultivated	O
in	O
the	O
15	O
main	O
tea	O
production	O
provinces	O
in	O
China	O
.	O

Multi-locus	O
phylogenetic	O
analysis	O
coupled	O
with	O
morphological	B-P
identification	I-P
showed	O
that	O
the	O
collected	O
isolates	O
belonged	O
to	O
11	O
species	O
,	O
including	O
6	O
known	O
species	O
(	O
C.	O
camelliae	O
,	O
C.	O
cliviae	O
,	O
C.	O
fioriniae	O
,	O
C.	O
fructicola	O
,	O
C.	O
karstii	O
,	O
and	O
C.	O
siamense	O
)	O
,	O
3	O
new	O
record	O
species	O
(	O
C.	O
aenigma	O
,	O
C.	O
endophytica	O
,	O
and	O
C.	O
truncatum	O
)	O
,	O
1	O
novel	O
species	O
(	O
C.	O
wuxiense	O
)	O
,	O
and	O
1	O
indistinguishable	O
strain	O
,	O
herein	O
described	O
as	O
Colletotrichum	O
sp	O
.	O

Of	O
these	O
species	O
,	O
C.	O
camelliae	O
and	O
C.	O
fructicola	O
were	O
the	O
dominant	O
species	O
causing	O
anthracnose	O
in	O
Ca	O
.	O

sinensis	O
.	O

In	O
addition	O
,	O
our	O
study	O
provided	O
further	O
evidence	O
that	O
phylogenetic	O
analysis	O
using	O
a	O
combination	O
of	O
ApMat	O
and	O
GS	O
sequences	O
can	O
be	O
used	O
to	O
effectively	O
resolve	O
the	O
taxonomic	O
relationships	O
within	O
the	O
C.	O
gloeosporioides	O
species	O
complex	O
.	O

Finally	O
,	O
pathogenicity	O
tests	B-P
suggested	O
that	O
C.	O
camelliae	O
,	O
C.	O
aenigma	O
,	O
and	O
C.	O
endophytica	O
are	O
more	O
invasive	O
than	O
other	O
species	O
after	O
the	O
inoculation	O
of	O
the	O
leaves	O
of	O
Ca	O
.	O

sinensis	O
.	O

Gastrointestinal	O
tract	O
cancers	O
:	O
Genetics	O
,	O
heritability	O
and	O
germ	O
line	O
mutations	O
.	O

Gastrointestinal	O
(	O
GI	O
)	O
tract	O
cancers	O
that	O
arise	O
due	O
to	O
genetic	O
mutations	O
affect	O
a	O
large	O
number	O
of	O
individuals	O
worldwide	O
.	O

Even	O
though	O
many	O
of	O
the	O
GI	O
tract	O
cancers	O
arise	O
sporadically	O
,	O
few	O
of	O
these	O
GI	O
tract	O
cancers	O
harboring	O
a	O
hereditary	O
predisposition	O
are	O
now	O
recognized	O
and	O
well	O
characterized	O
.	O

These	O
include	O
Cowden	O
syndrome	O
,	O
MUTYH-associated	O
polyposis	O
,	O
hereditary	O
pancreatic	O
cancer	O
,	O
Lynch	O
syndrome	O
,	O
Peutz-Jeghers	O
syndrome	O
,	O
familial	O
adenomatous	O
polyposis	O
(	O
FAP	O
)	O
,	O
attenuated	O
FAP	O
,	O
serrated	O
polyposis	O
syndrome	O
,	O
and	O
hereditary	O
gastric	O
cancer	O
.	O

Molecular	O
characterization	O
of	O
the	O
genes	O
that	O
are	O
involved	O
in	O
these	O
syndromes	O
was	O
useful	O
in	O
the	O
development	O
of	O
genetic	B-P
testing	I-P
for	O
diagnosis	B-P
and	O
also	O
facilitated	O
understanding	O
of	O
the	O
genetic	O
basis	O
of	O
GI	O
cancers	O
.	O

Current	O
knowledge	O
on	O
the	O
genetics	O
of	O
GI	O
cancers	O
with	O
emphasis	O
on	O
heritability	O
and	O
germ	O
line	O
mutations	O
forms	O
the	O
basis	O
of	O
the	O
present	O
review	O
.	O

Probing	B-P
bulky	O
ligand	O
entry	O
in	O
engineered	O
archaeal	O
ferritins	O
.	O

A	O
set	O
of	O
engineered	O
ferritin	O
mutants	O
from	O
Archaeoglobus	O
fulgidus	O
(	O
Af-Ft	O
)	O
and	O
Pyrococcus	O
furiosus	O
(	O
Pf-Ft	O
)	O
bearing	O
cysteine	O
thiols	O
in	O
selected	O
topological	O
positions	O
inside	O
or	O
outside	O
the	O
ferritin	O
shell	O
have	O
been	O
obtained	O
.	O

The	O
two	O
apo-proteins	O
were	O
taken	O
as	O
model	O
systems	O
for	O
ferritin	O
internal	O
cavity	O
accessibility	O
in	O
that	O
Af-Ft	O
is	O
characterized	O
by	O
the	O
presence	O
of	O
a	O
45Å	O
wide	O
aperture	O
on	O
the	O
protein	O
surface	O
whereas	O
Pf-Ft	O
displays	O
canonical	O
(	O
threefold	O
)	O
channels	O
.	O

Thiol	O
reactivity	O
has	O
been	O
probed	B-P
in	O
kinetic	O
experiments	O
in	O
order	O
to	O
assess	O
the	O
protein	O
matrix	O
permeation	O
properties	O
towards	O
the	O
bulky	O
thiol	O
reactive	O
DTNB	O
(	O
5,5'-dithiobis-2-nitrobenzoic	O
acid	O
)	O
molecule	O
.	O

Reaction	O
of	O
DTNB	O
with	O
thiols	O
was	O
observed	O
in	O
all	O
ferritin	O
mutants	O
,	O
including	O
those	O
bearing	O
free	O
cysteine	O
thiols	O
inside	O
the	O
ferritin	O
cavity	O
.	O

As	O
expected	O
,	O
a	O
ferritin	O
mutant	O
from	O
Pf-Ft	O
,	O
in	O
which	O
the	O
cysteine	O
thiol	O
is	O
on	O
the	O
outer	O
surface	O
displays	O
the	O
fastest	O
binding	O
kinetics	O
.	O

In	O
turn	O
,	O
also	O
the	O
Pf-Ft	O
mutant	O
in	O
which	O
the	O
cysteine	O
thiol	O
is	O
placed	O
within	O
the	O
internal	O
cavity	O
,	O
is	O
still	O
capable	O
of	O
full	O
stoichiometric	O
DTNB	O
binding	O
albeit	O
with	O
an	O
almost	O
200-	O
fold	O
slower	O
rate	O
.	O

The	O
behaviour	O
of	O
Af-Ft	O
bearing	O
a	O
cysteine	O
thiol	O
in	O
a	O
topological	O
ly	O
equivalent	O
position	O
in	O
the	O
internal	O
cavity	O
was	O
intermediate	O
among	O
the	O
two	O
Pf-Ft	O
mutants	O
.	O

The	O
data	O
thus	O
obtained	O
indicate	O
clearly	O
that	O
the	O
protein	O
matrix	O
in	O
archaea	O
ferritins	O
does	O
not	O
provide	O
a	O
significant	O
barrier	O
against	O
bulky	O
,	O
negatively	O
charged	O
ligand	O
s	O
such	O
as	O
DTNB	O
,	O
a	O
finding	O
of	O
relevance	O
in	O
view	O
of	O
the	O
multiple	O
biotechnological	O
applications	O
of	O
these	O
ferritins	O
that	O
envisage	O
ligand	O
encapsulation	O
within	O
the	O
internal	O
cavity	O
.	O

Laboratory	B-P
Bioassays	I-P
with	O
Three	O
Different	O
Substrates	O
to	O
Test	O
the	O
Efficacy	O
of	O
Insecticides	O
against	O
Various	O
Stages	O
of	O
Drosophila	O
suzukii	O
(	O
Diptera	O
:	O
Drosophilidae	O
)	O
.	O

Rapid	O
worldwide	O
spread	O
and	O
polyphagous	O
nature	O
of	O
the	O
spotted	O
wing	O
Drosophila	O
Drosophila	O
suzukii	O
Matsumura	O
(	O
Diptera	O
:	O
Drosophilidae	O
)	O
calls	O
for	O
efficient	O
and	O
selective	O
control	O
strategies	O
to	O
prevent	O
severe	O
economic	O
losses	O
in	O
various	O
fruit	O
crops	O
.	O

The	O
use	O
of	O
insecticides	O
is	O
one	O
option	O
for	O
management	O
of	O
this	O
invasive	O
pest	O
insect	O
.	O

Efficacy	O
of	O
insecticides	O
is	O
usually	O
assessed	O
first	O
in	O
laboratory	B-P
bioassays	I-P
,	O
which	O
are	O
compounded	O
by	O
the	O
cryptic	O
nature	O
of	O
D.	O
suzukii	O
larvae	O
and	O
the	O
fact	O
that	O
fruits	O
used	O
in	O
bioassays	B-P
often	O
start	O
to	O
rot	O
and	O
dissolve	O
before	O
larvae	O
have	O
reached	O
the	O
adult	O
stage	O
.	O

Here	O
,	O
we	O
report	O
on	O
laboratory	B-P
bioassays	I-P
using	O
three	O
different	O
types	O
of	O
substrates	O
allowing	O
a	O
thorough	O
screening	O
of	O
insecticides	O
for	O
their	O
potential	O
effects	O
against	O
D.	O
suzukii	O
eggs	O
,	O
larvae	O
and	O
adults	O
.	O

Suitability	O
of	O
our	O
bioassays	B-P
was	O
validated	O
in	O
an	O
assessment	O
of	O
the	O
efficacy	O
of	O
four	O
bioinsecticides	O
and	O
one	O
synthetic	O
insecticide	O
against	O
various	O
developmental	O
stages	O
of	O
D.	O
suzukii	O
Water-apple	O
juice	O
agar	O
used	O
as	O
a	O
bioassay	B-P
substrate	O
allowed	O
egg	B-P
counting	I-P
and	O
observation	O
of	O
larval	O
development	O
due	O
to	O
its	O
transparency	O
,	O
while	O
apple-nutrition	O
medium	O
allowed	O
complete	O
metamorphosis	O
.	O

Use	O
of	O
grape	O
berries	O
in	O
bioassays	B-P
made	O
it	O
possible	O
to	O
assess	O
effects	O
of	O
an	O
insecticide	O
present	O
on	O
a	O
fruit	O
's	O
surface	O
on	O
oviposition	O
and	O
larval	O
hatch	O
from	O
eggs	O
.	O

Insecticides	O
tested	O
in	O
these	O
three	O
different	O
bioassays	B-P
with	O
acetamiprid	O
,	O
spinosad	O
or	O
natural	O
pyrethrins	O
as	O
active	O
ingredients	O
achieved	O
a	O
significant	O
D.	O
suzukii	O
control	O
if	O
they	O
were	O
applied	O
before	O
egg	O
deposition	O
.	O

Number	O
of	O
adult	O
flies	O
was	O
significantly	O
reduced	O
if	O
the	O
bioassay	B-P
medium	O
was	O
treated	O
with	O
an	O
azadirachtin	O
A	O
containing	O
insecticide	O
both	O
before	O
or	O
after	O
egg	O
deposition	O
.	O

Dynamic	O
and	O
steady-state	O
oxygen	O
-	O
dependent	O
lung	B-P
relaxometry	I-P
using	O
inversion	B-P
recovery	I-P
ultra-fast	I-P
steady-state	I-P
free	I-P
precession	I-P
imaging	I-P
at	O
1.5	O
T.	O
To	O
demonstrate	O
the	O
feasibility	O
of	O
oxygen	O
-	O
dependent	O
relaxometry	O
in	O
human	O
lung	O
using	O
an	O
inversion	O
recovery	O
ultra-fast	O
steady-state	O
free	O
precession	O
(	O
IR-ufSSFP	O
)	O
technique	O
.	O

Electrocardiogram-triggered	B-P
pulmonary	I-P
relaxometry	I-P
with	O
IR-ufSSFP	B-P
was	O
performed	O
in	O
7	O
healthy	O
human	O
subjects	O
at	O
1.5	O
T.	O
The	O
data	O
were	O
acquired	O
under	O
both	O
normoxic	O
and	O
hyperoxic	O
conditions	O
.	O

In	O
a	O
single	O
breath	O
-	O
hold	O
of	O
less	O
than	O
9	O
seconds	O
,	O
30	O
transient	O
state	O
IR-ufSSFP	O
images	O
were	O
acquired	O
,	O
yielding	O
longitudinal	B-P
(	I-P
T1	I-P
)	I-P
and	O
transversal	B-P
(	I-P
T2	I-P
)	I-P
relaxometry	I-P
parameter	O
maps	O
using	O
voxel	O
-wise	O
nonlinear	O
fitting	O
.	O

Possible	O
spatial	O
misalignments	O
between	O
consecutive	O
IR-ufSSFP	B-P
parameter	O
maps	O
were	O
corrected	O
using	O
elastic	O
image	O
registration	O
.	O

Furthermore	O
,	O
dynamic	O
relaxometry	B-P
oxygen	O
wash-in	B-P
and	O
wash-out	B-P
scans	I-P
were	O
performed	O
in	O
one	O
volunteer	O
.	O

From	O
this	O
,	O
T1	O
-related	O
wash-in	O
and	O
wash-out	O
time	O
constants	O
(	O
τwi	O
,	O
τwo	O
)	O
were	O
calculated	O
voxel	O
-wise	O
on	O
registered	O
maps	O
using	O
an	O
exponential	O
fitting	O
model	O
.	O

For	O
healthy	O
lung	O
,	O
observed	O
T1	O
values	O
were	O
1399	O
±	O
77	O
and	O
1290	O
±	O
76	O
ms	O
under	O
normoxic	O
and	O
hyperoxic	O
conditions	O
,	O
respectively	O
.	O

Oxygen	O
-related	O
reduction	O
of	O
T1	O
was	O
statistically	O
significant	O
in	O
every	O
volunteer	O
.	O

No	O
statistically	O
significant	O
change	O
,	O
however	O
,	O
was	O
observed	O
in	O
T2	O
,	O
with	O
normoxic	O
and	O
hyperoxic	O
T2	O
values	O
of	O
55	O
±	O
16	O
and	O
56	O
±	O
17	O
ms	O
,	O
respectively	O
.	O

The	O
observed	O
average	O
τwi	O
was	O
87.0	O
±	O
28.7	O
seconds	O
,	O
whereas	O
the	O
average	O
τwo	O
was	O
73.5	O
±	O
21.6	O
seconds	O
.	O

IR-ufSSFP	B-P
allows	O
fast	O
,	O
steady-state	O
,	O
and	O
dynamic	O
oxygen	O
-	O
dependent	O
relaxometry	B-P
of	O
the	O
human	O
lung	O
.	O

Magn	O
Reson	O
Med	O
,	O
2017	O
.	O

©	O
2017	O
International	O
Society	O
for	O
Magnetic	O
Resonance	O
in	O
Medicine	O
.	O

Quantifying	O
macromolecular	O
interactions	O
in	O
living	O
cells	O
using	O
FRET	B-P
two-hybrid	O
assays	O
.	O

Förster	B-P
resonance	I-P
energy	I-P
transfer	I-P
(	O
FRET	B-P
)	O
is	O
a	O
versatile	B-P
method	I-P
for	O
analyzing	O
protein-protein	O
interactions	O
within	O
living	O
cells	O
.	O

This	O
protocol	O
describes	O
a	O
nondestructive	O
live-cell	O
FRET	B-P
assay	B-P
for	O
robust	O
quantification	O
of	O
relative	O
binding	O
affinities	O
for	O
protein-protein	O
interactions	O
.	O

Unlike	O
other	O
approaches	O
,	O
our	O
method	O
correlates	O
the	O
measured	O
FRET	B-P
efficiencies	O
to	O
relative	O
concentration	O
of	O
interacting	O
proteins	O
to	O
determine	O
binding	O
isotherms	O
while	O
including	O
collisional	O
FRET	B-P
corrections	O
.	O

We	O
detail	O
how	O
to	O
assemble	O
and	O
calibrate	O
the	O
equipment	O
using	O
experimental	O
and	O
theoretical	O
procedures	O
.	O

A	O
step-by-step	O
protocol	O
is	O
given	O
for	O
sample	O
preparation	O
,	O
data	O
acquisition	O
and	O
analysis	B-P
.	O

The	O
method	O
uses	O
relatively	O
inexpensive	O
and	O
widely	O
available	O
equipment	O
and	O
can	O
be	O
performed	O
with	O
minimal	O
training	O
.	O

Implementation	O
of	O
the	O
imaging	O
setup	O
requires	O
up	O
to	O
1	O
week	O
,	O
and	O
sample	O
preparation	O
takes	O
∼	O
1-3	O
d.	O
An	O
i	O
ndividual	O
FRET	B-P
experiment	O
,	O
including	O
control	O
measurements	O
,	O
can	O
be	O
completed	O
within	O
4-6	O
h	O
,	O
with	O
data	O
analysis	O
requiring	O
an	O
additional	O
1-3	O
h	O
.	O

MyHEART	O
:	O
A	O
Non	O
Randomized	O
Feasibility	O
Study	O
of	O
a	O
Young	O
Adult	O
Hypertension	O
Intervention	O
.	O

In	O
the	O
United	O
States	O
,	O
young	O
adults	O
(	O
18-39	O
year-olds	O
)	O
have	O
the	O
lowest	O
hypertension	O
control	O
rates	O
(	O
35	O
%	O
)	O
compared	O
to	O
middle-aged	O
(	O
58	O
%	O
)	O
and	O
older	O
(	O
54	O
%	O
)	O
adults	O
.	O

Ambulatory	O
care	O
for	O
hypertension	O
management	O
often	O
focuses	O
on	O
medication	O
with	O
little	O
time	O
for	O
self-management	O
and	O
behavioral	O
counseling	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
feasibility	O
of	O
MyHEART	O
,	O
a	O
telephone-based	O
health	O
coach	O
self-management	O
intervention	O
for	O
young	O
adults	O
.	O

The	O
goals	O
were	O
to	O
determine	O
the	O
intervention	O
's	O
ability	O
to	O
:	O
1	O
)	O
recruit	O
young	O
adults	O
with	O
uncontrolled	O
hypertension	O
,	O
2	O
)	O
maintain	O
ongoing	O
communication	O
between	O
the	O
coach	O
and	O
participants	O
,	O
3	O
)	O
increase	O
participants	O
'	O
engagement	O
in	O
self-management	O
,	O
4	O
)	O
document	O
coach	O
-	O
patient	O
communication	O
in	O
the	O
electronic	O
health	O
record	O
,	O
and	O
5	O
)	O
assess	O
patient	O
acceptability	O
.	O

Eligible	O
participants	O
were	O
identified	O
through	O
the	O
electronic	O
health	O
record	O
.	O

Inclusion	O
criteria	O
included	O
18-39	O
year-olds	O
,	O
with	O
ICD-9	O
hypertension	O
diagnoses	O
and	O
uncontrolled	O
hypertension	O
(	O
≥	O
140/90	O
mmHg	O
)	O
,	O
receiving	O
regular	O
primary	O
care	O
at	O
a	O
large	O
multispecialty	O
group	O
practice	O
.	O

The	O
intervention	O
consisted	O
of	O
6	O
telephone	O
self-management	O
sessions	O
by	O
a	O
health	O
coach	O
targeting	O
lifestyle	O
modifications	O
.	O

Patients	O
completed	O
an	O
open-ended	O
acceptability	O
survey	O
.	O

Study	O
uptake	O
was	O
47	O
%	O
(	O
9	O
enrolled/19	O
eligible	O
)	O
.	O

Mean	O
(	O
SD	O
)	O
age	O
was	O
35.8	O
(	O
2.6	O
)	O
years	O
,	O
78	O
%	O
male	O
,	O
and	O
33	O
%	O
Black	O
.	O

Over	O
85	O
%	O
of	O
enrolled	O
young	O
adults	O
maintained	O
communication	O
with	O
their	O
health	O
coach	O
.	O

At	O
baseline	O
,	O
11	O
%	O
reported	O
checking	O
their	O
blood	O
pressure	O
outside	O
of	O
clinic	O
;	O
44	O
%	O
reported	O
blood	O
pressure	O
monitoring	O
after	O
the	O
study	O
.	O

All	O
coach	O
-	O
patient	O
encounters	O
were	O
successfully	O
documented	O
in	O
the	O
electronic	O
health	O
record	O
for	O
primary	O
care	O
provider	O
review	O
.	O

Open-ended	O
responses	O
from	O
all	O
surveys	O
indicated	O
that	O
participants	O
had	O
a	O
positive	O
experience	O
with	O
the	O
MyHEART	O
intervention	O
.	O

This	O
study	O
demonstrated	O
that	O
MyHEART	O
was	O
feasible	O
and	O
acceptable	O
to	O
young	O
adults	O
with	O
uncontrolled	O
hypertension	O
.	O

Health	O
coaches	O
can	O
effectively	O
maintain	O
ongoing	O
communication	O
with	O
young	O
adults	O
,	O
document	O
communication	O
in	O
the	O
electronic	O
health	O
record	O
,	O
and	O
increase	O
engagement	O
with	O
home	B-P
blood	I-P
pressure	I-P
monitoring	I-P
.	O

The	O
results	O
of	O
this	O
study	O
will	O
inform	O
a	O
multi-center	O
young	O
adult	O
randomized	O
controlled	O
trial	O
of	O
MyHEART	O
.	O

A	O
Comparison	O
of	O
Thermal	O
Plasma	O
Energy	O
Versus	O
Argon	O
Beam	O
Coagulator	O
-	O
Induced	O
Intestinal	O
Injury	O
After	O
Vaporization	O
in	O
a	O
Porcine	O
Model	O
.	O

Complete	O
cytoreduction	O
of	O
ovarian	O
cancer	O
often	O
requires	O
excision	O
or	O
ablation	O
of	O
bowel	O
serosa	O
implants	O
.	O

Both	O
argon	O
beam	O
coagulator	O
(	O
ABC	O
)	O
and	O
thermal	O
plasma	O
energy	O
(	O
TPE	O
)	O
(	O
PlasmaJet	O
;	O
PlasmaSurgical	O
,	O
Roswell	O
,	O
Ga	O
)	O
have	O
been	O
used	O
to	O
ablate	O
bowel	O
serosa	O
implants	O
.	O

Our	O
objective	O
was	O
to	O
identify	O
comparable	O
power	O
settings	O
as	O
well	O
as	O
determine	O
the	O
rate	O
of	O
bowel	O
perforation	O
,	O
depth	O
of	O
thermal	O
injury	O
,	O
and	O
extent	O
of	O
inflammatory	O
response	O
with	O
ABC	O
versus	O
TPE	O
in	O
a	O
porcine	O
model	O
.	O

Nine	O
pigs	O
underwent	O
vaporization	O
of	O
small	O
bowel	O
and	O
colon	O
serosa	O
according	O
to	O
assigned	O
treatment	O
group	O
(	O
TPE	O
vs	O
ABC	O
)	O
and	O
settings	O
(	O
ABC	O
:	O
30	O
,	O
50	O
,	O
and	O
70	O
W	O
;	O
TPE	O
:	O
Cut	O
10U	O
,	O
20U	O
,	O
and	O
30U	O
and	O
Coagulation	O
10U	O
,	O
20U	O
,	O
and	O
30U	O
)	O
.	O

Animals	O
underwent	O
necropsy	B-P
with	O
blinded	O
histomorphologic	B-P
evaluation	I-P
on	O
days	O
0	O
,	O
3	O
,	O
and	O
10	O
postprocedure	O
to	O
assess	O
for	O
presence	O
of	O
bowel	O
perforation	O
,	O
depth	O
of	O
thermal	O
injury	O
,	O
and	O
extent	O
of	O
inflammatory	O
response	O
.	O

At	O
necropsy	B-P
,	O
bowel	O
perforation	O
was	O
not	O
identified	O
in	O
any	O
animals	O
.	O

Depth	O
of	O
treatment	O
with	O
ABC	O
in	O
the	O
porcine	O
colon	O
was	O
variable	O
and	O
unrelated	O
to	O
power	O
settings	O
whereas	O
TPE	O
was	O
associated	O
with	O
a	O
consistent	O
treatment	O
depth	O
of	O
1.0	O
mm	O
regardless	O
of	O
location	O
or	O
power	O
.	O

Treatment	O
with	O
ABC	O
resulted	O
in	O
greater	O
tissue	O
coagulation	O
and	O
desiccation	O
as	O
well	O
as	O
increased	O
rates	O
of	O
mucosal	O
necrosis	O
,	O
especially	O
at	O
higher	O
settings	O
(	O
>	O
50	O
W	O
)	O
.	O

Treatment	O
with	O
TPE	O
primarily	O
resulted	O
in	O
tissue	O
ablation	O
and	O
minimal	O
mucosal	O
necrosis	O
at	O
low	O
settings	O
(	O
Coag	O
10U-20U	O
)	O
.	O

The	O
inflammatory	O
response	O
associated	O
with	O
TPE	O
treatments	O
was	O
interpreted	O
as	O
biologically	O
benign	O
,	O
and	O
less	O
than	O
that	O
observed	O
with	O
the	O
ABC	O
regardless	O
of	O
treatment	O
settings	O
.	O

Both	O
ABC	O
and	O
TPE	O
effectively	O
ablate	O
bowel	O
serosa	O
in	O
a	O
porcine	O
model	O
.	O

The	O
TPE	O
seems	O
to	O
result	O
in	O
a	O
more	O
predictable	O
tissue	O
effect	O
with	O
less	O
inflammatory	O
response	O
,	O
especially	O
when	O
used	O
at	O
low	O
power	O
settings	O
such	O
as	O
Coag	O
10U	O
or	O
20U	O
.	O

These	O
characteristics	O
are	O
appealing	O
for	O
ablation	O
of	O
bowel	O
serosa	O
implants	O
during	O
ovarian	O
cancer	O
surgery	O
and	O
warrant	O
further	O
investigation	O
.	O

Metabolite	O
mapping	O
by	O
consecutive	O
nanostructure	O
and	O
silver-assisted	B-P
mass	I-P
spectrometry	I-P
imaging	I-P
on	O
tissue	O
sections	O
.	O

Nanostructure-based	B-P
mass	I-P
spectrometry	I-P
imaging	I-P
(	O
MSI	B-P
)	O
is	O
a	O
promising	O
technology	O
for	O
molecular	B-P
imaging	I-P
of	O
small	O
molecules	O
,	O
without	O
the	O
complex	O
chemical	O
background	O
typically	O
encountered	O
in	O
matrix-assisted	B-P
molecular	I-P
imaging	I-P
approaches	O
.	O

Here	O
,	O
we	O
have	O
enhanced	O
these	O
surfaces	O
with	O
silver	O
(	O
Ag	O
)	O
to	O
provide	O
a	O
second	O
tier	O
of	O
MSI	O
data	O
from	O
a	O
single	O
sample	O
.	O

MSI	O
data	O
was	O
acquired	O
through	O
the	O
application	O
of	O
laser	B-P
desorption/ionization	I-P
mass	I-P
spectrometry	I-P
to	O
biological	O
samples	O
imprinted	O
onto	O
desorption/ionization	O
on	O
silicon	O
(	O
DIOS	O
)	O
substrates	O
.	O

Following	O
initial	O
analysis	O
,	O
ultra-thin	O
Ag	O
layers	O
were	O
overlaid	O
onto	O
the	O
followed	O
by	O
MSI	B-P
analysis	I-P
(	O
Ag-DIOS	B-P
MSI	I-P
)	O
.	O

This	O
approach	O
was	O
first	O
demonstrated	O
for	O
fingermark	O
small	O
molecules	O
including	O
environmental	O
contaminants	O
and	O
sebum	O
components	O
.	O

Subsequently	O
,	O
this	O
bimodal	O
method	O
was	O
translated	O
to	O
lipids	O
and	O
metabolites	O
in	O
fore-stomach	O
sections	O
from	O
a	O
6-bromoisatin	O
chemopreventative	O
murine	O
mouse	O
model	O
.	O

DIOS	B-P
MSI	I-P
allowed	O
mapping	O
of	O
common	O
ions	O
in	O
fingermarks	O
as	O
well	O
as	O
6-bromoisatin	O
metabolites	O
and	O
lipids	O
in	O
murine	O
fore-stomach	O
.	O

Furthermore	O
,	O
DIOS	B-P
MSI	I-P
was	O
complemented	O
by	O
the	O
Ag-DIOS	B-P
MSI	I-P
of	O
Ag-adductable	O
lipids	O
such	O
as	O
wax	O
esters	O
in	O
fingermarks	O
and	O
cholesterol	O
in	O
murine	O
fore-stomach	O
.	O

Gastrointestinal	O
acid	O
condensation	O
products	O
of	O
6-bromoisatin	O
,	O
such	O
as	O
the	O
6,6'-dibromoindirubin	O
mapped	O
herein	O
,	O
are	O
very	O
challenging	O
to	O
isolate	B-P
and	O
characterize	O
.	O

By	O
re-analyzing	O
the	O
same	O
tissue	O
imprints	O
,	O
this	O
metabolite	O
was	O
readily	O
detected	O
by	O
DIOS	O
,	O
placed	O
in	O
a	O
tissue-specific	O
spatial	O
context	O
,	O
and	O
subsequently	O
overlaid	O
with	O
additional	O
lipid	O
distributions	O
acquired	O
using	O
Ag-DIOS	B-P
MSI	I-P
.	O

The	O
ability	O
to	O
place	O
metabolite	O
and	O
lipid	O
classes	O
in	O
a	O
tissue-specific	O
context	O
makes	O
this	O
novel	O
method	O
suited	O
to	O
MSI	B-P
analyses	I-P
where	O
the	O
collection	O
of	O
additional	O
information	O
from	O
the	O
same	O
sample	O
maximises	O
resource	O
use	O
,	O
and	O
also	O
maximises	O
the	O
number	O
of	O
annotated	O
small	O
molecules	O
,	O
in	O
particular	O
for	O
metabolites	O
that	O
are	O
typically	O
undetectable	O
with	O
traditional	O
platforms	O
.	O

Copyright	O
©	O
2017	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Determinants	O
of	O
On-Road	O
Driving	O
in	O
Multiple	O
Sclerosis	O
.	O

To	O
investigate	O
the	O
cognitive	O
,	O
visual	O
,	O
and	O
motor	O
deficits	O
underlying	O
poor	O
performance	O
on	O
different	O
dimensions	O
of	O
on-road	O
driving	O
in	O
individuals	O
with	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
.	O

Prospective	O
cross-sectional	O
study	O
.	O

MS	O
clinic	O
and	O
driving	O
simulator	O
lab	O
.	O

Active	O
drivers	O
(	O
N=102	O
)	O
with	O
various	O
types	O
of	O
MS.	O
Not	O
applicable	O
.	O

Off-road	O
cognitive	O
,	O
visual	O
,	O
and	O
motor	O
functions	O
,	O
as	O
well	O
as	O
13	O
specific	O
driving	O
skills	O
.	O

These	O
skills	O
were	O
categorized	O
into	O
hierarchic	O
clusters	O
of	O
operational	O
,	O
tactical	O
,	O
visuo-integrative	O
,	O
and	O
mixed	O
driving	O
.	O

Stepwise	O
regression	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
off-road	O
functions	O
influencing	O
performance	O
on	O
the	O
on-road	O
test	O
and	O
each	O
cluster	O
.	O

Visuospatial	O
function	O
(	O
P=.002	O
)	O
,	O
inhibition	O
(	O
P=.008	O
)	O
,	O
binocular	O
acuity	O
(	O
P=.04	O
)	O
,	O
vertical	B-P
visual	I-P
field	I-P
(	O
P=.02	O
)	O
,	O
and	O
stereopsis	O
(	O
P=.03	O
)	O
best	O
determined	O
variance	O
in	O
total	O
on-road	O
score	O
(	O
unadjusted	O
R	O
(	O
2	O
)	O
=.37	O
)	O
.	O

Attentional	O
shift	O
(	O
P=.0004	O
)	O
,	O
stereopsis	O
(	O
P=.007	O
)	O
,	O
glare	B-P
recovery	I-P
(	O
P=.047	O
)	O
,	O
and	O
use	O
of	O
assistive	O
devices	O
(	O
P=.03	O
)	O
best	O
predicted	O
the	O
operational	O
cluster	O
(	O
unadjusted	O
R	O
(	O
2	O
)	O
=.28	O
)	O
.	O

Visuospatial	O
function	O
(	O
P=.002	O
)	O
,	O
inhibition	O
(	O
P=.002	O
)	O
,	O
reasoning	O
(	O
P=.003	O
)	O
,	O
binocular	O
acuity	O
(	O
P=.04	O
)	O
,	O
and	O
stereopsis	O
(	O
P=.005	O
)	O
best	O
determined	O
the	O
tactical	O
cluster	O
(	O
unadjusted	O
R	O
(	O
2	O
)	O
=.41	O
)	O
.	O

The	O
visuo-integrative	O
mode	O
l	O
(	O
unadjusted	O
R	O
(	O
2	O
)	O
=.12	O
)	O
comprised	O
binocular	O
acuity	O
(	O
P=.007	O
)	O
and	O
stereopsis	O
(	O
P=.045	O
)	O
.	O

Inhibition	O
(	O
P=.0001	O
)	O
and	O
binocular	O
acuity	O
(	O
P=.001	O
)	O
provided	O
the	O
best	O
model	O
of	O
the	O
mixed	O
cluster	O
(	O
unadjusted	O
R	O
(	O
2	O
)	O
=.25	O
)	O
.	O

Our	O
results	O
provide	O
more	O
insights	O
into	O
the	O
specific	O
impairments	O
that	O
influence	O
different	O
dimensions	O
of	O
on-road	O
driving	O
and	O
may	O
be	O
used	O
as	O
a	O
framework	O
for	O
targeted	O
driving	O
intervention	O
programs	O
in	O
MS	O
.	O

Comparison	O
of	O
sonoelastography	B-P
with	O
sonourethrography	B-P
and	O
retrograde	B-P
urethrography	I-P
in	O
the	O
evaluation	O
of	O
male	O
anterior	O
urethral	O
strictures	O
.	O

Retrograde	B-P
urethrography	I-P
(	O
RUG	B-P
)	O
is	O
the	O
most	O
common	O
and	O
preferred	O
imaging	O
modality	O
for	O
imaging	B-P
of	O
the	O
anterior	O
urethral	O
strictures	O
despite	O
its	O
well-known	O
limitations	O
and	O
disadvantages	O
.	O

Sonourethrography	B-P
(	O
SUG	B-P
)	O
was	O
introduced	O
in	O
1988	O
to	O
overcome	O
the	O
limitations	O
of	O
RUG	B-P
and	O
to	O
provide	O
more	O
accurate	O
results	O
.	O

As	O
proper	O
selection	O
of	O
imaging	O
modality	O
is	O
very	O
important	O
for	O
planning	O
the	O
treatment	O
,	O
various	O
advances	O
in	O
this	O
area	O
are	O
required	O
.	O

One	O
of	O
the	O
major	O
factors	O
for	O
recurrence	O
of	O
stricture	O
disease	O
is	O
spongiofibrosis	O
.	O

Sonoelastography	B-P
(	O
SE	B-P
)	O
is	O
a	O
newer	O
technique	O
,	O
tried	O
in	O
various	O
other	O
pathologies	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
used	O
this	O
technique	O
for	O
the	O
first	O
time	O
to	O
assess	O
its	O
efficacy	O
in	O
the	O
evaluation	O
of	O
anterior	O
urethral	O
stricture	O
disease	O
by	O
comparison	O
with	O
RUG	B-P
and	O
SUG	B-P
.	O

Between	O
August	O
2014	O
and	O
May	O
2015	O
,	O
77	O
patients	O
with	O
clinical	O
features	O
of	O
anterior	O
urethral	O
stricture	O
disease	O
were	O
included	O
in	O
the	O
study	O
and	O
evaluated	O
by	O
RUG	B-P
followed	O
by	O
SUG	B-P
and	O
SE	B-P
for	O
stricture	O
location	O
,	O
length	O
,	O
depth	O
of	O
spongiofibrosis	O
and	O
periurethral	O
pathologies	O
.	O

The	O
results	O
were	O
then	O
correlated	O
with	O
operative	O
and	O
histopathological	O
findings	O
.	O

Overall	O
diagnostic	O
accuracy	O
of	O
SE	B-P
,	O
SUG	B-P
,	O
and	O
RGU	B-P
for	O
the	O
estimation	O
of	O
stricture	O
location	O
,	O
and	O
length	O
were	O
estimated	O
92.68	O
%	O
vs.	O
91.54	O
%	O
,	O
79	O
%	O
vs.	O
78.87	O
%	O
and	O
80.48	O
%	O
vs.	O
43.66	O
%	O
,	O
respectively	O
,	O
while	O
for	O
depth	O
of	O
spongiofibrosis	O
SE	B-P
,	O
and	O
SUG	B-P
had	O
accuracy	O
rates	O
of	O
87.3	O
%	O
,	O
48	O
%	O
,	O
respectively	O
.	O

The	O
mean	O
length	O
measured	O
on	O
SE	B-P
was	O
nearest	O
to	O
the	O
mean	O
intra-operative	O
stricture	O
length	O
(	O
21.34+11.8	O
mm	O
)	O
.	O

SE	B-P
findings	O
significantly	O
correlated	O
with	O
the	O
colour	O
of	O
bladder	O
mucosa	O
on	O
cystoscopic	B-P
examination	I-P
(	O
p=0.003	O
)	O
whereas	O
the	O
association	O
was	O
non-significant	O
(	O
p=0.127	O
)	O
for	O
difficulty	O
in	O
incision	O
.	O

While	O
a	O
nonsignificant	O
correlation	O
existed	O
between	O
SUG	B-P
findings	O
related	O
both	O
to	O
the	O
colour	O
of	O
the	O
bladder	O
mucosa	O
and	O
difficulty	O
in	O
incision	O
on	O
cystoscopy	B-P
,	O
SE	B-P
findings	O
had	O
a	O
significant	O
association	O
(	O
p	O
<	O
0.001	O
)	O
with	O
histopathology	O
findings	O
for	O
severe	O
degree	B-P
of	I-P
fibrosis	I-P
.	O

Sonoelastography	B-P
estimates	O
stricture	O
site	O
and	O
length	O
better	O
in	O
comparison	O
with	O
RUG	B-P
and	O
SUG	B-P
.	O

It	O
estimates	O
degree	O
of	O
spongiofibrosis	O
which	O
serves	O
as	O
an	O
important	O
prognostic	O
factor	O
for	O
stricture	O
recurrence	O
more	O
accurately	O
than	O
SUG	B-P
.	O

Living	O
on	O
the	O
edge	O
:	O
substrate	O
competition	O
explains	O
loss	O
of	O
robustness	O
in	O
mitochondrial	O
fatty-acid	O
oxidation	O
disorders	O
.	O

Defects	O
in	O
genes	O
involved	O
in	O
mitochondrial	O
fatty-acid	O
oxidation	O
(	O
mFAO	O
)	O
reduce	O
the	O
ability	O
of	O
patients	O
to	O
cope	O
with	O
metabolic	O
challenges	O
.	O

mFAO	O
enzymes	O
accept	O
multiple	O
substrates	O
of	O
different	O
chain	O
length	O
,	O
leading	O
to	O
molecular	O
competition	O
among	O
the	O
substrates	O
.	O

Here	O
,	O
we	O
combined	O
computational	B-P
modeling	I-P
with	O
quantitative	O
mouse	O
and	O
patient	O
data	O
to	O
investigate	O
whether	O
substrate	O
competition	O
affects	O
pathway	O
robustness	O
in	O
mFAO	O
disorders	O
.	O

First	O
,	O
we	O
used	O
comprehensive	O
biochemical	O
analyses	O
of	O
wild-type	O
mice	O
and	O
mice	O
deficient	O
for	O
medium-chain	O
acyl-CoA	O
dehydrogenase	O
(	O
MCAD	O
)	O
to	O
parameterize	O
a	O
detailed	O
computational	O
model	O
of	O
mFAO	O
.	O

Model	O
simulations	O
predicted	O
that	O
MCAD	O
deficiency	O
would	O
have	O
no	O
effect	O
on	O
the	O
pathway	O
flux	O
at	O
low	O
concentrations	O
of	O
the	O
mFAO	O
substrate	O
palmitoyl-CoA	O
.	O

However	O
,	O
high	O
concentrations	O
of	O
palmitoyl-CoA	O
would	O
induce	O
a	O
decline	O
in	O
flux	O
and	O
an	O
accumulation	O
of	O
intermediate	O
metabolites	O
.	O

We	O
proved	O
computationally	O
that	O
the	O
predicted	O
overload	O
behavior	O
was	O
due	O
to	O
substrate	O
competition	O
in	O
the	O
pathway	O
.	O

Second	O
,	O
to	O
study	O
the	O
clinical	O
relevance	O
of	O
this	O
mechanism	O
,	O
we	O
used	O
patients	O
'	O
metabolite	O
profiles	O
and	O
generated	O
a	O
humanized	O
version	O
of	O
the	O
computational	O
model	O
.	O

While	O
molecular	O
competition	O
did	O
not	O
affect	O
the	O
plasma	O
metabolite	O
profiles	O
during	O
MCAD	O
deficiency	O
,	O
it	O
was	O
a	O
key	O
factor	O
in	O
explaining	O
the	O
characteristic	O
acylcarnitine	O
profiles	O
of	O
multiple	O
acyl-CoA	O
dehydrogenase	O
deficient	O
patients	O
.	O

The	O
patient-specific	O
computational	O
models	O
allowed	O
us	O
to	O
predict	O
the	O
severity	O
of	O
the	O
disease	O
phenotype	O
,	O
providing	O
a	O
proof	O
of	O
principle	O
for	O
the	O
systems	O
medicine	O
approach	O
.	O

We	O
conclude	O
that	O
substrate	O
competition	O
is	O
at	O
the	O
basis	O
of	O
the	O
physiology	O
seen	O
in	O
patients	O
with	O
mFAO	O
disorders	O
,	O
a	O
finding	O
that	O
may	O
explain	O
why	O
these	O
patients	O
run	O
a	O
risk	O
of	O
a	O
life-threatening	O
metabolic	O
catastrophe	O
.	O

Mediastinal	O
mass	O
diagnosed	O
by	O
endobronchial	B-P
ultrasound	I-P
as	O
recurrent	O
hepatocellular	O
carcinoma	O
in	O
a	O
post	O
-	O
liver	O
transplantation	O
patient	O
.	O

We	O
presented	O
a	O
rare	O
case	O
of	O
recurrent	O
hepatocellular	O
carcinoma	O
after	O
liver	O
transplant	O
manifested	O
as	O
an	O
isolated	O
mediastinal	O
mass	O
.	O

A	O
62-	O
year	O
-	O
old	O
man	O
was	O
referred	O
for	O
evaluation	O
of	O
atypical	O
chest	O
pain	O
and	O
abnormal	O
finding	O
of	O
a	O
computed	B-P
tomography	I-P
of	I-P
the	I-P
chest	I-P
.	O

He	O
had	O
history	O
of	O
chronic	O
hepatitis	O
C	O
liver	O
cirrhosis	O
and	O
hepatocellular	O
carcinoma	O
underwent	O
orthotopic	O
liver	O
transplant	O
as	O
a	O
curative	O
treatment	O
three	O
years	O
earlier	O
.	O

The	O
computed	B-P
tomography	I-P
of	I-P
the	I-P
chest	I-P
demonstrated	O
paratracheal	O
mediastinal	O
lymphadenopathy	O
.	O

He	O
subsequently	O
underwent	O
endobronchial	B-P
ultrasound	I-P
with	I-P
transbronchial	I-P
needle	I-P
aspiration	I-P
(	O
EBUS-TBNA	B-P
)	O
.	O

The	O
right	O
paratracheal	O
lymph	O
node	O
station	O
4R	O
was	O
sampled	O
.	O

Rapid	O
on-site	O
cytology	O
evaluation	O
demonstrated	O
recurrent	O
metastatic	O
hepatocellular	O
carcinoma	O
.	O

Pulmonologist	O
should	O
be	O
cognizant	O
of	O
diagnostic	O
utility	O
of	O
EBUS-TBNA	B-P
in	O
this	O
clinical	O
setting	O
as	O
more	O
transplant	O
patients	O
on	O
immunosuppressive	O
medications	O
with	O
enlarged	O
mediastinal	O
lymphadenopathy	O
of	O
unknown	O
origin	O
will	O
be	O
referred	O
for	O
further	O
evaluation	O
.	O

Undiagnosed	O
Primary	O
Open-Angle	O
Glaucoma	O
in	O
Korea	O
:	O
The	O
Korean	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
2008-2009	O
.	O

To	O
evaluate	O
the	O
characteristics	O
of	O
patients	O
with	O
previously	O
undiagnosed	O
primary	O
open-angle	O
glaucoma	O
(	O
POAG	O
)	O
in	O
Korea	O
.	O

This	O
study	O
examined	O
data	O
from	O
391	O
subjects	O
obtained	O
from	O
the	O
2008-2009	O
Korean	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
KNHANES	O
)	O
.	O

The	O
KNHANES	O
is	O
a	O
population-based	O
,	O
cross-sectional	O
epidemiological	O
survey	O
.	O

Participants	O
aged	O
19	O
years	O
or	O
older	O
completed	O
standardized	O
interviews	O
and	O
dilated	O
ocular	O
examinations	O
,	O
including	O
measurement	O
of	O
intraocular	O
pressure	O
,	O
visual	O
fields	O
with	O
frequency	B-P
doubling	I-P
perimetry	I-P
,	O
and	O
fundus	B-P
photography	I-P
.	O

Data	O
from	O
the	O
361	O
patients	O
with	O
previously	O
undiagnosed	O
POAG	O
were	O
analyzed	O
and	O
compared	O
with	O
data	O
from	O
the	O
30	O
patients	O
with	O
previously	O
diagnosed	O
glaucoma	O
.	O

A	O
total	O
of	O
92.3	O
%	O
of	O
POAG	O
cases	O
were	O
undiagnosed	O
before	O
this	O
study	O
.	O

Adjusted	O
for	O
age	O
and	O
sex	O
,	O
the	O
strongest	O
risk	O
factor	O
for	O
undiagnosed	O
glaucoma	O
was	O
longer	O
elapsed	O
time	O
since	O
last	O
eye	O
doctor	O
visit	O
.	O

Glaucoma	O
patients	O
who	O
had	O
not	O
visited	O
an	O
eye	O
specialist	O
in	O
the	O
last	O
3	O
years	O
were	O
22	O
times	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
CI	O
,	O
4.49-105.64	O
,	O
p	O
<	O
0.001	O
)	O
more	O
likely	O
to	O
have	O
undiagnosed	O
disease	O
compared	O
with	O
patients	O
who	O
had	O
visited	O
an	O
eye	O
specialist	O
in	O
the	O
last	O
month	O
.	O

Another	O
significant	O
factor	O
for	O
previously	O
undiagnosed	O
glaucoma	O
was	O
smaller	O
cup-to-disc	O
ratio	O
(	O
odds	O
ratio	O
,	O
OR	O
,	O
0.60/0.1	O
units	O
,	O
95	O
%	O
CI	O
0.43-0.85/0.1	O
units	O
,	O
p	O
=	O
0.004	O
)	O
.	O

The	O
higher	O
vertical	O
cup-to-disc	O
ratio	O
of	O
a	O
subject	O
's	O
two	O
eyes	O
was	O
significantly	O
different	O
between	O
those	O
with	O
previously	O
undiagnosed	O
(	O
0.69	O
)	O
and	O
diagnosed	O
(	O
0.78	O
)	O
POAG	O
(	O
p	O
=	O
0.001	O
)	O
.	O

The	O
undiagnosed	O
POAG	O
group	O
had	O
a	O
longer	O
interval	O
from	O
last	O
eye	O
doctor	O
visit	O
and	O
smaller	O
vertical	O
cup-to-disc	O
ratio	O
compared	O
to	O
the	O
diagnosed	O
group	O
.	O

Water	O
pipe	O
(	O
Shisha	O
,	O
Hookah	O
,	O
Arghile	O
)	O
Smoking	O
and	O
Secondhand	O
Tobacco	O
Smoke	O
Effects	O
on	O
CYP1A2	O
and	O
CYP2A6	O
Phenotypes	O
as	O
Measured	O
by	O
Caffeine	B-P
Urine	I-P
Test	I-P
.	O

Public	O
policies	O
to	O
stop	O
or	O
reduce	O
cigarette	O
smoking	O
and	O
exposure	O
to	O
secondhand	O
smoke	O
and	O
associated	O
diseases	O
have	O
yielded	O
successful	O
results	O
over	O
the	O
past	O
decade	O
.	O

Yet	O
,	O
the	O
growing	O
worldwide	O
popularity	O
of	O
another	O
form	O
of	O
tobacco	O
consumption	O
,	O
water	O
pipe	O
smoking	O
,	O
has	O
received	O
relatively	O
less	O
attention	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
study	O
to	O
date	O
has	O
evaluated	O
the	O
effects	O
of	O
water	O
pipe	O
smoking	O
on	O
cytochrome	O
P450	O
(	O
CYP450	O
)	O
activities	O
and	O
drug	O
interaction	O
potential	O
in	O
humans	O
,	O
whereas	O
only	O
limited	O
information	O
is	O
available	O
on	O
the	O
impact	O
of	O
secondhand	O
smoke	O
on	O
drug	O
metabolism	O
.	O

In	O
a	O
sample	O
of	O
99	O
healthy	O
volunteers	O
(	O
28	O
water	O
pipe	O
smokers	O
,	O
30	O
secondhand	O
tobacco	O
smoke	O
exposed	O
persons	O
,	O
and	O
41	O
controls	O
)	O
,	O
we	O
systematically	O
compared	O
CYP1A2	O
and	O
CYP2A6	O
enzyme	O
activities	O
in	O
vivo	O
using	O
caffeine	B-P
urine	I-P
test	I-P
.	O

The	O
median	O
self-reported	O
duration	O
of	O
water	O
pipe	O
smoking	O
was	O
7.5	O
h	O
/	O
week	O
and	O
3	O
years	O
of	O
exposure	O
in	O
total	O
.	O

The	O
secondhand	O
smoke	O
group	O
had	O
a	O
median	O
of	O
14	O
h	O
of	O
self-reported	O
weekly	O
exposure	O
to	O
tobacco	O
smoke	O
indoor	O
where	O
a	O
minimum	O
of	O
five	O
cigarettes	O
were	O
smoked	O
/	O
hour	O
for	O
a	O
total	O
of	O
3.5	O
years	O
(	O
median	O
)	O
.	O

Analysis	O
of	O
variance	O
did	O
not	O
find	O
a	O
significant	O
difference	O
in	O
CYP1A2	O
and	O
CYP2A6	O
activities	O
among	O
the	O
three	O
study	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O

Nor	O
was	O
there	O
a	O
significant	O
association	O
between	O
the	O
extent	O
of	O
water	O
pipe	O
or	O
secondhand	O
smoke	O
exposure	O
and	O
the	O
CYP1A2	O
and	O
CYP2A6	O
activities	O
(	O
p	O
>	O
0.05	O
)	O
.	O

Further	O
analysis	O
in	O
a	O
subsample	O
with	O
smoke	O
exposure	O
more	O
than	O
the	O
median	O
values	O
also	O
did	O
not	O
reveal	O
a	O
significant	O
difference	O
from	O
the	O
controls	O
.	O

Although	O
we	O
do	O
not	O
rule	O
out	O
an	O
appreciable	O
possible	O
impact	O
of	O
water	O
pipe	O
smoke	O
and	O
secondhand	O
smoke	O
on	O
in	O
vivo	O
activities	O
of	O
these	O
two	O
drug	O
metabolism	O
pathways	O
,	O
variability	O
in	O
smoke	O
constituents	O
from	O
different	O
tobacco	O
consumption	O
methods	O
(	O
e.g.	O
,	O
water	O
pipe	O
)	O
might	O
affect	O
drug	O
metabolism	O
in	O
ways	O
that	O
might	O
differ	O
from	O
that	O
of	O
cigarette	O
smoke	O
.	O

Further	O
studies	O
in	O
larger	O
prospective	O
samples	O
are	O
recommended	O
to	O
evaluate	O
water	O
pipe	O
and	O
secondhand	O
tobacco	O
smoke	O
effects	O
on	O
CYP450	O
function	O
,	O
particularly	O
at	O
higher	O
smoke	O
exposure	O
conditions	O
.	O

The	O
use	O
of	O
Ocimum	O
americanum	O
essential	O
oil	O
against	O
the	O
pathogens	O
Aeromonas	O
hydrophila	O
and	O
Gyrodactylus	O
sp	O
.	O

in	O
silver	O
catfish	O
(	O
Rhamdia	O
quelen	O
)	O
.	O

The	O
bactericidal	O
activity	O
(	O
MIC-test	B-P
)	O
of	O
Ocimum	O
americanum	O
(	O
inflorescences	O
)	O
essential	O
oil	O
(	O
OAEO	O
)	O
against	O
Aeromonas	O
hydrophila	O
was	O
determined	O
in	O
this	O
study	O
.	O

It	O
was	O
also	O
investigated	O
the	O
potential	O
of	O
OAEO	O
and	O
the	O
main	O
compound	O
found	O
in	O
the	O
oil	O
(	O
linalool	O
)	O
at	O
subinhibitory	O
concentrations	O
to	O
be	O
inhibitors	O
of	O
hemolysis	O
caused	O
by	O
Aer	O
.	O

hydrophila	O
in	O
fish	O
erythrocytes	O
.	O

An	O
in	O
vivo	O
experiment	O
was	O
conducted	O
to	O
evaluate	O
survival	O
of	O
fish	O
(	O
Rhamdia	O
quelen	O
)	O
experimentally	O
infected	O
with	O
Aer	O
.	O

hydrophila	O
and	O
exposed	O
to	O
OAEO	O
.	O

A	O
second	O
experiment	O
was	O
conducted	O
to	O
evaluate	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
activity	O
of	O
OAEO	O
(	O
mix	O
from	O
inflorescences	O
and	O
leaves	O
)	O
against	O
the	O
parasite	O
Gyrodactylus	O
sp	O
.	O

The	O
OAEO	O
showed	O
weak	O
in	O
vitro	O
activity	O
against	O
Aer	O
.	O

hydrophila	O
(	O
6400	O
μg	O
ml	O
(	O
-1	O
)	O
)	O
.	O

At	O
subinhibitory	O
concentrations	O
OAEO	O
(	O
100	O
μg	O
ml	O
(	O
-1	O
)	O
)	O
inhibited	O
hemolysis	O
(	O
90	O
%	O
)	O
caused	O
by	O
Aer	O
.	O

hydrophila	O
in	O
fish	O
erythrocytes	O
,	O
however	O
,	O
linalool	O
did	O
not	O
present	O
hemolysis	O
inhibition	O
activity	O
.	O

At	O
low	O
concentrations	O
(	O
10	O
and	O
20	O
mg	O
l	O
(	O
-1	O
)	O
)	O
added	O
to	O
the	O
water	O
OAEO	O
promoted	O
survival	O
of	O
experimentally	O
infected	O
fish	O
with	O
Aer	O
.	O

hydrophila	O
.	O

Lastly	O
,	O
OAEO	O
-mix	O
(	O
50	O
mg	O
l	O
(	O
-1	O
)	O
)	O
was	O
effective	O
against	O
Gyrodactylus	O
sp	O
.	O

significantly	O
reducing	O
(	O
60	O
%	O
)	O
the	O
number	O
of	O
parasites	O
in	O
the	O
fish	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Protective	O
factors	O
against	O
cognitive	O
decline	O
among	O
community-dwelling	O
middle-aged	O
and	O
older	O
people	O
in	O
Taiwan	O
:	O
A	O
6-year	O
national	O
population	O
-based	O
study	O
.	O

Dementia	O
and	O
cognitive	O
impairment	O
are	O
important	O
public	O
health	O
challenges	O
to	O
a	O
rapidly	O
aging	O
country	O
.	O

The	O
present	O
study	O
aimed	O
to	O
explore	O
the	O
protective	O
factors	O
against	O
cognitive	O
decline	O
among	O
community-dwelling	O
middle-aged	O
and	O
older	O
people	O
from	O
health	O
,	O
social	O
,	O
and	O
lifestyle	O
perspectives	O
.	O

Data	O
of	O
the	O
Social	O
Environment	O
and	O
Biomarkers	O
of	O
Aging	O
Study	O
,	O
a	O
population	O
-based	O
cohort	O
study	O
in	O
Taiwan	O
,	O
were	O
retrieved	O
for	O
the	O
study	O
.	O

Overall	O
,	O
676	O
participants	O
with	O
intact	O
baseline	O
cognitive	O
function	O
(	O
measured	O
by	O
the	O
Short	O
Portable	O
Mental	O
Status	O
Questionnaire	O
)	O
were	O
enrolled	O
and	O
followed	O
for	O
six	O
years	O
.	O

Any	O
increasing	O
score	O
of	O
the	O
Short	O
Portable	O
Mental	O
Status	O
Questionnaire	O
in	O
the	O
observational	B-P
period	O
was	O
referred	O
to	O
as	O
cognitive	O
function	O
decline	O
.	O

Associated	O
factors	O
for	O
cognitive	O
decline	O
were	O
identified	O
by	O
the	O
logistic	O
regression	O
model	O
.	O

Among	O
all	O
participants	O
,	O
205	O
(	O
30	O
%	O
)	O
experienced	O
cognitive	O
decline	O
during	O
the	O
study	O
period	O
.	O

Crude	O
logistic	O
regression	O
showed	O
that	O
women	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
1.9	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.3-2.6	O
)	O
,	O
low	O
educational	O
level	O
(	O
OR	O
2.0	O
,	O
95	O
%	O
CI	O
1.4-3.0	O
)	O
and	O
low	O
mastery	O
(	O
OR	O
1.4	O
,	O
95	O
%	O
CI	O
1.0-1.9	O
)	O
were	O
associated	O
with	O
cognitive	O
decline	O
,	O
but	O
no	O
daily	O
consumption	O
of	O
vegetables	O
and	O
fruits	O
had	O
only	O
a	O
marginal	O
association	O
(	O
OR	O
1.3	O
,	O
95	O
%	O
CI	O
0.9-1.8	O
)	O
.	O

In	O
the	O
fully	O
adjusted	O
logistic	O
regression	O
analysis	O
,	O
old	O
age	O
,	O
women	O
,	O
low	O
educational	O
level	O
and	O
low	O
sense	O
of	O
mastery	O
were	O
independent	O
predictors	O
for	O
cognitive	O
decline	O
.	O

Participants	O
with	O
two	O
modifiable	O
factors	O
(	O
mastery	O
,	O
and	O
daily	O
consumptions	O
of	O
vegetables	O
and	O
fruits	O
)	O
had	O
a	O
lower	O
risk	O
of	O
cognitive	O
decline	O
(	O
OR	O
0.5	O
,	O
95	O
%	O
CI	O
0.3-0.9	O
)	O
,	O
compared	O
with	O
those	O
without	O
any	O
protective	O
factor	O
.	O

Participants	O
with	O
a	O
better	O
educational	O
level	O
,	O
better	O
personal	O
mastery	O
,	O
and	O
more	O
consumption	O
of	O
fruits	O
and	O
vegetables	O
were	O
less	O
likely	O
to	O
experience	O
cognitive	O
decline	O
.	O

An	O
intervention	O
study	O
combining	O
these	O
features	O
should	O
be	O
carried	O
out	O
to	O
promote	O
better	O
cognitive	O
health	O
in	O
communities	O
.	O

Geriatr	O
Gerontol	O
Int	O
2017	O
:	O
17	O
(	O
Suppl	O
.	O

1	O
)	O
:	O
20-27	O
.	O

Protective	O
effect	O
of	O
epigallocatechin-3-gallate	O
(	O
EGCG	O
)	O
via	O
Nrf2	O
pathway	O
against	O
oxalate	O
-induced	O
epithelial	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
of	O
renal	O
tubular	O
cells	O
.	O

This	O
study	O
evaluated	O
effect	O
of	O
oxalate	O
on	O
epithelial	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
and	O
potential	O
anti-fibrotic	O
property	O
of	O
epigallocatechin-3-gallate	O
(	O
EGCG	O
)	O
.	O

MDCK	O
renal	O
tubular	O
cells	O
were	O
incubated	B-P
with	O
0.5	O
mM	O
sodium	O
oxalate	O
for	O
24-h	O
with/without	O
1-h	O
pretreatment	O
with	O
25	O
μM	O
EGCG	O
.	O

Microscopic	B-P
examination	I-P
,	O
immunoblotting	B-P
and	O
immunofluorescence	B-P
staining	I-P
revealed	O
that	O
oxalate	O
-treated	O
cells	O
gained	O
mesenchymal	O
phenotypes	O
by	O
fibroblast	O
-like	O
morphological	O
change	O
and	O
increasing	O
expression	O
of	O
vimentin	O
and	O
fibronectin	O
,	O
while	O
levels	O
of	O
epithelial	O
markers	O
(	O
E-cadherin	O
,	O
occludin	O
,	O
cytokeratin	O
and	O
ZO-1	O
)	O
were	O
decreased	O
.	O

EGCG	O
pretreatment	O
could	O
prevent	O
all	O
these	O
changes	O
and	O
molecular	O
mechanisms	O
underlying	O
the	O
prevention	O
by	O
EGCG	O
were	O
most	O
likely	O
due	O
to	O
reduced	O
production	O
of	O
intracellular	O
ROS	O
through	O
activation	O
of	O
Nrf2	O
signaling	O
and	O
increased	O
catalase	O
anti-oxidant	O
enzyme	O
.	O

Knockdown	O
of	O
Nrf2	O
by	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
abrogated	O
all	O
the	O
effects	O
of	O
EGCG	O
,	O
confirming	O
that	O
the	O
EGCG	O
protection	O
against	O
oxalate	O
-induced	O
EMT	O
was	O
mediated	O
via	O
Nrf2	O
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
oxalate	O
turned	O
on	O
EMT	O
of	O
renal	O
tubular	O
cells	O
that	O
could	O
be	O
prevented	O
by	O
EGCG	O
via	O
Nrf2	O
pathway	O
.	O

These	O
findings	O
also	O
shed	O
light	O
onto	O
development	O
of	O
novel	O
therapeutics	O
or	O
preventive	O
strategies	O
of	O
renal	O
fibrosis	O
in	O
the	O
future	O
.	O

Automated	O
basal	O
cell	O
carcinoma	O
detection	O
in	O
high-definition	B-P
optical	I-P
coherence	I-P
tomography	I-P
.	O

Basal	O
cell	O
carcinoma	O
(	O
BCC	O
)	O
is	O
the	O
most	O
common	O
non-melanoma	O
skin	O
cancer	O
.	O

Conventional	O
diagnosis	O
of	O
BCC	O
requires	O
invasive	O
biopsies	B-P
.	O

Recently	O
,	O
a	O
high-definition	B-P
optical	I-P
coherence	I-P
tomography	I-P
(	O
HD-OCT	B-P
)	O
technique	O
has	O
been	O
developed	O
,	O
which	O
provides	O
a	O
non-invasive	O
in	B-P
vivo	I-P
imaging	I-P
method	I-P
of	O
skin	O
.	O

Good	O
agreements	O
of	O
BCC	O
features	O
between	O
HD-OCT	B-P
images	O
and	O
histopathological	O
architecture	O
have	O
been	O
found	O
.	O

Therefore	O
it	O
is	O
possible	O
to	O
automatically	O
detect	O
BCC	O
using	O
HD-OCT	B-P
.	O

This	O
paper	O
presents	O
a	O
novel	O
BCC	O
detection	B-P
method	I-P
that	O
consists	O
of	O
four	O
steps	O
:	O
graph	O
based	O
skin	O
surface	O
segmentation	O
,	O
surface	O
flattening	O
,	O
deep	O
feature	O
extraction	O
and	O
the	O
BCC	O
classification	O
.	O

The	O
effectiveness	O
of	O
the	O
proposed	O
method	O
is	O
well	O
demonstrated	O
on	O
a	O
dataset	O
of	O
5,040	O
images	O
.	O

It	O
can	O
therefore	O
serve	O
as	O
an	O
automatic	O
tool	O
for	O
screening	O
BCC	O
.	O

A	O
new	O
marker	O
for	O
breast	B-P
cancer	I-P
diagnosis	I-P
,	O
human	O
epididymis	O
protein	O
4	O
:	O
A	O
preliminary	O
study	O
.	O

Breast	O
cancer	O
is	O
the	O
most	O
frequently	O
diagnosed	O
cancer	O
type	O
in	O
women	O
.	O

Tumor	O
markers	O
have	O
been	O
widely	O
used	O
for	O
assessing	O
the	O
treatment	O
response	O
and	O
early	B-P
diagnosis	I-P
of	O
recurrence	O
.	O

Human	O
epididymis	O
protein	O
4	O
(	O
HE4	O
)	O
is	O
expressed	O
in	O
ductal	O
carcinoma	O
of	O
the	O
breast	O
tissue	O
;	O
however	O
,	O
its	O
serum	O
levels	O
and	O
their	O
diagnostic	O
and	O
prognostic	O
potential	O
in	O
breast	O
cancer	O
have	O
not	O
been	O
investigated	O
,	O
which	O
was	O
therefore	O
the	O
aim	O
of	O
the	O
present	O
study	O
.	O

The	O
serum	O
levels	O
of	O
HE4	O
were	O
determined	B-P
in	O
36	O
breast	O
cancer	O
patients	O
,	O
11	O
ovarian	O
cancer	O
patients	O
and	O
16	O
healthy	O
volunteers	O
.	O

The	O
association	O
between	O
clinicopathological	O
characteristics	O
of	O
breast	O
cancer	O
and	O
serum	O
HE4	O
levels	O
was	O
investigated	O
.	O

A	O
significant	O
difference	O
in	O
the	O
median	O
serum	O
levels	O
of	O
HE4	O
was	O
identified	O
between	O
breast	O
cancer	O
patients	O
,	O
ovarian	O
cancer	O
patients	O
and	O
healthy	O
volunteers	O
(	O
P=0.013	O
)	O
.	O

The	O
cutoff	O
value	O
for	O
the	O
prediction	O
of	O
breast	O
cancer	O
was	O
determined	B-P
at	O
>	O
13.24	O
pmol/l	O
for	O
HE4	O
,	O
with	O
a	O
sensitivity	O
of	O
61.11	O
%	O
,	O
specificity	O
of	O
68.75	O
%	O
,	O
positive	O
predictive	O
value	O
of	O
81.48	O
%	O
,	O
negative	O
predictive	O
value	O
of	O
44.0	O
%	O
and	O
accuracy	O
of	O
63.46	O
%	O
.	O

Furthermore	O
,	O
a	O
positive	O
correlation	O
between	O
the	O
serum	O
levels	O
of	O
HE4	O
and	O
cancer	O
antigen	O
15-3	O
was	O
determined	B-P
(	O
r=0.399	O
,	O
P=0.026	O
)	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
present	O
study	O
was	O
the	O
first	O
to	O
determine	B-P
the	O
diagnostic	O
value	O
of	O
serum	O
HE4	O
for	O
breast	O
cancer	O
.	O

A	O
significant	O
elevation	O
of	O
serum	O
HE4	O
levels	O
in	O
patients	O
with	O
breast	O
cancer	O
compared	O
with	O
that	O
in	O
healthy	O
controls	O
was	O
identified	O
.	O

HE4	O
may	O
serve	O
as	O
a	O
novel	O
biomarker	O
for	O
the	O
diagnosis	O
of	O
breast	O
cancer	O
.	O

Development	O
of	O
Dual	B-P
Quantitative	I-P
Lateral	I-P
Flow	I-P
Immunoassay	I-P
for	O
the	O
Detection	O
of	O
Mycotoxins	O
.	O

Lateral	B-P
flow	I-P
immunoassays	I-P
have	O
been	O
widely	O
used	O
in	O
recent	O
years	O
for	O
detection	O
of	O
toxins	O
,	O
heavy	O
metals	O
,	O
and	O
biomarkers	O
.	O

To	O
improve	O
the	O
efficiency	O
of	O
individual	B-P
lateral	I-P
flow	I-P
immunoassays	I-P
,	O
multiplex	O
analytical	O
strips	O
play	O
an	O
important	O
role	O
in	O
the	O
detection	O
of	O
several	O
important	O
analytes	O
.	O

In	O
this	O
chapter	O
,	O
development	O
of	O
a	O
dual	B-P
lateral	I-P
flow	I-P
immunoassay	I-P
is	O
presented	O
for	O
detection	O
of	O
a	O
variety	O
of	O
low	O
molecular	O
weight	O
molecules	O
.	O

Various	O
buffers	O
,	O
additives	O
,	O
and	O
materials	O
are	O
introduced	O
and	O
evaluated	O
.	O

Depending	O
on	O
the	O
analyte	O
to	O
be	O
tested	O
,	O
the	O
technique	O
allows	O
for	O
selection	O
of	O
optimum	O
buffers	O
,	O
additives	O
,	O
and	O
other	O
materials	O
.	O

Patient	O
Factors	O
Associated	O
With	O
Higher	O
Expectations	O
From	O
Foot	O
and	O
Ankle	O
Surgery	O
.	O

Few	O
authors	O
have	O
investigated	O
patients	O
'	O
expectations	O
from	O
foot	O
and	O
ankle	O
surgery	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
examine	O
relationships	O
between	O
patients	O
'	O
preoperative	O
expectations	O
and	O
their	O
demographic	O
and	O
clinical	O
characteristics	O
.	O

We	O
hypothesized	O
that	O
patients	O
with	O
more	O
disability	O
and	O
those	O
with	O
anxiety	O
or	O
depressive	O
symptoms	O
would	O
have	O
greater	O
expectations	O
.	O

All	O
adult	O
patients	O
scheduled	O
for	O
elective	O
foot	O
or	O
ankle	O
surgery	O
by	O
1	O
of	O
6	O
orthopaedic	O
foot	O
and	O
ankle	O
surgeons	O
were	O
screened	O
for	O
inclusion	O
over	O
8	O
months	O
.	O

Preoperatively	O
,	O
all	O
patients	O
completed	O
the	O
Hospital	O
for	O
Special	O
Surgery	O
Foot	O
&	O
Ankle	O
Surgery	O
Expectations	O
Survey	O
in	O
addition	O
to	O
the	O
Foot	O
&	O
Ankle	O
Outcome	O
Score	O
(	O
FAOS	O
)	O
,	O
Short	O
Form	O
(	O
SF	O
)	O
-12	O
,	O
Patient	O
Health	O
Questionnaire	O
(	O
PHQ	O
)	O
-8	O
,	O
Generalized	O
Anxiety	O
Disorder	O
7-item	O
scale	O
(	O
GAD-7	O
)	O
,	O
and	O
pain	B-P
visual	I-P
analog	I-P
scale	I-P
(	O
VAS	B-P
)	O
.	O

The	O
expectations	O
survey	O
contained	O
23	O
expectations	O
categories	O
,	O
each	O
with	O
5	O
answer	O
choices	O
ranging	O
from	O
``	O
I	O
do	O
not	O
have	O
this	O
expectation	O
``	O
to	O
``	O
complete	O
improvement	O
``	O
expected	O
.	O

It	O
was	O
scored	O
from	O
0	O
to	O
100	O
,	O
with	O
higher	O
scores	O
indicating	O
more	O
expectations	O
.	O

Differences	O
in	O
expectations	O
relating	O
to	O
numerous	O
patient	O
demographic	O
and	O
clinical	O
variables	O
were	O
assessed	O
.	O

In	O
total	O
,	O
352	O
patients	O
with	O
an	O
average	O
age	O
of	O
55	O
±	O
15	O
(	O
range	O
,	O
18-86	O
)	O
years	O
were	O
enrolled	O
.	O

Expectations	O
scores	O
were	O
not	O
related	O
to	O
age	O
(	O
P	O
=	O
.36	O
)	O
.	O

On	O
average	O
,	O
women	O
expected	O
to	O
achieve	O
complete	O
improvement	O
more	O
often	O
than	O
men	O
(	O
P	O
=	O
.011	O
)	O
.	O

Variables	O
that	O
were	O
significantly	O
associated	O
with	O
higher	O
expectations	O
scores	O
(	O
P	O
<	O
.05	O
)	O
included	O
nonwhite	O
race	O
,	O
use	O
of	O
a	O
cane	O
or	O
other	O
assistive	O
device	O
,	O
and	O
greater	O
medical	O
comorbidity	O
.	O

Worse	O
function	O
and	O
quality	O
of	O
life	O
(	O
as	O
assessed	O
by	O
all	O
FAOS	O
subscales	O
and	O
the	O
SF-12	O
physical	O
and	O
mental	O
components	O
)	O
,	O
more	O
depressive	O
and	O
anxiety	O
symptoms	O
,	O
and	O
higher	O
pain	O
VAS	O
scores	O
were	O
associated	O
with	O
higher	O
expectations	O
scores	O
and	O
more	O
expectations	O
(	O
P	O
<	O
.01	O
for	O
all	O
)	O
.	O

The	O
results	O
of	O
this	O
study	O
may	O
help	O
inform	O
surgeons	O
'	O
preoperative	O
discussions	O
with	O
their	O
patients	O
regarding	O
realistic	O
expectations	O
from	O
surgery	O
.	O

Generally	O
,	O
patients	O
with	O
worse	O
function	O
and	O
more	O
disability	O
had	O
higher	O
expectations	O
from	O
surgery	O
.	O

Addressing	O
these	O
patients	O
'	O
expectations	O
preoperatively	O
may	O
help	O
improve	O
their	O
ultimate	O
satisfaction	O
with	O
surgery	O
.	O

Level	O
II	O
,	O
cross	O
sectional	O
study	O
.	O

TANGO	O
-	O
a	O
screening	O
tool	O
to	O
identify	O
comorbidities	O
on	O
the	O
causal	O
pathway	O
of	O
nocturia	O
.	O

To	O
develop	O
a	O
robust	O
screening	O
metric	O
for	O
use	O
in	O
identifying	O
non-lower	O
urinary	O
tract	O
comorbidities	O
pertinent	O
to	O
the	O
multidisciplinary	B-P
assessment	I-P
of	O
patients	O
with	O
nocturia	O
.	O

Variables	O
having	O
a	O
significant	O
risk	O
association	O
with	O
nocturia	O
of	O
greater	O
than	O
once	O
per	O
night	O
were	O
identified	O
.	O

Discriminating	O
items	O
from	O
validated	O
and	O
reliable	O
tools	O
measuring	O
these	O
comorbidities	O
were	O
identified	O
.	O

A	O
self-completed	O
57-item	O
questionnaire	O
was	O
developed	O
and	O
a	O
medical	O
checklist	O
and	O
pertinent	O
clinical	O
measures	O
added	O
.	O

Pre-determined	O
criteria	O
were	O
applied	O
to	O
retain	O
or	O
remove	O
items	O
in	O
the	O
development	O
of	O
the	O
Short-Form	O
(	O
SF	O
)	O
screening	O
tool	O
.	O

The	O
tool	O
was	O
administered	O
to	O
252	O
individuals	O
with	O
nocturia	O
who	O
were	O
attending	O
either	O
a	O
tertiary	O
level	O
Sleep	O
,	O
Continence	O
,	O
Falls	O
or	O
Rehabilitation	O
service	O
for	O
routine	O
care	O
.	O

Data	O
collected	O
were	O
subjected	O
to	O
descriptive	O
analysis	O
;	O
criteria	O
were	O
applied	O
to	O
reduce	O
the	O
number	O
of	O
items	O
.	O

Using	O
pre-determined	O
domains	O
,	O
a	O
nocturia	O
screening	O
metric	O
,	O
entitled	O
TANGO	O
,	O
was	O
generated	O
.	O

The	O
acronym	O
TANGO	O
stands	O
for	O
Targeting	O
the	O
individual	O
's	O
Aetiology	O
of	O
Nocturia	O
to	O
Guide	O
Outcomes	O
.	O

The	O
demographic	O
characteristics	O
of	O
the	O
sample	O
are	O
described	O
,	O
along	O
with	O
item	O
endorsement	O
levels	O
.	O

The	O
statistical	O
and	O
structural	O
framework	O
to	O
justify	O
deleting	O
or	O
retaining	O
of	O
items	O
from	O
the	O
TANGO	O
Long-Form	O
to	O
the	O
SF	O
is	O
presented	O
.	O

The	O
resultant	O
TANGO	O
-	O
SF	O
patient	O
-completed	O
nocturia	O
screening	O
tool	O
is	O
reported	O
.	O

A	O
novel	O
all-cause	O
diagnostic	O
metric	O
for	O
identifying	O
co-existing	O
morbidities	O
of	O
clinical	O
relevance	O
to	O
nocturia	O
in	O
patients	O
who	O
present	O
across	O
disciplines	O
and	O
medical	O
specialties	O
has	O
been	O
developed	O
.	O

TANGO	O
has	O
the	O
potential	O
to	O
improve	O
practice	O
and	O
smooth	O
inequalities	O
associated	O
with	O
a	O
siloed	O
approach	O
to	O
assessment	O
and	O
subsequent	O
care	O
of	O
patients	O
with	O
nocturia	O
.	O

Mapping	B-P
how	O
local	O
perturbations	O
influence	O
systems-level	O
brain	O
dynamics	O
.	O

The	O
human	O
brain	O
exhibits	O
a	O
distinct	O
spatiotemporal	O
organization	O
that	O
supports	O
brain	O
function	O
and	O
can	O
be	O
manipulated	O
via	O
local	O
brain	O
stimulation	O
.	O

Such	O
perturbations	O
to	O
local	O
cortical	O
dynamics	O
are	O
globally	O
integrated	O
by	O
distinct	O
neural	O
systems	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
how	O
local	O
changes	O
in	O
neural	O
activity	O
affect	O
large-scale	O
system	O
dynamics	O
.	O

Here	O
,	O
we	O
briefly	O
review	O
empirical	O
and	O
computational	O
studies	O
addressing	O
how	O
localized	O
perturbations	O
affect	O
brain	O
activity	O
.	O

We	O
then	O
systematically	O
analyze	O
a	O
model	O
of	O
large-scale	O
brain	O
dynamics	O
,	O
assessing	O
how	O
localized	O
changes	O
in	O
brain	O
activity	O
at	O
the	O
different	O
sites	O
affect	O
whole-brain	O
dynamics	O
.	O

We	O
find	O
that	O
local	O
stimulation	O
induces	O
changes	O
in	O
brain	O
activity	O
that	O
can	O
be	O
summarized	O
by	O
relatively	O
smooth	O
tuning	O
curves	O
,	O
which	O
relate	O
a	O
region	O
's	O
effectiveness	O
as	O
a	O
stimulation	O
site	O
to	O
its	O
position	O
within	O
the	O
cortical	O
hierarchy	O
.	O

Our	O
results	O
also	O
support	O
the	O
notion	O
that	O
brain	O
hubs	O
,	O
operating	O
in	O
a	O
slower	O
regime	O
,	O
are	O
more	O
resilient	O
to	O
focal	O
perturbations	O
and	O
critically	O
contribute	O
to	O
maintain	O
stability	O
in	O
global	O
brain	O
dynamics	O
.	O

In	O
contrast	O
,	O
perturbations	O
of	O
peripheral	O
regions	O
,	O
characterized	O
by	O
faster	O
activity	O
,	O
have	O
greater	O
impact	O
on	O
functional	O
connectivity	O
.	O

As	O
a	O
parallel	O
with	O
this	O
region-level	O
result	O
,	O
we	O
also	O
find	O
that	O
peripheral	O
systems	O
such	O
as	O
the	O
visual	O
and	O
sensorimotor	O
networks	O
were	O
more	O
affected	O
by	O
local	O
perturbations	O
than	O
high-level	O
systems	O
such	O
as	O
the	O
cingulo-opercular	O
network	O
.	O

Our	O
findings	O
highlight	O
the	O
importance	O
of	O
a	O
periphery-to-core	O
hierarchy	O
to	O
determine	O
the	O
effect	O
of	O
local	O
stimulation	O
on	O
the	O
brain	O
network	O
.	O

This	O
study	O
also	O
provides	O
novel	O
resources	O
to	O
orient	O
empirical	O
work	O
aiming	O
at	O
manipulating	O
functional	O
connectivity	O
using	O
non-invasive	O
brain	O
stimulation	O
.	O

Feasibility	O
and	O
energetic	O
evaluation	O
of	O
air	O
stripping	O
for	O
bioethanol	O
production	O
.	O

Stripping	O
of	O
mashes	O
with	O
air	O
as	O
stripping	O
gas	O
and	O
low	O
ethanol	O
contents	O
between	O
3	O
and	O
5wt	O
%	O
was	O
investigated	O
in	O
terms	O
of	O
its	O
suitability	O
for	O
continuous	O
bioethanol	O
production	O
.	O

Experiments	O
in	O
a	O
Blenke	O
cascade	O
system	O
were	O
carried	O
out	O
and	O
the	O
results	O
were	O
compared	O
with	O
values	O
obtained	O
from	O
theoretical	O
vapour-liquid-equilibrium	O
calculations	O
.	O

The	O
whole	O
stripping	O
process	O
was	O
energetically	O
evaluated	O
by	O
a	O
simulation	O
in	O
ChemCAD	O
and	O
compared	O
to	O
conventional	B-P
distillation	I-P
.	O

Therefore	O
several	O
parameters	O
such	O
as	O
temperature	O
,	O
air	O
volume	O
flow	O
and	O
initial	O
ethanol	O
load	O
of	O
the	O
mash	O
were	O
varied	O
.	O

Air	O
stripping	O
was	O
found	O
to	O
be	O
a	O
suitable	O
separation	O
method	O
for	O
bioethanol	O
from	O
mashes	O
with	O
low	O
concentrations	O
.	O

However	O
,	O
energetic	O
aspects	O
have	O
to	O
be	O
considered	O
,	O
when	O
developing	O
a	O
new	O
process	O
.	O

Cdc45	O
-	O
induced	O
loading	O
of	O
human	O
RPA	O
onto	O
single-stranded	O
DNA	O
.	O

Cell	O
division	O
cycle	O
protein	O
45	O
(	O
Cdc45	O
)	O
is	O
an	O
essential	O
component	O
of	O
the	O
eukaryotic	O
replicative	O
DNA	O
helicase	O
.	O

We	O
found	O
that	O
human	O
Cdc45	O
forms	O
a	O
complex	O
with	O
the	O
single-stranded	O
DNA	O
(	O
ssDNA	O
)	O
binding	O
protein	O
RPA	O
.	O

Moreover	O
,	O
it	O
actively	O
loads	O
RPA	O
onto	O
nascent	O
ssDNA	O
.	O

Pull-down	B-P
assays	I-P
and	O
surface	O
plasmon	O
resonance	O
studies	O
revealed	O
that	O
Cdc45	O
-	O
bound	O
RPA	O
complexed	O
with	O
ssDNA	O
in	O
the	O
8-10	O
nucleotide	O
binding	O
mode	O
,	O
but	O
dissociated	O
when	O
RPA	O
covered	O
a	O
30-mer	O
.	O

Real-time	B-P
analysis	I-P
of	O
RPA	O
-	O
ssDNA	O
binding	O
demonstrated	O
that	O
Cdc45	O
catalytically	O
loaded	O
RPA	O
onto	O
ssDNA	O
.	O

This	O
placement	O
reaction	O
required	O
physical	O
contacts	O
of	O
Cdc45	O
with	O
the	O
RPA70A	O
subdomain	O
.	O

Our	O
results	O
imply	O
that	O
Cdc45	O
controlled	O
stabilization	O
of	O
the	O
8-	O
nt	O
RPA	O
binding	O
mode	O
,	O
the	O
subsequent	O
RPA	O
transition	O
into	O
30-mer	O
mode	O
and	O
facilitated	O
an	O
ordered	O
binding	O
to	O
ssDNA	O
.	O

We	O
propose	O
that	O
a	O
Cdc45	O
-mediated	O
loading	O
guarantees	O
a	O
seamless	O
deposition	O
of	O
RPA	O
on	O
newly	O
emerging	O
ssDNA	O
at	O
the	O
nascent	O
replication	O
fork	O
.	O

